bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
tolerance is a Outcome_Other, bronchoprotective effect is a Outcome_Physical, salmeterol / fluticasone is a Intervention_Pharmacological, salmeterol / fluticasone propionate is a Intervention_Pharmacological, early airway response ( EAR ) is a Outcome_Physical, placebo is a Intervention_Control, allergen challenge ( T1 ) is a Intervention_Pharmacological, single dose of salmeterol / fluticasone is a Intervention_Pharmacological, allergen challenge ( T2 ) is a Intervention_Pharmacological, allergen challenge ( T3 ) is a Intervention_Pharmacological, FEV1 is a Outcome_Physical, MaxDeltaFEV1 % is a Outcome_Physical, area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge is a Outcome_Physical, significantly greater is a Outcome_Other, No difference is a Outcome_Other, area under the curve is a Outcome_Physical, protected against EAR is a Outcome_Physical, protected against EAR . is a Outcome_Physical, tolerance to the protective effect is a Outcome_Physical	24706_task1	Sentence: Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge . In order to assess whether the administration of salmeterol/fluticasone propionate combination ( 50/250 mcg by Diskus ) for 1 week induces tolerance to the bronchoprotective effect of salmeterol on allergen challenge , a single-blind , cross-over study was carried out . We studied nine subjects ( eight men and one woman ; mean age+/-SD : 31.3+/-11.0 yr ) with mild intermittent allergic asthma , never treated with regular beta2-agonists or inhaled corticosteroids . In a previous allergen challenge all subjects had shown a positive early airway response ( EAR ) to allergen . They underwent allergen challenge after 1-week treatment with placebo and a single dose of placebo immediately before allergen challenge ( T1 ) , or 1-week treatment with placebo and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T2 ) , or 1-week treatment with salmeterol/fluticasone combination bid and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T3 ) . EAR was evaluated both as maximum decrease in FEV1 ( MaxDeltaFEV1 % ) after allergen challenge and as area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge protected by placebo ( T1 ) was significantly greater than MaxDeltaFEV1 % during allergen challenges protected by single dose of salmeterol/fluticasone ( T2 ) and by salmeterol/fluticasone 1-week treatment ( T3 ) . No difference was found in MaxDeltaFEV1 % between T2 and T3 . The same results were observed also after computing the area under the curve for each challenge . When individually considered , all subjects were protected against EAR ( protection index > or = 80 % ) at T2 , while at 3 seven out of nine subjects were still protected against EAR . In conclusion , the simultaneous administration of salmeterol and fluticasone in the same device prevents in almost 80 % of examined subjects the development of tolerance to the protective effect of salmeterol on allergen challenge . This observation may contribute to explain the positive interaction between inhaled beta2-agonists and corticosteroids in the long-term treatment of asthma . Instructions: please typing these entity words according to sentence: tolerance, bronchoprotective effect, salmeterol / fluticasone, salmeterol / fluticasone propionate, early airway response ( EAR ), placebo, allergen challenge ( T1 ), single dose of salmeterol / fluticasone, allergen challenge ( T2 ), allergen challenge ( T3 ), FEV1, MaxDeltaFEV1 %, area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge, significantly greater, No difference, area under the curve, protected against EAR, protected against EAR ., tolerance to the protective effect Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Intervention_Control	[ "O", "B-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge . In order to assess whether the administration of salmeterol/fluticasone propionate combination ( 50/250 mcg by Diskus ) for 1 week induces tolerance to the bronchoprotective effect of salmeterol on allergen challenge , a single-blind , cross-over study was carried out . We studied nine subjects ( eight men and one woman ; mean age+/-SD : 31.3+/-11.0 yr ) with mild intermittent allergic asthma , never treated with regular beta2-agonists or inhaled corticosteroids . In a previous allergen challenge all subjects had shown a positive early airway response ( EAR ) to allergen . They underwent allergen challenge after 1-week treatment with placebo and a single dose of placebo immediately before allergen challenge ( T1 ) , or 1-week treatment with placebo and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T2 ) , or 1-week treatment with salmeterol/fluticasone combination bid and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T3 ) . EAR was evaluated both as maximum decrease in FEV1 ( MaxDeltaFEV1 % ) after allergen challenge and as area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge protected by placebo ( T1 ) was significantly greater than MaxDeltaFEV1 % during allergen challenges protected by single dose of salmeterol/fluticasone ( T2 ) and by salmeterol/fluticasone 1-week treatment ( T3 ) . No difference was found in MaxDeltaFEV1 % between T2 and T3 . The same results were observed also after computing the area under the curve for each challenge . When individually considered , all subjects were protected against EAR ( protection index > or = 80 % ) at T2 , while at 3 seven out of nine subjects were still protected against EAR . In conclusion , the simultaneous administration of salmeterol and fluticasone in the same device prevents in almost 80 % of examined subjects the development of tolerance to the protective effect of salmeterol on allergen challenge . This observation may contribute to explain the positive interaction between inhaled beta2-agonists and corticosteroids in the long-term treatment of asthma .	[ "Minimal", "tolerance", "to", "the", "bronchoprotective", "effect", "of", "inhaled", "salmeterol", "/", "fluticasone", "combination", "on", "allergene", "challenge", ".", "In", "order", "to", "assess", "whether", "the", "administration", "of", "salmeterol", "/", "fluticasone", "propionate", "combination", "(", "50/250", "mcg", "by", "Diskus", ")", "for", "1", "week", "induces", "tolerance", "to", "the", "bronchoprotective", "effect", "of", "salmeterol", "on", "allergen", "challenge", ",", "a", "single", "-", "blind", ",", "cross", "-", "over", "study", "was", "carried", "out", ".", "We", "studied", "nine", "subjects", "(", "eight", "men", "and", "one", "woman", ";", "mean", "age+/-SD", ":", "31.3+/-11.0", "yr", ")", "with", "mild", "intermittent", "allergic", "asthma", ",", "never", "treated", "with", "regular", "beta2-agonists", "or", "inhaled", "corticosteroids", ".", "In", "a", "previous", "allergen", "challenge", "all", "subjects", "had", "shown", "a", "positive", "early", "airway", "response", "(", "EAR", ")", "to", "allergen", ".", "They", "underwent", "allergen", "challenge", "after", "1-week", "treatment", "with", "placebo", "and", "a", "single", "dose", "of", "placebo", "immediately", "before", "allergen", "challenge", "(", "T1", ")", ",", "or", "1-week", "treatment", "with", "placebo", "and", "a", "single", "dose", "of", "salmeterol", "/", "fluticasone", "immediately", "before", "allergen", "challenge", "(", "T2", ")", ",", "or", "1-week", "treatment", "with", "salmeterol", "/", "fluticasone", "combination", "bid", "and", "a", "single", "dose", "of", "salmeterol", "/", "fluticasone", "immediately", "before", "allergen", "challenge", "(", "T3", ")", ".", "EAR", "was", "evaluated", "both", "as", "maximum", "decrease", "in", "FEV1", "(", "MaxDeltaFEV1", "%", ")", "after", "allergen", "challenge", "and", "as", "area", "under", "FEV1", "-time", "curve", ".", "MaxDeltaFEV1", "%", "during", "allergen", "challenge", "protected", "by", "placebo", "(", "T1", ")", "was", "significantly", "greater", "than", "MaxDeltaFEV1", "%", "during", "allergen", "challenges", "protected", "by", "single", "dose", "of", "salmeterol", "/", "fluticasone", "(", "T2", ")", "and", "by", "salmeterol", "/", "fluticasone", "1-week", "treatment", "(", "T3", ")", ".", "No", "difference", "was", "found", "in", "MaxDeltaFEV1", "%", "between", "T2", "and", "T3", ".", "The", "same", "results", "were", "observed", "also", "after", "computing", "the", "area", "under", "the", "curve", "for", "each", "challenge", ".", "When", "individually", "considered", ",", "all", "subjects", "were", "protected", "against", "EAR", "(", "protection", "index", ">", "or", "=", "80", "%", ")", "at", "T2", ",", "while", "at", "3", "seven", "out", "of", "nine", "subjects", "were", "still", "protected", "against", "EAR", ".", "In", "conclusion", ",", "the", "simultaneous", "administration", "of", "salmeterol", "and", "fluticasone", "in", "the", "same", "device", "prevents", "in", "almost", "80", "%", "of", "examined", "subjects", "the", "development", "of", "tolerance", "to", "the", "protective", "effect", "of", "salmeterol", "on", "allergen", "challenge", ".", "This", "observation", "may", "contribute", "to", "explain", "the", "positive", "interaction", "between", "inhaled", "beta2-agonists", "and", "corticosteroids", "in", "the", "long", "-", "term", "treatment", "of", "asthma", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Intervention_Control" ]
tolerance, bronchoprotective effect, salmeterol / fluticasone, salmeterol / fluticasone propionate, early airway response ( EAR ), placebo, allergen challenge ( T1 ), single dose of salmeterol / fluticasone, allergen challenge ( T2 ), allergen challenge ( T3 ), FEV1, MaxDeltaFEV1 %, area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge, significantly greater, No difference, area under the curve, protected against EAR, protected against EAR ., tolerance to the protective effect	24706_task2	Sentence: Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge . In order to assess whether the administration of salmeterol/fluticasone propionate combination ( 50/250 mcg by Diskus ) for 1 week induces tolerance to the bronchoprotective effect of salmeterol on allergen challenge , a single-blind , cross-over study was carried out . We studied nine subjects ( eight men and one woman ; mean age+/-SD : 31.3+/-11.0 yr ) with mild intermittent allergic asthma , never treated with regular beta2-agonists or inhaled corticosteroids . In a previous allergen challenge all subjects had shown a positive early airway response ( EAR ) to allergen . They underwent allergen challenge after 1-week treatment with placebo and a single dose of placebo immediately before allergen challenge ( T1 ) , or 1-week treatment with placebo and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T2 ) , or 1-week treatment with salmeterol/fluticasone combination bid and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T3 ) . EAR was evaluated both as maximum decrease in FEV1 ( MaxDeltaFEV1 % ) after allergen challenge and as area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge protected by placebo ( T1 ) was significantly greater than MaxDeltaFEV1 % during allergen challenges protected by single dose of salmeterol/fluticasone ( T2 ) and by salmeterol/fluticasone 1-week treatment ( T3 ) . No difference was found in MaxDeltaFEV1 % between T2 and T3 . The same results were observed also after computing the area under the curve for each challenge . When individually considered , all subjects were protected against EAR ( protection index > or = 80 % ) at T2 , while at 3 seven out of nine subjects were still protected against EAR . In conclusion , the simultaneous administration of salmeterol and fluticasone in the same device prevents in almost 80 % of examined subjects the development of tolerance to the protective effect of salmeterol on allergen challenge . This observation may contribute to explain the positive interaction between inhaled beta2-agonists and corticosteroids in the long-term treatment of asthma . Instructions: please extract entity words from the input sentence	[ "O", "B-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge . In order to assess whether the administration of salmeterol/fluticasone propionate combination ( 50/250 mcg by Diskus ) for 1 week induces tolerance to the bronchoprotective effect of salmeterol on allergen challenge , a single-blind , cross-over study was carried out . We studied nine subjects ( eight men and one woman ; mean age+/-SD : 31.3+/-11.0 yr ) with mild intermittent allergic asthma , never treated with regular beta2-agonists or inhaled corticosteroids . In a previous allergen challenge all subjects had shown a positive early airway response ( EAR ) to allergen . They underwent allergen challenge after 1-week treatment with placebo and a single dose of placebo immediately before allergen challenge ( T1 ) , or 1-week treatment with placebo and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T2 ) , or 1-week treatment with salmeterol/fluticasone combination bid and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T3 ) . EAR was evaluated both as maximum decrease in FEV1 ( MaxDeltaFEV1 % ) after allergen challenge and as area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge protected by placebo ( T1 ) was significantly greater than MaxDeltaFEV1 % during allergen challenges protected by single dose of salmeterol/fluticasone ( T2 ) and by salmeterol/fluticasone 1-week treatment ( T3 ) . No difference was found in MaxDeltaFEV1 % between T2 and T3 . The same results were observed also after computing the area under the curve for each challenge . When individually considered , all subjects were protected against EAR ( protection index > or = 80 % ) at T2 , while at 3 seven out of nine subjects were still protected against EAR . In conclusion , the simultaneous administration of salmeterol and fluticasone in the same device prevents in almost 80 % of examined subjects the development of tolerance to the protective effect of salmeterol on allergen challenge . This observation may contribute to explain the positive interaction between inhaled beta2-agonists and corticosteroids in the long-term treatment of asthma .	[ "Minimal", "tolerance", "to", "the", "bronchoprotective", "effect", "of", "inhaled", "salmeterol", "/", "fluticasone", "combination", "on", "allergene", "challenge", ".", "In", "order", "to", "assess", "whether", "the", "administration", "of", "salmeterol", "/", "fluticasone", "propionate", "combination", "(", "50/250", "mcg", "by", "Diskus", ")", "for", "1", "week", "induces", "tolerance", "to", "the", "bronchoprotective", "effect", "of", "salmeterol", "on", "allergen", "challenge", ",", "a", "single", "-", "blind", ",", "cross", "-", "over", "study", "was", "carried", "out", ".", "We", "studied", "nine", "subjects", "(", "eight", "men", "and", "one", "woman", ";", "mean", "age+/-SD", ":", "31.3+/-11.0", "yr", ")", "with", "mild", "intermittent", "allergic", "asthma", ",", "never", "treated", "with", "regular", "beta2-agonists", "or", "inhaled", "corticosteroids", ".", "In", "a", "previous", "allergen", "challenge", "all", "subjects", "had", "shown", "a", "positive", "early", "airway", "response", "(", "EAR", ")", "to", "allergen", ".", "They", "underwent", "allergen", "challenge", "after", "1-week", "treatment", "with", "placebo", "and", "a", "single", "dose", "of", "placebo", "immediately", "before", "allergen", "challenge", "(", "T1", ")", ",", "or", "1-week", "treatment", "with", "placebo", "and", "a", "single", "dose", "of", "salmeterol", "/", "fluticasone", "immediately", "before", "allergen", "challenge", "(", "T2", ")", ",", "or", "1-week", "treatment", "with", "salmeterol", "/", "fluticasone", "combination", "bid", "and", "a", "single", "dose", "of", "salmeterol", "/", "fluticasone", "immediately", "before", "allergen", "challenge", "(", "T3", ")", ".", "EAR", "was", "evaluated", "both", "as", "maximum", "decrease", "in", "FEV1", "(", "MaxDeltaFEV1", "%", ")", "after", "allergen", "challenge", "and", "as", "area", "under", "FEV1", "-time", "curve", ".", "MaxDeltaFEV1", "%", "during", "allergen", "challenge", "protected", "by", "placebo", "(", "T1", ")", "was", "significantly", "greater", "than", "MaxDeltaFEV1", "%", "during", "allergen", "challenges", "protected", "by", "single", "dose", "of", "salmeterol", "/", "fluticasone", "(", "T2", ")", "and", "by", "salmeterol", "/", "fluticasone", "1-week", "treatment", "(", "T3", ")", ".", "No", "difference", "was", "found", "in", "MaxDeltaFEV1", "%", "between", "T2", "and", "T3", ".", "The", "same", "results", "were", "observed", "also", "after", "computing", "the", "area", "under", "the", "curve", "for", "each", "challenge", ".", "When", "individually", "considered", ",", "all", "subjects", "were", "protected", "against", "EAR", "(", "protection", "index", ">", "or", "=", "80", "%", ")", "at", "T2", ",", "while", "at", "3", "seven", "out", "of", "nine", "subjects", "were", "still", "protected", "against", "EAR", ".", "In", "conclusion", ",", "the", "simultaneous", "administration", "of", "salmeterol", "and", "fluticasone", "in", "the", "same", "device", "prevents", "in", "almost", "80", "%", "of", "examined", "subjects", "the", "development", "of", "tolerance", "to", "the", "protective", "effect", "of", "salmeterol", "on", "allergen", "challenge", ".", "This", "observation", "may", "contribute", "to", "explain", "the", "positive", "interaction", "between", "inhaled", "beta2-agonists", "and", "corticosteroids", "in", "the", "long", "-", "term", "treatment", "of", "asthma", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Intervention_Control" ]
gaviscon preparation is a Intervention_Pharmacological, esophageal is a Outcome_Physical, functional dyspepsia is a Outcome_Physical, elderly patients with GERD ] is a Participant_Condition, Geviskon is a Intervention_Pharmacological, aluminum - magnesium antacids is a Intervention_Pharmacological, alginate product -- Geviskon forte dose of 10 ml is a Intervention_Pharmacological, aluminum - magnesium antacid drug at a dose of 1 sachet is a Intervention_Pharmacological, frequency is a Outcome_Physical, severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia is a Outcome_Physical, degree of esophageal mucosal injury is a Outcome_Physical, relief of heartburn , regurgitation , chronic cough , sore throat , and EBS . is a Outcome_Physical	49818_task0	Sentence: [ Using gaviscon preparation for relief of esophageal , extraesophageal syndromes and functional dyspepsia in elderly patients with GERD ] . OBJECTIVE To compare the clinical efficacy of alginate drug Geviskon and aluminum-magnesium antacids to relieve symptoms of esophageal , extraesophageal syndrome and functional dyspepsia at 3 and 7 days of study in patients with GERD elderly . MATERIALS AND METHODS An open , longitudinal , randomized , parallel-group . The study included 60 patients with " A " degree of ERD , consistently received in-patient treatment in the Municipal KGVV , mean age 79.0 +/- 6.8 years . During the first 12 hours of hospital stay by " sealed envelopes " them randomly divided into equal groups of comparison , given 3 times a day : alginate product -- Geviskon forte dose of 10 ml and aluminum-magnesium antacid drug at a dose of 1 sachet . Assess the frequency and severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia at 3 and 7 days of study on 5-point scale Likert . The degree of esophageal mucosal injury was determined during endoscopy before the study . RESULTS The technique of alginate compared with antacids provided significantly more complete and earlier effect on the relief of heartburn , regurgitation , chronic cough , sore throat , and EBS . Only Geviskon influenced the symptoms of PPD in patients with GERD . CONCLUSION The clinical features Geviskon the frequency and timing of relief of symptoms of esophageal , extraesophageal syndrome , functional dyspepsia with GERD in the older age groups is higher than that of antacids . Suspension Geviskon may be recommended in patients with middle and old age as an effective and safe symptomatic funds in the first days of exchange rate earlier generations of PPI therapy , as well as monotherapy -- to maintain remission . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition	[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	[ Using gaviscon preparation for relief of esophageal , extraesophageal syndromes and functional dyspepsia in elderly patients with GERD ] . OBJECTIVE To compare the clinical efficacy of alginate drug Geviskon and aluminum-magnesium antacids to relieve symptoms of esophageal , extraesophageal syndrome and functional dyspepsia at 3 and 7 days of study in patients with GERD elderly . MATERIALS AND METHODS An open , longitudinal , randomized , parallel-group . The study included 60 patients with " A " degree of ERD , consistently received in-patient treatment in the Municipal KGVV , mean age 79.0 +/- 6.8 years . During the first 12 hours of hospital stay by " sealed envelopes " them randomly divided into equal groups of comparison , given 3 times a day : alginate product -- Geviskon forte dose of 10 ml and aluminum-magnesium antacid drug at a dose of 1 sachet . Assess the frequency and severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia at 3 and 7 days of study on 5-point scale Likert . The degree of esophageal mucosal injury was determined during endoscopy before the study . RESULTS The technique of alginate compared with antacids provided significantly more complete and earlier effect on the relief of heartburn , regurgitation , chronic cough , sore throat , and EBS . Only Geviskon influenced the symptoms of PPD in patients with GERD . CONCLUSION The clinical features Geviskon the frequency and timing of relief of symptoms of esophageal , extraesophageal syndrome , functional dyspepsia with GERD in the older age groups is higher than that of antacids . Suspension Geviskon may be recommended in patients with middle and old age as an effective and safe symptomatic funds in the first days of exchange rate earlier generations of PPI therapy , as well as monotherapy -- to maintain remission .	[ "[", "Using", "gaviscon", "preparation", "for", "relief", "of", "esophageal", ",", "extraesophageal", "syndromes", "and", "functional", "dyspepsia", "in", "elderly", "patients", "with", "GERD", "]", ".", "OBJECTIVE", "To", "compare", "the", "clinical", "efficacy", "of", "alginate", "drug", "Geviskon", "and", "aluminum", "-", "magnesium", "antacids", "to", "relieve", "symptoms", "of", "esophageal", ",", "extraesophageal", "syndrome", "and", "functional", "dyspepsia", "at", "3", "and", "7", "days", "of", "study", "in", "patients", "with", "GERD", "elderly", ".", "MATERIALS", "AND", "METHODS", "An", "open", ",", "longitudinal", ",", "randomized", ",", "parallel", "-", "group", ".", "The", "study", "included", "60", "patients", "with", "\"", "A", "\"", "degree", "of", "ERD", ",", "consistently", "received", "in", "-", "patient", "treatment", "in", "the", "Municipal", "KGVV", ",", "mean", "age", "79.0", "+", "/-", "6.8", "years", ".", "During", "the", "first", "12", "hours", "of", "hospital", "stay", "by", "\"", "sealed", "envelopes", "\"", "them", "randomly", "divided", "into", "equal", "groups", "of", "comparison", ",", "given", "3", "times", "a", "day", ":", "alginate", "product", "--", "Geviskon", "forte", "dose", "of", "10", "ml", "and", "aluminum", "-", "magnesium", "antacid", "drug", "at", "a", "dose", "of", "1", "sachet", ".", "Assess", "the", "frequency", "and", "severity", "of", "esophageal", "symptoms", ",", "extraesophageal", "syndrome", ",", "functional", "dyspepsia", "at", "3", "and", "7", "days", "of", "study", "on", "5-point", "scale", "Likert", ".", "The", "degree", "of", "esophageal", "mucosal", "injury", "was", "determined", "during", "endoscopy", "before", "the", "study", ".", "RESULTS", "The", "technique", "of", "alginate", "compared", "with", "antacids", "provided", "significantly", "more", "complete", "and", "earlier", "effect", "on", "the", "relief", "of", "heartburn", ",", "regurgitation", ",", "chronic", "cough", ",", "sore", "throat", ",", "and", "EBS", ".", "Only", "Geviskon", "influenced", "the", "symptoms", "of", "PPD", "in", "patients", "with", "GERD", ".", "CONCLUSION", "The", "clinical", "features", "Geviskon", "the", "frequency", "and", "timing", "of", "relief", "of", "symptoms", "of", "esophageal", ",", "extraesophageal", "syndrome", ",", "functional", "dyspepsia", "with", "GERD", "in", "the", "older", "age", "groups", "is", "higher", "than", "that", "of", "antacids", ".", "Suspension", "Geviskon", "may", "be", "recommended", "in", "patients", "with", "middle", "and", "old", "age", "as", "an", "effective", "and", "safe", "symptomatic", "funds", "in", "the", "first", "days", "of", "exchange", "rate", "earlier", "generations", "of", "PPI", "therapy", ",", "as", "well", "as", "monotherapy", "--", "to", "maintain", "remission", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Condition" ]
gaviscon preparation is a Intervention_Pharmacological, esophageal is a Outcome_Physical, functional dyspepsia is a Outcome_Physical, elderly patients with GERD ] is a Participant_Condition, Geviskon is a Intervention_Pharmacological, aluminum - magnesium antacids is a Intervention_Pharmacological, alginate product -- Geviskon forte dose of 10 ml is a Intervention_Pharmacological, aluminum - magnesium antacid drug at a dose of 1 sachet is a Intervention_Pharmacological, frequency is a Outcome_Physical, severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia is a Outcome_Physical, degree of esophageal mucosal injury is a Outcome_Physical, relief of heartburn , regurgitation , chronic cough , sore throat , and EBS . is a Outcome_Physical	49818_task1	Sentence: [ Using gaviscon preparation for relief of esophageal , extraesophageal syndromes and functional dyspepsia in elderly patients with GERD ] . OBJECTIVE To compare the clinical efficacy of alginate drug Geviskon and aluminum-magnesium antacids to relieve symptoms of esophageal , extraesophageal syndrome and functional dyspepsia at 3 and 7 days of study in patients with GERD elderly . MATERIALS AND METHODS An open , longitudinal , randomized , parallel-group . The study included 60 patients with " A " degree of ERD , consistently received in-patient treatment in the Municipal KGVV , mean age 79.0 +/- 6.8 years . During the first 12 hours of hospital stay by " sealed envelopes " them randomly divided into equal groups of comparison , given 3 times a day : alginate product -- Geviskon forte dose of 10 ml and aluminum-magnesium antacid drug at a dose of 1 sachet . Assess the frequency and severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia at 3 and 7 days of study on 5-point scale Likert . The degree of esophageal mucosal injury was determined during endoscopy before the study . RESULTS The technique of alginate compared with antacids provided significantly more complete and earlier effect on the relief of heartburn , regurgitation , chronic cough , sore throat , and EBS . Only Geviskon influenced the symptoms of PPD in patients with GERD . CONCLUSION The clinical features Geviskon the frequency and timing of relief of symptoms of esophageal , extraesophageal syndrome , functional dyspepsia with GERD in the older age groups is higher than that of antacids . Suspension Geviskon may be recommended in patients with middle and old age as an effective and safe symptomatic funds in the first days of exchange rate earlier generations of PPI therapy , as well as monotherapy -- to maintain remission . Instructions: please typing these entity words according to sentence: gaviscon preparation, esophageal, functional dyspepsia, elderly patients with GERD ], Geviskon, aluminum - magnesium antacids, alginate product -- Geviskon forte dose of 10 ml, aluminum - magnesium antacid drug at a dose of 1 sachet, frequency, severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia, degree of esophageal mucosal injury, relief of heartburn , regurgitation , chronic cough , sore throat , and EBS . Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition	[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	[ Using gaviscon preparation for relief of esophageal , extraesophageal syndromes and functional dyspepsia in elderly patients with GERD ] . OBJECTIVE To compare the clinical efficacy of alginate drug Geviskon and aluminum-magnesium antacids to relieve symptoms of esophageal , extraesophageal syndrome and functional dyspepsia at 3 and 7 days of study in patients with GERD elderly . MATERIALS AND METHODS An open , longitudinal , randomized , parallel-group . The study included 60 patients with " A " degree of ERD , consistently received in-patient treatment in the Municipal KGVV , mean age 79.0 +/- 6.8 years . During the first 12 hours of hospital stay by " sealed envelopes " them randomly divided into equal groups of comparison , given 3 times a day : alginate product -- Geviskon forte dose of 10 ml and aluminum-magnesium antacid drug at a dose of 1 sachet . Assess the frequency and severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia at 3 and 7 days of study on 5-point scale Likert . The degree of esophageal mucosal injury was determined during endoscopy before the study . RESULTS The technique of alginate compared with antacids provided significantly more complete and earlier effect on the relief of heartburn , regurgitation , chronic cough , sore throat , and EBS . Only Geviskon influenced the symptoms of PPD in patients with GERD . CONCLUSION The clinical features Geviskon the frequency and timing of relief of symptoms of esophageal , extraesophageal syndrome , functional dyspepsia with GERD in the older age groups is higher than that of antacids . Suspension Geviskon may be recommended in patients with middle and old age as an effective and safe symptomatic funds in the first days of exchange rate earlier generations of PPI therapy , as well as monotherapy -- to maintain remission .	[ "[", "Using", "gaviscon", "preparation", "for", "relief", "of", "esophageal", ",", "extraesophageal", "syndromes", "and", "functional", "dyspepsia", "in", "elderly", "patients", "with", "GERD", "]", ".", "OBJECTIVE", "To", "compare", "the", "clinical", "efficacy", "of", "alginate", "drug", "Geviskon", "and", "aluminum", "-", "magnesium", "antacids", "to", "relieve", "symptoms", "of", "esophageal", ",", "extraesophageal", "syndrome", "and", "functional", "dyspepsia", "at", "3", "and", "7", "days", "of", "study", "in", "patients", "with", "GERD", "elderly", ".", "MATERIALS", "AND", "METHODS", "An", "open", ",", "longitudinal", ",", "randomized", ",", "parallel", "-", "group", ".", "The", "study", "included", "60", "patients", "with", "\"", "A", "\"", "degree", "of", "ERD", ",", "consistently", "received", "in", "-", "patient", "treatment", "in", "the", "Municipal", "KGVV", ",", "mean", "age", "79.0", "+", "/-", "6.8", "years", ".", "During", "the", "first", "12", "hours", "of", "hospital", "stay", "by", "\"", "sealed", "envelopes", "\"", "them", "randomly", "divided", "into", "equal", "groups", "of", "comparison", ",", "given", "3", "times", "a", "day", ":", "alginate", "product", "--", "Geviskon", "forte", "dose", "of", "10", "ml", "and", "aluminum", "-", "magnesium", "antacid", "drug", "at", "a", "dose", "of", "1", "sachet", ".", "Assess", "the", "frequency", "and", "severity", "of", "esophageal", "symptoms", ",", "extraesophageal", "syndrome", ",", "functional", "dyspepsia", "at", "3", "and", "7", "days", "of", "study", "on", "5-point", "scale", "Likert", ".", "The", "degree", "of", "esophageal", "mucosal", "injury", "was", "determined", "during", "endoscopy", "before", "the", "study", ".", "RESULTS", "The", "technique", "of", "alginate", "compared", "with", "antacids", "provided", "significantly", "more", "complete", "and", "earlier", "effect", "on", "the", "relief", "of", "heartburn", ",", "regurgitation", ",", "chronic", "cough", ",", "sore", "throat", ",", "and", "EBS", ".", "Only", "Geviskon", "influenced", "the", "symptoms", "of", "PPD", "in", "patients", "with", "GERD", ".", "CONCLUSION", "The", "clinical", "features", "Geviskon", "the", "frequency", "and", "timing", "of", "relief", "of", "symptoms", "of", "esophageal", ",", "extraesophageal", "syndrome", ",", "functional", "dyspepsia", "with", "GERD", "in", "the", "older", "age", "groups", "is", "higher", "than", "that", "of", "antacids", ".", "Suspension", "Geviskon", "may", "be", "recommended", "in", "patients", "with", "middle", "and", "old", "age", "as", "an", "effective", "and", "safe", "symptomatic", "funds", "in", "the", "first", "days", "of", "exchange", "rate", "earlier", "generations", "of", "PPI", "therapy", ",", "as", "well", "as", "monotherapy", "--", "to", "maintain", "remission", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Condition" ]
gaviscon preparation, esophageal, functional dyspepsia, elderly patients with GERD ], Geviskon, aluminum - magnesium antacids, alginate product -- Geviskon forte dose of 10 ml, aluminum - magnesium antacid drug at a dose of 1 sachet, frequency, severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia, degree of esophageal mucosal injury, relief of heartburn , regurgitation , chronic cough , sore throat , and EBS .	49818_task2	Sentence: [ Using gaviscon preparation for relief of esophageal , extraesophageal syndromes and functional dyspepsia in elderly patients with GERD ] . OBJECTIVE To compare the clinical efficacy of alginate drug Geviskon and aluminum-magnesium antacids to relieve symptoms of esophageal , extraesophageal syndrome and functional dyspepsia at 3 and 7 days of study in patients with GERD elderly . MATERIALS AND METHODS An open , longitudinal , randomized , parallel-group . The study included 60 patients with " A " degree of ERD , consistently received in-patient treatment in the Municipal KGVV , mean age 79.0 +/- 6.8 years . During the first 12 hours of hospital stay by " sealed envelopes " them randomly divided into equal groups of comparison , given 3 times a day : alginate product -- Geviskon forte dose of 10 ml and aluminum-magnesium antacid drug at a dose of 1 sachet . Assess the frequency and severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia at 3 and 7 days of study on 5-point scale Likert . The degree of esophageal mucosal injury was determined during endoscopy before the study . RESULTS The technique of alginate compared with antacids provided significantly more complete and earlier effect on the relief of heartburn , regurgitation , chronic cough , sore throat , and EBS . Only Geviskon influenced the symptoms of PPD in patients with GERD . CONCLUSION The clinical features Geviskon the frequency and timing of relief of symptoms of esophageal , extraesophageal syndrome , functional dyspepsia with GERD in the older age groups is higher than that of antacids . Suspension Geviskon may be recommended in patients with middle and old age as an effective and safe symptomatic funds in the first days of exchange rate earlier generations of PPI therapy , as well as monotherapy -- to maintain remission . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	[ Using gaviscon preparation for relief of esophageal , extraesophageal syndromes and functional dyspepsia in elderly patients with GERD ] . OBJECTIVE To compare the clinical efficacy of alginate drug Geviskon and aluminum-magnesium antacids to relieve symptoms of esophageal , extraesophageal syndrome and functional dyspepsia at 3 and 7 days of study in patients with GERD elderly . MATERIALS AND METHODS An open , longitudinal , randomized , parallel-group . The study included 60 patients with " A " degree of ERD , consistently received in-patient treatment in the Municipal KGVV , mean age 79.0 +/- 6.8 years . During the first 12 hours of hospital stay by " sealed envelopes " them randomly divided into equal groups of comparison , given 3 times a day : alginate product -- Geviskon forte dose of 10 ml and aluminum-magnesium antacid drug at a dose of 1 sachet . Assess the frequency and severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia at 3 and 7 days of study on 5-point scale Likert . The degree of esophageal mucosal injury was determined during endoscopy before the study . RESULTS The technique of alginate compared with antacids provided significantly more complete and earlier effect on the relief of heartburn , regurgitation , chronic cough , sore throat , and EBS . Only Geviskon influenced the symptoms of PPD in patients with GERD . CONCLUSION The clinical features Geviskon the frequency and timing of relief of symptoms of esophageal , extraesophageal syndrome , functional dyspepsia with GERD in the older age groups is higher than that of antacids . Suspension Geviskon may be recommended in patients with middle and old age as an effective and safe symptomatic funds in the first days of exchange rate earlier generations of PPI therapy , as well as monotherapy -- to maintain remission .	[ "[", "Using", "gaviscon", "preparation", "for", "relief", "of", "esophageal", ",", "extraesophageal", "syndromes", "and", "functional", "dyspepsia", "in", "elderly", "patients", "with", "GERD", "]", ".", "OBJECTIVE", "To", "compare", "the", "clinical", "efficacy", "of", "alginate", "drug", "Geviskon", "and", "aluminum", "-", "magnesium", "antacids", "to", "relieve", "symptoms", "of", "esophageal", ",", "extraesophageal", "syndrome", "and", "functional", "dyspepsia", "at", "3", "and", "7", "days", "of", "study", "in", "patients", "with", "GERD", "elderly", ".", "MATERIALS", "AND", "METHODS", "An", "open", ",", "longitudinal", ",", "randomized", ",", "parallel", "-", "group", ".", "The", "study", "included", "60", "patients", "with", "\"", "A", "\"", "degree", "of", "ERD", ",", "consistently", "received", "in", "-", "patient", "treatment", "in", "the", "Municipal", "KGVV", ",", "mean", "age", "79.0", "+", "/-", "6.8", "years", ".", "During", "the", "first", "12", "hours", "of", "hospital", "stay", "by", "\"", "sealed", "envelopes", "\"", "them", "randomly", "divided", "into", "equal", "groups", "of", "comparison", ",", "given", "3", "times", "a", "day", ":", "alginate", "product", "--", "Geviskon", "forte", "dose", "of", "10", "ml", "and", "aluminum", "-", "magnesium", "antacid", "drug", "at", "a", "dose", "of", "1", "sachet", ".", "Assess", "the", "frequency", "and", "severity", "of", "esophageal", "symptoms", ",", "extraesophageal", "syndrome", ",", "functional", "dyspepsia", "at", "3", "and", "7", "days", "of", "study", "on", "5-point", "scale", "Likert", ".", "The", "degree", "of", "esophageal", "mucosal", "injury", "was", "determined", "during", "endoscopy", "before", "the", "study", ".", "RESULTS", "The", "technique", "of", "alginate", "compared", "with", "antacids", "provided", "significantly", "more", "complete", "and", "earlier", "effect", "on", "the", "relief", "of", "heartburn", ",", "regurgitation", ",", "chronic", "cough", ",", "sore", "throat", ",", "and", "EBS", ".", "Only", "Geviskon", "influenced", "the", "symptoms", "of", "PPD", "in", "patients", "with", "GERD", ".", "CONCLUSION", "The", "clinical", "features", "Geviskon", "the", "frequency", "and", "timing", "of", "relief", "of", "symptoms", "of", "esophageal", ",", "extraesophageal", "syndrome", ",", "functional", "dyspepsia", "with", "GERD", "in", "the", "older", "age", "groups", "is", "higher", "than", "that", "of", "antacids", ".", "Suspension", "Geviskon", "may", "be", "recommended", "in", "patients", "with", "middle", "and", "old", "age", "as", "an", "effective", "and", "safe", "symptomatic", "funds", "in", "the", "first", "days", "of", "exchange", "rate", "earlier", "generations", "of", "PPI", "therapy", ",", "as", "well", "as", "monotherapy", "--", "to", "maintain", "remission", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Condition" ]
Elena is a NOMBRE_SUJETO_ASISTENCIA, Justo Pascual is a NOMBRE_SUJETO_ASISTENCIA, 7401311 is a ID_SUJETO_ASISTENCIA, 47 16203430 65 is a ID_ASEGURAMIENTO, Calle Joaquin Vidal , 12 is a CALLE, Guadalajara is a TERRITORIO, 19001 is a TERRITORIO, 13/06/1939 is a FECHAS, España is a PAIS, 76 años is a EDAD_SUJETO_ASISTENCIA, 26/11/2015 is a FECHAS, Gabriel de Arriba is a NOMBRE_PERSONAL_SANITARIO, 19 19 87402 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, 76 años is a EDAD_SUJETO_ASISTENCIA, Gabriel de Arriba is a NOMBRE_PERSONAL_SANITARIO, Hospital Universitario de Guadalajara is a HOSPITAL, Universidad de Alcalá is a INSTITUCION, garribad@senefro.org is a CORREO_ELECTRONICO	114_task0	Sentence: Datos del paciente. Nombre: Elena. Apellidos: Justo Pascual. NHC: 7401311. NASS: 47 16203430 65. Domicilio: Calle Joaquin Vidal, 12. Localidad/ Provincia: Guadalajara. CP: 19001. Datos asistenciales. Fecha de nacimiento: 13/06/1939. País de nacimiento: España. Edad: 76 años Sexo: H. Fecha de Ingreso: 26/11/2015. Médico: Gabriel de Arriba NºCol: 19 19 87402. Informe clínico del paciente: Mujer de 76 años con antecedente de diabetes mellitus tipo 2, dislipemia y síndrome depresivo. Estaba en tratamiento con metformina 850 mg/8 horas, escitalopram 20 mg/24h, mirtazapina 30 mg/24 horas y simvastatina 40 mg/24 horas. En una analítica realizada seis meses antes tenía una Cr de 0,81 mg/dl. Dos semanas antes del ingreso comenzó tratamiento con ibuprofeno (600 mg/8 horas) por lumbalgia. Una semana antes tuvo náuseas, vómitos y diarrea, por lo que acudió a urgencias. En la exploración tenía sequedad de piel y mucosas y en la analítica la Cr plasmática fue de 9 mg/dl, glucosa de 189 mg/dl, urea de 196 mg/dl, hemoglobina de 10,9 g/dl, sodio de 125 mEq/l, potasio de 8,6 mEq/l y ácido láctico de 6,3 mmol/l. En la gasometría arterial tenía pH de 7,23 y bicarbonato de 15 mEq/l. Se realizó una ecografía abdominal en la que aparecía una ureterohidronefrosis bilateral por neoplasia vesical. Ante la inestabilidad hemodinámica de la paciente se realizó hemodiálisis durante dos horas, teniendo posteriormente una Cr de 5,9 mg/dl, potasio de 6,1 mEq/l, pH de 7,39 y bicarbonato de 22 mEq/l. Posteriormente se colocó nefrostomía bilateral con mejoría de cuadro clínico y normalización de cifras analíticas con Cr de 1,1 mg/dl, pH de 7,31 y bicarbonato de 23 mEq/l. Responsable clínico: Dr. Gabriel de Arriba, Sección de Nefrología, Hospital Universitario de Guadalajara. Departamento de Medicina. Universidad de Alcalá E-mail: garribad@senefro.org Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, INSTITUCION, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Elena. Apellidos: Justo Pascual. NHC: 7401311. NASS: 47 16203430 65. Domicilio: Calle Joaquin Vidal, 12. Localidad/ Provincia: Guadalajara. CP: 19001. Datos asistenciales. Fecha de nacimiento: 13/06/1939. País de nacimiento: España. Edad: 76 años Sexo: H. Fecha de Ingreso: 26/11/2015. Médico: Gabriel de Arriba NºCol: 19 19 87402. Informe clínico del paciente: Mujer de 76 años con antecedente de diabetes mellitus tipo 2, dislipemia y síndrome depresivo. Estaba en tratamiento con metformina 850 mg/8 horas, escitalopram 20 mg/24h, mirtazapina 30 mg/24 horas y simvastatina 40 mg/24 horas. En una analítica realizada seis meses antes tenía una Cr de 0,81 mg/dl. Dos semanas antes del ingreso comenzó tratamiento con ibuprofeno (600 mg/8 horas) por lumbalgia. Una semana antes tuvo náuseas, vómitos y diarrea, por lo que acudió a urgencias. En la exploración tenía sequedad de piel y mucosas y en la analítica la Cr plasmática fue de 9 mg/dl, glucosa de 189 mg/dl, urea de 196 mg/dl, hemoglobina de 10,9 g/dl, sodio de 125 mEq/l, potasio de 8,6 mEq/l y ácido láctico de 6,3 mmol/l. En la gasometría arterial tenía pH de 7,23 y bicarbonato de 15 mEq/l. Se realizó una ecografía abdominal en la que aparecía una ureterohidronefrosis bilateral por neoplasia vesical. Ante la inestabilidad hemodinámica de la paciente se realizó hemodiálisis durante dos horas, teniendo posteriormente una Cr de 5,9 mg/dl, potasio de 6,1 mEq/l, pH de 7,39 y bicarbonato de 22 mEq/l. Posteriormente se colocó nefrostomía bilateral con mejoría de cuadro clínico y normalización de cifras analíticas con Cr de 1,1 mg/dl, pH de 7,31 y bicarbonato de 23 mEq/l. Responsable clínico: Dr. Gabriel de Arriba, Sección de Nefrología, Hospital Universitario de Guadalajara. Departamento de Medicina. Universidad de Alcalá E-mail: garribad@senefro.org	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Elena", ".", "\n", "Apellidos", ":", "Justo", "Pascual", ".", "\n", "NHC", ":", "7401311", ".", "\n", "NASS", ":", "47", "16203430", "65", ".", "\n", "Domicilio", ":", "Calle", "Joaquin", "Vidal", ",", "12", ".", "\n", "Localidad/", "Provincia", ":", "Guadalajara", ".", "\n", "CP", ":", "19001", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "13/06/1939", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "76", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "26/11/2015", ".", "\n", "Médico", ":", "Gabriel", "de", "Arriba", "NºCol", ":", "19", "19", "87402", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "76", "años", "con", "antecedente", "de", "diabetes", "mellitus", "tipo", "2", ",", "dislipemia", "y", "síndrome", "depresivo", ".", "Estaba", "en", "tratamiento", "con", "metformina", "850", "mg/8", "horas", ",", "escitalopram", "20", "mg/24h", ",", "mirtazapina", "30", "mg/24", "horas", "y", "simvastatina", "40", "mg/24", "horas", ".", "En", "una", "analítica", "realizada", "seis", "meses", "antes", "tenía", "una", "Cr", "de", "0,81", "mg", "/", "dl", ".", "\n", "Dos", "semanas", "antes", "del", "ingreso", "comenzó", "tratamiento", "con", "ibuprofeno", "(", "600", "mg/8", "horas", ")", "por", "lumbalgia", ".", "Una", "semana", "antes", "tuvo", "náuseas", ",", "vómitos", "y", "diarrea", ",", "por", "lo", "que", "acudió", "a", "urgencias", ".", "En", "la", "exploración", "tenía", "sequedad", "de", "piel", "y", "mucosas", "y", "en", "la", "analítica", "la", "Cr", "plasmática", "fue", "de", "9", "mg", "/", "dl", ",", "glucosa", "de", "189", "mg", "/", "dl", ",", "urea", "de", "196", "mg", "/", "dl", ",", "hemoglobina", "de", "10,9", "g", "/", "dl", ",", "sodio", "de", "125", "mEq", "/", "l", ",", "potasio", "de", "8,6", "mEq", "/", "l", "y", "ácido", "láctico", "de", "6,3", "mmol", "/", "l.", "En", "la", "gasometría", "arterial", "tenía", "pH", "de", "7,23", "y", "bicarbonato", "de", "15", "mEq", "/", "l.", "Se", "realizó", "una", "ecografía", "abdominal", "en", "la", "que", "aparecía", "una", "ureterohidronefrosis", "bilateral", "por", "neoplasia", "vesical", ".", "Ante", "la", "inestabilidad", "hemodinámica", "de", "la", "paciente", "se", "realizó", "hemodiálisis", "durante", "dos", "horas", ",", "teniendo", "posteriormente", "una", "Cr", "de", "5,9", "mg", "/", "dl", ",", "potasio", "de", "6,1", "mEq", "/", "l", ",", "pH", "de", "7,39", "y", "bicarbonato", "de", "22", "mEq", "/", "l.", "Posteriormente", "se", "colocó", "nefrostomía", "bilateral", "con", "mejoría", "de", "cuadro", "clínico", "y", "normalización", "de", "cifras", "analíticas", "con", "Cr", "de", "1,1", "mg", "/", "dl", ",", "pH", "de", "7,31", "y", "bicarbonato", "de", "23", "mEq", "/", "l.", "\n", "Responsable", "clínico", ":", "Dr", ".", "Gabriel", "de", "Arriba", ",", "Sección", "de", "Nefrología", ",", "Hospital", "Universitario", "de", "Guadalajara", ".", "Departamento", "de", "Medicina", ".", "Universidad", "de", "Alcalá", "E", "-", "mail", ":", "garribad@senefro.org", "\n" ]	[ "HOSPITAL", "CALLE", "INSTITUCION", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "TERRITORIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Elena is a NOMBRE_SUJETO_ASISTENCIA, Justo Pascual is a NOMBRE_SUJETO_ASISTENCIA, 7401311 is a ID_SUJETO_ASISTENCIA, 47 16203430 65 is a ID_ASEGURAMIENTO, Calle Joaquin Vidal , 12 is a CALLE, Guadalajara is a TERRITORIO, 19001 is a TERRITORIO, 13/06/1939 is a FECHAS, España is a PAIS, 76 años is a EDAD_SUJETO_ASISTENCIA, 26/11/2015 is a FECHAS, Gabriel de Arriba is a NOMBRE_PERSONAL_SANITARIO, 19 19 87402 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, 76 años is a EDAD_SUJETO_ASISTENCIA, Gabriel de Arriba is a NOMBRE_PERSONAL_SANITARIO, Hospital Universitario de Guadalajara is a HOSPITAL, Universidad de Alcalá is a INSTITUCION, garribad@senefro.org is a CORREO_ELECTRONICO	114_task1	Sentence: Datos del paciente. Nombre: Elena. Apellidos: Justo Pascual. NHC: 7401311. NASS: 47 16203430 65. Domicilio: Calle Joaquin Vidal, 12. Localidad/ Provincia: Guadalajara. CP: 19001. Datos asistenciales. Fecha de nacimiento: 13/06/1939. País de nacimiento: España. Edad: 76 años Sexo: H. Fecha de Ingreso: 26/11/2015. Médico: Gabriel de Arriba NºCol: 19 19 87402. Informe clínico del paciente: Mujer de 76 años con antecedente de diabetes mellitus tipo 2, dislipemia y síndrome depresivo. Estaba en tratamiento con metformina 850 mg/8 horas, escitalopram 20 mg/24h, mirtazapina 30 mg/24 horas y simvastatina 40 mg/24 horas. En una analítica realizada seis meses antes tenía una Cr de 0,81 mg/dl. Dos semanas antes del ingreso comenzó tratamiento con ibuprofeno (600 mg/8 horas) por lumbalgia. Una semana antes tuvo náuseas, vómitos y diarrea, por lo que acudió a urgencias. En la exploración tenía sequedad de piel y mucosas y en la analítica la Cr plasmática fue de 9 mg/dl, glucosa de 189 mg/dl, urea de 196 mg/dl, hemoglobina de 10,9 g/dl, sodio de 125 mEq/l, potasio de 8,6 mEq/l y ácido láctico de 6,3 mmol/l. En la gasometría arterial tenía pH de 7,23 y bicarbonato de 15 mEq/l. Se realizó una ecografía abdominal en la que aparecía una ureterohidronefrosis bilateral por neoplasia vesical. Ante la inestabilidad hemodinámica de la paciente se realizó hemodiálisis durante dos horas, teniendo posteriormente una Cr de 5,9 mg/dl, potasio de 6,1 mEq/l, pH de 7,39 y bicarbonato de 22 mEq/l. Posteriormente se colocó nefrostomía bilateral con mejoría de cuadro clínico y normalización de cifras analíticas con Cr de 1,1 mg/dl, pH de 7,31 y bicarbonato de 23 mEq/l. Responsable clínico: Dr. Gabriel de Arriba, Sección de Nefrología, Hospital Universitario de Guadalajara. Departamento de Medicina. Universidad de Alcalá E-mail: garribad@senefro.org Instructions: please typing these entity words according to sentence: Elena, Justo Pascual, 7401311, 47 16203430 65, Calle Joaquin Vidal , 12, Guadalajara, 19001, 13/06/1939, España, 76 años, 26/11/2015, Gabriel de Arriba, 19 19 87402, Mujer, 76 años, Gabriel de Arriba, Hospital Universitario de Guadalajara, Universidad de Alcalá, garribad@senefro.org Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, INSTITUCION, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Elena. Apellidos: Justo Pascual. NHC: 7401311. NASS: 47 16203430 65. Domicilio: Calle Joaquin Vidal, 12. Localidad/ Provincia: Guadalajara. CP: 19001. Datos asistenciales. Fecha de nacimiento: 13/06/1939. País de nacimiento: España. Edad: 76 años Sexo: H. Fecha de Ingreso: 26/11/2015. Médico: Gabriel de Arriba NºCol: 19 19 87402. Informe clínico del paciente: Mujer de 76 años con antecedente de diabetes mellitus tipo 2, dislipemia y síndrome depresivo. Estaba en tratamiento con metformina 850 mg/8 horas, escitalopram 20 mg/24h, mirtazapina 30 mg/24 horas y simvastatina 40 mg/24 horas. En una analítica realizada seis meses antes tenía una Cr de 0,81 mg/dl. Dos semanas antes del ingreso comenzó tratamiento con ibuprofeno (600 mg/8 horas) por lumbalgia. Una semana antes tuvo náuseas, vómitos y diarrea, por lo que acudió a urgencias. En la exploración tenía sequedad de piel y mucosas y en la analítica la Cr plasmática fue de 9 mg/dl, glucosa de 189 mg/dl, urea de 196 mg/dl, hemoglobina de 10,9 g/dl, sodio de 125 mEq/l, potasio de 8,6 mEq/l y ácido láctico de 6,3 mmol/l. En la gasometría arterial tenía pH de 7,23 y bicarbonato de 15 mEq/l. Se realizó una ecografía abdominal en la que aparecía una ureterohidronefrosis bilateral por neoplasia vesical. Ante la inestabilidad hemodinámica de la paciente se realizó hemodiálisis durante dos horas, teniendo posteriormente una Cr de 5,9 mg/dl, potasio de 6,1 mEq/l, pH de 7,39 y bicarbonato de 22 mEq/l. Posteriormente se colocó nefrostomía bilateral con mejoría de cuadro clínico y normalización de cifras analíticas con Cr de 1,1 mg/dl, pH de 7,31 y bicarbonato de 23 mEq/l. Responsable clínico: Dr. Gabriel de Arriba, Sección de Nefrología, Hospital Universitario de Guadalajara. Departamento de Medicina. Universidad de Alcalá E-mail: garribad@senefro.org	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Elena", ".", "\n", "Apellidos", ":", "Justo", "Pascual", ".", "\n", "NHC", ":", "7401311", ".", "\n", "NASS", ":", "47", "16203430", "65", ".", "\n", "Domicilio", ":", "Calle", "Joaquin", "Vidal", ",", "12", ".", "\n", "Localidad/", "Provincia", ":", "Guadalajara", ".", "\n", "CP", ":", "19001", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "13/06/1939", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "76", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "26/11/2015", ".", "\n", "Médico", ":", "Gabriel", "de", "Arriba", "NºCol", ":", "19", "19", "87402", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "76", "años", "con", "antecedente", "de", "diabetes", "mellitus", "tipo", "2", ",", "dislipemia", "y", "síndrome", "depresivo", ".", "Estaba", "en", "tratamiento", "con", "metformina", "850", "mg/8", "horas", ",", "escitalopram", "20", "mg/24h", ",", "mirtazapina", "30", "mg/24", "horas", "y", "simvastatina", "40", "mg/24", "horas", ".", "En", "una", "analítica", "realizada", "seis", "meses", "antes", "tenía", "una", "Cr", "de", "0,81", "mg", "/", "dl", ".", "\n", "Dos", "semanas", "antes", "del", "ingreso", "comenzó", "tratamiento", "con", "ibuprofeno", "(", "600", "mg/8", "horas", ")", "por", "lumbalgia", ".", "Una", "semana", "antes", "tuvo", "náuseas", ",", "vómitos", "y", "diarrea", ",", "por", "lo", "que", "acudió", "a", "urgencias", ".", "En", "la", "exploración", "tenía", "sequedad", "de", "piel", "y", "mucosas", "y", "en", "la", "analítica", "la", "Cr", "plasmática", "fue", "de", "9", "mg", "/", "dl", ",", "glucosa", "de", "189", "mg", "/", "dl", ",", "urea", "de", "196", "mg", "/", "dl", ",", "hemoglobina", "de", "10,9", "g", "/", "dl", ",", "sodio", "de", "125", "mEq", "/", "l", ",", "potasio", "de", "8,6", "mEq", "/", "l", "y", "ácido", "láctico", "de", "6,3", "mmol", "/", "l.", "En", "la", "gasometría", "arterial", "tenía", "pH", "de", "7,23", "y", "bicarbonato", "de", "15", "mEq", "/", "l.", "Se", "realizó", "una", "ecografía", "abdominal", "en", "la", "que", "aparecía", "una", "ureterohidronefrosis", "bilateral", "por", "neoplasia", "vesical", ".", "Ante", "la", "inestabilidad", "hemodinámica", "de", "la", "paciente", "se", "realizó", "hemodiálisis", "durante", "dos", "horas", ",", "teniendo", "posteriormente", "una", "Cr", "de", "5,9", "mg", "/", "dl", ",", "potasio", "de", "6,1", "mEq", "/", "l", ",", "pH", "de", "7,39", "y", "bicarbonato", "de", "22", "mEq", "/", "l.", "Posteriormente", "se", "colocó", "nefrostomía", "bilateral", "con", "mejoría", "de", "cuadro", "clínico", "y", "normalización", "de", "cifras", "analíticas", "con", "Cr", "de", "1,1", "mg", "/", "dl", ",", "pH", "de", "7,31", "y", "bicarbonato", "de", "23", "mEq", "/", "l.", "\n", "Responsable", "clínico", ":", "Dr", ".", "Gabriel", "de", "Arriba", ",", "Sección", "de", "Nefrología", ",", "Hospital", "Universitario", "de", "Guadalajara", ".", "Departamento", "de", "Medicina", ".", "Universidad", "de", "Alcalá", "E", "-", "mail", ":", "garribad@senefro.org", "\n" ]	[ "HOSPITAL", "CALLE", "INSTITUCION", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "TERRITORIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Elena, Justo Pascual, 7401311, 47 16203430 65, Calle Joaquin Vidal , 12, Guadalajara, 19001, 13/06/1939, España, 76 años, 26/11/2015, Gabriel de Arriba, 19 19 87402, Mujer, 76 años, Gabriel de Arriba, Hospital Universitario de Guadalajara, Universidad de Alcalá, garribad@senefro.org	114_task2	Sentence: Datos del paciente. Nombre: Elena. Apellidos: Justo Pascual. NHC: 7401311. NASS: 47 16203430 65. Domicilio: Calle Joaquin Vidal, 12. Localidad/ Provincia: Guadalajara. CP: 19001. Datos asistenciales. Fecha de nacimiento: 13/06/1939. País de nacimiento: España. Edad: 76 años Sexo: H. Fecha de Ingreso: 26/11/2015. Médico: Gabriel de Arriba NºCol: 19 19 87402. Informe clínico del paciente: Mujer de 76 años con antecedente de diabetes mellitus tipo 2, dislipemia y síndrome depresivo. Estaba en tratamiento con metformina 850 mg/8 horas, escitalopram 20 mg/24h, mirtazapina 30 mg/24 horas y simvastatina 40 mg/24 horas. En una analítica realizada seis meses antes tenía una Cr de 0,81 mg/dl. Dos semanas antes del ingreso comenzó tratamiento con ibuprofeno (600 mg/8 horas) por lumbalgia. Una semana antes tuvo náuseas, vómitos y diarrea, por lo que acudió a urgencias. En la exploración tenía sequedad de piel y mucosas y en la analítica la Cr plasmática fue de 9 mg/dl, glucosa de 189 mg/dl, urea de 196 mg/dl, hemoglobina de 10,9 g/dl, sodio de 125 mEq/l, potasio de 8,6 mEq/l y ácido láctico de 6,3 mmol/l. En la gasometría arterial tenía pH de 7,23 y bicarbonato de 15 mEq/l. Se realizó una ecografía abdominal en la que aparecía una ureterohidronefrosis bilateral por neoplasia vesical. Ante la inestabilidad hemodinámica de la paciente se realizó hemodiálisis durante dos horas, teniendo posteriormente una Cr de 5,9 mg/dl, potasio de 6,1 mEq/l, pH de 7,39 y bicarbonato de 22 mEq/l. Posteriormente se colocó nefrostomía bilateral con mejoría de cuadro clínico y normalización de cifras analíticas con Cr de 1,1 mg/dl, pH de 7,31 y bicarbonato de 23 mEq/l. Responsable clínico: Dr. Gabriel de Arriba, Sección de Nefrología, Hospital Universitario de Guadalajara. Departamento de Medicina. Universidad de Alcalá E-mail: garribad@senefro.org Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Elena. Apellidos: Justo Pascual. NHC: 7401311. NASS: 47 16203430 65. Domicilio: Calle Joaquin Vidal, 12. Localidad/ Provincia: Guadalajara. CP: 19001. Datos asistenciales. Fecha de nacimiento: 13/06/1939. País de nacimiento: España. Edad: 76 años Sexo: H. Fecha de Ingreso: 26/11/2015. Médico: Gabriel de Arriba NºCol: 19 19 87402. Informe clínico del paciente: Mujer de 76 años con antecedente de diabetes mellitus tipo 2, dislipemia y síndrome depresivo. Estaba en tratamiento con metformina 850 mg/8 horas, escitalopram 20 mg/24h, mirtazapina 30 mg/24 horas y simvastatina 40 mg/24 horas. En una analítica realizada seis meses antes tenía una Cr de 0,81 mg/dl. Dos semanas antes del ingreso comenzó tratamiento con ibuprofeno (600 mg/8 horas) por lumbalgia. Una semana antes tuvo náuseas, vómitos y diarrea, por lo que acudió a urgencias. En la exploración tenía sequedad de piel y mucosas y en la analítica la Cr plasmática fue de 9 mg/dl, glucosa de 189 mg/dl, urea de 196 mg/dl, hemoglobina de 10,9 g/dl, sodio de 125 mEq/l, potasio de 8,6 mEq/l y ácido láctico de 6,3 mmol/l. En la gasometría arterial tenía pH de 7,23 y bicarbonato de 15 mEq/l. Se realizó una ecografía abdominal en la que aparecía una ureterohidronefrosis bilateral por neoplasia vesical. Ante la inestabilidad hemodinámica de la paciente se realizó hemodiálisis durante dos horas, teniendo posteriormente una Cr de 5,9 mg/dl, potasio de 6,1 mEq/l, pH de 7,39 y bicarbonato de 22 mEq/l. Posteriormente se colocó nefrostomía bilateral con mejoría de cuadro clínico y normalización de cifras analíticas con Cr de 1,1 mg/dl, pH de 7,31 y bicarbonato de 23 mEq/l. Responsable clínico: Dr. Gabriel de Arriba, Sección de Nefrología, Hospital Universitario de Guadalajara. Departamento de Medicina. Universidad de Alcalá E-mail: garribad@senefro.org	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Elena", ".", "\n", "Apellidos", ":", "Justo", "Pascual", ".", "\n", "NHC", ":", "7401311", ".", "\n", "NASS", ":", "47", "16203430", "65", ".", "\n", "Domicilio", ":", "Calle", "Joaquin", "Vidal", ",", "12", ".", "\n", "Localidad/", "Provincia", ":", "Guadalajara", ".", "\n", "CP", ":", "19001", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "13/06/1939", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "76", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "26/11/2015", ".", "\n", "Médico", ":", "Gabriel", "de", "Arriba", "NºCol", ":", "19", "19", "87402", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "76", "años", "con", "antecedente", "de", "diabetes", "mellitus", "tipo", "2", ",", "dislipemia", "y", "síndrome", "depresivo", ".", "Estaba", "en", "tratamiento", "con", "metformina", "850", "mg/8", "horas", ",", "escitalopram", "20", "mg/24h", ",", "mirtazapina", "30", "mg/24", "horas", "y", "simvastatina", "40", "mg/24", "horas", ".", "En", "una", "analítica", "realizada", "seis", "meses", "antes", "tenía", "una", "Cr", "de", "0,81", "mg", "/", "dl", ".", "\n", "Dos", "semanas", "antes", "del", "ingreso", "comenzó", "tratamiento", "con", "ibuprofeno", "(", "600", "mg/8", "horas", ")", "por", "lumbalgia", ".", "Una", "semana", "antes", "tuvo", "náuseas", ",", "vómitos", "y", "diarrea", ",", "por", "lo", "que", "acudió", "a", "urgencias", ".", "En", "la", "exploración", "tenía", "sequedad", "de", "piel", "y", "mucosas", "y", "en", "la", "analítica", "la", "Cr", "plasmática", "fue", "de", "9", "mg", "/", "dl", ",", "glucosa", "de", "189", "mg", "/", "dl", ",", "urea", "de", "196", "mg", "/", "dl", ",", "hemoglobina", "de", "10,9", "g", "/", "dl", ",", "sodio", "de", "125", "mEq", "/", "l", ",", "potasio", "de", "8,6", "mEq", "/", "l", "y", "ácido", "láctico", "de", "6,3", "mmol", "/", "l.", "En", "la", "gasometría", "arterial", "tenía", "pH", "de", "7,23", "y", "bicarbonato", "de", "15", "mEq", "/", "l.", "Se", "realizó", "una", "ecografía", "abdominal", "en", "la", "que", "aparecía", "una", "ureterohidronefrosis", "bilateral", "por", "neoplasia", "vesical", ".", "Ante", "la", "inestabilidad", "hemodinámica", "de", "la", "paciente", "se", "realizó", "hemodiálisis", "durante", "dos", "horas", ",", "teniendo", "posteriormente", "una", "Cr", "de", "5,9", "mg", "/", "dl", ",", "potasio", "de", "6,1", "mEq", "/", "l", ",", "pH", "de", "7,39", "y", "bicarbonato", "de", "22", "mEq", "/", "l.", "Posteriormente", "se", "colocó", "nefrostomía", "bilateral", "con", "mejoría", "de", "cuadro", "clínico", "y", "normalización", "de", "cifras", "analíticas", "con", "Cr", "de", "1,1", "mg", "/", "dl", ",", "pH", "de", "7,31", "y", "bicarbonato", "de", "23", "mEq", "/", "l.", "\n", "Responsable", "clínico", ":", "Dr", ".", "Gabriel", "de", "Arriba", ",", "Sección", "de", "Nefrología", ",", "Hospital", "Universitario", "de", "Guadalajara", ".", "Departamento", "de", "Medicina", ".", "Universidad", "de", "Alcalá", "E", "-", "mail", ":", "garribad@senefro.org", "\n" ]	[ "HOSPITAL", "CALLE", "INSTITUCION", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "TERRITORIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
pleomorphic adenoma is an umlsterm, parotid gland is an umlsterm, tumour is an umlsterm, congenital is an umlsterm, tumours is an umlsterm, salivary glands is an umlsterm, tumour is an umlsterm, tumour is an umlsterm, birth is an umlsterm, cellular structures is an umlsterm, classification is an umlsterm, malignant tumour is an umlsterm, tissue is an umlsterm, embryogenesis is an umlsterm, cell is an umlsterm, cell is an umlsterm, cell is an umlsterm, Differential diagnosis is an umlsterm, pleomorphic adenoma is an umlsterm, congenital is an umlsterm, salivary gland is an umlsterm, tumours is an umlsterm, congenital is an umlsterm, basal cell adenoma is an umlsterm, hybrid is an umlsterm, basal cell adenoma is an umlsterm, adenoid cystic carcinoma is an umlsterm, salivary gland is an umlsterm, tumour is an umlsterm	DerPathologe.80190286.eng.abstr_task0	Sentence: Juvenile pleomorphic adenoma of the parotid gland represents an extremely rare tumour entity and is comparable to congenital tumours of the salivary glands concerning its embryonal structure . The clinical detection of the tumour in a 7-year-old girl does not exclude that the tumour had developed either earlier or immediately after the birth . The high cellularity and the evidence of primitive epithelial and myoepithelial cellular structures do not justify its classification as a malignant tumour . However the presence of embryonal tissue structures associated with the end of the third month of embryogenesis is characterized by more solid cell formations in partly verticillate arrangement . The absence of further differentiation into lobular structures and differentiated duct or acinic cell formations may be due to cell arrest . Differential diagnosis of juvenile pleomorphic adenoma must distinguished it from other congenital salivary gland tumours ( e.g. congenital basal cell adenoma , hybrid basal cell adenoma - adenoid cystic carcinoma , sialoblastoma , salivary gland anlage tumour ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O" ]	Juvenile pleomorphic adenoma of the parotid gland represents an extremely rare tumour entity and is comparable to congenital tumours of the salivary glands concerning its embryonal structure . The clinical detection of the tumour in a 7-year-old girl does not exclude that the tumour had developed either earlier or immediately after the birth . The high cellularity and the evidence of primitive epithelial and myoepithelial cellular structures do not justify its classification as a malignant tumour . However the presence of embryonal tissue structures associated with the end of the third month of embryogenesis is characterized by more solid cell formations in partly verticillate arrangement . The absence of further differentiation into lobular structures and differentiated duct or acinic cell formations may be due to cell arrest . Differential diagnosis of juvenile pleomorphic adenoma must distinguished it from other congenital salivary gland tumours ( e.g. congenital basal cell adenoma , hybrid basal cell adenoma - adenoid cystic carcinoma , sialoblastoma , salivary gland anlage tumour ) .	[ "Juvenile", "pleomorphic", "adenoma", "of", "the", "parotid", "gland", "represents", "an", "extremely", "rare", "tumour", "entity", "and", "is", "comparable", "to", "congenital", "tumours", "of", "the", "salivary", "glands", "concerning", "its", "embryonal", "structure", ".", "The", "clinical", "detection", "of", "the", "tumour", "in", "a", "7-year", "-", "old", "girl", "does", "not", "exclude", "that", "the", "tumour", "had", "developed", "either", "earlier", "or", "immediately", "after", "the", "birth", ".", "The", "high", "cellularity", "and", "the", "evidence", "of", "primitive", "epithelial", "and", "myoepithelial", "cellular", "structures", "do", "not", "justify", "its", "classification", "as", "a", "malignant", "tumour", ".", "However", "the", "presence", "of", "embryonal", "tissue", "structures", "associated", "with", "the", "end", "of", "the", "third", "month", "of", "embryogenesis", "is", "characterized", "by", "more", "solid", "cell", "formations", "in", "partly", "verticillate", "arrangement", ".", "The", "absence", "of", "further", "differentiation", "into", "lobular", "structures", "and", "differentiated", "duct", "or", "acinic", "cell", "formations", "may", "be", "due", "to", "cell", "arrest", ".", "Differential", "diagnosis", "of", "juvenile", "pleomorphic", "adenoma", "must", "distinguished", "it", "from", "other", "congenital", "salivary", "gland", "tumours", "(", "e.g", ".", "congenital", "basal", "cell", "adenoma", ",", "hybrid", "basal", "cell", "adenoma", "-", "adenoid", "cystic", "carcinoma", ",", "sialoblastoma", ",", "salivary", "gland", "anlage", "tumour", ")", "." ]	[ "umlsterm" ]
pleomorphic adenoma is an umlsterm, parotid gland is an umlsterm, tumour is an umlsterm, congenital is an umlsterm, tumours is an umlsterm, salivary glands is an umlsterm, tumour is an umlsterm, tumour is an umlsterm, birth is an umlsterm, cellular structures is an umlsterm, classification is an umlsterm, malignant tumour is an umlsterm, tissue is an umlsterm, embryogenesis is an umlsterm, cell is an umlsterm, cell is an umlsterm, cell is an umlsterm, Differential diagnosis is an umlsterm, pleomorphic adenoma is an umlsterm, congenital is an umlsterm, salivary gland is an umlsterm, tumours is an umlsterm, congenital is an umlsterm, basal cell adenoma is an umlsterm, hybrid is an umlsterm, basal cell adenoma is an umlsterm, adenoid cystic carcinoma is an umlsterm, salivary gland is an umlsterm, tumour is an umlsterm	DerPathologe.80190286.eng.abstr_task1	Sentence: Juvenile pleomorphic adenoma of the parotid gland represents an extremely rare tumour entity and is comparable to congenital tumours of the salivary glands concerning its embryonal structure . The clinical detection of the tumour in a 7-year-old girl does not exclude that the tumour had developed either earlier or immediately after the birth . The high cellularity and the evidence of primitive epithelial and myoepithelial cellular structures do not justify its classification as a malignant tumour . However the presence of embryonal tissue structures associated with the end of the third month of embryogenesis is characterized by more solid cell formations in partly verticillate arrangement . The absence of further differentiation into lobular structures and differentiated duct or acinic cell formations may be due to cell arrest . Differential diagnosis of juvenile pleomorphic adenoma must distinguished it from other congenital salivary gland tumours ( e.g. congenital basal cell adenoma , hybrid basal cell adenoma - adenoid cystic carcinoma , sialoblastoma , salivary gland anlage tumour ) . Instructions: please typing these entity words according to sentence: pleomorphic adenoma, parotid gland, tumour, congenital, tumours, salivary glands, tumour, tumour, birth, cellular structures, classification, malignant tumour, tissue, embryogenesis, cell, cell, cell, Differential diagnosis, pleomorphic adenoma, congenital, salivary gland, tumours, congenital, basal cell adenoma, hybrid, basal cell adenoma, adenoid cystic carcinoma, salivary gland, tumour Options: umlsterm	[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O" ]	Juvenile pleomorphic adenoma of the parotid gland represents an extremely rare tumour entity and is comparable to congenital tumours of the salivary glands concerning its embryonal structure . The clinical detection of the tumour in a 7-year-old girl does not exclude that the tumour had developed either earlier or immediately after the birth . The high cellularity and the evidence of primitive epithelial and myoepithelial cellular structures do not justify its classification as a malignant tumour . However the presence of embryonal tissue structures associated with the end of the third month of embryogenesis is characterized by more solid cell formations in partly verticillate arrangement . The absence of further differentiation into lobular structures and differentiated duct or acinic cell formations may be due to cell arrest . Differential diagnosis of juvenile pleomorphic adenoma must distinguished it from other congenital salivary gland tumours ( e.g. congenital basal cell adenoma , hybrid basal cell adenoma - adenoid cystic carcinoma , sialoblastoma , salivary gland anlage tumour ) .	[ "Juvenile", "pleomorphic", "adenoma", "of", "the", "parotid", "gland", "represents", "an", "extremely", "rare", "tumour", "entity", "and", "is", "comparable", "to", "congenital", "tumours", "of", "the", "salivary", "glands", "concerning", "its", "embryonal", "structure", ".", "The", "clinical", "detection", "of", "the", "tumour", "in", "a", "7-year", "-", "old", "girl", "does", "not", "exclude", "that", "the", "tumour", "had", "developed", "either", "earlier", "or", "immediately", "after", "the", "birth", ".", "The", "high", "cellularity", "and", "the", "evidence", "of", "primitive", "epithelial", "and", "myoepithelial", "cellular", "structures", "do", "not", "justify", "its", "classification", "as", "a", "malignant", "tumour", ".", "However", "the", "presence", "of", "embryonal", "tissue", "structures", "associated", "with", "the", "end", "of", "the", "third", "month", "of", "embryogenesis", "is", "characterized", "by", "more", "solid", "cell", "formations", "in", "partly", "verticillate", "arrangement", ".", "The", "absence", "of", "further", "differentiation", "into", "lobular", "structures", "and", "differentiated", "duct", "or", "acinic", "cell", "formations", "may", "be", "due", "to", "cell", "arrest", ".", "Differential", "diagnosis", "of", "juvenile", "pleomorphic", "adenoma", "must", "distinguished", "it", "from", "other", "congenital", "salivary", "gland", "tumours", "(", "e.g", ".", "congenital", "basal", "cell", "adenoma", ",", "hybrid", "basal", "cell", "adenoma", "-", "adenoid", "cystic", "carcinoma", ",", "sialoblastoma", ",", "salivary", "gland", "anlage", "tumour", ")", "." ]	[ "umlsterm" ]
pleomorphic adenoma, parotid gland, tumour, congenital, tumours, salivary glands, tumour, tumour, birth, cellular structures, classification, malignant tumour, tissue, embryogenesis, cell, cell, cell, Differential diagnosis, pleomorphic adenoma, congenital, salivary gland, tumours, congenital, basal cell adenoma, hybrid, basal cell adenoma, adenoid cystic carcinoma, salivary gland, tumour	DerPathologe.80190286.eng.abstr_task2	Sentence: Juvenile pleomorphic adenoma of the parotid gland represents an extremely rare tumour entity and is comparable to congenital tumours of the salivary glands concerning its embryonal structure . The clinical detection of the tumour in a 7-year-old girl does not exclude that the tumour had developed either earlier or immediately after the birth . The high cellularity and the evidence of primitive epithelial and myoepithelial cellular structures do not justify its classification as a malignant tumour . However the presence of embryonal tissue structures associated with the end of the third month of embryogenesis is characterized by more solid cell formations in partly verticillate arrangement . The absence of further differentiation into lobular structures and differentiated duct or acinic cell formations may be due to cell arrest . Differential diagnosis of juvenile pleomorphic adenoma must distinguished it from other congenital salivary gland tumours ( e.g. congenital basal cell adenoma , hybrid basal cell adenoma - adenoid cystic carcinoma , sialoblastoma , salivary gland anlage tumour ) . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O" ]	Juvenile pleomorphic adenoma of the parotid gland represents an extremely rare tumour entity and is comparable to congenital tumours of the salivary glands concerning its embryonal structure . The clinical detection of the tumour in a 7-year-old girl does not exclude that the tumour had developed either earlier or immediately after the birth . The high cellularity and the evidence of primitive epithelial and myoepithelial cellular structures do not justify its classification as a malignant tumour . However the presence of embryonal tissue structures associated with the end of the third month of embryogenesis is characterized by more solid cell formations in partly verticillate arrangement . The absence of further differentiation into lobular structures and differentiated duct or acinic cell formations may be due to cell arrest . Differential diagnosis of juvenile pleomorphic adenoma must distinguished it from other congenital salivary gland tumours ( e.g. congenital basal cell adenoma , hybrid basal cell adenoma - adenoid cystic carcinoma , sialoblastoma , salivary gland anlage tumour ) .	[ "Juvenile", "pleomorphic", "adenoma", "of", "the", "parotid", "gland", "represents", "an", "extremely", "rare", "tumour", "entity", "and", "is", "comparable", "to", "congenital", "tumours", "of", "the", "salivary", "glands", "concerning", "its", "embryonal", "structure", ".", "The", "clinical", "detection", "of", "the", "tumour", "in", "a", "7-year", "-", "old", "girl", "does", "not", "exclude", "that", "the", "tumour", "had", "developed", "either", "earlier", "or", "immediately", "after", "the", "birth", ".", "The", "high", "cellularity", "and", "the", "evidence", "of", "primitive", "epithelial", "and", "myoepithelial", "cellular", "structures", "do", "not", "justify", "its", "classification", "as", "a", "malignant", "tumour", ".", "However", "the", "presence", "of", "embryonal", "tissue", "structures", "associated", "with", "the", "end", "of", "the", "third", "month", "of", "embryogenesis", "is", "characterized", "by", "more", "solid", "cell", "formations", "in", "partly", "verticillate", "arrangement", ".", "The", "absence", "of", "further", "differentiation", "into", "lobular", "structures", "and", "differentiated", "duct", "or", "acinic", "cell", "formations", "may", "be", "due", "to", "cell", "arrest", ".", "Differential", "diagnosis", "of", "juvenile", "pleomorphic", "adenoma", "must", "distinguished", "it", "from", "other", "congenital", "salivary", "gland", "tumours", "(", "e.g", ".", "congenital", "basal", "cell", "adenoma", ",", "hybrid", "basal", "cell", "adenoma", "-", "adenoid", "cystic", "carcinoma", ",", "sialoblastoma", ",", "salivary", "gland", "anlage", "tumour", ")", "." ]	[ "umlsterm" ]
Elektronenstrahltomographie is an umlsterm, Herzdiagnostik is an umlsterm, Methoden is an umlsterm, Methode is an umlsterm, Diagnostik is an umlsterm, Stenosen is an umlsterm, Injektion is an umlsterm, Roentgenkontrastmittel is an umlsterm, Elektronenstrahltomographie is an umlsterm, Methoden is an umlsterm, Myokardperfusion is an umlsterm, Elektronenstrahltomographie is an umlsterm	ZfuerKardiologie.0089vii11.ger.abstr_task0	Sentence: Mit der Elektronenstrahltomographie steht ein nichtinvasives Schnittbildverfahren fuer die Herzdiagnostik zur Verfuegung , das insbesondere neue Einblicke in die Erkrankungen der Herzkranzgefaesse gestattet . Durch Quantifizierung koronararterieller Verkalkungen kann eine schnelle , wenig belastende und kostenguenstige Einschaetzung des koronaren Risikos geleistet werden , die bisherige Methoden an prognostischer Aussagekraft deutlich uebertrifft . Als Methode zur nichtinvasiven Diagnostik koronararterieller Stenosen unter periphervenoeser Injektion von Roentgenkontrastmittel erreicht die Elektronenstrahltomographie hoehere Testqualitaeten als bisher verfuegbare nichtinvasive Methoden . Die Quantifizierung der Myokardperfusion stellt insbesondere als Belastungsuntersuchung eine realistische Alternative zu anderen Perfusionsuntersuchungen dar . Die hohe zeitliche Aufloesung der Elektronenstrahltomographie gestattet ausserdem eine akkurate Erfassung der kardialen Bewegungsablaeufe . Zusaetzliche Indikationen bestehen in der Abklaerung kardialer Raumforderungen , perikardialer Erkrankungen sowie in der Untersuchung der grossen Gefaesse . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mit der Elektronenstrahltomographie steht ein nichtinvasives Schnittbildverfahren fuer die Herzdiagnostik zur Verfuegung , das insbesondere neue Einblicke in die Erkrankungen der Herzkranzgefaesse gestattet . Durch Quantifizierung koronararterieller Verkalkungen kann eine schnelle , wenig belastende und kostenguenstige Einschaetzung des koronaren Risikos geleistet werden , die bisherige Methoden an prognostischer Aussagekraft deutlich uebertrifft . Als Methode zur nichtinvasiven Diagnostik koronararterieller Stenosen unter periphervenoeser Injektion von Roentgenkontrastmittel erreicht die Elektronenstrahltomographie hoehere Testqualitaeten als bisher verfuegbare nichtinvasive Methoden . Die Quantifizierung der Myokardperfusion stellt insbesondere als Belastungsuntersuchung eine realistische Alternative zu anderen Perfusionsuntersuchungen dar . Die hohe zeitliche Aufloesung der Elektronenstrahltomographie gestattet ausserdem eine akkurate Erfassung der kardialen Bewegungsablaeufe . Zusaetzliche Indikationen bestehen in der Abklaerung kardialer Raumforderungen , perikardialer Erkrankungen sowie in der Untersuchung der grossen Gefaesse .	[ "Mit", "der", "Elektronenstrahltomographie", "steht", "ein", "nichtinvasives", "Schnittbildverfahren", "fuer", "die", "Herzdiagnostik", "zur", "Verfuegung", ",", "das", "insbesondere", "neue", "Einblicke", "in", "die", "Erkrankungen", "der", "Herzkranzgefaesse", "gestattet", ".", "Durch", "Quantifizierung", "koronararterieller", "Verkalkungen", "kann", "eine", "schnelle", ",", "wenig", "belastende", "und", "kostenguenstige", "Einschaetzung", "des", "koronaren", "Risikos", "geleistet", "werden", ",", "die", "bisherige", "Methoden", "an", "prognostischer", "Aussagekraft", "deutlich", "uebertrifft", ".", "Als", "Methode", "zur", "nichtinvasiven", "Diagnostik", "koronararterieller", "Stenosen", "unter", "periphervenoeser", "Injektion", "von", "Roentgenkontrastmittel", "erreicht", "die", "Elektronenstrahltomographie", "hoehere", "Testqualitaeten", "als", "bisher", "verfuegbare", "nichtinvasive", "Methoden", ".", "Die", "Quantifizierung", "der", "Myokardperfusion", "stellt", "insbesondere", "als", "Belastungsuntersuchung", "eine", "realistische", "Alternative", "zu", "anderen", "Perfusionsuntersuchungen", "dar", ".", "Die", "hohe", "zeitliche", "Aufloesung", "der", "Elektronenstrahltomographie", "gestattet", "ausserdem", "eine", "akkurate", "Erfassung", "der", "kardialen", "Bewegungsablaeufe", ".", "Zusaetzliche", "Indikationen", "bestehen", "in", "der", "Abklaerung", "kardialer", "Raumforderungen", ",", "perikardialer", "Erkrankungen", "sowie", "in", "der", "Untersuchung", "der", "grossen", "Gefaesse", "." ]	[ "umlsterm" ]
Elektronenstrahltomographie is an umlsterm, Herzdiagnostik is an umlsterm, Methoden is an umlsterm, Methode is an umlsterm, Diagnostik is an umlsterm, Stenosen is an umlsterm, Injektion is an umlsterm, Roentgenkontrastmittel is an umlsterm, Elektronenstrahltomographie is an umlsterm, Methoden is an umlsterm, Myokardperfusion is an umlsterm, Elektronenstrahltomographie is an umlsterm	ZfuerKardiologie.0089vii11.ger.abstr_task1	Sentence: Mit der Elektronenstrahltomographie steht ein nichtinvasives Schnittbildverfahren fuer die Herzdiagnostik zur Verfuegung , das insbesondere neue Einblicke in die Erkrankungen der Herzkranzgefaesse gestattet . Durch Quantifizierung koronararterieller Verkalkungen kann eine schnelle , wenig belastende und kostenguenstige Einschaetzung des koronaren Risikos geleistet werden , die bisherige Methoden an prognostischer Aussagekraft deutlich uebertrifft . Als Methode zur nichtinvasiven Diagnostik koronararterieller Stenosen unter periphervenoeser Injektion von Roentgenkontrastmittel erreicht die Elektronenstrahltomographie hoehere Testqualitaeten als bisher verfuegbare nichtinvasive Methoden . Die Quantifizierung der Myokardperfusion stellt insbesondere als Belastungsuntersuchung eine realistische Alternative zu anderen Perfusionsuntersuchungen dar . Die hohe zeitliche Aufloesung der Elektronenstrahltomographie gestattet ausserdem eine akkurate Erfassung der kardialen Bewegungsablaeufe . Zusaetzliche Indikationen bestehen in der Abklaerung kardialer Raumforderungen , perikardialer Erkrankungen sowie in der Untersuchung der grossen Gefaesse . Instructions: please typing these entity words according to sentence: Elektronenstrahltomographie, Herzdiagnostik, Methoden, Methode, Diagnostik, Stenosen, Injektion, Roentgenkontrastmittel, Elektronenstrahltomographie, Methoden, Myokardperfusion, Elektronenstrahltomographie Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mit der Elektronenstrahltomographie steht ein nichtinvasives Schnittbildverfahren fuer die Herzdiagnostik zur Verfuegung , das insbesondere neue Einblicke in die Erkrankungen der Herzkranzgefaesse gestattet . Durch Quantifizierung koronararterieller Verkalkungen kann eine schnelle , wenig belastende und kostenguenstige Einschaetzung des koronaren Risikos geleistet werden , die bisherige Methoden an prognostischer Aussagekraft deutlich uebertrifft . Als Methode zur nichtinvasiven Diagnostik koronararterieller Stenosen unter periphervenoeser Injektion von Roentgenkontrastmittel erreicht die Elektronenstrahltomographie hoehere Testqualitaeten als bisher verfuegbare nichtinvasive Methoden . Die Quantifizierung der Myokardperfusion stellt insbesondere als Belastungsuntersuchung eine realistische Alternative zu anderen Perfusionsuntersuchungen dar . Die hohe zeitliche Aufloesung der Elektronenstrahltomographie gestattet ausserdem eine akkurate Erfassung der kardialen Bewegungsablaeufe . Zusaetzliche Indikationen bestehen in der Abklaerung kardialer Raumforderungen , perikardialer Erkrankungen sowie in der Untersuchung der grossen Gefaesse .	[ "Mit", "der", "Elektronenstrahltomographie", "steht", "ein", "nichtinvasives", "Schnittbildverfahren", "fuer", "die", "Herzdiagnostik", "zur", "Verfuegung", ",", "das", "insbesondere", "neue", "Einblicke", "in", "die", "Erkrankungen", "der", "Herzkranzgefaesse", "gestattet", ".", "Durch", "Quantifizierung", "koronararterieller", "Verkalkungen", "kann", "eine", "schnelle", ",", "wenig", "belastende", "und", "kostenguenstige", "Einschaetzung", "des", "koronaren", "Risikos", "geleistet", "werden", ",", "die", "bisherige", "Methoden", "an", "prognostischer", "Aussagekraft", "deutlich", "uebertrifft", ".", "Als", "Methode", "zur", "nichtinvasiven", "Diagnostik", "koronararterieller", "Stenosen", "unter", "periphervenoeser", "Injektion", "von", "Roentgenkontrastmittel", "erreicht", "die", "Elektronenstrahltomographie", "hoehere", "Testqualitaeten", "als", "bisher", "verfuegbare", "nichtinvasive", "Methoden", ".", "Die", "Quantifizierung", "der", "Myokardperfusion", "stellt", "insbesondere", "als", "Belastungsuntersuchung", "eine", "realistische", "Alternative", "zu", "anderen", "Perfusionsuntersuchungen", "dar", ".", "Die", "hohe", "zeitliche", "Aufloesung", "der", "Elektronenstrahltomographie", "gestattet", "ausserdem", "eine", "akkurate", "Erfassung", "der", "kardialen", "Bewegungsablaeufe", ".", "Zusaetzliche", "Indikationen", "bestehen", "in", "der", "Abklaerung", "kardialer", "Raumforderungen", ",", "perikardialer", "Erkrankungen", "sowie", "in", "der", "Untersuchung", "der", "grossen", "Gefaesse", "." ]	[ "umlsterm" ]
Elektronenstrahltomographie, Herzdiagnostik, Methoden, Methode, Diagnostik, Stenosen, Injektion, Roentgenkontrastmittel, Elektronenstrahltomographie, Methoden, Myokardperfusion, Elektronenstrahltomographie	ZfuerKardiologie.0089vii11.ger.abstr_task2	Sentence: Mit der Elektronenstrahltomographie steht ein nichtinvasives Schnittbildverfahren fuer die Herzdiagnostik zur Verfuegung , das insbesondere neue Einblicke in die Erkrankungen der Herzkranzgefaesse gestattet . Durch Quantifizierung koronararterieller Verkalkungen kann eine schnelle , wenig belastende und kostenguenstige Einschaetzung des koronaren Risikos geleistet werden , die bisherige Methoden an prognostischer Aussagekraft deutlich uebertrifft . Als Methode zur nichtinvasiven Diagnostik koronararterieller Stenosen unter periphervenoeser Injektion von Roentgenkontrastmittel erreicht die Elektronenstrahltomographie hoehere Testqualitaeten als bisher verfuegbare nichtinvasive Methoden . Die Quantifizierung der Myokardperfusion stellt insbesondere als Belastungsuntersuchung eine realistische Alternative zu anderen Perfusionsuntersuchungen dar . Die hohe zeitliche Aufloesung der Elektronenstrahltomographie gestattet ausserdem eine akkurate Erfassung der kardialen Bewegungsablaeufe . Zusaetzliche Indikationen bestehen in der Abklaerung kardialer Raumforderungen , perikardialer Erkrankungen sowie in der Untersuchung der grossen Gefaesse . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mit der Elektronenstrahltomographie steht ein nichtinvasives Schnittbildverfahren fuer die Herzdiagnostik zur Verfuegung , das insbesondere neue Einblicke in die Erkrankungen der Herzkranzgefaesse gestattet . Durch Quantifizierung koronararterieller Verkalkungen kann eine schnelle , wenig belastende und kostenguenstige Einschaetzung des koronaren Risikos geleistet werden , die bisherige Methoden an prognostischer Aussagekraft deutlich uebertrifft . Als Methode zur nichtinvasiven Diagnostik koronararterieller Stenosen unter periphervenoeser Injektion von Roentgenkontrastmittel erreicht die Elektronenstrahltomographie hoehere Testqualitaeten als bisher verfuegbare nichtinvasive Methoden . Die Quantifizierung der Myokardperfusion stellt insbesondere als Belastungsuntersuchung eine realistische Alternative zu anderen Perfusionsuntersuchungen dar . Die hohe zeitliche Aufloesung der Elektronenstrahltomographie gestattet ausserdem eine akkurate Erfassung der kardialen Bewegungsablaeufe . Zusaetzliche Indikationen bestehen in der Abklaerung kardialer Raumforderungen , perikardialer Erkrankungen sowie in der Untersuchung der grossen Gefaesse .	[ "Mit", "der", "Elektronenstrahltomographie", "steht", "ein", "nichtinvasives", "Schnittbildverfahren", "fuer", "die", "Herzdiagnostik", "zur", "Verfuegung", ",", "das", "insbesondere", "neue", "Einblicke", "in", "die", "Erkrankungen", "der", "Herzkranzgefaesse", "gestattet", ".", "Durch", "Quantifizierung", "koronararterieller", "Verkalkungen", "kann", "eine", "schnelle", ",", "wenig", "belastende", "und", "kostenguenstige", "Einschaetzung", "des", "koronaren", "Risikos", "geleistet", "werden", ",", "die", "bisherige", "Methoden", "an", "prognostischer", "Aussagekraft", "deutlich", "uebertrifft", ".", "Als", "Methode", "zur", "nichtinvasiven", "Diagnostik", "koronararterieller", "Stenosen", "unter", "periphervenoeser", "Injektion", "von", "Roentgenkontrastmittel", "erreicht", "die", "Elektronenstrahltomographie", "hoehere", "Testqualitaeten", "als", "bisher", "verfuegbare", "nichtinvasive", "Methoden", ".", "Die", "Quantifizierung", "der", "Myokardperfusion", "stellt", "insbesondere", "als", "Belastungsuntersuchung", "eine", "realistische", "Alternative", "zu", "anderen", "Perfusionsuntersuchungen", "dar", ".", "Die", "hohe", "zeitliche", "Aufloesung", "der", "Elektronenstrahltomographie", "gestattet", "ausserdem", "eine", "akkurate", "Erfassung", "der", "kardialen", "Bewegungsablaeufe", ".", "Zusaetzliche", "Indikationen", "bestehen", "in", "der", "Abklaerung", "kardialer", "Raumforderungen", ",", "perikardialer", "Erkrankungen", "sowie", "in", "der", "Untersuchung", "der", "grossen", "Gefaesse", "." ]	[ "umlsterm" ]
interferon regulatory factor-1 is a protein_molecule, NF kappa B is a protein_molecule, Sp1 is a protein_molecule, transcription factors is a protein_family_or_group	100169_task0	Sentence: Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF kappa B, and Sp1 transcription factors. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_family_or_group, protein_molecule	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_molecule", "B-protein_family_or_group", "I-protein_family_or_group", "O" ]	Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF kappa B, and Sp1 transcription factors.	[ "Triggering", "of", "the", "human", "interleukin-6", "gene", "by", "interferon", "-", "gamma", "and", "tumor", "necrosis", "factor", "-", "alpha", "in", "monocytic", "cells", "involves", "cooperation", "between", "interferon", "regulatory", "factor-1", ",", "NF", "kappa", "B", ",", "and", "Sp1", "transcription", "factors", "." ]	[ "DNA_domain_or_region", "protein_molecule", "protein_complex", "protein_family_or_group", "other_name", "cell_type", "lipid" ]
interferon regulatory factor-1 is a protein_molecule, NF kappa B is a protein_molecule, Sp1 is a protein_molecule, transcription factors is a protein_family_or_group	100169_task1	Sentence: Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF kappa B, and Sp1 transcription factors. Instructions: please typing these entity words according to sentence: interferon regulatory factor-1, NF kappa B, Sp1, transcription factors Options: protein_family_or_group, protein_molecule	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_molecule", "B-protein_family_or_group", "I-protein_family_or_group", "O" ]	Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF kappa B, and Sp1 transcription factors.	[ "Triggering", "of", "the", "human", "interleukin-6", "gene", "by", "interferon", "-", "gamma", "and", "tumor", "necrosis", "factor", "-", "alpha", "in", "monocytic", "cells", "involves", "cooperation", "between", "interferon", "regulatory", "factor-1", ",", "NF", "kappa", "B", ",", "and", "Sp1", "transcription", "factors", "." ]	[ "DNA_domain_or_region", "protein_molecule", "protein_complex", "protein_family_or_group", "other_name", "cell_type", "lipid" ]
interferon regulatory factor-1, NF kappa B, Sp1, transcription factors	100169_task2	Sentence: Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF kappa B, and Sp1 transcription factors. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_molecule", "B-protein_family_or_group", "I-protein_family_or_group", "O" ]	Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF kappa B, and Sp1 transcription factors.	[ "Triggering", "of", "the", "human", "interleukin-6", "gene", "by", "interferon", "-", "gamma", "and", "tumor", "necrosis", "factor", "-", "alpha", "in", "monocytic", "cells", "involves", "cooperation", "between", "interferon", "regulatory", "factor-1", ",", "NF", "kappa", "B", ",", "and", "Sp1", "transcription", "factors", "." ]	[ "DNA_domain_or_region", "protein_molecule", "protein_complex", "protein_family_or_group", "other_name", "cell_type", "lipid" ]
HIV is a Condition, controlled is a Qualifier, at least 12 weeks is a Temporal, Viral load is a Measurement, < 200 copies is a Value, BMI is a Person, > 27 to 45 is a Value, DM type 2 is a Condition, A1-C is a Measurement, > 7 to 15 is a Value	NCT02743598_inc_task0	Sentence: HIV controlled on therapy for at least 12 weeks Viral load < 200 copies BMI >27 to 45 Diagnosis of DM type 2 with A1-C >7 to 15 Participants must be willing to comply with all study related procedures Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Person, Measurement	[ "B-Condition", "B-Qualifier", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	HIV controlled on therapy for at least 12 weeks Viral load < 200 copies BMI >27 to 45 Diagnosis of DM type 2 with A1-C >7 to 15 Participants must be willing to comply with all study related procedures	[ "HIV", "controlled", "on", "therapy", "for", "at", "least", "12", "weeks", "\n", "Viral", "load", "<", "200", "copies", "\n", "BMI", ">", "27", "to", "45", "\n", "Diagnosis", "of", "DM", "type", "2", "with", "A1-C", ">", "7", "to", "15", "\n", "Participants", "must", "be", "willing", "to", "comply", "with", "all", "study", "related", "procedures", "\n" ]	[ "Temporal", "Value", "Qualifier", "Measurement", "Condition", "Person" ]
HIV is a Condition, controlled is a Qualifier, at least 12 weeks is a Temporal, Viral load is a Measurement, < 200 copies is a Value, BMI is a Person, > 27 to 45 is a Value, DM type 2 is a Condition, A1-C is a Measurement, > 7 to 15 is a Value	NCT02743598_inc_task1	Sentence: HIV controlled on therapy for at least 12 weeks Viral load < 200 copies BMI >27 to 45 Diagnosis of DM type 2 with A1-C >7 to 15 Participants must be willing to comply with all study related procedures Instructions: please typing these entity words according to sentence: HIV, controlled, at least 12 weeks, Viral load, < 200 copies, BMI, > 27 to 45, DM type 2, A1-C, > 7 to 15 Options: Temporal, Condition, Qualifier, Value, Person, Measurement	[ "B-Condition", "B-Qualifier", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	HIV controlled on therapy for at least 12 weeks Viral load < 200 copies BMI >27 to 45 Diagnosis of DM type 2 with A1-C >7 to 15 Participants must be willing to comply with all study related procedures	[ "HIV", "controlled", "on", "therapy", "for", "at", "least", "12", "weeks", "\n", "Viral", "load", "<", "200", "copies", "\n", "BMI", ">", "27", "to", "45", "\n", "Diagnosis", "of", "DM", "type", "2", "with", "A1-C", ">", "7", "to", "15", "\n", "Participants", "must", "be", "willing", "to", "comply", "with", "all", "study", "related", "procedures", "\n" ]	[ "Temporal", "Value", "Qualifier", "Measurement", "Condition", "Person" ]
HIV, controlled, at least 12 weeks, Viral load, < 200 copies, BMI, > 27 to 45, DM type 2, A1-C, > 7 to 15	NCT02743598_inc_task2	Sentence: HIV controlled on therapy for at least 12 weeks Viral load < 200 copies BMI >27 to 45 Diagnosis of DM type 2 with A1-C >7 to 15 Participants must be willing to comply with all study related procedures Instructions: please extract entity words from the input sentence	[ "B-Condition", "B-Qualifier", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	HIV controlled on therapy for at least 12 weeks Viral load < 200 copies BMI >27 to 45 Diagnosis of DM type 2 with A1-C >7 to 15 Participants must be willing to comply with all study related procedures	[ "HIV", "controlled", "on", "therapy", "for", "at", "least", "12", "weeks", "\n", "Viral", "load", "<", "200", "copies", "\n", "BMI", ">", "27", "to", "45", "\n", "Diagnosis", "of", "DM", "type", "2", "with", "A1-C", ">", "7", "to", "15", "\n", "Participants", "must", "be", "willing", "to", "comply", "with", "all", "study", "related", "procedures", "\n" ]	[ "Temporal", "Value", "Qualifier", "Measurement", "Condition", "Person" ]
ST6GalNAc I is a Protein, ST6GalNAc I is a Protein, ST6GalNAc I is a Protein, ST6GalNAc I is a Protein, ST6GalNAc I is a Protein	172_task0	Sentence: ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Sialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Sialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells.	[ "ST6GalNAc", "I", "expression", "in", "MDA", "-", "MB-231", "breast", "cancer", "cells", "greatly", "modifies", "their", "O", "-", "glycosylation", "pattern", "and", "enhances", "their", "tumourigenicity", ".", "\n", "Sialyl", "-", "Tn", "is", "a", "carbohydrate", "antigen", "overexpressed", "in", "several", "epithelial", "cancers", ",", "including", "breast", "cancer", ",", "and", "usually", "associated", "with", "poor", "prognosis", ".", "Sialyl", "-", "Tn", "is", "synthesized", "by", "a", "CMP", "-", "Neu5Ac", ":", "GalNAcalpha2,6-sialyltransferase", ":", "CMP", "-", "Neu5Ac", ":", "R", "-", "GalNAcalpha1-O", "-", "Ser", "/", "Thr", "alpha2,6-sialyltransferase", "(", "EC", "2.4.99.3", ")", "(", "ST6GalNAc", "I", ")", ",", "which", "transfers", "a", "sialic", "acid", "residue", "in", "alpha2,6-linkage", "to", "the", "GalNAcalpha1-O", "-", "Ser", "/", "Thr", "structure", ".", "However", ",", "established", "breast", "cancer", "cell", "lines", "express", "neither", "ST6GalNAc", "I", "nor", "sialyl", "-", "Tn", ".", "We", "have", "previously", "shown", "that", "stable", "transfection", "of", "MDA", "-", "MB-231", ",", "a", "human", "breast", "cancer", "cell", "line", ",", "with", "ST6GalNAc", "I", "cDNA", "induces", "sialyl", "-", "Tn", "antigen", "(", "STn", ")", "expression", ".", "We", "report", "here", "the", "modifications", "of", "the", "O", "-", "glycosylation", "pattern", "of", "a", "MUC1-related", "recombinant", "protein", "secreted", "by", "MDA", "-", "MB-231", "sialyl", "-", "Tn", "positive", "cells", ".", "We", "also", "show", "that", "sialyl", "-", "Tn", "expression", "and", "concomitant", "changes", "in", "the", "overall", "O", "-", "glycan", "profiles", "induce", "a", "decrease", "of", "adhesion", "and", "an", "increase", "of", "migration", "of", "MDA", "-", "MB-231", ".", "Moreover", ",", "STn", "positive", "clones", "exhibit", "an", "increased", "tumour", "growth", "in", "severe", "combined", "immunodeficiency", "(", "SCID", ")", "mice", ".", "These", "observations", "suggest", "that", "modification", "of", "the", "O", "-", "glycosylation", "pattern", "induced", "by", "ST6GalNAc", "I", "expression", "are", "sufficient", "to", "enhance", "the", "tumourigenicity", "of", "MDA", "-", "MB-231", "breast", "cancer", "cells", ".", "\n" ]	[ "Protein" ]
ST6GalNAc I is a Protein, ST6GalNAc I is a Protein, ST6GalNAc I is a Protein, ST6GalNAc I is a Protein, ST6GalNAc I is a Protein	172_task1	Sentence: ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Sialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells. Instructions: please typing these entity words according to sentence: ST6GalNAc I, ST6GalNAc I, ST6GalNAc I, ST6GalNAc I, ST6GalNAc I Options: Protein	[ "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Sialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells.	[ "ST6GalNAc", "I", "expression", "in", "MDA", "-", "MB-231", "breast", "cancer", "cells", "greatly", "modifies", "their", "O", "-", "glycosylation", "pattern", "and", "enhances", "their", "tumourigenicity", ".", "\n", "Sialyl", "-", "Tn", "is", "a", "carbohydrate", "antigen", "overexpressed", "in", "several", "epithelial", "cancers", ",", "including", "breast", "cancer", ",", "and", "usually", "associated", "with", "poor", "prognosis", ".", "Sialyl", "-", "Tn", "is", "synthesized", "by", "a", "CMP", "-", "Neu5Ac", ":", "GalNAcalpha2,6-sialyltransferase", ":", "CMP", "-", "Neu5Ac", ":", "R", "-", "GalNAcalpha1-O", "-", "Ser", "/", "Thr", "alpha2,6-sialyltransferase", "(", "EC", "2.4.99.3", ")", "(", "ST6GalNAc", "I", ")", ",", "which", "transfers", "a", "sialic", "acid", "residue", "in", "alpha2,6-linkage", "to", "the", "GalNAcalpha1-O", "-", "Ser", "/", "Thr", "structure", ".", "However", ",", "established", "breast", "cancer", "cell", "lines", "express", "neither", "ST6GalNAc", "I", "nor", "sialyl", "-", "Tn", ".", "We", "have", "previously", "shown", "that", "stable", "transfection", "of", "MDA", "-", "MB-231", ",", "a", "human", "breast", "cancer", "cell", "line", ",", "with", "ST6GalNAc", "I", "cDNA", "induces", "sialyl", "-", "Tn", "antigen", "(", "STn", ")", "expression", ".", "We", "report", "here", "the", "modifications", "of", "the", "O", "-", "glycosylation", "pattern", "of", "a", "MUC1-related", "recombinant", "protein", "secreted", "by", "MDA", "-", "MB-231", "sialyl", "-", "Tn", "positive", "cells", ".", "We", "also", "show", "that", "sialyl", "-", "Tn", "expression", "and", "concomitant", "changes", "in", "the", "overall", "O", "-", "glycan", "profiles", "induce", "a", "decrease", "of", "adhesion", "and", "an", "increase", "of", "migration", "of", "MDA", "-", "MB-231", ".", "Moreover", ",", "STn", "positive", "clones", "exhibit", "an", "increased", "tumour", "growth", "in", "severe", "combined", "immunodeficiency", "(", "SCID", ")", "mice", ".", "These", "observations", "suggest", "that", "modification", "of", "the", "O", "-", "glycosylation", "pattern", "induced", "by", "ST6GalNAc", "I", "expression", "are", "sufficient", "to", "enhance", "the", "tumourigenicity", "of", "MDA", "-", "MB-231", "breast", "cancer", "cells", ".", "\n" ]	[ "Protein" ]
ST6GalNAc I, ST6GalNAc I, ST6GalNAc I, ST6GalNAc I, ST6GalNAc I	172_task2	Sentence: ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Sialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells. Instructions: please extract entity words from the input sentence	[ "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Sialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells.	[ "ST6GalNAc", "I", "expression", "in", "MDA", "-", "MB-231", "breast", "cancer", "cells", "greatly", "modifies", "their", "O", "-", "glycosylation", "pattern", "and", "enhances", "their", "tumourigenicity", ".", "\n", "Sialyl", "-", "Tn", "is", "a", "carbohydrate", "antigen", "overexpressed", "in", "several", "epithelial", "cancers", ",", "including", "breast", "cancer", ",", "and", "usually", "associated", "with", "poor", "prognosis", ".", "Sialyl", "-", "Tn", "is", "synthesized", "by", "a", "CMP", "-", "Neu5Ac", ":", "GalNAcalpha2,6-sialyltransferase", ":", "CMP", "-", "Neu5Ac", ":", "R", "-", "GalNAcalpha1-O", "-", "Ser", "/", "Thr", "alpha2,6-sialyltransferase", "(", "EC", "2.4.99.3", ")", "(", "ST6GalNAc", "I", ")", ",", "which", "transfers", "a", "sialic", "acid", "residue", "in", "alpha2,6-linkage", "to", "the", "GalNAcalpha1-O", "-", "Ser", "/", "Thr", "structure", ".", "However", ",", "established", "breast", "cancer", "cell", "lines", "express", "neither", "ST6GalNAc", "I", "nor", "sialyl", "-", "Tn", ".", "We", "have", "previously", "shown", "that", "stable", "transfection", "of", "MDA", "-", "MB-231", ",", "a", "human", "breast", "cancer", "cell", "line", ",", "with", "ST6GalNAc", "I", "cDNA", "induces", "sialyl", "-", "Tn", "antigen", "(", "STn", ")", "expression", ".", "We", "report", "here", "the", "modifications", "of", "the", "O", "-", "glycosylation", "pattern", "of", "a", "MUC1-related", "recombinant", "protein", "secreted", "by", "MDA", "-", "MB-231", "sialyl", "-", "Tn", "positive", "cells", ".", "We", "also", "show", "that", "sialyl", "-", "Tn", "expression", "and", "concomitant", "changes", "in", "the", "overall", "O", "-", "glycan", "profiles", "induce", "a", "decrease", "of", "adhesion", "and", "an", "increase", "of", "migration", "of", "MDA", "-", "MB-231", ".", "Moreover", ",", "STn", "positive", "clones", "exhibit", "an", "increased", "tumour", "growth", "in", "severe", "combined", "immunodeficiency", "(", "SCID", ")", "mice", ".", "These", "observations", "suggest", "that", "modification", "of", "the", "O", "-", "glycosylation", "pattern", "induced", "by", "ST6GalNAc", "I", "expression", "are", "sufficient", "to", "enhance", "the", "tumourigenicity", "of", "MDA", "-", "MB-231", "breast", "cancer", "cells", ".", "\n" ]	[ "Protein" ]
Langzeitwirkungen is an umlsterm, ASS is an umlsterm, Dipyridamol is an umlsterm, Phenprocoumon is an umlsterm, Patienten is an umlsterm	ZfuerKardiologie.80870865.ger.abstr_task0	Sentence: In einer prospektiven randomisierten Studie wurden die plaettchenhemmenden Langzeitwirkungen von 50 mg Azetylsalizylsaeure ASS ) ( allein und in Kombination mit Dipyridamol ( 2x200 mg ) im Vergleich zu Phenprocoumon bei 42 Patienten nach ACB-OP untersucht . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	In einer prospektiven randomisierten Studie wurden die plaettchenhemmenden Langzeitwirkungen von 50 mg Azetylsalizylsaeure ASS ) ( allein und in Kombination mit Dipyridamol ( 2x200 mg ) im Vergleich zu Phenprocoumon bei 42 Patienten nach ACB-OP untersucht .	[ "In", "einer", "prospektiven", "randomisierten", "Studie", "wurden", "die", "plaettchenhemmenden", "Langzeitwirkungen", "von", "50", "mg", "Azetylsalizylsaeure", "ASS", ")", "(", "allein", "und", "in", "Kombination", "mit", "Dipyridamol", "(", "2x200", "mg", ")", "im", "Vergleich", "zu", "Phenprocoumon", "bei", "42", "Patienten", "nach", "ACB", "-", "OP", "untersucht", "." ]	[ "umlsterm" ]
Langzeitwirkungen is an umlsterm, ASS is an umlsterm, Dipyridamol is an umlsterm, Phenprocoumon is an umlsterm, Patienten is an umlsterm	ZfuerKardiologie.80870865.ger.abstr_task1	Sentence: In einer prospektiven randomisierten Studie wurden die plaettchenhemmenden Langzeitwirkungen von 50 mg Azetylsalizylsaeure ASS ) ( allein und in Kombination mit Dipyridamol ( 2x200 mg ) im Vergleich zu Phenprocoumon bei 42 Patienten nach ACB-OP untersucht . Instructions: please typing these entity words according to sentence: Langzeitwirkungen, ASS, Dipyridamol, Phenprocoumon, Patienten Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	In einer prospektiven randomisierten Studie wurden die plaettchenhemmenden Langzeitwirkungen von 50 mg Azetylsalizylsaeure ASS ) ( allein und in Kombination mit Dipyridamol ( 2x200 mg ) im Vergleich zu Phenprocoumon bei 42 Patienten nach ACB-OP untersucht .	[ "In", "einer", "prospektiven", "randomisierten", "Studie", "wurden", "die", "plaettchenhemmenden", "Langzeitwirkungen", "von", "50", "mg", "Azetylsalizylsaeure", "ASS", ")", "(", "allein", "und", "in", "Kombination", "mit", "Dipyridamol", "(", "2x200", "mg", ")", "im", "Vergleich", "zu", "Phenprocoumon", "bei", "42", "Patienten", "nach", "ACB", "-", "OP", "untersucht", "." ]	[ "umlsterm" ]
Langzeitwirkungen, ASS, Dipyridamol, Phenprocoumon, Patienten	ZfuerKardiologie.80870865.ger.abstr_task2	Sentence: In einer prospektiven randomisierten Studie wurden die plaettchenhemmenden Langzeitwirkungen von 50 mg Azetylsalizylsaeure ASS ) ( allein und in Kombination mit Dipyridamol ( 2x200 mg ) im Vergleich zu Phenprocoumon bei 42 Patienten nach ACB-OP untersucht . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	In einer prospektiven randomisierten Studie wurden die plaettchenhemmenden Langzeitwirkungen von 50 mg Azetylsalizylsaeure ASS ) ( allein und in Kombination mit Dipyridamol ( 2x200 mg ) im Vergleich zu Phenprocoumon bei 42 Patienten nach ACB-OP untersucht .	[ "In", "einer", "prospektiven", "randomisierten", "Studie", "wurden", "die", "plaettchenhemmenden", "Langzeitwirkungen", "von", "50", "mg", "Azetylsalizylsaeure", "ASS", ")", "(", "allein", "und", "in", "Kombination", "mit", "Dipyridamol", "(", "2x200", "mg", ")", "im", "Vergleich", "zu", "Phenprocoumon", "bei", "42", "Patienten", "nach", "ACB", "-", "OP", "untersucht", "." ]	[ "umlsterm" ]
hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, ovarian cancer cell is a Cell, LL-37 is a Gene_or_gene_product, human cationic antimicrobial protein 18 is a Gene_or_gene_product, hCAP-18 is a Gene_or_gene_product, cancer is a Pathological_formation, tissue is a Tissue, LL-37 is a Gene_or_gene_product, tumor is a Pathological_formation, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, ovarian tissue is a Tissue, LL-37 is a Gene_or_gene_product, ovarian cancer cells is a Cell, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, immune is a Cell, granulosa cells is a Cell, normal ovarian tissue is a Tissue, ovarian tumors is a Pathological_formation, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, tumor is a Cell, stromal cells is a Cell, immune cell is a Cell, microvessel is a Tissue, epithelial - derived ovarian tumors is a Pathological_formation, ovarian tumor tissue lysates is a Organism_substance, ovarian cancer cell lines is a Cell, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, ovarian cancer cell lines is a Cell, LL-37 is a Gene_or_gene_product, matrix metalloproteinase is a Gene_or_gene_product, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, ovarian tumors is a Pathological_formation, LL-37 is a Gene_or_gene_product, tumor cells is a Cell, immune cells is a Cell, ovarian cancer is a Pathological_formation	72_task0	Sentence: Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. The role of the pro-inflammatory peptide, LL-37, and its pro-form, human cationic antimicrobial protein 18 (hCAP-18), in cancer development and progression is poorly understood. In damaged and inflamed tissue, LL-37 functions as a chemoattractant, mitogen and pro-angiogenic factor suggesting that the peptide may potentiate tumor progression. The aim of this study was to characterize the distribution of hCAP-18/LL-37 in normal and cancerous ovarian tissue and to examine the effects of LL-37 on ovarian cancer cells. Expression of hCAP-18/LL-37 was localized to immune and granulosa cells of normal ovarian tissue. By contrast, ovarian tumors displayed significantly higher levels of hCAP-18/LL-37 where expression was observed in tumor and stromal cells. Protein expression was statistically compared to the degree of immune cell infiltration and microvessel density in epithelial-derived ovarian tumors and a significant correlation was observed for both. It was demonstrated that ovarian tumor tissue lysates and ovarian cancer cell lines express hCAP-18/LL-37. Treatment of ovarian cancer cell lines with recombinant LL-37 stimulated proliferation, chemotaxis, invasion and matrix metalloproteinase expression. These data demonstrate for the first time that hCAP-18/LL-37 is significantly overexpressed in ovarian tumors and suggest LL-37 may contribute to ovarian tumorigenesis through direct stimulation of tumor cells, initiation of angiogenesis and recruitment of immune cells. These data provide further evidence of the existing relationship between pro-inflammatory molecules and ovarian cancer progression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, Cell, Pathological_formation, Gene_or_gene_product, Organism_substance	[ "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Tissue", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "I-Organism_substance", "I-Organism_substance", "I-Organism_substance", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "O", "O", "O" ]	Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. The role of the pro-inflammatory peptide, LL-37, and its pro-form, human cationic antimicrobial protein 18 (hCAP-18), in cancer development and progression is poorly understood. In damaged and inflamed tissue, LL-37 functions as a chemoattractant, mitogen and pro-angiogenic factor suggesting that the peptide may potentiate tumor progression. The aim of this study was to characterize the distribution of hCAP-18/LL-37 in normal and cancerous ovarian tissue and to examine the effects of LL-37 on ovarian cancer cells. Expression of hCAP-18/LL-37 was localized to immune and granulosa cells of normal ovarian tissue. By contrast, ovarian tumors displayed significantly higher levels of hCAP-18/LL-37 where expression was observed in tumor and stromal cells. Protein expression was statistically compared to the degree of immune cell infiltration and microvessel density in epithelial-derived ovarian tumors and a significant correlation was observed for both. It was demonstrated that ovarian tumor tissue lysates and ovarian cancer cell lines express hCAP-18/LL-37. Treatment of ovarian cancer cell lines with recombinant LL-37 stimulated proliferation, chemotaxis, invasion and matrix metalloproteinase expression. These data demonstrate for the first time that hCAP-18/LL-37 is significantly overexpressed in ovarian tumors and suggest LL-37 may contribute to ovarian tumorigenesis through direct stimulation of tumor cells, initiation of angiogenesis and recruitment of immune cells. These data provide further evidence of the existing relationship between pro-inflammatory molecules and ovarian cancer progression.	[ "Ovarian", "cancers", "overexpress", "the", "antimicrobial", "protein", "hCAP-18", "and", "its", "derivative", "LL-37", "increases", "ovarian", "cancer", "cell", "proliferation", "and", "invasion", ".", "\n\n", "The", "role", "of", "the", "pro", "-", "inflammatory", "peptide", ",", "LL-37", ",", "and", "its", "pro", "-", "form", ",", "human", "cationic", "antimicrobial", "protein", "18", "(", "hCAP-18", ")", ",", "in", "cancer", "development", "and", "progression", "is", "poorly", "understood", ".", "In", "damaged", "and", "inflamed", "tissue", ",", "LL-37", "functions", "as", "a", "chemoattractant", ",", "mitogen", "and", "pro", "-", "angiogenic", "factor", "suggesting", "that", "the", "peptide", "may", "potentiate", "tumor", "progression", ".", "The", "aim", "of", "this", "study", "was", "to", "characterize", "the", "distribution", "of", "hCAP-18", "/", "LL-37", "in", "normal", "and", "cancerous", "ovarian", "tissue", "and", "to", "examine", "the", "effects", "of", "LL-37", "on", "ovarian", "cancer", "cells", ".", "Expression", "of", "hCAP-18", "/", "LL-37", "was", "localized", "to", "immune", "and", "granulosa", "cells", "of", "normal", "ovarian", "tissue", ".", "By", "contrast", ",", "ovarian", "tumors", "displayed", "significantly", "higher", "levels", "of", "hCAP-18", "/", "LL-37", "where", "expression", "was", "observed", "in", "tumor", "and", "stromal", "cells", ".", "Protein", "expression", "was", "statistically", "compared", "to", "the", "degree", "of", "immune", "cell", "infiltration", "and", "microvessel", "density", "in", "epithelial", "-", "derived", "ovarian", "tumors", "and", "a", "significant", "correlation", "was", "observed", "for", "both", ".", "It", "was", "demonstrated", "that", "ovarian", "tumor", "tissue", "lysates", "and", "ovarian", "cancer", "cell", "lines", "express", "hCAP-18", "/", "LL-37", ".", "Treatment", "of", "ovarian", "cancer", "cell", "lines", "with", "recombinant", "LL-37", "stimulated", "proliferation", ",", "chemotaxis", ",", "invasion", "and", "matrix", "metalloproteinase", "expression", ".", "These", "data", "demonstrate", "for", "the", "first", "time", "that", "hCAP-18", "/", "LL-37", "is", "significantly", "overexpressed", "in", "ovarian", "tumors", "and", "suggest", "LL-37", "may", "contribute", "to", "ovarian", "tumorigenesis", "through", "direct", "stimulation", "of", "tumor", "cells", ",", "initiation", "of", "angiogenesis", "and", "recruitment", "of", "immune", "cells", ".", "These", "data", "provide", "further", "evidence", "of", "the", "existing", "relationship", "between", "pro", "-", "inflammatory", "molecules", "and", "ovarian", "cancer", "progression", ".", "\n" ]	[ "Gene_or_gene_product", "Pathological_formation", "Organism_substance", "Cell", "Tissue" ]
hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, ovarian cancer cell is a Cell, LL-37 is a Gene_or_gene_product, human cationic antimicrobial protein 18 is a Gene_or_gene_product, hCAP-18 is a Gene_or_gene_product, cancer is a Pathological_formation, tissue is a Tissue, LL-37 is a Gene_or_gene_product, tumor is a Pathological_formation, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, ovarian tissue is a Tissue, LL-37 is a Gene_or_gene_product, ovarian cancer cells is a Cell, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, immune is a Cell, granulosa cells is a Cell, normal ovarian tissue is a Tissue, ovarian tumors is a Pathological_formation, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, tumor is a Cell, stromal cells is a Cell, immune cell is a Cell, microvessel is a Tissue, epithelial - derived ovarian tumors is a Pathological_formation, ovarian tumor tissue lysates is a Organism_substance, ovarian cancer cell lines is a Cell, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, ovarian cancer cell lines is a Cell, LL-37 is a Gene_or_gene_product, matrix metalloproteinase is a Gene_or_gene_product, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, ovarian tumors is a Pathological_formation, LL-37 is a Gene_or_gene_product, tumor cells is a Cell, immune cells is a Cell, ovarian cancer is a Pathological_formation	72_task1	Sentence: Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. The role of the pro-inflammatory peptide, LL-37, and its pro-form, human cationic antimicrobial protein 18 (hCAP-18), in cancer development and progression is poorly understood. In damaged and inflamed tissue, LL-37 functions as a chemoattractant, mitogen and pro-angiogenic factor suggesting that the peptide may potentiate tumor progression. The aim of this study was to characterize the distribution of hCAP-18/LL-37 in normal and cancerous ovarian tissue and to examine the effects of LL-37 on ovarian cancer cells. Expression of hCAP-18/LL-37 was localized to immune and granulosa cells of normal ovarian tissue. By contrast, ovarian tumors displayed significantly higher levels of hCAP-18/LL-37 where expression was observed in tumor and stromal cells. Protein expression was statistically compared to the degree of immune cell infiltration and microvessel density in epithelial-derived ovarian tumors and a significant correlation was observed for both. It was demonstrated that ovarian tumor tissue lysates and ovarian cancer cell lines express hCAP-18/LL-37. Treatment of ovarian cancer cell lines with recombinant LL-37 stimulated proliferation, chemotaxis, invasion and matrix metalloproteinase expression. These data demonstrate for the first time that hCAP-18/LL-37 is significantly overexpressed in ovarian tumors and suggest LL-37 may contribute to ovarian tumorigenesis through direct stimulation of tumor cells, initiation of angiogenesis and recruitment of immune cells. These data provide further evidence of the existing relationship between pro-inflammatory molecules and ovarian cancer progression. Instructions: please typing these entity words according to sentence: hCAP-18, LL-37, ovarian cancer cell, LL-37, human cationic antimicrobial protein 18, hCAP-18, cancer, tissue, LL-37, tumor, hCAP-18, LL-37, ovarian tissue, LL-37, ovarian cancer cells, hCAP-18, LL-37, immune, granulosa cells, normal ovarian tissue, ovarian tumors, hCAP-18, LL-37, tumor, stromal cells, immune cell, microvessel, epithelial - derived ovarian tumors, ovarian tumor tissue lysates, ovarian cancer cell lines, hCAP-18, LL-37, ovarian cancer cell lines, LL-37, matrix metalloproteinase, hCAP-18, LL-37, ovarian tumors, LL-37, tumor cells, immune cells, ovarian cancer Options: Tissue, Cell, Pathological_formation, Gene_or_gene_product, Organism_substance	[ "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Tissue", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "I-Organism_substance", "I-Organism_substance", "I-Organism_substance", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "O", "O", "O" ]	Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. The role of the pro-inflammatory peptide, LL-37, and its pro-form, human cationic antimicrobial protein 18 (hCAP-18), in cancer development and progression is poorly understood. In damaged and inflamed tissue, LL-37 functions as a chemoattractant, mitogen and pro-angiogenic factor suggesting that the peptide may potentiate tumor progression. The aim of this study was to characterize the distribution of hCAP-18/LL-37 in normal and cancerous ovarian tissue and to examine the effects of LL-37 on ovarian cancer cells. Expression of hCAP-18/LL-37 was localized to immune and granulosa cells of normal ovarian tissue. By contrast, ovarian tumors displayed significantly higher levels of hCAP-18/LL-37 where expression was observed in tumor and stromal cells. Protein expression was statistically compared to the degree of immune cell infiltration and microvessel density in epithelial-derived ovarian tumors and a significant correlation was observed for both. It was demonstrated that ovarian tumor tissue lysates and ovarian cancer cell lines express hCAP-18/LL-37. Treatment of ovarian cancer cell lines with recombinant LL-37 stimulated proliferation, chemotaxis, invasion and matrix metalloproteinase expression. These data demonstrate for the first time that hCAP-18/LL-37 is significantly overexpressed in ovarian tumors and suggest LL-37 may contribute to ovarian tumorigenesis through direct stimulation of tumor cells, initiation of angiogenesis and recruitment of immune cells. These data provide further evidence of the existing relationship between pro-inflammatory molecules and ovarian cancer progression.	[ "Ovarian", "cancers", "overexpress", "the", "antimicrobial", "protein", "hCAP-18", "and", "its", "derivative", "LL-37", "increases", "ovarian", "cancer", "cell", "proliferation", "and", "invasion", ".", "\n\n", "The", "role", "of", "the", "pro", "-", "inflammatory", "peptide", ",", "LL-37", ",", "and", "its", "pro", "-", "form", ",", "human", "cationic", "antimicrobial", "protein", "18", "(", "hCAP-18", ")", ",", "in", "cancer", "development", "and", "progression", "is", "poorly", "understood", ".", "In", "damaged", "and", "inflamed", "tissue", ",", "LL-37", "functions", "as", "a", "chemoattractant", ",", "mitogen", "and", "pro", "-", "angiogenic", "factor", "suggesting", "that", "the", "peptide", "may", "potentiate", "tumor", "progression", ".", "The", "aim", "of", "this", "study", "was", "to", "characterize", "the", "distribution", "of", "hCAP-18", "/", "LL-37", "in", "normal", "and", "cancerous", "ovarian", "tissue", "and", "to", "examine", "the", "effects", "of", "LL-37", "on", "ovarian", "cancer", "cells", ".", "Expression", "of", "hCAP-18", "/", "LL-37", "was", "localized", "to", "immune", "and", "granulosa", "cells", "of", "normal", "ovarian", "tissue", ".", "By", "contrast", ",", "ovarian", "tumors", "displayed", "significantly", "higher", "levels", "of", "hCAP-18", "/", "LL-37", "where", "expression", "was", "observed", "in", "tumor", "and", "stromal", "cells", ".", "Protein", "expression", "was", "statistically", "compared", "to", "the", "degree", "of", "immune", "cell", "infiltration", "and", "microvessel", "density", "in", "epithelial", "-", "derived", "ovarian", "tumors", "and", "a", "significant", "correlation", "was", "observed", "for", "both", ".", "It", "was", "demonstrated", "that", "ovarian", "tumor", "tissue", "lysates", "and", "ovarian", "cancer", "cell", "lines", "express", "hCAP-18", "/", "LL-37", ".", "Treatment", "of", "ovarian", "cancer", "cell", "lines", "with", "recombinant", "LL-37", "stimulated", "proliferation", ",", "chemotaxis", ",", "invasion", "and", "matrix", "metalloproteinase", "expression", ".", "These", "data", "demonstrate", "for", "the", "first", "time", "that", "hCAP-18", "/", "LL-37", "is", "significantly", "overexpressed", "in", "ovarian", "tumors", "and", "suggest", "LL-37", "may", "contribute", "to", "ovarian", "tumorigenesis", "through", "direct", "stimulation", "of", "tumor", "cells", ",", "initiation", "of", "angiogenesis", "and", "recruitment", "of", "immune", "cells", ".", "These", "data", "provide", "further", "evidence", "of", "the", "existing", "relationship", "between", "pro", "-", "inflammatory", "molecules", "and", "ovarian", "cancer", "progression", ".", "\n" ]	[ "Gene_or_gene_product", "Pathological_formation", "Organism_substance", "Cell", "Tissue" ]
hCAP-18, LL-37, ovarian cancer cell, LL-37, human cationic antimicrobial protein 18, hCAP-18, cancer, tissue, LL-37, tumor, hCAP-18, LL-37, ovarian tissue, LL-37, ovarian cancer cells, hCAP-18, LL-37, immune, granulosa cells, normal ovarian tissue, ovarian tumors, hCAP-18, LL-37, tumor, stromal cells, immune cell, microvessel, epithelial - derived ovarian tumors, ovarian tumor tissue lysates, ovarian cancer cell lines, hCAP-18, LL-37, ovarian cancer cell lines, LL-37, matrix metalloproteinase, hCAP-18, LL-37, ovarian tumors, LL-37, tumor cells, immune cells, ovarian cancer	72_task2	Sentence: Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. The role of the pro-inflammatory peptide, LL-37, and its pro-form, human cationic antimicrobial protein 18 (hCAP-18), in cancer development and progression is poorly understood. In damaged and inflamed tissue, LL-37 functions as a chemoattractant, mitogen and pro-angiogenic factor suggesting that the peptide may potentiate tumor progression. The aim of this study was to characterize the distribution of hCAP-18/LL-37 in normal and cancerous ovarian tissue and to examine the effects of LL-37 on ovarian cancer cells. Expression of hCAP-18/LL-37 was localized to immune and granulosa cells of normal ovarian tissue. By contrast, ovarian tumors displayed significantly higher levels of hCAP-18/LL-37 where expression was observed in tumor and stromal cells. Protein expression was statistically compared to the degree of immune cell infiltration and microvessel density in epithelial-derived ovarian tumors and a significant correlation was observed for both. It was demonstrated that ovarian tumor tissue lysates and ovarian cancer cell lines express hCAP-18/LL-37. Treatment of ovarian cancer cell lines with recombinant LL-37 stimulated proliferation, chemotaxis, invasion and matrix metalloproteinase expression. These data demonstrate for the first time that hCAP-18/LL-37 is significantly overexpressed in ovarian tumors and suggest LL-37 may contribute to ovarian tumorigenesis through direct stimulation of tumor cells, initiation of angiogenesis and recruitment of immune cells. These data provide further evidence of the existing relationship between pro-inflammatory molecules and ovarian cancer progression. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Tissue", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "I-Organism_substance", "I-Organism_substance", "I-Organism_substance", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "O", "O", "O" ]	Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. The role of the pro-inflammatory peptide, LL-37, and its pro-form, human cationic antimicrobial protein 18 (hCAP-18), in cancer development and progression is poorly understood. In damaged and inflamed tissue, LL-37 functions as a chemoattractant, mitogen and pro-angiogenic factor suggesting that the peptide may potentiate tumor progression. The aim of this study was to characterize the distribution of hCAP-18/LL-37 in normal and cancerous ovarian tissue and to examine the effects of LL-37 on ovarian cancer cells. Expression of hCAP-18/LL-37 was localized to immune and granulosa cells of normal ovarian tissue. By contrast, ovarian tumors displayed significantly higher levels of hCAP-18/LL-37 where expression was observed in tumor and stromal cells. Protein expression was statistically compared to the degree of immune cell infiltration and microvessel density in epithelial-derived ovarian tumors and a significant correlation was observed for both. It was demonstrated that ovarian tumor tissue lysates and ovarian cancer cell lines express hCAP-18/LL-37. Treatment of ovarian cancer cell lines with recombinant LL-37 stimulated proliferation, chemotaxis, invasion and matrix metalloproteinase expression. These data demonstrate for the first time that hCAP-18/LL-37 is significantly overexpressed in ovarian tumors and suggest LL-37 may contribute to ovarian tumorigenesis through direct stimulation of tumor cells, initiation of angiogenesis and recruitment of immune cells. These data provide further evidence of the existing relationship between pro-inflammatory molecules and ovarian cancer progression.	[ "Ovarian", "cancers", "overexpress", "the", "antimicrobial", "protein", "hCAP-18", "and", "its", "derivative", "LL-37", "increases", "ovarian", "cancer", "cell", "proliferation", "and", "invasion", ".", "\n\n", "The", "role", "of", "the", "pro", "-", "inflammatory", "peptide", ",", "LL-37", ",", "and", "its", "pro", "-", "form", ",", "human", "cationic", "antimicrobial", "protein", "18", "(", "hCAP-18", ")", ",", "in", "cancer", "development", "and", "progression", "is", "poorly", "understood", ".", "In", "damaged", "and", "inflamed", "tissue", ",", "LL-37", "functions", "as", "a", "chemoattractant", ",", "mitogen", "and", "pro", "-", "angiogenic", "factor", "suggesting", "that", "the", "peptide", "may", "potentiate", "tumor", "progression", ".", "The", "aim", "of", "this", "study", "was", "to", "characterize", "the", "distribution", "of", "hCAP-18", "/", "LL-37", "in", "normal", "and", "cancerous", "ovarian", "tissue", "and", "to", "examine", "the", "effects", "of", "LL-37", "on", "ovarian", "cancer", "cells", ".", "Expression", "of", "hCAP-18", "/", "LL-37", "was", "localized", "to", "immune", "and", "granulosa", "cells", "of", "normal", "ovarian", "tissue", ".", "By", "contrast", ",", "ovarian", "tumors", "displayed", "significantly", "higher", "levels", "of", "hCAP-18", "/", "LL-37", "where", "expression", "was", "observed", "in", "tumor", "and", "stromal", "cells", ".", "Protein", "expression", "was", "statistically", "compared", "to", "the", "degree", "of", "immune", "cell", "infiltration", "and", "microvessel", "density", "in", "epithelial", "-", "derived", "ovarian", "tumors", "and", "a", "significant", "correlation", "was", "observed", "for", "both", ".", "It", "was", "demonstrated", "that", "ovarian", "tumor", "tissue", "lysates", "and", "ovarian", "cancer", "cell", "lines", "express", "hCAP-18", "/", "LL-37", ".", "Treatment", "of", "ovarian", "cancer", "cell", "lines", "with", "recombinant", "LL-37", "stimulated", "proliferation", ",", "chemotaxis", ",", "invasion", "and", "matrix", "metalloproteinase", "expression", ".", "These", "data", "demonstrate", "for", "the", "first", "time", "that", "hCAP-18", "/", "LL-37", "is", "significantly", "overexpressed", "in", "ovarian", "tumors", "and", "suggest", "LL-37", "may", "contribute", "to", "ovarian", "tumorigenesis", "through", "direct", "stimulation", "of", "tumor", "cells", ",", "initiation", "of", "angiogenesis", "and", "recruitment", "of", "immune", "cells", ".", "These", "data", "provide", "further", "evidence", "of", "the", "existing", "relationship", "between", "pro", "-", "inflammatory", "molecules", "and", "ovarian", "cancer", "progression", ".", "\n" ]	[ "Gene_or_gene_product", "Pathological_formation", "Organism_substance", "Cell", "Tissue" ]
prospective study is an umlsterm, quality of life is an umlsterm, life is an umlsterm, satisfaction is an umlsterm, health is an umlsterm, time is an umlsterm, heart transplantation is an umlsterm, patients is an umlsterm, questionnaires is an umlsterm, heart is an umlsterm, transplant is an umlsterm, symptom is an umlsterm, quality of life is an umlsterm, assessment is an umlsterm, life quality is an umlsterm, life changes is an umlsterm, language is an umlsterm, age is an umlsterm, evaluation is an umlsterm, standard is an umlsterm, Quality of life is an umlsterm, patients is an umlsterm, congestive heart failure is an umlsterm, quality of life is an umlsterm, health status is an umlsterm, health status is an umlsterm, Quality of life is an umlsterm, health is an umlsterm, satisfaction is an umlsterm, health status is an umlsterm, recreational activities is an umlsterm, patients is an umlsterm, quality of life is an umlsterm, postoperative is an umlsterm, life is an umlsterm, patients is an umlsterm	ZfuerKardiologie.80870808.eng.abstr_task0	Sentence: This prospective study was designed to compare quality of life , life satisfaction , and subjective ratings of health before and at variable time intervals after heart transplantation ( HTx ) . 175 patients were included between February 1994 and December 1997. Every six months before and 1,5 , 3 , 6 , and 12 months after HTx , they received the following standardized and validated questionnaires : German SF 36 , heart failure and specific transplant symptom list , global quality of life assessment , Munich life quality dimension list , expected/experienced life changes after HTx , good command of the German language , and a minimum age of 18 years . During data evaluation , median ( Me ) , mean ( M ) , and standard deviation ( SD ) were created from individual parameters . Quality of life was rated as very poor by 84% of patients with congestive heart failure . Only 6 weeks after HTx , 74% rated their quality of life as significantly better . Before HTx 80% were very unsatisfied about their health status and 87% about physical performance . Six weeks after HTx , this parameter improved significantly and 76% were very satisfied about their health status and 50% about physical performance . While somatic changes expected before HTx corresponded well with experienced ones , psychological improvements were smaller than expected , but one year after HTx they were significant ( before : M=3.66; SD=0.9; Range ( R ) =3 . 78 vs 12 months postop : M=4.61; SD=0.6; R=2.67; p 0.05 ) . Quality of life correlated before HTx best with subjectively rated health ( r=0.61, p 0.01 ) and 6 months after with satisfaction about health status ( r=0.76, p 0.01 ) . Only in 25% were expected improvements fulfilled regarding sexual activity/satisfaction , professional situation , and recreational activities . 90% of posttransplant patients reported physical compaints , most by effects of immunsuppression , but were coping well . The study shows that already 6 weeks after successful HTx all quality of life parameters improved significantly . Despite some unfulfilled expectations and complaints , the postoperative life situation of HTx patients appeared significantly improved . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	This prospective study was designed to compare quality of life , life satisfaction , and subjective ratings of health before and at variable time intervals after heart transplantation ( HTx ) . 175 patients were included between February 1994 and December 1997. Every six months before and 1,5 , 3 , 6 , and 12 months after HTx , they received the following standardized and validated questionnaires : German SF 36 , heart failure and specific transplant symptom list , global quality of life assessment , Munich life quality dimension list , expected/experienced life changes after HTx , good command of the German language , and a minimum age of 18 years . During data evaluation , median ( Me ) , mean ( M ) , and standard deviation ( SD ) were created from individual parameters . Quality of life was rated as very poor by 84% of patients with congestive heart failure . Only 6 weeks after HTx , 74% rated their quality of life as significantly better . Before HTx 80% were very unsatisfied about their health status and 87% about physical performance . Six weeks after HTx , this parameter improved significantly and 76% were very satisfied about their health status and 50% about physical performance . While somatic changes expected before HTx corresponded well with experienced ones , psychological improvements were smaller than expected , but one year after HTx they were significant ( before : M=3.66; SD=0.9; Range ( R ) =3 . 78 vs 12 months postop : M=4.61; SD=0.6; R=2.67; p 0.05 ) . Quality of life correlated before HTx best with subjectively rated health ( r=0.61, p 0.01 ) and 6 months after with satisfaction about health status ( r=0.76, p 0.01 ) . Only in 25% were expected improvements fulfilled regarding sexual activity/satisfaction , professional situation , and recreational activities . 90% of posttransplant patients reported physical compaints , most by effects of immunsuppression , but were coping well . The study shows that already 6 weeks after successful HTx all quality of life parameters improved significantly . Despite some unfulfilled expectations and complaints , the postoperative life situation of HTx patients appeared significantly improved .	[ "This", "prospective", "study", "was", "designed", "to", "compare", "quality", "of", "life", ",", "life", "satisfaction", ",", "and", "subjective", "ratings", "of", "health", "before", "and", "at", "variable", "time", "intervals", "after", "heart", "transplantation", "(", "HTx", ")", ".", "175", "patients", "were", "included", "between", "February", "1994", "and", "December", "1997", ".", "Every", "six", "months", "before", "and", "1,5", ",", "3", ",", "6", ",", "and", "12", "months", "after", "HTx", ",", "they", "received", "the", "following", "standardized", "and", "validated", "questionnaires", ":", "German", "SF", "36", ",", "heart", "failure", "and", "specific", "transplant", "symptom", "list", ",", "global", "quality", "of", "life", "assessment", ",", "Munich", "life", "quality", "dimension", "list", ",", "expected", "/", "experienced", "life", "changes", "after", "HTx", ",", "good", "command", "of", "the", "German", "language", ",", "and", "a", "minimum", "age", "of", "18", "years", ".", "During", "data", "evaluation", ",", "median", "(", "Me", ")", ",", "mean", "(", "M", ")", ",", "and", "standard", "deviation", "(", "SD", ")", "were", "created", "from", "individual", "parameters", ".", "Quality", "of", "life", "was", "rated", "as", "very", "poor", "by", "84", "%", "of", "patients", "with", "congestive", "heart", "failure", ".", "Only", "6", "weeks", "after", "HTx", ",", "74", "%", "rated", "their", "quality", "of", "life", "as", "significantly", "better", ".", "Before", "HTx", "80", "%", "were", "very", "unsatisfied", "about", "their", "health", "status", "and", "87", "%", "about", "physical", "performance", ".", "Six", "weeks", "after", "HTx", ",", "this", "parameter", "improved", "significantly", "and", "76", "%", "were", "very", "satisfied", "about", "their", "health", "status", "and", "50", "%", "about", "physical", "performance", ".", "While", "somatic", "changes", "expected", "before", "HTx", "corresponded", "well", "with", "experienced", "ones", ",", "psychological", "improvements", "were", "smaller", "than", "expected", ",", "but", "one", "year", "after", "HTx", "they", "were", "significant", "(", "before", ":", "M=3.66", ";", "SD=0.9", ";", "Range", "(", "R", ")", "=3", ".", "78", "vs", "12", "months", "postop", ":", "M=4.61", ";", "SD=0.6", ";", "R=2.67", ";", "p", "0.05", ")", ".", "Quality", "of", "life", "correlated", "before", "HTx", "best", "with", "subjectively", "rated", "health", "(", "r=0.61", ",", "p", "0.01", ")", "and", "6", "months", "after", "with", "satisfaction", "about", "health", "status", "(", "r=0.76", ",", "p", "0.01", ")", ".", "Only", "in", "25", "%", "were", "expected", "improvements", "fulfilled", "regarding", "sexual", "activity", "/", "satisfaction", ",", "professional", "situation", ",", "and", "recreational", "activities", ".", "90", "%", "of", "posttransplant", "patients", "reported", "physical", "compaints", ",", "most", "by", "effects", "of", "immunsuppression", ",", "but", "were", "coping", "well", ".", "The", "study", "shows", "that", "already", "6", "weeks", "after", "successful", "HTx", "all", "quality", "of", "life", "parameters", "improved", "significantly", ".", "Despite", "some", "unfulfilled", "expectations", "and", "complaints", ",", "the", "postoperative", "life", "situation", "of", "HTx", "patients", "appeared", "significantly", "improved", "." ]	[ "umlsterm" ]
prospective study is an umlsterm, quality of life is an umlsterm, life is an umlsterm, satisfaction is an umlsterm, health is an umlsterm, time is an umlsterm, heart transplantation is an umlsterm, patients is an umlsterm, questionnaires is an umlsterm, heart is an umlsterm, transplant is an umlsterm, symptom is an umlsterm, quality of life is an umlsterm, assessment is an umlsterm, life quality is an umlsterm, life changes is an umlsterm, language is an umlsterm, age is an umlsterm, evaluation is an umlsterm, standard is an umlsterm, Quality of life is an umlsterm, patients is an umlsterm, congestive heart failure is an umlsterm, quality of life is an umlsterm, health status is an umlsterm, health status is an umlsterm, Quality of life is an umlsterm, health is an umlsterm, satisfaction is an umlsterm, health status is an umlsterm, recreational activities is an umlsterm, patients is an umlsterm, quality of life is an umlsterm, postoperative is an umlsterm, life is an umlsterm, patients is an umlsterm	ZfuerKardiologie.80870808.eng.abstr_task1	Sentence: This prospective study was designed to compare quality of life , life satisfaction , and subjective ratings of health before and at variable time intervals after heart transplantation ( HTx ) . 175 patients were included between February 1994 and December 1997. Every six months before and 1,5 , 3 , 6 , and 12 months after HTx , they received the following standardized and validated questionnaires : German SF 36 , heart failure and specific transplant symptom list , global quality of life assessment , Munich life quality dimension list , expected/experienced life changes after HTx , good command of the German language , and a minimum age of 18 years . During data evaluation , median ( Me ) , mean ( M ) , and standard deviation ( SD ) were created from individual parameters . Quality of life was rated as very poor by 84% of patients with congestive heart failure . Only 6 weeks after HTx , 74% rated their quality of life as significantly better . Before HTx 80% were very unsatisfied about their health status and 87% about physical performance . Six weeks after HTx , this parameter improved significantly and 76% were very satisfied about their health status and 50% about physical performance . While somatic changes expected before HTx corresponded well with experienced ones , psychological improvements were smaller than expected , but one year after HTx they were significant ( before : M=3.66; SD=0.9; Range ( R ) =3 . 78 vs 12 months postop : M=4.61; SD=0.6; R=2.67; p 0.05 ) . Quality of life correlated before HTx best with subjectively rated health ( r=0.61, p 0.01 ) and 6 months after with satisfaction about health status ( r=0.76, p 0.01 ) . Only in 25% were expected improvements fulfilled regarding sexual activity/satisfaction , professional situation , and recreational activities . 90% of posttransplant patients reported physical compaints , most by effects of immunsuppression , but were coping well . The study shows that already 6 weeks after successful HTx all quality of life parameters improved significantly . Despite some unfulfilled expectations and complaints , the postoperative life situation of HTx patients appeared significantly improved . Instructions: please typing these entity words according to sentence: prospective study, quality of life, life, satisfaction, health, time, heart transplantation, patients, questionnaires, heart, transplant, symptom, quality of life, assessment, life quality, life changes, language, age, evaluation, standard, Quality of life, patients, congestive heart failure, quality of life, health status, health status, Quality of life, health, satisfaction, health status, recreational activities, patients, quality of life, postoperative, life, patients Options: umlsterm	[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	This prospective study was designed to compare quality of life , life satisfaction , and subjective ratings of health before and at variable time intervals after heart transplantation ( HTx ) . 175 patients were included between February 1994 and December 1997. Every six months before and 1,5 , 3 , 6 , and 12 months after HTx , they received the following standardized and validated questionnaires : German SF 36 , heart failure and specific transplant symptom list , global quality of life assessment , Munich life quality dimension list , expected/experienced life changes after HTx , good command of the German language , and a minimum age of 18 years . During data evaluation , median ( Me ) , mean ( M ) , and standard deviation ( SD ) were created from individual parameters . Quality of life was rated as very poor by 84% of patients with congestive heart failure . Only 6 weeks after HTx , 74% rated their quality of life as significantly better . Before HTx 80% were very unsatisfied about their health status and 87% about physical performance . Six weeks after HTx , this parameter improved significantly and 76% were very satisfied about their health status and 50% about physical performance . While somatic changes expected before HTx corresponded well with experienced ones , psychological improvements were smaller than expected , but one year after HTx they were significant ( before : M=3.66; SD=0.9; Range ( R ) =3 . 78 vs 12 months postop : M=4.61; SD=0.6; R=2.67; p 0.05 ) . Quality of life correlated before HTx best with subjectively rated health ( r=0.61, p 0.01 ) and 6 months after with satisfaction about health status ( r=0.76, p 0.01 ) . Only in 25% were expected improvements fulfilled regarding sexual activity/satisfaction , professional situation , and recreational activities . 90% of posttransplant patients reported physical compaints , most by effects of immunsuppression , but were coping well . The study shows that already 6 weeks after successful HTx all quality of life parameters improved significantly . Despite some unfulfilled expectations and complaints , the postoperative life situation of HTx patients appeared significantly improved .	[ "This", "prospective", "study", "was", "designed", "to", "compare", "quality", "of", "life", ",", "life", "satisfaction", ",", "and", "subjective", "ratings", "of", "health", "before", "and", "at", "variable", "time", "intervals", "after", "heart", "transplantation", "(", "HTx", ")", ".", "175", "patients", "were", "included", "between", "February", "1994", "and", "December", "1997", ".", "Every", "six", "months", "before", "and", "1,5", ",", "3", ",", "6", ",", "and", "12", "months", "after", "HTx", ",", "they", "received", "the", "following", "standardized", "and", "validated", "questionnaires", ":", "German", "SF", "36", ",", "heart", "failure", "and", "specific", "transplant", "symptom", "list", ",", "global", "quality", "of", "life", "assessment", ",", "Munich", "life", "quality", "dimension", "list", ",", "expected", "/", "experienced", "life", "changes", "after", "HTx", ",", "good", "command", "of", "the", "German", "language", ",", "and", "a", "minimum", "age", "of", "18", "years", ".", "During", "data", "evaluation", ",", "median", "(", "Me", ")", ",", "mean", "(", "M", ")", ",", "and", "standard", "deviation", "(", "SD", ")", "were", "created", "from", "individual", "parameters", ".", "Quality", "of", "life", "was", "rated", "as", "very", "poor", "by", "84", "%", "of", "patients", "with", "congestive", "heart", "failure", ".", "Only", "6", "weeks", "after", "HTx", ",", "74", "%", "rated", "their", "quality", "of", "life", "as", "significantly", "better", ".", "Before", "HTx", "80", "%", "were", "very", "unsatisfied", "about", "their", "health", "status", "and", "87", "%", "about", "physical", "performance", ".", "Six", "weeks", "after", "HTx", ",", "this", "parameter", "improved", "significantly", "and", "76", "%", "were", "very", "satisfied", "about", "their", "health", "status", "and", "50", "%", "about", "physical", "performance", ".", "While", "somatic", "changes", "expected", "before", "HTx", "corresponded", "well", "with", "experienced", "ones", ",", "psychological", "improvements", "were", "smaller", "than", "expected", ",", "but", "one", "year", "after", "HTx", "they", "were", "significant", "(", "before", ":", "M=3.66", ";", "SD=0.9", ";", "Range", "(", "R", ")", "=3", ".", "78", "vs", "12", "months", "postop", ":", "M=4.61", ";", "SD=0.6", ";", "R=2.67", ";", "p", "0.05", ")", ".", "Quality", "of", "life", "correlated", "before", "HTx", "best", "with", "subjectively", "rated", "health", "(", "r=0.61", ",", "p", "0.01", ")", "and", "6", "months", "after", "with", "satisfaction", "about", "health", "status", "(", "r=0.76", ",", "p", "0.01", ")", ".", "Only", "in", "25", "%", "were", "expected", "improvements", "fulfilled", "regarding", "sexual", "activity", "/", "satisfaction", ",", "professional", "situation", ",", "and", "recreational", "activities", ".", "90", "%", "of", "posttransplant", "patients", "reported", "physical", "compaints", ",", "most", "by", "effects", "of", "immunsuppression", ",", "but", "were", "coping", "well", ".", "The", "study", "shows", "that", "already", "6", "weeks", "after", "successful", "HTx", "all", "quality", "of", "life", "parameters", "improved", "significantly", ".", "Despite", "some", "unfulfilled", "expectations", "and", "complaints", ",", "the", "postoperative", "life", "situation", "of", "HTx", "patients", "appeared", "significantly", "improved", "." ]	[ "umlsterm" ]
prospective study, quality of life, life, satisfaction, health, time, heart transplantation, patients, questionnaires, heart, transplant, symptom, quality of life, assessment, life quality, life changes, language, age, evaluation, standard, Quality of life, patients, congestive heart failure, quality of life, health status, health status, Quality of life, health, satisfaction, health status, recreational activities, patients, quality of life, postoperative, life, patients	ZfuerKardiologie.80870808.eng.abstr_task2	Sentence: This prospective study was designed to compare quality of life , life satisfaction , and subjective ratings of health before and at variable time intervals after heart transplantation ( HTx ) . 175 patients were included between February 1994 and December 1997. Every six months before and 1,5 , 3 , 6 , and 12 months after HTx , they received the following standardized and validated questionnaires : German SF 36 , heart failure and specific transplant symptom list , global quality of life assessment , Munich life quality dimension list , expected/experienced life changes after HTx , good command of the German language , and a minimum age of 18 years . During data evaluation , median ( Me ) , mean ( M ) , and standard deviation ( SD ) were created from individual parameters . Quality of life was rated as very poor by 84% of patients with congestive heart failure . Only 6 weeks after HTx , 74% rated their quality of life as significantly better . Before HTx 80% were very unsatisfied about their health status and 87% about physical performance . Six weeks after HTx , this parameter improved significantly and 76% were very satisfied about their health status and 50% about physical performance . While somatic changes expected before HTx corresponded well with experienced ones , psychological improvements were smaller than expected , but one year after HTx they were significant ( before : M=3.66; SD=0.9; Range ( R ) =3 . 78 vs 12 months postop : M=4.61; SD=0.6; R=2.67; p 0.05 ) . Quality of life correlated before HTx best with subjectively rated health ( r=0.61, p 0.01 ) and 6 months after with satisfaction about health status ( r=0.76, p 0.01 ) . Only in 25% were expected improvements fulfilled regarding sexual activity/satisfaction , professional situation , and recreational activities . 90% of posttransplant patients reported physical compaints , most by effects of immunsuppression , but were coping well . The study shows that already 6 weeks after successful HTx all quality of life parameters improved significantly . Despite some unfulfilled expectations and complaints , the postoperative life situation of HTx patients appeared significantly improved . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	This prospective study was designed to compare quality of life , life satisfaction , and subjective ratings of health before and at variable time intervals after heart transplantation ( HTx ) . 175 patients were included between February 1994 and December 1997. Every six months before and 1,5 , 3 , 6 , and 12 months after HTx , they received the following standardized and validated questionnaires : German SF 36 , heart failure and specific transplant symptom list , global quality of life assessment , Munich life quality dimension list , expected/experienced life changes after HTx , good command of the German language , and a minimum age of 18 years . During data evaluation , median ( Me ) , mean ( M ) , and standard deviation ( SD ) were created from individual parameters . Quality of life was rated as very poor by 84% of patients with congestive heart failure . Only 6 weeks after HTx , 74% rated their quality of life as significantly better . Before HTx 80% were very unsatisfied about their health status and 87% about physical performance . Six weeks after HTx , this parameter improved significantly and 76% were very satisfied about their health status and 50% about physical performance . While somatic changes expected before HTx corresponded well with experienced ones , psychological improvements were smaller than expected , but one year after HTx they were significant ( before : M=3.66; SD=0.9; Range ( R ) =3 . 78 vs 12 months postop : M=4.61; SD=0.6; R=2.67; p 0.05 ) . Quality of life correlated before HTx best with subjectively rated health ( r=0.61, p 0.01 ) and 6 months after with satisfaction about health status ( r=0.76, p 0.01 ) . Only in 25% were expected improvements fulfilled regarding sexual activity/satisfaction , professional situation , and recreational activities . 90% of posttransplant patients reported physical compaints , most by effects of immunsuppression , but were coping well . The study shows that already 6 weeks after successful HTx all quality of life parameters improved significantly . Despite some unfulfilled expectations and complaints , the postoperative life situation of HTx patients appeared significantly improved .	[ "This", "prospective", "study", "was", "designed", "to", "compare", "quality", "of", "life", ",", "life", "satisfaction", ",", "and", "subjective", "ratings", "of", "health", "before", "and", "at", "variable", "time", "intervals", "after", "heart", "transplantation", "(", "HTx", ")", ".", "175", "patients", "were", "included", "between", "February", "1994", "and", "December", "1997", ".", "Every", "six", "months", "before", "and", "1,5", ",", "3", ",", "6", ",", "and", "12", "months", "after", "HTx", ",", "they", "received", "the", "following", "standardized", "and", "validated", "questionnaires", ":", "German", "SF", "36", ",", "heart", "failure", "and", "specific", "transplant", "symptom", "list", ",", "global", "quality", "of", "life", "assessment", ",", "Munich", "life", "quality", "dimension", "list", ",", "expected", "/", "experienced", "life", "changes", "after", "HTx", ",", "good", "command", "of", "the", "German", "language", ",", "and", "a", "minimum", "age", "of", "18", "years", ".", "During", "data", "evaluation", ",", "median", "(", "Me", ")", ",", "mean", "(", "M", ")", ",", "and", "standard", "deviation", "(", "SD", ")", "were", "created", "from", "individual", "parameters", ".", "Quality", "of", "life", "was", "rated", "as", "very", "poor", "by", "84", "%", "of", "patients", "with", "congestive", "heart", "failure", ".", "Only", "6", "weeks", "after", "HTx", ",", "74", "%", "rated", "their", "quality", "of", "life", "as", "significantly", "better", ".", "Before", "HTx", "80", "%", "were", "very", "unsatisfied", "about", "their", "health", "status", "and", "87", "%", "about", "physical", "performance", ".", "Six", "weeks", "after", "HTx", ",", "this", "parameter", "improved", "significantly", "and", "76", "%", "were", "very", "satisfied", "about", "their", "health", "status", "and", "50", "%", "about", "physical", "performance", ".", "While", "somatic", "changes", "expected", "before", "HTx", "corresponded", "well", "with", "experienced", "ones", ",", "psychological", "improvements", "were", "smaller", "than", "expected", ",", "but", "one", "year", "after", "HTx", "they", "were", "significant", "(", "before", ":", "M=3.66", ";", "SD=0.9", ";", "Range", "(", "R", ")", "=3", ".", "78", "vs", "12", "months", "postop", ":", "M=4.61", ";", "SD=0.6", ";", "R=2.67", ";", "p", "0.05", ")", ".", "Quality", "of", "life", "correlated", "before", "HTx", "best", "with", "subjectively", "rated", "health", "(", "r=0.61", ",", "p", "0.01", ")", "and", "6", "months", "after", "with", "satisfaction", "about", "health", "status", "(", "r=0.76", ",", "p", "0.01", ")", ".", "Only", "in", "25", "%", "were", "expected", "improvements", "fulfilled", "regarding", "sexual", "activity", "/", "satisfaction", ",", "professional", "situation", ",", "and", "recreational", "activities", ".", "90", "%", "of", "posttransplant", "patients", "reported", "physical", "compaints", ",", "most", "by", "effects", "of", "immunsuppression", ",", "but", "were", "coping", "well", ".", "The", "study", "shows", "that", "already", "6", "weeks", "after", "successful", "HTx", "all", "quality", "of", "life", "parameters", "improved", "significantly", ".", "Despite", "some", "unfulfilled", "expectations", "and", "complaints", ",", "the", "postoperative", "life", "situation", "of", "HTx", "patients", "appeared", "significantly", "improved", "." ]	[ "umlsterm" ]
beta - lactam is a FAMILY, amoxicillin is a TRIVIAL, clavulanic acid is a TRIVIAL, CA is a ABBREVIATION, ticarcillin is a TRIVIAL, CA is a ABBREVIATION, amoxicillin is a TRIVIAL, sulbactam is a TRIVIAL, piperacillin is a TRIVIAL, tazobactam is a TRIVIAL, amoxicillin is a TRIVIAL, beta - lactam is a FAMILY, beta - lactam is a FAMILY, beta - lactam is a FAMILY, penicillins is a TRIVIAL, cephalothin is a TRIVIAL, beta - lactam is a FAMILY, piperacillin is a TRIVIAL, tazobactam is a TRIVIAL, amoxicillin is a TRIVIAL, cefoxitin is a TRIVIAL, cephalothin is a TRIVIAL, cefotaxime is a TRIVIAL, cefotaxime is a TRIVIAL, piperacillin is a TRIVIAL, tazobactam is a TRIVIAL, CA is a ABBREVIATION, amoxicillin is a TRIVIAL, ticarcillin is a TRIVIAL, sulbactam is a TRIVIAL, amoxicillin is a TRIVIAL, penicillins is a TRIVIAL, Piperacillin is a TRIVIAL	example-51_task0	Sentence: 8654448 Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents. The efficacy of the clinically available beta-lactam/beta-lactamase inhibitor combinations (amoxicillin/clavulanic acid (CA), ticarcillin/CA, amoxicillin/sulbactam, and piperacillin/tazobactam) was evaluated on amoxicillin-resistant Escherichia coli isolates having the main patterns of beta-lactam resistance. The patterns, which reflect the production of various beta-lactamase enzymes, were analyzed by a principal component analysis of susceptibility to 11 beta-lactam antibiotics or beta-lactam/beta-lactamase inhibitor combinations. Sixty-two percent of strains were not very susceptible to penicillins, cephalothin, or any beta-lactam/beta-lactamase inhibitor combinations except for piperacillin/tazobactam; these strains may represent high-level broad-spectrum beta-lactamase (so-called penicillinase) production phenotype or inhibitor-resistant TEM-like enzyme production phenotype. Of the strains, 14.7% were resistant to amoxicillin andticarcillin compatible with low-level broad-spectrum beta-lactamase production phenotype; 5.7% were cefoxitin resistant and were postulated to present a high-level cephalosporinase production phenotype; and 2.6% were resistant to cephalothin only, attributable to a low-level cephalosporinase production phenotype. Three percent of strains were intermediate or resistant to cefotaxime and may produce an extended-spectrum beta-lactamase, and the remaining strains (12 %), resistant to all tested antibiotics except for cefotaxime and piperacillin/tazobactam, were hypothesized to produce both broad-spectrum beta-lactamase plus cephalosporinase. The minimal inhibitory concentration (MIC) for these phenotype patterns indicated that combinations of CA plus amoxicillin or ticarcillin, or sulbactam plus amoxicillin, restored the activity of penicillins against phenotype 1 strains, whereas these combinations remained inactive against the other phenotype strains. Piperacillin plus tazobactamshowed the best in vitro effect against the strains of all resistance phenotypes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: FAMILY, TRIVIAL, ABBREVIATION	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "B-ABBREVIATION", "O", "O", "B-TRIVIAL", "O", "B-ABBREVIATION", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ABBREVIATION", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	8654448 Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents. The efficacy of the clinically available beta-lactam/beta-lactamase inhibitor combinations (amoxicillin/clavulanic acid (CA), ticarcillin/CA, amoxicillin/sulbactam, and piperacillin/tazobactam) was evaluated on amoxicillin-resistant Escherichia coli isolates having the main patterns of beta-lactam resistance. The patterns, which reflect the production of various beta-lactamase enzymes, were analyzed by a principal component analysis of susceptibility to 11 beta-lactam antibiotics or beta-lactam/beta-lactamase inhibitor combinations. Sixty-two percent of strains were not very susceptible to penicillins, cephalothin, or any beta-lactam/beta-lactamase inhibitor combinations except for piperacillin/tazobactam; these strains may represent high-level broad-spectrum beta-lactamase (so-called penicillinase) production phenotype or inhibitor-resistant TEM-like enzyme production phenotype. Of the strains, 14.7% were resistant to amoxicillin andticarcillin compatible with low-level broad-spectrum beta-lactamase production phenotype; 5.7% were cefoxitin resistant and were postulated to present a high-level cephalosporinase production phenotype; and 2.6% were resistant to cephalothin only, attributable to a low-level cephalosporinase production phenotype. Three percent of strains were intermediate or resistant to cefotaxime and may produce an extended-spectrum beta-lactamase, and the remaining strains (12 %), resistant to all tested antibiotics except for cefotaxime and piperacillin/tazobactam, were hypothesized to produce both broad-spectrum beta-lactamase plus cephalosporinase. The minimal inhibitory concentration (MIC) for these phenotype patterns indicated that combinations of CA plus amoxicillin or ticarcillin, or sulbactam plus amoxicillin, restored the activity of penicillins against phenotype 1 strains, whereas these combinations remained inactive against the other phenotype strains. Piperacillin plus tazobactamshowed the best in vitro effect against the strains of all resistance phenotypes.	[ "8654448", " ", "Activity", "of", "beta", "-", "lactamase", "inhibitor", "combinations", "on", "Escherichia", "coli", "isolates", "exhibiting", "various", "patterns", "of", "resistance", "to", "beta", "-", "lactam", "agents", ".", " ", "The", "efficacy", "of", "the", "clinically", "available", "beta", "-", "lactam", "/", "beta", "-", "lactamase", "inhibitor", "combinations", "(", "amoxicillin", "/", "clavulanic", "acid", "(", "CA", ")", ",", "ticarcillin", "/", "CA", ",", "amoxicillin", "/", "sulbactam", ",", "and", "piperacillin", "/", "tazobactam", ")", "was", "evaluated", "on", " ", "amoxicillin", "-", "resistant", "Escherichia", "coli", "isolates", "having", "the", "main", "patterns", "of", "beta", "-", "lactam", "resistance", ".", "The", "patterns", ",", "which", "reflect", "the", "production", "of", "various", "beta", "-", "lactamase", "enzymes", ",", "were", "analyzed", "by", "a", "principal", "component", "analysis", "of", "susceptibility", "to", "11", "beta", "-", "lactam", "antibiotics", "or", "beta", "-", "lactam", "/", "beta", "-", "lactamase", "inhibitor", "combinations", ".", "Sixty", "-", "two", "percent", "of", "strains", "were", "not", "very", "susceptible", "to", "penicillins", ",", "cephalothin", ",", "or", "any", "beta", "-", "lactam", "/", "beta", "-", "lactamase", "inhibitor", "combinations", "except", "for", "piperacillin", "/", "tazobactam", ";", "these", "strains", "may", "represent", "high", "-", "level", "broad", "-", "spectrum", "beta", "-", "lactamase", "(", "so", "-", "called", "penicillinase", ")", "production", "phenotype", "or", "inhibitor", "-", "resistant", "TEM", "-", "like", "enzyme", "production", "phenotype", ".", "Of", "the", "strains", ",", "14.7", "%", "were", "resistant", "to", "amoxicillin", "andticarcillin", " ", "compatible", "with", "low", "-", "level", "broad", "-", "spectrum", "beta", "-", "lactamase", "production", "phenotype", ";", "5.7", "%", "were", "cefoxitin", "resistant", "and", "were", "postulated", "to", "present", "a", "high", "-", "level", "cephalosporinase", "production", "phenotype", ";", "and", "2.6", "%", "were", "resistant", "to", "cephalothin", "only", ",", "attributable", "to", "a", "low", "-", "level", "cephalosporinase", "production", "phenotype", ".", "Three", "percent", "of", "strains", "were", "intermediate", "or", "resistant", "to", "cefotaxime", "and", "may", "produce", "an", "extended", "-", "spectrum", "beta", "-", "lactamase", ",", "and", "the", "remaining", "strains", "(", "12", "%", ")", ",", "resistant", "to", "all", "tested", "antibiotics", "except", "for", "cefotaxime", "and", "piperacillin", "/", "tazobactam", ",", "were", "hypothesized", "to", "produce", "both", "broad", "-", "spectrum", "beta", "-", "lactamase", "plus", "cephalosporinase", ".", "The", "minimal", "inhibitory", "concentration", "(", "MIC", ")", "for", "these", "phenotype", "patterns", "indicated", "that", "combinations", "of", "CA", "plus", "amoxicillin", "or", "ticarcillin", ",", "or", "sulbactam", "plus", "amoxicillin", ",", "restored", "the", "activity", "of", "penicillins", "against", "phenotype", "1", "strains", ",", "whereas", "these", "combinations", "remained", "inactive", "against", "the", "other", "phenotype", "strains", ".", "Piperacillin", "plus", "tazobactamshowed", " ", "the", "best", "in", "vitro", "effect", "against", "the", "strains", "of", "all", "resistance", "phenotypes", "." ]	[ "TRIVIAL", "FAMILY", "ABBREVIATION" ]
beta - lactam is a FAMILY, amoxicillin is a TRIVIAL, clavulanic acid is a TRIVIAL, CA is a ABBREVIATION, ticarcillin is a TRIVIAL, CA is a ABBREVIATION, amoxicillin is a TRIVIAL, sulbactam is a TRIVIAL, piperacillin is a TRIVIAL, tazobactam is a TRIVIAL, amoxicillin is a TRIVIAL, beta - lactam is a FAMILY, beta - lactam is a FAMILY, beta - lactam is a FAMILY, penicillins is a TRIVIAL, cephalothin is a TRIVIAL, beta - lactam is a FAMILY, piperacillin is a TRIVIAL, tazobactam is a TRIVIAL, amoxicillin is a TRIVIAL, cefoxitin is a TRIVIAL, cephalothin is a TRIVIAL, cefotaxime is a TRIVIAL, cefotaxime is a TRIVIAL, piperacillin is a TRIVIAL, tazobactam is a TRIVIAL, CA is a ABBREVIATION, amoxicillin is a TRIVIAL, ticarcillin is a TRIVIAL, sulbactam is a TRIVIAL, amoxicillin is a TRIVIAL, penicillins is a TRIVIAL, Piperacillin is a TRIVIAL	example-51_task1	Sentence: 8654448 Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents. The efficacy of the clinically available beta-lactam/beta-lactamase inhibitor combinations (amoxicillin/clavulanic acid (CA), ticarcillin/CA, amoxicillin/sulbactam, and piperacillin/tazobactam) was evaluated on amoxicillin-resistant Escherichia coli isolates having the main patterns of beta-lactam resistance. The patterns, which reflect the production of various beta-lactamase enzymes, were analyzed by a principal component analysis of susceptibility to 11 beta-lactam antibiotics or beta-lactam/beta-lactamase inhibitor combinations. Sixty-two percent of strains were not very susceptible to penicillins, cephalothin, or any beta-lactam/beta-lactamase inhibitor combinations except for piperacillin/tazobactam; these strains may represent high-level broad-spectrum beta-lactamase (so-called penicillinase) production phenotype or inhibitor-resistant TEM-like enzyme production phenotype. Of the strains, 14.7% were resistant to amoxicillin andticarcillin compatible with low-level broad-spectrum beta-lactamase production phenotype; 5.7% were cefoxitin resistant and were postulated to present a high-level cephalosporinase production phenotype; and 2.6% were resistant to cephalothin only, attributable to a low-level cephalosporinase production phenotype. Three percent of strains were intermediate or resistant to cefotaxime and may produce an extended-spectrum beta-lactamase, and the remaining strains (12 %), resistant to all tested antibiotics except for cefotaxime and piperacillin/tazobactam, were hypothesized to produce both broad-spectrum beta-lactamase plus cephalosporinase. The minimal inhibitory concentration (MIC) for these phenotype patterns indicated that combinations of CA plus amoxicillin or ticarcillin, or sulbactam plus amoxicillin, restored the activity of penicillins against phenotype 1 strains, whereas these combinations remained inactive against the other phenotype strains. Piperacillin plus tazobactamshowed the best in vitro effect against the strains of all resistance phenotypes. Instructions: please typing these entity words according to sentence: beta - lactam, amoxicillin, clavulanic acid, CA, ticarcillin, CA, amoxicillin, sulbactam, piperacillin, tazobactam, amoxicillin, beta - lactam, beta - lactam, beta - lactam, penicillins, cephalothin, beta - lactam, piperacillin, tazobactam, amoxicillin, cefoxitin, cephalothin, cefotaxime, cefotaxime, piperacillin, tazobactam, CA, amoxicillin, ticarcillin, sulbactam, amoxicillin, penicillins, Piperacillin Options: FAMILY, TRIVIAL, ABBREVIATION	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "B-ABBREVIATION", "O", "O", "B-TRIVIAL", "O", "B-ABBREVIATION", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ABBREVIATION", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	8654448 Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents. The efficacy of the clinically available beta-lactam/beta-lactamase inhibitor combinations (amoxicillin/clavulanic acid (CA), ticarcillin/CA, amoxicillin/sulbactam, and piperacillin/tazobactam) was evaluated on amoxicillin-resistant Escherichia coli isolates having the main patterns of beta-lactam resistance. The patterns, which reflect the production of various beta-lactamase enzymes, were analyzed by a principal component analysis of susceptibility to 11 beta-lactam antibiotics or beta-lactam/beta-lactamase inhibitor combinations. Sixty-two percent of strains were not very susceptible to penicillins, cephalothin, or any beta-lactam/beta-lactamase inhibitor combinations except for piperacillin/tazobactam; these strains may represent high-level broad-spectrum beta-lactamase (so-called penicillinase) production phenotype or inhibitor-resistant TEM-like enzyme production phenotype. Of the strains, 14.7% were resistant to amoxicillin andticarcillin compatible with low-level broad-spectrum beta-lactamase production phenotype; 5.7% were cefoxitin resistant and were postulated to present a high-level cephalosporinase production phenotype; and 2.6% were resistant to cephalothin only, attributable to a low-level cephalosporinase production phenotype. Three percent of strains were intermediate or resistant to cefotaxime and may produce an extended-spectrum beta-lactamase, and the remaining strains (12 %), resistant to all tested antibiotics except for cefotaxime and piperacillin/tazobactam, were hypothesized to produce both broad-spectrum beta-lactamase plus cephalosporinase. The minimal inhibitory concentration (MIC) for these phenotype patterns indicated that combinations of CA plus amoxicillin or ticarcillin, or sulbactam plus amoxicillin, restored the activity of penicillins against phenotype 1 strains, whereas these combinations remained inactive against the other phenotype strains. Piperacillin plus tazobactamshowed the best in vitro effect against the strains of all resistance phenotypes.	[ "8654448", " ", "Activity", "of", "beta", "-", "lactamase", "inhibitor", "combinations", "on", "Escherichia", "coli", "isolates", "exhibiting", "various", "patterns", "of", "resistance", "to", "beta", "-", "lactam", "agents", ".", " ", "The", "efficacy", "of", "the", "clinically", "available", "beta", "-", "lactam", "/", "beta", "-", "lactamase", "inhibitor", "combinations", "(", "amoxicillin", "/", "clavulanic", "acid", "(", "CA", ")", ",", "ticarcillin", "/", "CA", ",", "amoxicillin", "/", "sulbactam", ",", "and", "piperacillin", "/", "tazobactam", ")", "was", "evaluated", "on", " ", "amoxicillin", "-", "resistant", "Escherichia", "coli", "isolates", "having", "the", "main", "patterns", "of", "beta", "-", "lactam", "resistance", ".", "The", "patterns", ",", "which", "reflect", "the", "production", "of", "various", "beta", "-", "lactamase", "enzymes", ",", "were", "analyzed", "by", "a", "principal", "component", "analysis", "of", "susceptibility", "to", "11", "beta", "-", "lactam", "antibiotics", "or", "beta", "-", "lactam", "/", "beta", "-", "lactamase", "inhibitor", "combinations", ".", "Sixty", "-", "two", "percent", "of", "strains", "were", "not", "very", "susceptible", "to", "penicillins", ",", "cephalothin", ",", "or", "any", "beta", "-", "lactam", "/", "beta", "-", "lactamase", "inhibitor", "combinations", "except", "for", "piperacillin", "/", "tazobactam", ";", "these", "strains", "may", "represent", "high", "-", "level", "broad", "-", "spectrum", "beta", "-", "lactamase", "(", "so", "-", "called", "penicillinase", ")", "production", "phenotype", "or", "inhibitor", "-", "resistant", "TEM", "-", "like", "enzyme", "production", "phenotype", ".", "Of", "the", "strains", ",", "14.7", "%", "were", "resistant", "to", "amoxicillin", "andticarcillin", " ", "compatible", "with", "low", "-", "level", "broad", "-", "spectrum", "beta", "-", "lactamase", "production", "phenotype", ";", "5.7", "%", "were", "cefoxitin", "resistant", "and", "were", "postulated", "to", "present", "a", "high", "-", "level", "cephalosporinase", "production", "phenotype", ";", "and", "2.6", "%", "were", "resistant", "to", "cephalothin", "only", ",", "attributable", "to", "a", "low", "-", "level", "cephalosporinase", "production", "phenotype", ".", "Three", "percent", "of", "strains", "were", "intermediate", "or", "resistant", "to", "cefotaxime", "and", "may", "produce", "an", "extended", "-", "spectrum", "beta", "-", "lactamase", ",", "and", "the", "remaining", "strains", "(", "12", "%", ")", ",", "resistant", "to", "all", "tested", "antibiotics", "except", "for", "cefotaxime", "and", "piperacillin", "/", "tazobactam", ",", "were", "hypothesized", "to", "produce", "both", "broad", "-", "spectrum", "beta", "-", "lactamase", "plus", "cephalosporinase", ".", "The", "minimal", "inhibitory", "concentration", "(", "MIC", ")", "for", "these", "phenotype", "patterns", "indicated", "that", "combinations", "of", "CA", "plus", "amoxicillin", "or", "ticarcillin", ",", "or", "sulbactam", "plus", "amoxicillin", ",", "restored", "the", "activity", "of", "penicillins", "against", "phenotype", "1", "strains", ",", "whereas", "these", "combinations", "remained", "inactive", "against", "the", "other", "phenotype", "strains", ".", "Piperacillin", "plus", "tazobactamshowed", " ", "the", "best", "in", "vitro", "effect", "against", "the", "strains", "of", "all", "resistance", "phenotypes", "." ]	[ "TRIVIAL", "FAMILY", "ABBREVIATION" ]
beta - lactam, amoxicillin, clavulanic acid, CA, ticarcillin, CA, amoxicillin, sulbactam, piperacillin, tazobactam, amoxicillin, beta - lactam, beta - lactam, beta - lactam, penicillins, cephalothin, beta - lactam, piperacillin, tazobactam, amoxicillin, cefoxitin, cephalothin, cefotaxime, cefotaxime, piperacillin, tazobactam, CA, amoxicillin, ticarcillin, sulbactam, amoxicillin, penicillins, Piperacillin	example-51_task2	Sentence: 8654448 Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents. The efficacy of the clinically available beta-lactam/beta-lactamase inhibitor combinations (amoxicillin/clavulanic acid (CA), ticarcillin/CA, amoxicillin/sulbactam, and piperacillin/tazobactam) was evaluated on amoxicillin-resistant Escherichia coli isolates having the main patterns of beta-lactam resistance. The patterns, which reflect the production of various beta-lactamase enzymes, were analyzed by a principal component analysis of susceptibility to 11 beta-lactam antibiotics or beta-lactam/beta-lactamase inhibitor combinations. Sixty-two percent of strains were not very susceptible to penicillins, cephalothin, or any beta-lactam/beta-lactamase inhibitor combinations except for piperacillin/tazobactam; these strains may represent high-level broad-spectrum beta-lactamase (so-called penicillinase) production phenotype or inhibitor-resistant TEM-like enzyme production phenotype. Of the strains, 14.7% were resistant to amoxicillin andticarcillin compatible with low-level broad-spectrum beta-lactamase production phenotype; 5.7% were cefoxitin resistant and were postulated to present a high-level cephalosporinase production phenotype; and 2.6% were resistant to cephalothin only, attributable to a low-level cephalosporinase production phenotype. Three percent of strains were intermediate or resistant to cefotaxime and may produce an extended-spectrum beta-lactamase, and the remaining strains (12 %), resistant to all tested antibiotics except for cefotaxime and piperacillin/tazobactam, were hypothesized to produce both broad-spectrum beta-lactamase plus cephalosporinase. The minimal inhibitory concentration (MIC) for these phenotype patterns indicated that combinations of CA plus amoxicillin or ticarcillin, or sulbactam plus amoxicillin, restored the activity of penicillins against phenotype 1 strains, whereas these combinations remained inactive against the other phenotype strains. Piperacillin plus tazobactamshowed the best in vitro effect against the strains of all resistance phenotypes. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "B-ABBREVIATION", "O", "O", "B-TRIVIAL", "O", "B-ABBREVIATION", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ABBREVIATION", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	8654448 Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents. The efficacy of the clinically available beta-lactam/beta-lactamase inhibitor combinations (amoxicillin/clavulanic acid (CA), ticarcillin/CA, amoxicillin/sulbactam, and piperacillin/tazobactam) was evaluated on amoxicillin-resistant Escherichia coli isolates having the main patterns of beta-lactam resistance. The patterns, which reflect the production of various beta-lactamase enzymes, were analyzed by a principal component analysis of susceptibility to 11 beta-lactam antibiotics or beta-lactam/beta-lactamase inhibitor combinations. Sixty-two percent of strains were not very susceptible to penicillins, cephalothin, or any beta-lactam/beta-lactamase inhibitor combinations except for piperacillin/tazobactam; these strains may represent high-level broad-spectrum beta-lactamase (so-called penicillinase) production phenotype or inhibitor-resistant TEM-like enzyme production phenotype. Of the strains, 14.7% were resistant to amoxicillin andticarcillin compatible with low-level broad-spectrum beta-lactamase production phenotype; 5.7% were cefoxitin resistant and were postulated to present a high-level cephalosporinase production phenotype; and 2.6% were resistant to cephalothin only, attributable to a low-level cephalosporinase production phenotype. Three percent of strains were intermediate or resistant to cefotaxime and may produce an extended-spectrum beta-lactamase, and the remaining strains (12 %), resistant to all tested antibiotics except for cefotaxime and piperacillin/tazobactam, were hypothesized to produce both broad-spectrum beta-lactamase plus cephalosporinase. The minimal inhibitory concentration (MIC) for these phenotype patterns indicated that combinations of CA plus amoxicillin or ticarcillin, or sulbactam plus amoxicillin, restored the activity of penicillins against phenotype 1 strains, whereas these combinations remained inactive against the other phenotype strains. Piperacillin plus tazobactamshowed the best in vitro effect against the strains of all resistance phenotypes.	[ "8654448", " ", "Activity", "of", "beta", "-", "lactamase", "inhibitor", "combinations", "on", "Escherichia", "coli", "isolates", "exhibiting", "various", "patterns", "of", "resistance", "to", "beta", "-", "lactam", "agents", ".", " ", "The", "efficacy", "of", "the", "clinically", "available", "beta", "-", "lactam", "/", "beta", "-", "lactamase", "inhibitor", "combinations", "(", "amoxicillin", "/", "clavulanic", "acid", "(", "CA", ")", ",", "ticarcillin", "/", "CA", ",", "amoxicillin", "/", "sulbactam", ",", "and", "piperacillin", "/", "tazobactam", ")", "was", "evaluated", "on", " ", "amoxicillin", "-", "resistant", "Escherichia", "coli", "isolates", "having", "the", "main", "patterns", "of", "beta", "-", "lactam", "resistance", ".", "The", "patterns", ",", "which", "reflect", "the", "production", "of", "various", "beta", "-", "lactamase", "enzymes", ",", "were", "analyzed", "by", "a", "principal", "component", "analysis", "of", "susceptibility", "to", "11", "beta", "-", "lactam", "antibiotics", "or", "beta", "-", "lactam", "/", "beta", "-", "lactamase", "inhibitor", "combinations", ".", "Sixty", "-", "two", "percent", "of", "strains", "were", "not", "very", "susceptible", "to", "penicillins", ",", "cephalothin", ",", "or", "any", "beta", "-", "lactam", "/", "beta", "-", "lactamase", "inhibitor", "combinations", "except", "for", "piperacillin", "/", "tazobactam", ";", "these", "strains", "may", "represent", "high", "-", "level", "broad", "-", "spectrum", "beta", "-", "lactamase", "(", "so", "-", "called", "penicillinase", ")", "production", "phenotype", "or", "inhibitor", "-", "resistant", "TEM", "-", "like", "enzyme", "production", "phenotype", ".", "Of", "the", "strains", ",", "14.7", "%", "were", "resistant", "to", "amoxicillin", "andticarcillin", " ", "compatible", "with", "low", "-", "level", "broad", "-", "spectrum", "beta", "-", "lactamase", "production", "phenotype", ";", "5.7", "%", "were", "cefoxitin", "resistant", "and", "were", "postulated", "to", "present", "a", "high", "-", "level", "cephalosporinase", "production", "phenotype", ";", "and", "2.6", "%", "were", "resistant", "to", "cephalothin", "only", ",", "attributable", "to", "a", "low", "-", "level", "cephalosporinase", "production", "phenotype", ".", "Three", "percent", "of", "strains", "were", "intermediate", "or", "resistant", "to", "cefotaxime", "and", "may", "produce", "an", "extended", "-", "spectrum", "beta", "-", "lactamase", ",", "and", "the", "remaining", "strains", "(", "12", "%", ")", ",", "resistant", "to", "all", "tested", "antibiotics", "except", "for", "cefotaxime", "and", "piperacillin", "/", "tazobactam", ",", "were", "hypothesized", "to", "produce", "both", "broad", "-", "spectrum", "beta", "-", "lactamase", "plus", "cephalosporinase", ".", "The", "minimal", "inhibitory", "concentration", "(", "MIC", ")", "for", "these", "phenotype", "patterns", "indicated", "that", "combinations", "of", "CA", "plus", "amoxicillin", "or", "ticarcillin", ",", "or", "sulbactam", "plus", "amoxicillin", ",", "restored", "the", "activity", "of", "penicillins", "against", "phenotype", "1", "strains", ",", "whereas", "these", "combinations", "remained", "inactive", "against", "the", "other", "phenotype", "strains", ".", "Piperacillin", "plus", "tazobactamshowed", " ", "the", "best", "in", "vitro", "effect", "against", "the", "strains", "of", "all", "resistance", "phenotypes", "." ]	[ "TRIVIAL", "FAMILY", "ABBREVIATION" ]
MRI signal hyperintensities is a Outcome_Physical, and is a Outcome_Mental, failure to remit is a Outcome_Physical, antidepressant treatment is a Intervention_Pharmacological, . is a Outcome_Mental, remission is a Outcome_Physical, total lesion volume is a Outcome_Physical, geriatric depression is a Participant_Condition, lesion volume by region of interest ( ROI ) is a Outcome_Physical, Thirty - eight is a Participant_Sample-size, baseline MRIs is a Intervention_Physical, sertraline is a Intervention_Pharmacological, nortriptyline is a Intervention_Pharmacological, late - life depression is a Participant_Condition, DWMH is a Outcome_Physical, , and is a Outcome_Mental, PVH volumes is a Outcome_Physical, Remission from depression is a Outcome_Mental, Hamilton Rating Scale for Depression score is a Outcome_Mental	51155_task0	Sentence: MRI signal hyperintensities and failure to remit following antidepressant treatment . BACKGROUND MRI signal hyperintensities predict poor remission to antidepressant treatment . Previous studies using volumetrics in outpatient samples have relied on total lesion volume . The purpose of this study was to test whether remission from geriatric depression depends on lesion volume by region of interest ( ROI ) . METHOD Thirty-eight patients received baseline MRIs as part of a larger 12-week , randomized clinical trial comparing sertraline and nortriptyline in the treatment of late-life depression . MRIcro was used to quantify MRI-hyperintensity volume into total hyperintensity , deep white matter hyperintensity ( DWMH ) , and periventricular hyperintensity ( PVH ) volumes . High versus low total , DWMH , and PVH volumes were defined based on the highest quartile of their respective distributions . Remission from depression was defined as a 24-item Hamilton Rating Scale for Depression score ≤ 7 for two consecutive weeks . RESULTS Patients classified as having high DWMH were 7.14 times more likely not to remit following antidepressant treatment compared to patients classified as having low DWMH ( p=0.02 ) . Similar odds ratios were obtained for PVH ( OR=4.17 , p=0.16 ) and total volumes ( OR=5.00 , p=0.05 ) . Importantly , adjusting for age did not change the magnitude of these effects . LIMITATIONS A small and predominantly White sample . CONCLUSIONS This is the first study to test whether remission from geriatric depression depends on lesion volume by ROI in an outpatient sample . The pattern of remission rates and odds ratios was similar when patients were classified as having high DWMH , PVH or total volume suggesting that lesion location may not be critical . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Mental	[ "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Mental", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	MRI signal hyperintensities and failure to remit following antidepressant treatment . BACKGROUND MRI signal hyperintensities predict poor remission to antidepressant treatment . Previous studies using volumetrics in outpatient samples have relied on total lesion volume . The purpose of this study was to test whether remission from geriatric depression depends on lesion volume by region of interest ( ROI ) . METHOD Thirty-eight patients received baseline MRIs as part of a larger 12-week , randomized clinical trial comparing sertraline and nortriptyline in the treatment of late-life depression . MRIcro was used to quantify MRI-hyperintensity volume into total hyperintensity , deep white matter hyperintensity ( DWMH ) , and periventricular hyperintensity ( PVH ) volumes . High versus low total , DWMH , and PVH volumes were defined based on the highest quartile of their respective distributions . Remission from depression was defined as a 24-item Hamilton Rating Scale for Depression score ≤ 7 for two consecutive weeks . RESULTS Patients classified as having high DWMH were 7.14 times more likely not to remit following antidepressant treatment compared to patients classified as having low DWMH ( p=0.02 ) . Similar odds ratios were obtained for PVH ( OR=4.17 , p=0.16 ) and total volumes ( OR=5.00 , p=0.05 ) . Importantly , adjusting for age did not change the magnitude of these effects . LIMITATIONS A small and predominantly White sample . CONCLUSIONS This is the first study to test whether remission from geriatric depression depends on lesion volume by ROI in an outpatient sample . The pattern of remission rates and odds ratios was similar when patients were classified as having high DWMH , PVH or total volume suggesting that lesion location may not be critical .	[ "MRI", "signal", "hyperintensities", "and", "failure", "to", "remit", "following", "antidepressant", "treatment", ".", "BACKGROUND", "MRI", "signal", "hyperintensities", "predict", "poor", "remission", "to", "antidepressant", "treatment", ".", "Previous", "studies", "using", "volumetrics", "in", "outpatient", "samples", "have", "relied", "on", "total", "lesion", "volume", ".", "The", "purpose", "of", "this", "study", "was", "to", "test", "whether", "remission", "from", "geriatric", "depression", "depends", "on", "lesion", "volume", "by", "region", "of", "interest", "(", "ROI", ")", ".", "METHOD", "Thirty", "-", "eight", "patients", "received", "baseline", "MRIs", "as", "part", "of", "a", "larger", "12-week", ",", "randomized", "clinical", "trial", "comparing", "sertraline", "and", "nortriptyline", "in", "the", "treatment", "of", "late", "-", "life", "depression", ".", "MRIcro", "was", "used", "to", "quantify", "MRI", "-", "hyperintensity", "volume", "into", "total", "hyperintensity", ",", "deep", "white", "matter", "hyperintensity", "(", "DWMH", ")", ",", "and", "periventricular", "hyperintensity", "(", "PVH", ")", "volumes", ".", "High", "versus", "low", "total", ",", "DWMH", ",", "and", "PVH", "volumes", "were", "defined", "based", "on", "the", "highest", "quartile", "of", "their", "respective", "distributions", ".", "Remission", "from", "depression", "was", "defined", "as", "a", "24-item", "Hamilton", "Rating", "Scale", "for", "Depression", "score", "≤", "7", "for", "two", "consecutive", "weeks", ".", "RESULTS", "Patients", "classified", "as", "having", "high", "DWMH", "were", "7.14", "times", "more", "likely", "not", "to", "remit", "following", "antidepressant", "treatment", "compared", "to", "patients", "classified", "as", "having", "low", "DWMH", "(", "p=0.02", ")", ".", "Similar", "odds", "ratios", "were", "obtained", "for", "PVH", "(", "OR=4.17", ",", "p=0.16", ")", "and", "total", "volumes", "(", "OR=5.00", ",", "p=0.05", ")", ".", "Importantly", ",", "adjusting", "for", "age", "did", "not", "change", "the", "magnitude", "of", "these", "effects", ".", "LIMITATIONS", "A", "small", "and", "predominantly", "White", "sample", ".", "CONCLUSIONS", "This", "is", "the", "first", "study", "to", "test", "whether", "remission", "from", "geriatric", "depression", "depends", "on", "lesion", "volume", "by", "ROI", "in", "an", "outpatient", "sample", ".", "The", "pattern", "of", "remission", "rates", "and", "odds", "ratios", "was", "similar", "when", "patients", "were", "classified", "as", "having", "high", "DWMH", ",", "PVH", "or", "total", "volume", "suggesting", "that", "lesion", "location", "may", "not", "be", "critical", "." ]	[ "Outcome_Physical", "Outcome_Mental", "Intervention_Pharmacological", "Participant_Condition", "Intervention_Physical", "Participant_Sample-size" ]
MRI signal hyperintensities is a Outcome_Physical, and is a Outcome_Mental, failure to remit is a Outcome_Physical, antidepressant treatment is a Intervention_Pharmacological, . is a Outcome_Mental, remission is a Outcome_Physical, total lesion volume is a Outcome_Physical, geriatric depression is a Participant_Condition, lesion volume by region of interest ( ROI ) is a Outcome_Physical, Thirty - eight is a Participant_Sample-size, baseline MRIs is a Intervention_Physical, sertraline is a Intervention_Pharmacological, nortriptyline is a Intervention_Pharmacological, late - life depression is a Participant_Condition, DWMH is a Outcome_Physical, , and is a Outcome_Mental, PVH volumes is a Outcome_Physical, Remission from depression is a Outcome_Mental, Hamilton Rating Scale for Depression score is a Outcome_Mental	51155_task1	Sentence: MRI signal hyperintensities and failure to remit following antidepressant treatment . BACKGROUND MRI signal hyperintensities predict poor remission to antidepressant treatment . Previous studies using volumetrics in outpatient samples have relied on total lesion volume . The purpose of this study was to test whether remission from geriatric depression depends on lesion volume by region of interest ( ROI ) . METHOD Thirty-eight patients received baseline MRIs as part of a larger 12-week , randomized clinical trial comparing sertraline and nortriptyline in the treatment of late-life depression . MRIcro was used to quantify MRI-hyperintensity volume into total hyperintensity , deep white matter hyperintensity ( DWMH ) , and periventricular hyperintensity ( PVH ) volumes . High versus low total , DWMH , and PVH volumes were defined based on the highest quartile of their respective distributions . Remission from depression was defined as a 24-item Hamilton Rating Scale for Depression score ≤ 7 for two consecutive weeks . RESULTS Patients classified as having high DWMH were 7.14 times more likely not to remit following antidepressant treatment compared to patients classified as having low DWMH ( p=0.02 ) . Similar odds ratios were obtained for PVH ( OR=4.17 , p=0.16 ) and total volumes ( OR=5.00 , p=0.05 ) . Importantly , adjusting for age did not change the magnitude of these effects . LIMITATIONS A small and predominantly White sample . CONCLUSIONS This is the first study to test whether remission from geriatric depression depends on lesion volume by ROI in an outpatient sample . The pattern of remission rates and odds ratios was similar when patients were classified as having high DWMH , PVH or total volume suggesting that lesion location may not be critical . Instructions: please typing these entity words according to sentence: MRI signal hyperintensities, and, failure to remit, antidepressant treatment, ., remission, total lesion volume, geriatric depression, lesion volume by region of interest ( ROI ), Thirty - eight, baseline MRIs, sertraline, nortriptyline, late - life depression, DWMH, , and, PVH volumes, Remission from depression, Hamilton Rating Scale for Depression score Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Mental	[ "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Mental", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	MRI signal hyperintensities and failure to remit following antidepressant treatment . BACKGROUND MRI signal hyperintensities predict poor remission to antidepressant treatment . Previous studies using volumetrics in outpatient samples have relied on total lesion volume . The purpose of this study was to test whether remission from geriatric depression depends on lesion volume by region of interest ( ROI ) . METHOD Thirty-eight patients received baseline MRIs as part of a larger 12-week , randomized clinical trial comparing sertraline and nortriptyline in the treatment of late-life depression . MRIcro was used to quantify MRI-hyperintensity volume into total hyperintensity , deep white matter hyperintensity ( DWMH ) , and periventricular hyperintensity ( PVH ) volumes . High versus low total , DWMH , and PVH volumes were defined based on the highest quartile of their respective distributions . Remission from depression was defined as a 24-item Hamilton Rating Scale for Depression score ≤ 7 for two consecutive weeks . RESULTS Patients classified as having high DWMH were 7.14 times more likely not to remit following antidepressant treatment compared to patients classified as having low DWMH ( p=0.02 ) . Similar odds ratios were obtained for PVH ( OR=4.17 , p=0.16 ) and total volumes ( OR=5.00 , p=0.05 ) . Importantly , adjusting for age did not change the magnitude of these effects . LIMITATIONS A small and predominantly White sample . CONCLUSIONS This is the first study to test whether remission from geriatric depression depends on lesion volume by ROI in an outpatient sample . The pattern of remission rates and odds ratios was similar when patients were classified as having high DWMH , PVH or total volume suggesting that lesion location may not be critical .	[ "MRI", "signal", "hyperintensities", "and", "failure", "to", "remit", "following", "antidepressant", "treatment", ".", "BACKGROUND", "MRI", "signal", "hyperintensities", "predict", "poor", "remission", "to", "antidepressant", "treatment", ".", "Previous", "studies", "using", "volumetrics", "in", "outpatient", "samples", "have", "relied", "on", "total", "lesion", "volume", ".", "The", "purpose", "of", "this", "study", "was", "to", "test", "whether", "remission", "from", "geriatric", "depression", "depends", "on", "lesion", "volume", "by", "region", "of", "interest", "(", "ROI", ")", ".", "METHOD", "Thirty", "-", "eight", "patients", "received", "baseline", "MRIs", "as", "part", "of", "a", "larger", "12-week", ",", "randomized", "clinical", "trial", "comparing", "sertraline", "and", "nortriptyline", "in", "the", "treatment", "of", "late", "-", "life", "depression", ".", "MRIcro", "was", "used", "to", "quantify", "MRI", "-", "hyperintensity", "volume", "into", "total", "hyperintensity", ",", "deep", "white", "matter", "hyperintensity", "(", "DWMH", ")", ",", "and", "periventricular", "hyperintensity", "(", "PVH", ")", "volumes", ".", "High", "versus", "low", "total", ",", "DWMH", ",", "and", "PVH", "volumes", "were", "defined", "based", "on", "the", "highest", "quartile", "of", "their", "respective", "distributions", ".", "Remission", "from", "depression", "was", "defined", "as", "a", "24-item", "Hamilton", "Rating", "Scale", "for", "Depression", "score", "≤", "7", "for", "two", "consecutive", "weeks", ".", "RESULTS", "Patients", "classified", "as", "having", "high", "DWMH", "were", "7.14", "times", "more", "likely", "not", "to", "remit", "following", "antidepressant", "treatment", "compared", "to", "patients", "classified", "as", "having", "low", "DWMH", "(", "p=0.02", ")", ".", "Similar", "odds", "ratios", "were", "obtained", "for", "PVH", "(", "OR=4.17", ",", "p=0.16", ")", "and", "total", "volumes", "(", "OR=5.00", ",", "p=0.05", ")", ".", "Importantly", ",", "adjusting", "for", "age", "did", "not", "change", "the", "magnitude", "of", "these", "effects", ".", "LIMITATIONS", "A", "small", "and", "predominantly", "White", "sample", ".", "CONCLUSIONS", "This", "is", "the", "first", "study", "to", "test", "whether", "remission", "from", "geriatric", "depression", "depends", "on", "lesion", "volume", "by", "ROI", "in", "an", "outpatient", "sample", ".", "The", "pattern", "of", "remission", "rates", "and", "odds", "ratios", "was", "similar", "when", "patients", "were", "classified", "as", "having", "high", "DWMH", ",", "PVH", "or", "total", "volume", "suggesting", "that", "lesion", "location", "may", "not", "be", "critical", "." ]	[ "Outcome_Physical", "Outcome_Mental", "Intervention_Pharmacological", "Participant_Condition", "Intervention_Physical", "Participant_Sample-size" ]
MRI signal hyperintensities, and, failure to remit, antidepressant treatment, ., remission, total lesion volume, geriatric depression, lesion volume by region of interest ( ROI ), Thirty - eight, baseline MRIs, sertraline, nortriptyline, late - life depression, DWMH, , and, PVH volumes, Remission from depression, Hamilton Rating Scale for Depression score	51155_task2	Sentence: MRI signal hyperintensities and failure to remit following antidepressant treatment . BACKGROUND MRI signal hyperintensities predict poor remission to antidepressant treatment . Previous studies using volumetrics in outpatient samples have relied on total lesion volume . The purpose of this study was to test whether remission from geriatric depression depends on lesion volume by region of interest ( ROI ) . METHOD Thirty-eight patients received baseline MRIs as part of a larger 12-week , randomized clinical trial comparing sertraline and nortriptyline in the treatment of late-life depression . MRIcro was used to quantify MRI-hyperintensity volume into total hyperintensity , deep white matter hyperintensity ( DWMH ) , and periventricular hyperintensity ( PVH ) volumes . High versus low total , DWMH , and PVH volumes were defined based on the highest quartile of their respective distributions . Remission from depression was defined as a 24-item Hamilton Rating Scale for Depression score ≤ 7 for two consecutive weeks . RESULTS Patients classified as having high DWMH were 7.14 times more likely not to remit following antidepressant treatment compared to patients classified as having low DWMH ( p=0.02 ) . Similar odds ratios were obtained for PVH ( OR=4.17 , p=0.16 ) and total volumes ( OR=5.00 , p=0.05 ) . Importantly , adjusting for age did not change the magnitude of these effects . LIMITATIONS A small and predominantly White sample . CONCLUSIONS This is the first study to test whether remission from geriatric depression depends on lesion volume by ROI in an outpatient sample . The pattern of remission rates and odds ratios was similar when patients were classified as having high DWMH , PVH or total volume suggesting that lesion location may not be critical . Instructions: please extract entity words from the input sentence	[ "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Mental", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	MRI signal hyperintensities and failure to remit following antidepressant treatment . BACKGROUND MRI signal hyperintensities predict poor remission to antidepressant treatment . Previous studies using volumetrics in outpatient samples have relied on total lesion volume . The purpose of this study was to test whether remission from geriatric depression depends on lesion volume by region of interest ( ROI ) . METHOD Thirty-eight patients received baseline MRIs as part of a larger 12-week , randomized clinical trial comparing sertraline and nortriptyline in the treatment of late-life depression . MRIcro was used to quantify MRI-hyperintensity volume into total hyperintensity , deep white matter hyperintensity ( DWMH ) , and periventricular hyperintensity ( PVH ) volumes . High versus low total , DWMH , and PVH volumes were defined based on the highest quartile of their respective distributions . Remission from depression was defined as a 24-item Hamilton Rating Scale for Depression score ≤ 7 for two consecutive weeks . RESULTS Patients classified as having high DWMH were 7.14 times more likely not to remit following antidepressant treatment compared to patients classified as having low DWMH ( p=0.02 ) . Similar odds ratios were obtained for PVH ( OR=4.17 , p=0.16 ) and total volumes ( OR=5.00 , p=0.05 ) . Importantly , adjusting for age did not change the magnitude of these effects . LIMITATIONS A small and predominantly White sample . CONCLUSIONS This is the first study to test whether remission from geriatric depression depends on lesion volume by ROI in an outpatient sample . The pattern of remission rates and odds ratios was similar when patients were classified as having high DWMH , PVH or total volume suggesting that lesion location may not be critical .	[ "MRI", "signal", "hyperintensities", "and", "failure", "to", "remit", "following", "antidepressant", "treatment", ".", "BACKGROUND", "MRI", "signal", "hyperintensities", "predict", "poor", "remission", "to", "antidepressant", "treatment", ".", "Previous", "studies", "using", "volumetrics", "in", "outpatient", "samples", "have", "relied", "on", "total", "lesion", "volume", ".", "The", "purpose", "of", "this", "study", "was", "to", "test", "whether", "remission", "from", "geriatric", "depression", "depends", "on", "lesion", "volume", "by", "region", "of", "interest", "(", "ROI", ")", ".", "METHOD", "Thirty", "-", "eight", "patients", "received", "baseline", "MRIs", "as", "part", "of", "a", "larger", "12-week", ",", "randomized", "clinical", "trial", "comparing", "sertraline", "and", "nortriptyline", "in", "the", "treatment", "of", "late", "-", "life", "depression", ".", "MRIcro", "was", "used", "to", "quantify", "MRI", "-", "hyperintensity", "volume", "into", "total", "hyperintensity", ",", "deep", "white", "matter", "hyperintensity", "(", "DWMH", ")", ",", "and", "periventricular", "hyperintensity", "(", "PVH", ")", "volumes", ".", "High", "versus", "low", "total", ",", "DWMH", ",", "and", "PVH", "volumes", "were", "defined", "based", "on", "the", "highest", "quartile", "of", "their", "respective", "distributions", ".", "Remission", "from", "depression", "was", "defined", "as", "a", "24-item", "Hamilton", "Rating", "Scale", "for", "Depression", "score", "≤", "7", "for", "two", "consecutive", "weeks", ".", "RESULTS", "Patients", "classified", "as", "having", "high", "DWMH", "were", "7.14", "times", "more", "likely", "not", "to", "remit", "following", "antidepressant", "treatment", "compared", "to", "patients", "classified", "as", "having", "low", "DWMH", "(", "p=0.02", ")", ".", "Similar", "odds", "ratios", "were", "obtained", "for", "PVH", "(", "OR=4.17", ",", "p=0.16", ")", "and", "total", "volumes", "(", "OR=5.00", ",", "p=0.05", ")", ".", "Importantly", ",", "adjusting", "for", "age", "did", "not", "change", "the", "magnitude", "of", "these", "effects", ".", "LIMITATIONS", "A", "small", "and", "predominantly", "White", "sample", ".", "CONCLUSIONS", "This", "is", "the", "first", "study", "to", "test", "whether", "remission", "from", "geriatric", "depression", "depends", "on", "lesion", "volume", "by", "ROI", "in", "an", "outpatient", "sample", ".", "The", "pattern", "of", "remission", "rates", "and", "odds", "ratios", "was", "similar", "when", "patients", "were", "classified", "as", "having", "high", "DWMH", ",", "PVH", "or", "total", "volume", "suggesting", "that", "lesion", "location", "may", "not", "be", "critical", "." ]	[ "Outcome_Physical", "Outcome_Mental", "Intervention_Pharmacological", "Participant_Condition", "Intervention_Physical", "Participant_Sample-size" ]
mouse carbonic anhydrase V is a GENE-Y, The carbonic anhydrase V is a GENE-Y, amino is a CHEMICAL, amino acids is a CHEMICAL, carbonic anhydrase ( CA ) V is a GENE-Y, CA V is a GENE-Y, CO2 is a CHEMICAL, mouse CA V is a GENE-Y, CA I is a GENE-Y, acetazolamide is a CHEMICAL, ethoxzolamide is a CHEMICAL, cyanate is a CHEMICAL, CA V is a GENE-Y, CA II is a GENE-Y, Mouse CA V is a GENE-Y, histidine is a CHEMICAL, CA V is a GENE-Y, Tyr64 - ->His is a GENE-N, CA V is a GENE-Y, tyrosine is a CHEMICAL	27984_task0	Sentence: Catalytic properties of mouse carbonic anhydrase V. A cDNA encoding the mouse carbonic anhydrase V gene was isolated by reverse transcription and polymerase chain reaction from BALB/c mouse liver mRNA. Vectors containing the full coding sequence as well as two different NH2-terminal truncated genes expressed enzymatically active protein in Escherichia coli. The carbonic anhydrase V produced by a vector containing the full coding sequence, which includes a possible NH2-terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several amino-terminal ends. The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 amino acids, yielding a protein equivalent to a carbonic anhydrase (CA) V isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions. These latter two forms of CA V had identical steady-state constants for the hydration of CO2, with maximal values of kcat/Km at 3 x 10(7) M-1 s-1 and kcat at 3 x 10(5) s-1 with an apparent pKa for catalysis of 7.4 determined from kcat/Km. In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II. Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway. Investigation of a site-specific mutant of CA V containing the replacement Tyr64-->His showed that the unique kinetic properties of CA V are not due to the presence of tyrosine at position 64. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O" ]	Catalytic properties of mouse carbonic anhydrase V. A cDNA encoding the mouse carbonic anhydrase V gene was isolated by reverse transcription and polymerase chain reaction from BALB/c mouse liver mRNA. Vectors containing the full coding sequence as well as two different NH2-terminal truncated genes expressed enzymatically active protein in Escherichia coli. The carbonic anhydrase V produced by a vector containing the full coding sequence, which includes a possible NH2-terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several amino-terminal ends. The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 amino acids, yielding a protein equivalent to a carbonic anhydrase (CA) V isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions. These latter two forms of CA V had identical steady-state constants for the hydration of CO2, with maximal values of kcat/Km at 3 x 10(7) M-1 s-1 and kcat at 3 x 10(5) s-1 with an apparent pKa for catalysis of 7.4 determined from kcat/Km. In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II. Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway. Investigation of a site-specific mutant of CA V containing the replacement Tyr64-->His showed that the unique kinetic properties of CA V are not due to the presence of tyrosine at position 64.	[ "Catalytic", "properties", "of", "mouse", "carbonic", "anhydrase", "V.", "\n", "A", "cDNA", "encoding", "the", "mouse", "carbonic", "anhydrase", "V", "gene", "was", "isolated", "by", "reverse", "transcription", "and", "polymerase", "chain", "reaction", "from", "BALB", "/", "c", "mouse", "liver", "mRNA", ".", "Vectors", "containing", "the", "full", "coding", "sequence", "as", "well", "as", "two", "different", "NH2-terminal", "truncated", "genes", "expressed", "enzymatically", "active", "protein", "in", "Escherichia", "coli", ".", "The", "carbonic", "anhydrase", "V", "produced", "by", "a", "vector", "containing", "the", "full", "coding", "sequence", ",", "which", "includes", "a", "possible", "NH2-terminal", "mitochondrial", "targeting", "signal", ",", "was", "proteolytically", "processed", "by", "E.", "coli", "and", "contained", "several", "amino", "-", "terminal", "ends", ".", "The", "two", "NH2-terminal", "truncated", "vectors", "deleted", ",", "respectively", ",", "1", ")", "the", "29-amino", "acid", "putative", "targeting", "sequence", "and", "2", ")", "51", "amino", "acids", ",", "yielding", "a", "protein", "equivalent", "to", "a", "carbonic", "anhydrase", "(", "CA", ")", "V", "isolated", "from", "mouse", "liver", "mitochondria", ";", "and", "both", "vectors", "produced", "homogeneous", "protein", "fractions", ".", "These", "latter", "two", "forms", "of", "CA", "V", "had", "identical", "steady", "-", "state", "constants", "for", "the", "hydration", "of", "CO2", ",", "with", "maximal", "values", "of", "kcat", "/", "Km", "at", "3", "x", "10(7", ")", "M-1", "s-1", "and", "kcat", "at", "3", "x", "10(5", ")", "s-1", "with", "an", "apparent", "pKa", "for", "catalysis", "of", "7.4", "determined", "from", "kcat", "/", "Km", ".", "In", "catalytic", "properties", ",", "mouse", "CA", "V", "is", "closest", "to", "CA", "I", ";", "however", ",", "in", "inhibition", "by", "acetazolamide", ",", "ethoxzolamide", ",", "and", "cyanate", ",", "CA", "V", "is", "very", "similar", "to", "CA", "II", ".", "Mouse", "CA", "V", "has", "a", "tyrosine", "at", "position", "64", ",", "where", "the", "highly", "active", "isozyme", "II", "has", "histidine", "serving", "as", "a", "proton", "shuttle", "in", "the", "catalytic", "pathway", ".", "Investigation", "of", "a", "site", "-", "specific", "mutant", "of", "CA", "V", "containing", "the", "replacement", "Tyr64", "-", "->His", "showed", "that", "the", "unique", "kinetic", "properties", "of", "CA", "V", "are", "not", "due", "to", "the", "presence", "of", "tyrosine", "at", "position", "64", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
mouse carbonic anhydrase V is a GENE-Y, The carbonic anhydrase V is a GENE-Y, amino is a CHEMICAL, amino acids is a CHEMICAL, carbonic anhydrase ( CA ) V is a GENE-Y, CA V is a GENE-Y, CO2 is a CHEMICAL, mouse CA V is a GENE-Y, CA I is a GENE-Y, acetazolamide is a CHEMICAL, ethoxzolamide is a CHEMICAL, cyanate is a CHEMICAL, CA V is a GENE-Y, CA II is a GENE-Y, Mouse CA V is a GENE-Y, histidine is a CHEMICAL, CA V is a GENE-Y, Tyr64 - ->His is a GENE-N, CA V is a GENE-Y, tyrosine is a CHEMICAL	27984_task1	Sentence: Catalytic properties of mouse carbonic anhydrase V. A cDNA encoding the mouse carbonic anhydrase V gene was isolated by reverse transcription and polymerase chain reaction from BALB/c mouse liver mRNA. Vectors containing the full coding sequence as well as two different NH2-terminal truncated genes expressed enzymatically active protein in Escherichia coli. The carbonic anhydrase V produced by a vector containing the full coding sequence, which includes a possible NH2-terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several amino-terminal ends. The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 amino acids, yielding a protein equivalent to a carbonic anhydrase (CA) V isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions. These latter two forms of CA V had identical steady-state constants for the hydration of CO2, with maximal values of kcat/Km at 3 x 10(7) M-1 s-1 and kcat at 3 x 10(5) s-1 with an apparent pKa for catalysis of 7.4 determined from kcat/Km. In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II. Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway. Investigation of a site-specific mutant of CA V containing the replacement Tyr64-->His showed that the unique kinetic properties of CA V are not due to the presence of tyrosine at position 64. Instructions: please typing these entity words according to sentence: mouse carbonic anhydrase V, The carbonic anhydrase V, amino, amino acids, carbonic anhydrase ( CA ) V, CA V, CO2, mouse CA V, CA I, acetazolamide, ethoxzolamide, cyanate, CA V, CA II, Mouse CA V, histidine, CA V, Tyr64 - ->His, CA V, tyrosine Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O" ]	Catalytic properties of mouse carbonic anhydrase V. A cDNA encoding the mouse carbonic anhydrase V gene was isolated by reverse transcription and polymerase chain reaction from BALB/c mouse liver mRNA. Vectors containing the full coding sequence as well as two different NH2-terminal truncated genes expressed enzymatically active protein in Escherichia coli. The carbonic anhydrase V produced by a vector containing the full coding sequence, which includes a possible NH2-terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several amino-terminal ends. The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 amino acids, yielding a protein equivalent to a carbonic anhydrase (CA) V isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions. These latter two forms of CA V had identical steady-state constants for the hydration of CO2, with maximal values of kcat/Km at 3 x 10(7) M-1 s-1 and kcat at 3 x 10(5) s-1 with an apparent pKa for catalysis of 7.4 determined from kcat/Km. In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II. Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway. Investigation of a site-specific mutant of CA V containing the replacement Tyr64-->His showed that the unique kinetic properties of CA V are not due to the presence of tyrosine at position 64.	[ "Catalytic", "properties", "of", "mouse", "carbonic", "anhydrase", "V.", "\n", "A", "cDNA", "encoding", "the", "mouse", "carbonic", "anhydrase", "V", "gene", "was", "isolated", "by", "reverse", "transcription", "and", "polymerase", "chain", "reaction", "from", "BALB", "/", "c", "mouse", "liver", "mRNA", ".", "Vectors", "containing", "the", "full", "coding", "sequence", "as", "well", "as", "two", "different", "NH2-terminal", "truncated", "genes", "expressed", "enzymatically", "active", "protein", "in", "Escherichia", "coli", ".", "The", "carbonic", "anhydrase", "V", "produced", "by", "a", "vector", "containing", "the", "full", "coding", "sequence", ",", "which", "includes", "a", "possible", "NH2-terminal", "mitochondrial", "targeting", "signal", ",", "was", "proteolytically", "processed", "by", "E.", "coli", "and", "contained", "several", "amino", "-", "terminal", "ends", ".", "The", "two", "NH2-terminal", "truncated", "vectors", "deleted", ",", "respectively", ",", "1", ")", "the", "29-amino", "acid", "putative", "targeting", "sequence", "and", "2", ")", "51", "amino", "acids", ",", "yielding", "a", "protein", "equivalent", "to", "a", "carbonic", "anhydrase", "(", "CA", ")", "V", "isolated", "from", "mouse", "liver", "mitochondria", ";", "and", "both", "vectors", "produced", "homogeneous", "protein", "fractions", ".", "These", "latter", "two", "forms", "of", "CA", "V", "had", "identical", "steady", "-", "state", "constants", "for", "the", "hydration", "of", "CO2", ",", "with", "maximal", "values", "of", "kcat", "/", "Km", "at", "3", "x", "10(7", ")", "M-1", "s-1", "and", "kcat", "at", "3", "x", "10(5", ")", "s-1", "with", "an", "apparent", "pKa", "for", "catalysis", "of", "7.4", "determined", "from", "kcat", "/", "Km", ".", "In", "catalytic", "properties", ",", "mouse", "CA", "V", "is", "closest", "to", "CA", "I", ";", "however", ",", "in", "inhibition", "by", "acetazolamide", ",", "ethoxzolamide", ",", "and", "cyanate", ",", "CA", "V", "is", "very", "similar", "to", "CA", "II", ".", "Mouse", "CA", "V", "has", "a", "tyrosine", "at", "position", "64", ",", "where", "the", "highly", "active", "isozyme", "II", "has", "histidine", "serving", "as", "a", "proton", "shuttle", "in", "the", "catalytic", "pathway", ".", "Investigation", "of", "a", "site", "-", "specific", "mutant", "of", "CA", "V", "containing", "the", "replacement", "Tyr64", "-", "->His", "showed", "that", "the", "unique", "kinetic", "properties", "of", "CA", "V", "are", "not", "due", "to", "the", "presence", "of", "tyrosine", "at", "position", "64", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
mouse carbonic anhydrase V, The carbonic anhydrase V, amino, amino acids, carbonic anhydrase ( CA ) V, CA V, CO2, mouse CA V, CA I, acetazolamide, ethoxzolamide, cyanate, CA V, CA II, Mouse CA V, histidine, CA V, Tyr64 - ->His, CA V, tyrosine	27984_task2	Sentence: Catalytic properties of mouse carbonic anhydrase V. A cDNA encoding the mouse carbonic anhydrase V gene was isolated by reverse transcription and polymerase chain reaction from BALB/c mouse liver mRNA. Vectors containing the full coding sequence as well as two different NH2-terminal truncated genes expressed enzymatically active protein in Escherichia coli. The carbonic anhydrase V produced by a vector containing the full coding sequence, which includes a possible NH2-terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several amino-terminal ends. The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 amino acids, yielding a protein equivalent to a carbonic anhydrase (CA) V isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions. These latter two forms of CA V had identical steady-state constants for the hydration of CO2, with maximal values of kcat/Km at 3 x 10(7) M-1 s-1 and kcat at 3 x 10(5) s-1 with an apparent pKa for catalysis of 7.4 determined from kcat/Km. In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II. Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway. Investigation of a site-specific mutant of CA V containing the replacement Tyr64-->His showed that the unique kinetic properties of CA V are not due to the presence of tyrosine at position 64. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O" ]	Catalytic properties of mouse carbonic anhydrase V. A cDNA encoding the mouse carbonic anhydrase V gene was isolated by reverse transcription and polymerase chain reaction from BALB/c mouse liver mRNA. Vectors containing the full coding sequence as well as two different NH2-terminal truncated genes expressed enzymatically active protein in Escherichia coli. The carbonic anhydrase V produced by a vector containing the full coding sequence, which includes a possible NH2-terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several amino-terminal ends. The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 amino acids, yielding a protein equivalent to a carbonic anhydrase (CA) V isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions. These latter two forms of CA V had identical steady-state constants for the hydration of CO2, with maximal values of kcat/Km at 3 x 10(7) M-1 s-1 and kcat at 3 x 10(5) s-1 with an apparent pKa for catalysis of 7.4 determined from kcat/Km. In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II. Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway. Investigation of a site-specific mutant of CA V containing the replacement Tyr64-->His showed that the unique kinetic properties of CA V are not due to the presence of tyrosine at position 64.	[ "Catalytic", "properties", "of", "mouse", "carbonic", "anhydrase", "V.", "\n", "A", "cDNA", "encoding", "the", "mouse", "carbonic", "anhydrase", "V", "gene", "was", "isolated", "by", "reverse", "transcription", "and", "polymerase", "chain", "reaction", "from", "BALB", "/", "c", "mouse", "liver", "mRNA", ".", "Vectors", "containing", "the", "full", "coding", "sequence", "as", "well", "as", "two", "different", "NH2-terminal", "truncated", "genes", "expressed", "enzymatically", "active", "protein", "in", "Escherichia", "coli", ".", "The", "carbonic", "anhydrase", "V", "produced", "by", "a", "vector", "containing", "the", "full", "coding", "sequence", ",", "which", "includes", "a", "possible", "NH2-terminal", "mitochondrial", "targeting", "signal", ",", "was", "proteolytically", "processed", "by", "E.", "coli", "and", "contained", "several", "amino", "-", "terminal", "ends", ".", "The", "two", "NH2-terminal", "truncated", "vectors", "deleted", ",", "respectively", ",", "1", ")", "the", "29-amino", "acid", "putative", "targeting", "sequence", "and", "2", ")", "51", "amino", "acids", ",", "yielding", "a", "protein", "equivalent", "to", "a", "carbonic", "anhydrase", "(", "CA", ")", "V", "isolated", "from", "mouse", "liver", "mitochondria", ";", "and", "both", "vectors", "produced", "homogeneous", "protein", "fractions", ".", "These", "latter", "two", "forms", "of", "CA", "V", "had", "identical", "steady", "-", "state", "constants", "for", "the", "hydration", "of", "CO2", ",", "with", "maximal", "values", "of", "kcat", "/", "Km", "at", "3", "x", "10(7", ")", "M-1", "s-1", "and", "kcat", "at", "3", "x", "10(5", ")", "s-1", "with", "an", "apparent", "pKa", "for", "catalysis", "of", "7.4", "determined", "from", "kcat", "/", "Km", ".", "In", "catalytic", "properties", ",", "mouse", "CA", "V", "is", "closest", "to", "CA", "I", ";", "however", ",", "in", "inhibition", "by", "acetazolamide", ",", "ethoxzolamide", ",", "and", "cyanate", ",", "CA", "V", "is", "very", "similar", "to", "CA", "II", ".", "Mouse", "CA", "V", "has", "a", "tyrosine", "at", "position", "64", ",", "where", "the", "highly", "active", "isozyme", "II", "has", "histidine", "serving", "as", "a", "proton", "shuttle", "in", "the", "catalytic", "pathway", ".", "Investigation", "of", "a", "site", "-", "specific", "mutant", "of", "CA", "V", "containing", "the", "replacement", "Tyr64", "-", "->His", "showed", "that", "the", "unique", "kinetic", "properties", "of", "CA", "V", "are", "not", "due", "to", "the", "presence", "of", "tyrosine", "at", "position", "64", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
glucagon is a Intervention_Pharmacological, hyoscine N - butyl bromide is a Intervention_Pharmacological, endoscopic retrograde cholangiopancreatography is a Intervention_Physical, endoscopic retrograde cholangiopancreatography ( ERCP ) . is a Participant_Condition, basal blood sugar and amylase levels . is a Outcome_Physical, basal pulse and duodenal peristaltic rates is a Outcome_Physical, 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N - butyl bromide ( n = 36 ) is a Participant_Condition, Glucagon is a Intervention_Pharmacological, hyperglycemia is a Outcome_Physical, anticholinergic effect . is a Outcome_Physical, necessary interval for ERCP is a Outcome_Other, success rate for cholangiopancreatography is a Outcome_Other, hyperamylasemia nor pancreatitis is a Outcome_Physical, performance of ERCP is a Outcome_Other	81074_task0	Sentence: A randomized study comparing glucagon and hyoscine N-butyl bromide before endoscopic retrograde cholangiopancreatography . BACKGROUND This study tried to resolve whether glucagon is a better premedication for endoscopic retrograde cholangiopancreatography ( ERCP ) . METHODS We first measured the basal blood sugar and amylase levels . Then an endoscope was placed in the duodenum without premedication , and basal pulse and duodenal peristaltic rates were measured . ERCP began after studied subjects were randomly premedicated with either 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N-butyl bromide ( n = 36 ) intravenously . Ten minutes later the variables were measured again . RESULTS Glucagon elicited hyperglycemia whereas hyoscine N-butyl bromide manifested an anticholinergic effect . No difference was found between these two groups with regard to the necessary interval for ERCP ( 20.6 +/- 14.1 min versus 21.4 +/- 14.7 min ; NS ) or the success rate for cholangiopancreatography ( 92.1 % versus 91.7 % ; NS ) . Neither hyperamylasemia nor pancreatitis was preventable when glucagon was used . CONCLUSIONS The two premedications appear equally effective in the performance of ERCP . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Physical, Outcome_Other	[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]	A randomized study comparing glucagon and hyoscine N-butyl bromide before endoscopic retrograde cholangiopancreatography . BACKGROUND This study tried to resolve whether glucagon is a better premedication for endoscopic retrograde cholangiopancreatography ( ERCP ) . METHODS We first measured the basal blood sugar and amylase levels . Then an endoscope was placed in the duodenum without premedication , and basal pulse and duodenal peristaltic rates were measured . ERCP began after studied subjects were randomly premedicated with either 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N-butyl bromide ( n = 36 ) intravenously . Ten minutes later the variables were measured again . RESULTS Glucagon elicited hyperglycemia whereas hyoscine N-butyl bromide manifested an anticholinergic effect . No difference was found between these two groups with regard to the necessary interval for ERCP ( 20.6 +/- 14.1 min versus 21.4 +/- 14.7 min ; NS ) or the success rate for cholangiopancreatography ( 92.1 % versus 91.7 % ; NS ) . Neither hyperamylasemia nor pancreatitis was preventable when glucagon was used . CONCLUSIONS The two premedications appear equally effective in the performance of ERCP .	[ "A", "randomized", "study", "comparing", "glucagon", "and", "hyoscine", "N", "-", "butyl", "bromide", "before", "endoscopic", "retrograde", "cholangiopancreatography", ".", "BACKGROUND", "This", "study", "tried", "to", "resolve", "whether", "glucagon", "is", "a", "better", "premedication", "for", "endoscopic", "retrograde", "cholangiopancreatography", "(", "ERCP", ")", ".", "METHODS", "We", "first", "measured", "the", "basal", "blood", "sugar", "and", "amylase", "levels", ".", "Then", "an", "endoscope", "was", "placed", "in", "the", "duodenum", "without", "premedication", ",", "and", "basal", "pulse", "and", "duodenal", "peristaltic", "rates", "were", "measured", ".", "ERCP", "began", "after", "studied", "subjects", "were", "randomly", "premedicated", "with", "either", "1", "mg", "glucagon", "(", "n", "=", "38", ")", "or", "40", "mg", "hyoscine", "N", "-", "butyl", "bromide", "(", "n", "=", "36", ")", "intravenously", ".", "Ten", "minutes", "later", "the", "variables", "were", "measured", "again", ".", "RESULTS", "Glucagon", "elicited", "hyperglycemia", "whereas", "hyoscine", "N", "-", "butyl", "bromide", "manifested", "an", "anticholinergic", "effect", ".", "No", "difference", "was", "found", "between", "these", "two", "groups", "with", "regard", "to", "the", "necessary", "interval", "for", "ERCP", "(", "20.6", "+", "/-", "14.1", "min", "versus", "21.4", "+", "/-", "14.7", "min", ";", "NS", ")", "or", "the", "success", "rate", "for", "cholangiopancreatography", "(", "92.1", "%", "versus", "91.7", "%", ";", "NS", ")", ".", "Neither", "hyperamylasemia", "nor", "pancreatitis", "was", "preventable", "when", "glucagon", "was", "used", ".", "CONCLUSIONS", "The", "two", "premedications", "appear", "equally", "effective", "in", "the", "performance", "of", "ERCP", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Physical", "Outcome_Other", "Intervention_Pharmacological" ]
glucagon is a Intervention_Pharmacological, hyoscine N - butyl bromide is a Intervention_Pharmacological, endoscopic retrograde cholangiopancreatography is a Intervention_Physical, endoscopic retrograde cholangiopancreatography ( ERCP ) . is a Participant_Condition, basal blood sugar and amylase levels . is a Outcome_Physical, basal pulse and duodenal peristaltic rates is a Outcome_Physical, 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N - butyl bromide ( n = 36 ) is a Participant_Condition, Glucagon is a Intervention_Pharmacological, hyperglycemia is a Outcome_Physical, anticholinergic effect . is a Outcome_Physical, necessary interval for ERCP is a Outcome_Other, success rate for cholangiopancreatography is a Outcome_Other, hyperamylasemia nor pancreatitis is a Outcome_Physical, performance of ERCP is a Outcome_Other	81074_task1	Sentence: A randomized study comparing glucagon and hyoscine N-butyl bromide before endoscopic retrograde cholangiopancreatography . BACKGROUND This study tried to resolve whether glucagon is a better premedication for endoscopic retrograde cholangiopancreatography ( ERCP ) . METHODS We first measured the basal blood sugar and amylase levels . Then an endoscope was placed in the duodenum without premedication , and basal pulse and duodenal peristaltic rates were measured . ERCP began after studied subjects were randomly premedicated with either 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N-butyl bromide ( n = 36 ) intravenously . Ten minutes later the variables were measured again . RESULTS Glucagon elicited hyperglycemia whereas hyoscine N-butyl bromide manifested an anticholinergic effect . No difference was found between these two groups with regard to the necessary interval for ERCP ( 20.6 +/- 14.1 min versus 21.4 +/- 14.7 min ; NS ) or the success rate for cholangiopancreatography ( 92.1 % versus 91.7 % ; NS ) . Neither hyperamylasemia nor pancreatitis was preventable when glucagon was used . CONCLUSIONS The two premedications appear equally effective in the performance of ERCP . Instructions: please typing these entity words according to sentence: glucagon, hyoscine N - butyl bromide, endoscopic retrograde cholangiopancreatography, endoscopic retrograde cholangiopancreatography ( ERCP ) ., basal blood sugar and amylase levels ., basal pulse and duodenal peristaltic rates, 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N - butyl bromide ( n = 36 ), Glucagon, hyperglycemia, anticholinergic effect ., necessary interval for ERCP, success rate for cholangiopancreatography, hyperamylasemia nor pancreatitis, performance of ERCP Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Physical, Outcome_Other	[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]	A randomized study comparing glucagon and hyoscine N-butyl bromide before endoscopic retrograde cholangiopancreatography . BACKGROUND This study tried to resolve whether glucagon is a better premedication for endoscopic retrograde cholangiopancreatography ( ERCP ) . METHODS We first measured the basal blood sugar and amylase levels . Then an endoscope was placed in the duodenum without premedication , and basal pulse and duodenal peristaltic rates were measured . ERCP began after studied subjects were randomly premedicated with either 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N-butyl bromide ( n = 36 ) intravenously . Ten minutes later the variables were measured again . RESULTS Glucagon elicited hyperglycemia whereas hyoscine N-butyl bromide manifested an anticholinergic effect . No difference was found between these two groups with regard to the necessary interval for ERCP ( 20.6 +/- 14.1 min versus 21.4 +/- 14.7 min ; NS ) or the success rate for cholangiopancreatography ( 92.1 % versus 91.7 % ; NS ) . Neither hyperamylasemia nor pancreatitis was preventable when glucagon was used . CONCLUSIONS The two premedications appear equally effective in the performance of ERCP .	[ "A", "randomized", "study", "comparing", "glucagon", "and", "hyoscine", "N", "-", "butyl", "bromide", "before", "endoscopic", "retrograde", "cholangiopancreatography", ".", "BACKGROUND", "This", "study", "tried", "to", "resolve", "whether", "glucagon", "is", "a", "better", "premedication", "for", "endoscopic", "retrograde", "cholangiopancreatography", "(", "ERCP", ")", ".", "METHODS", "We", "first", "measured", "the", "basal", "blood", "sugar", "and", "amylase", "levels", ".", "Then", "an", "endoscope", "was", "placed", "in", "the", "duodenum", "without", "premedication", ",", "and", "basal", "pulse", "and", "duodenal", "peristaltic", "rates", "were", "measured", ".", "ERCP", "began", "after", "studied", "subjects", "were", "randomly", "premedicated", "with", "either", "1", "mg", "glucagon", "(", "n", "=", "38", ")", "or", "40", "mg", "hyoscine", "N", "-", "butyl", "bromide", "(", "n", "=", "36", ")", "intravenously", ".", "Ten", "minutes", "later", "the", "variables", "were", "measured", "again", ".", "RESULTS", "Glucagon", "elicited", "hyperglycemia", "whereas", "hyoscine", "N", "-", "butyl", "bromide", "manifested", "an", "anticholinergic", "effect", ".", "No", "difference", "was", "found", "between", "these", "two", "groups", "with", "regard", "to", "the", "necessary", "interval", "for", "ERCP", "(", "20.6", "+", "/-", "14.1", "min", "versus", "21.4", "+", "/-", "14.7", "min", ";", "NS", ")", "or", "the", "success", "rate", "for", "cholangiopancreatography", "(", "92.1", "%", "versus", "91.7", "%", ";", "NS", ")", ".", "Neither", "hyperamylasemia", "nor", "pancreatitis", "was", "preventable", "when", "glucagon", "was", "used", ".", "CONCLUSIONS", "The", "two", "premedications", "appear", "equally", "effective", "in", "the", "performance", "of", "ERCP", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Physical", "Outcome_Other", "Intervention_Pharmacological" ]
glucagon, hyoscine N - butyl bromide, endoscopic retrograde cholangiopancreatography, endoscopic retrograde cholangiopancreatography ( ERCP ) ., basal blood sugar and amylase levels ., basal pulse and duodenal peristaltic rates, 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N - butyl bromide ( n = 36 ), Glucagon, hyperglycemia, anticholinergic effect ., necessary interval for ERCP, success rate for cholangiopancreatography, hyperamylasemia nor pancreatitis, performance of ERCP	81074_task2	Sentence: A randomized study comparing glucagon and hyoscine N-butyl bromide before endoscopic retrograde cholangiopancreatography . BACKGROUND This study tried to resolve whether glucagon is a better premedication for endoscopic retrograde cholangiopancreatography ( ERCP ) . METHODS We first measured the basal blood sugar and amylase levels . Then an endoscope was placed in the duodenum without premedication , and basal pulse and duodenal peristaltic rates were measured . ERCP began after studied subjects were randomly premedicated with either 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N-butyl bromide ( n = 36 ) intravenously . Ten minutes later the variables were measured again . RESULTS Glucagon elicited hyperglycemia whereas hyoscine N-butyl bromide manifested an anticholinergic effect . No difference was found between these two groups with regard to the necessary interval for ERCP ( 20.6 +/- 14.1 min versus 21.4 +/- 14.7 min ; NS ) or the success rate for cholangiopancreatography ( 92.1 % versus 91.7 % ; NS ) . Neither hyperamylasemia nor pancreatitis was preventable when glucagon was used . CONCLUSIONS The two premedications appear equally effective in the performance of ERCP . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]	A randomized study comparing glucagon and hyoscine N-butyl bromide before endoscopic retrograde cholangiopancreatography . BACKGROUND This study tried to resolve whether glucagon is a better premedication for endoscopic retrograde cholangiopancreatography ( ERCP ) . METHODS We first measured the basal blood sugar and amylase levels . Then an endoscope was placed in the duodenum without premedication , and basal pulse and duodenal peristaltic rates were measured . ERCP began after studied subjects were randomly premedicated with either 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N-butyl bromide ( n = 36 ) intravenously . Ten minutes later the variables were measured again . RESULTS Glucagon elicited hyperglycemia whereas hyoscine N-butyl bromide manifested an anticholinergic effect . No difference was found between these two groups with regard to the necessary interval for ERCP ( 20.6 +/- 14.1 min versus 21.4 +/- 14.7 min ; NS ) or the success rate for cholangiopancreatography ( 92.1 % versus 91.7 % ; NS ) . Neither hyperamylasemia nor pancreatitis was preventable when glucagon was used . CONCLUSIONS The two premedications appear equally effective in the performance of ERCP .	[ "A", "randomized", "study", "comparing", "glucagon", "and", "hyoscine", "N", "-", "butyl", "bromide", "before", "endoscopic", "retrograde", "cholangiopancreatography", ".", "BACKGROUND", "This", "study", "tried", "to", "resolve", "whether", "glucagon", "is", "a", "better", "premedication", "for", "endoscopic", "retrograde", "cholangiopancreatography", "(", "ERCP", ")", ".", "METHODS", "We", "first", "measured", "the", "basal", "blood", "sugar", "and", "amylase", "levels", ".", "Then", "an", "endoscope", "was", "placed", "in", "the", "duodenum", "without", "premedication", ",", "and", "basal", "pulse", "and", "duodenal", "peristaltic", "rates", "were", "measured", ".", "ERCP", "began", "after", "studied", "subjects", "were", "randomly", "premedicated", "with", "either", "1", "mg", "glucagon", "(", "n", "=", "38", ")", "or", "40", "mg", "hyoscine", "N", "-", "butyl", "bromide", "(", "n", "=", "36", ")", "intravenously", ".", "Ten", "minutes", "later", "the", "variables", "were", "measured", "again", ".", "RESULTS", "Glucagon", "elicited", "hyperglycemia", "whereas", "hyoscine", "N", "-", "butyl", "bromide", "manifested", "an", "anticholinergic", "effect", ".", "No", "difference", "was", "found", "between", "these", "two", "groups", "with", "regard", "to", "the", "necessary", "interval", "for", "ERCP", "(", "20.6", "+", "/-", "14.1", "min", "versus", "21.4", "+", "/-", "14.7", "min", ";", "NS", ")", "or", "the", "success", "rate", "for", "cholangiopancreatography", "(", "92.1", "%", "versus", "91.7", "%", ";", "NS", ")", ".", "Neither", "hyperamylasemia", "nor", "pancreatitis", "was", "preventable", "when", "glucagon", "was", "used", ".", "CONCLUSIONS", "The", "two", "premedications", "appear", "equally", "effective", "in", "the", "performance", "of", "ERCP", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Physical", "Outcome_Other", "Intervention_Pharmacological" ]
patients is an umlsterm, pancreatic is an umlsterm, carcinoma is an umlsterm, carcinoma is an umlsterm, pancreatitis is an umlsterm, role is an umlsterm, CA is an umlsterm, diagnosis is an umlsterm, head is an umlsterm, pancreas is an umlsterm, sensitivity is an umlsterm, pancreatic is an umlsterm, carcinoma is an umlsterm, carcinoma is an umlsterm, specificity is an umlsterm, Carcinoembryonic antigen is an umlsterm, patient is an umlsterm, tumor markers is an umlsterm, sensitivity is an umlsterm, specificity is an umlsterm, obstructive jaundice is an umlsterm, cancer is an umlsterm, patients is an umlsterm, pancreatitis is an umlsterm, CA is an umlsterm, prognosis is an umlsterm, patients is an umlsterm, tumor markers is an umlsterm	DerChirurg.60671007.eng.abstr_task0	Sentence: In 96 patients ( ductal pancreatic carcinoma , n = 34 ; periampullary carcinoma , n = 43 ; chronic pancreatitis , n = 19 ) the role of CA 19-9 in the diagnosis of lesions of the head of the pancreas were evaluated . The sensitivity for ductal pancreatic carcinoma was 73.3 % , for periampullary carcinoma 48.8 % , and specificity was 63.2 % . Carcinoembryonic antigen was elevated only in every fifth patient . Even when combining the two tumor markers no increase in sensitivity could be observed . The low specificity of 63 % , which decreased to 33 % in the case of obstructive jaundice , does not allow adequate preoperative differentiation between cancer patients and those with chronic pancreatitis . In cases of postoperatively elevated CA 19-9 level the prognosis is worse than in patients with normal tumor markers . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	In 96 patients ( ductal pancreatic carcinoma , n = 34 ; periampullary carcinoma , n = 43 ; chronic pancreatitis , n = 19 ) the role of CA 19-9 in the diagnosis of lesions of the head of the pancreas were evaluated . The sensitivity for ductal pancreatic carcinoma was 73.3 % , for periampullary carcinoma 48.8 % , and specificity was 63.2 % . Carcinoembryonic antigen was elevated only in every fifth patient . Even when combining the two tumor markers no increase in sensitivity could be observed . The low specificity of 63 % , which decreased to 33 % in the case of obstructive jaundice , does not allow adequate preoperative differentiation between cancer patients and those with chronic pancreatitis . In cases of postoperatively elevated CA 19-9 level the prognosis is worse than in patients with normal tumor markers .	[ "In", "96", "patients", "(", "ductal", "pancreatic", "carcinoma", ",", "n", "=", "34", ";", "periampullary", "carcinoma", ",", "n", "=", "43", ";", "chronic", "pancreatitis", ",", "n", "=", "19", ")", "the", "role", "of", "CA", "19", "-", "9", "in", "the", "diagnosis", "of", "lesions", "of", "the", "head", "of", "the", "pancreas", "were", "evaluated", ".", "The", "sensitivity", "for", "ductal", "pancreatic", "carcinoma", "was", "73.3", "%", ",", "for", "periampullary", "carcinoma", "48.8", "%", ",", "and", "specificity", "was", "63.2", "%", ".", "Carcinoembryonic", "antigen", "was", "elevated", "only", "in", "every", "fifth", "patient", ".", "Even", "when", "combining", "the", "two", "tumor", "markers", "no", "increase", "in", "sensitivity", "could", "be", "observed", ".", "The", "low", "specificity", "of", "63", "%", ",", "which", "decreased", "to", "33", "%", "in", "the", "case", "of", "obstructive", "jaundice", ",", "does", "not", "allow", "adequate", "preoperative", "differentiation", "between", "cancer", "patients", "and", "those", "with", "chronic", "pancreatitis", ".", "In", "cases", "of", "postoperatively", "elevated", "CA", "19", "-", "9", "level", "the", "prognosis", "is", "worse", "than", "in", "patients", "with", "normal", "tumor", "markers", "." ]	[ "umlsterm" ]
patients is an umlsterm, pancreatic is an umlsterm, carcinoma is an umlsterm, carcinoma is an umlsterm, pancreatitis is an umlsterm, role is an umlsterm, CA is an umlsterm, diagnosis is an umlsterm, head is an umlsterm, pancreas is an umlsterm, sensitivity is an umlsterm, pancreatic is an umlsterm, carcinoma is an umlsterm, carcinoma is an umlsterm, specificity is an umlsterm, Carcinoembryonic antigen is an umlsterm, patient is an umlsterm, tumor markers is an umlsterm, sensitivity is an umlsterm, specificity is an umlsterm, obstructive jaundice is an umlsterm, cancer is an umlsterm, patients is an umlsterm, pancreatitis is an umlsterm, CA is an umlsterm, prognosis is an umlsterm, patients is an umlsterm, tumor markers is an umlsterm	DerChirurg.60671007.eng.abstr_task1	Sentence: In 96 patients ( ductal pancreatic carcinoma , n = 34 ; periampullary carcinoma , n = 43 ; chronic pancreatitis , n = 19 ) the role of CA 19-9 in the diagnosis of lesions of the head of the pancreas were evaluated . The sensitivity for ductal pancreatic carcinoma was 73.3 % , for periampullary carcinoma 48.8 % , and specificity was 63.2 % . Carcinoembryonic antigen was elevated only in every fifth patient . Even when combining the two tumor markers no increase in sensitivity could be observed . The low specificity of 63 % , which decreased to 33 % in the case of obstructive jaundice , does not allow adequate preoperative differentiation between cancer patients and those with chronic pancreatitis . In cases of postoperatively elevated CA 19-9 level the prognosis is worse than in patients with normal tumor markers . Instructions: please typing these entity words according to sentence: patients, pancreatic, carcinoma, carcinoma, pancreatitis, role, CA, diagnosis, head, pancreas, sensitivity, pancreatic, carcinoma, carcinoma, specificity, Carcinoembryonic antigen, patient, tumor markers, sensitivity, specificity, obstructive jaundice, cancer, patients, pancreatitis, CA, prognosis, patients, tumor markers Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	In 96 patients ( ductal pancreatic carcinoma , n = 34 ; periampullary carcinoma , n = 43 ; chronic pancreatitis , n = 19 ) the role of CA 19-9 in the diagnosis of lesions of the head of the pancreas were evaluated . The sensitivity for ductal pancreatic carcinoma was 73.3 % , for periampullary carcinoma 48.8 % , and specificity was 63.2 % . Carcinoembryonic antigen was elevated only in every fifth patient . Even when combining the two tumor markers no increase in sensitivity could be observed . The low specificity of 63 % , which decreased to 33 % in the case of obstructive jaundice , does not allow adequate preoperative differentiation between cancer patients and those with chronic pancreatitis . In cases of postoperatively elevated CA 19-9 level the prognosis is worse than in patients with normal tumor markers .	[ "In", "96", "patients", "(", "ductal", "pancreatic", "carcinoma", ",", "n", "=", "34", ";", "periampullary", "carcinoma", ",", "n", "=", "43", ";", "chronic", "pancreatitis", ",", "n", "=", "19", ")", "the", "role", "of", "CA", "19", "-", "9", "in", "the", "diagnosis", "of", "lesions", "of", "the", "head", "of", "the", "pancreas", "were", "evaluated", ".", "The", "sensitivity", "for", "ductal", "pancreatic", "carcinoma", "was", "73.3", "%", ",", "for", "periampullary", "carcinoma", "48.8", "%", ",", "and", "specificity", "was", "63.2", "%", ".", "Carcinoembryonic", "antigen", "was", "elevated", "only", "in", "every", "fifth", "patient", ".", "Even", "when", "combining", "the", "two", "tumor", "markers", "no", "increase", "in", "sensitivity", "could", "be", "observed", ".", "The", "low", "specificity", "of", "63", "%", ",", "which", "decreased", "to", "33", "%", "in", "the", "case", "of", "obstructive", "jaundice", ",", "does", "not", "allow", "adequate", "preoperative", "differentiation", "between", "cancer", "patients", "and", "those", "with", "chronic", "pancreatitis", ".", "In", "cases", "of", "postoperatively", "elevated", "CA", "19", "-", "9", "level", "the", "prognosis", "is", "worse", "than", "in", "patients", "with", "normal", "tumor", "markers", "." ]	[ "umlsterm" ]
patients, pancreatic, carcinoma, carcinoma, pancreatitis, role, CA, diagnosis, head, pancreas, sensitivity, pancreatic, carcinoma, carcinoma, specificity, Carcinoembryonic antigen, patient, tumor markers, sensitivity, specificity, obstructive jaundice, cancer, patients, pancreatitis, CA, prognosis, patients, tumor markers	DerChirurg.60671007.eng.abstr_task2	Sentence: In 96 patients ( ductal pancreatic carcinoma , n = 34 ; periampullary carcinoma , n = 43 ; chronic pancreatitis , n = 19 ) the role of CA 19-9 in the diagnosis of lesions of the head of the pancreas were evaluated . The sensitivity for ductal pancreatic carcinoma was 73.3 % , for periampullary carcinoma 48.8 % , and specificity was 63.2 % . Carcinoembryonic antigen was elevated only in every fifth patient . Even when combining the two tumor markers no increase in sensitivity could be observed . The low specificity of 63 % , which decreased to 33 % in the case of obstructive jaundice , does not allow adequate preoperative differentiation between cancer patients and those with chronic pancreatitis . In cases of postoperatively elevated CA 19-9 level the prognosis is worse than in patients with normal tumor markers . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	In 96 patients ( ductal pancreatic carcinoma , n = 34 ; periampullary carcinoma , n = 43 ; chronic pancreatitis , n = 19 ) the role of CA 19-9 in the diagnosis of lesions of the head of the pancreas were evaluated . The sensitivity for ductal pancreatic carcinoma was 73.3 % , for periampullary carcinoma 48.8 % , and specificity was 63.2 % . Carcinoembryonic antigen was elevated only in every fifth patient . Even when combining the two tumor markers no increase in sensitivity could be observed . The low specificity of 63 % , which decreased to 33 % in the case of obstructive jaundice , does not allow adequate preoperative differentiation between cancer patients and those with chronic pancreatitis . In cases of postoperatively elevated CA 19-9 level the prognosis is worse than in patients with normal tumor markers .	[ "In", "96", "patients", "(", "ductal", "pancreatic", "carcinoma", ",", "n", "=", "34", ";", "periampullary", "carcinoma", ",", "n", "=", "43", ";", "chronic", "pancreatitis", ",", "n", "=", "19", ")", "the", "role", "of", "CA", "19", "-", "9", "in", "the", "diagnosis", "of", "lesions", "of", "the", "head", "of", "the", "pancreas", "were", "evaluated", ".", "The", "sensitivity", "for", "ductal", "pancreatic", "carcinoma", "was", "73.3", "%", ",", "for", "periampullary", "carcinoma", "48.8", "%", ",", "and", "specificity", "was", "63.2", "%", ".", "Carcinoembryonic", "antigen", "was", "elevated", "only", "in", "every", "fifth", "patient", ".", "Even", "when", "combining", "the", "two", "tumor", "markers", "no", "increase", "in", "sensitivity", "could", "be", "observed", ".", "The", "low", "specificity", "of", "63", "%", ",", "which", "decreased", "to", "33", "%", "in", "the", "case", "of", "obstructive", "jaundice", ",", "does", "not", "allow", "adequate", "preoperative", "differentiation", "between", "cancer", "patients", "and", "those", "with", "chronic", "pancreatitis", ".", "In", "cases", "of", "postoperatively", "elevated", "CA", "19", "-", "9", "level", "the", "prognosis", "is", "worse", "than", "in", "patients", "with", "normal", "tumor", "markers", "." ]	[ "umlsterm" ]
Placebo - Controlled is a Intervention_Control, Olprinone is a Intervention_Pharmacological, olprinone is a Intervention_Pharmacological	72165_task0	Sentence: A Double-Blind Placebo-Controlled Study of the Effects of Olprinone , a Specific Phosphodiesterase III Inhibitor , for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer . BACKGROUND We previously reported that patients with elevated preoperative B-type natriuretic peptide ( BNP ) levels have an increased risk for postoperative atrial fibrillation following lung cancer surgery . The present study evaluated whether the specific phosphodiesterase III inhibitor olprinone can reduce the incidence of postoperative atrial fibrillation in patients with elevated BNP levels undergoing pulmonary resection for lung cancer . METHODS A prospective randomized study was conducted with 40 patients who had elevated preoperative BNP levels ( ≥ 30 pg/mL ) and underwent scheduled lung cancer surgery . All patients were in sinus rhythm at surgery . Low-dose olprinone or placebo was continuously infused for 24 h and started just before anesthesia induction . The primary end point was the incidence of postoperative atrial fibrillation . The secondary end points were perioperative hemodynamics and levels of BNP , WBC counts , and C-reactive protein . RESULTS The incidence of postoperative atrial fibrillation was significantly lower in the olprinone group than in the placebo group ( 10 % vs 60 % , P < .001 ) . Patients in the olprinone group showed significantly lower BNP , WBC counts , and C-reactive protein levels after surgery . CONCLUSIONS Continuous infusion of olprinone during lung cancer surgery was safe and reduced the incidence of postoperative atrial fibrillation following pulmonary resection in patients with elevated preoperative BNP levels . TRIAL REGISTRY Japan Primary Registries Network ; No . : JPRN-UMIN2404 ; URL : http : //www.umin.ac.jp/ctr/ . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control	[ "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A Double-Blind Placebo-Controlled Study of the Effects of Olprinone , a Specific Phosphodiesterase III Inhibitor , for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer . BACKGROUND We previously reported that patients with elevated preoperative B-type natriuretic peptide ( BNP ) levels have an increased risk for postoperative atrial fibrillation following lung cancer surgery . The present study evaluated whether the specific phosphodiesterase III inhibitor olprinone can reduce the incidence of postoperative atrial fibrillation in patients with elevated BNP levels undergoing pulmonary resection for lung cancer . METHODS A prospective randomized study was conducted with 40 patients who had elevated preoperative BNP levels ( ≥ 30 pg/mL ) and underwent scheduled lung cancer surgery . All patients were in sinus rhythm at surgery . Low-dose olprinone or placebo was continuously infused for 24 h and started just before anesthesia induction . The primary end point was the incidence of postoperative atrial fibrillation . The secondary end points were perioperative hemodynamics and levels of BNP , WBC counts , and C-reactive protein . RESULTS The incidence of postoperative atrial fibrillation was significantly lower in the olprinone group than in the placebo group ( 10 % vs 60 % , P < .001 ) . Patients in the olprinone group showed significantly lower BNP , WBC counts , and C-reactive protein levels after surgery . CONCLUSIONS Continuous infusion of olprinone during lung cancer surgery was safe and reduced the incidence of postoperative atrial fibrillation following pulmonary resection in patients with elevated preoperative BNP levels . TRIAL REGISTRY Japan Primary Registries Network ; No . : JPRN-UMIN2404 ; URL : http : //www.umin.ac.jp/ctr/ .	[ "A", "Double", "-", "Blind", "Placebo", "-", "Controlled", "Study", "of", "the", "Effects", "of", "Olprinone", ",", "a", "Specific", "Phosphodiesterase", "III", "Inhibitor", ",", "for", "Preventing", "Postoperative", "Atrial", "Fibrillation", "in", "Patients", "Undergoing", "Pulmonary", "Resection", "for", "Lung", "Cancer", ".", "BACKGROUND", "We", "previously", "reported", "that", "patients", "with", "elevated", "preoperative", "B", "-", "type", "natriuretic", "peptide", "(", "BNP", ")", "levels", "have", "an", "increased", "risk", "for", "postoperative", "atrial", "fibrillation", "following", "lung", "cancer", "surgery", ".", "The", "present", "study", "evaluated", "whether", "the", "specific", "phosphodiesterase", "III", "inhibitor", "olprinone", "can", "reduce", "the", "incidence", "of", "postoperative", "atrial", "fibrillation", "in", "patients", "with", "elevated", "BNP", "levels", "undergoing", "pulmonary", "resection", "for", "lung", "cancer", ".", "METHODS", "A", "prospective", "randomized", "study", "was", "conducted", "with", "40", "patients", "who", "had", "elevated", "preoperative", "BNP", "levels", "(", "≥", "30", "pg", "/", "mL", ")", "and", "underwent", "scheduled", "lung", "cancer", "surgery", ".", "All", "patients", "were", "in", "sinus", "rhythm", "at", "surgery", ".", "Low", "-", "dose", "olprinone", "or", "placebo", "was", "continuously", "infused", "for", "24", "h", "and", "started", "just", "before", "anesthesia", "induction", ".", "The", "primary", "end", "point", "was", "the", "incidence", "of", "postoperative", "atrial", "fibrillation", ".", "The", "secondary", "end", "points", "were", "perioperative", "hemodynamics", "and", "levels", "of", "BNP", ",", "WBC", "counts", ",", "and", "C", "-", "reactive", "protein", ".", "RESULTS", "The", "incidence", "of", "postoperative", "atrial", "fibrillation", "was", "significantly", "lower", "in", "the", "olprinone", "group", "than", "in", "the", "placebo", "group", "(", "10", "%", "vs", "60", "%", ",", "P", "<", ".001", ")", ".", "Patients", "in", "the", "olprinone", "group", "showed", "significantly", "lower", "BNP", ",", "WBC", "counts", ",", "and", "C", "-", "reactive", "protein", "levels", "after", "surgery", ".", "CONCLUSIONS", "Continuous", "infusion", "of", "olprinone", "during", "lung", "cancer", "surgery", "was", "safe", "and", "reduced", "the", "incidence", "of", "postoperative", "atrial", "fibrillation", "following", "pulmonary", "resection", "in", "patients", "with", "elevated", "preoperative", "BNP", "levels", ".", "TRIAL", "REGISTRY", "Japan", "Primary", "Registries", "Network", ";", "No", ".", ":", "JPRN", "-", "UMIN2404", ";", "URL", ":", "http", ":", "//www.umin.ac.jp", "/", "ctr/", "." ]	[ "Intervention_Control", "Intervention_Pharmacological" ]
Placebo - Controlled is a Intervention_Control, Olprinone is a Intervention_Pharmacological, olprinone is a Intervention_Pharmacological	72165_task1	Sentence: A Double-Blind Placebo-Controlled Study of the Effects of Olprinone , a Specific Phosphodiesterase III Inhibitor , for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer . BACKGROUND We previously reported that patients with elevated preoperative B-type natriuretic peptide ( BNP ) levels have an increased risk for postoperative atrial fibrillation following lung cancer surgery . The present study evaluated whether the specific phosphodiesterase III inhibitor olprinone can reduce the incidence of postoperative atrial fibrillation in patients with elevated BNP levels undergoing pulmonary resection for lung cancer . METHODS A prospective randomized study was conducted with 40 patients who had elevated preoperative BNP levels ( ≥ 30 pg/mL ) and underwent scheduled lung cancer surgery . All patients were in sinus rhythm at surgery . Low-dose olprinone or placebo was continuously infused for 24 h and started just before anesthesia induction . The primary end point was the incidence of postoperative atrial fibrillation . The secondary end points were perioperative hemodynamics and levels of BNP , WBC counts , and C-reactive protein . RESULTS The incidence of postoperative atrial fibrillation was significantly lower in the olprinone group than in the placebo group ( 10 % vs 60 % , P < .001 ) . Patients in the olprinone group showed significantly lower BNP , WBC counts , and C-reactive protein levels after surgery . CONCLUSIONS Continuous infusion of olprinone during lung cancer surgery was safe and reduced the incidence of postoperative atrial fibrillation following pulmonary resection in patients with elevated preoperative BNP levels . TRIAL REGISTRY Japan Primary Registries Network ; No . : JPRN-UMIN2404 ; URL : http : //www.umin.ac.jp/ctr/ . Instructions: please typing these entity words according to sentence: Placebo - Controlled, Olprinone, olprinone Options: Intervention_Pharmacological, Intervention_Control	[ "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A Double-Blind Placebo-Controlled Study of the Effects of Olprinone , a Specific Phosphodiesterase III Inhibitor , for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer . BACKGROUND We previously reported that patients with elevated preoperative B-type natriuretic peptide ( BNP ) levels have an increased risk for postoperative atrial fibrillation following lung cancer surgery . The present study evaluated whether the specific phosphodiesterase III inhibitor olprinone can reduce the incidence of postoperative atrial fibrillation in patients with elevated BNP levels undergoing pulmonary resection for lung cancer . METHODS A prospective randomized study was conducted with 40 patients who had elevated preoperative BNP levels ( ≥ 30 pg/mL ) and underwent scheduled lung cancer surgery . All patients were in sinus rhythm at surgery . Low-dose olprinone or placebo was continuously infused for 24 h and started just before anesthesia induction . The primary end point was the incidence of postoperative atrial fibrillation . The secondary end points were perioperative hemodynamics and levels of BNP , WBC counts , and C-reactive protein . RESULTS The incidence of postoperative atrial fibrillation was significantly lower in the olprinone group than in the placebo group ( 10 % vs 60 % , P < .001 ) . Patients in the olprinone group showed significantly lower BNP , WBC counts , and C-reactive protein levels after surgery . CONCLUSIONS Continuous infusion of olprinone during lung cancer surgery was safe and reduced the incidence of postoperative atrial fibrillation following pulmonary resection in patients with elevated preoperative BNP levels . TRIAL REGISTRY Japan Primary Registries Network ; No . : JPRN-UMIN2404 ; URL : http : //www.umin.ac.jp/ctr/ .	[ "A", "Double", "-", "Blind", "Placebo", "-", "Controlled", "Study", "of", "the", "Effects", "of", "Olprinone", ",", "a", "Specific", "Phosphodiesterase", "III", "Inhibitor", ",", "for", "Preventing", "Postoperative", "Atrial", "Fibrillation", "in", "Patients", "Undergoing", "Pulmonary", "Resection", "for", "Lung", "Cancer", ".", "BACKGROUND", "We", "previously", "reported", "that", "patients", "with", "elevated", "preoperative", "B", "-", "type", "natriuretic", "peptide", "(", "BNP", ")", "levels", "have", "an", "increased", "risk", "for", "postoperative", "atrial", "fibrillation", "following", "lung", "cancer", "surgery", ".", "The", "present", "study", "evaluated", "whether", "the", "specific", "phosphodiesterase", "III", "inhibitor", "olprinone", "can", "reduce", "the", "incidence", "of", "postoperative", "atrial", "fibrillation", "in", "patients", "with", "elevated", "BNP", "levels", "undergoing", "pulmonary", "resection", "for", "lung", "cancer", ".", "METHODS", "A", "prospective", "randomized", "study", "was", "conducted", "with", "40", "patients", "who", "had", "elevated", "preoperative", "BNP", "levels", "(", "≥", "30", "pg", "/", "mL", ")", "and", "underwent", "scheduled", "lung", "cancer", "surgery", ".", "All", "patients", "were", "in", "sinus", "rhythm", "at", "surgery", ".", "Low", "-", "dose", "olprinone", "or", "placebo", "was", "continuously", "infused", "for", "24", "h", "and", "started", "just", "before", "anesthesia", "induction", ".", "The", "primary", "end", "point", "was", "the", "incidence", "of", "postoperative", "atrial", "fibrillation", ".", "The", "secondary", "end", "points", "were", "perioperative", "hemodynamics", "and", "levels", "of", "BNP", ",", "WBC", "counts", ",", "and", "C", "-", "reactive", "protein", ".", "RESULTS", "The", "incidence", "of", "postoperative", "atrial", "fibrillation", "was", "significantly", "lower", "in", "the", "olprinone", "group", "than", "in", "the", "placebo", "group", "(", "10", "%", "vs", "60", "%", ",", "P", "<", ".001", ")", ".", "Patients", "in", "the", "olprinone", "group", "showed", "significantly", "lower", "BNP", ",", "WBC", "counts", ",", "and", "C", "-", "reactive", "protein", "levels", "after", "surgery", ".", "CONCLUSIONS", "Continuous", "infusion", "of", "olprinone", "during", "lung", "cancer", "surgery", "was", "safe", "and", "reduced", "the", "incidence", "of", "postoperative", "atrial", "fibrillation", "following", "pulmonary", "resection", "in", "patients", "with", "elevated", "preoperative", "BNP", "levels", ".", "TRIAL", "REGISTRY", "Japan", "Primary", "Registries", "Network", ";", "No", ".", ":", "JPRN", "-", "UMIN2404", ";", "URL", ":", "http", ":", "//www.umin.ac.jp", "/", "ctr/", "." ]	[ "Intervention_Control", "Intervention_Pharmacological" ]
Placebo - Controlled, Olprinone, olprinone	72165_task2	Sentence: A Double-Blind Placebo-Controlled Study of the Effects of Olprinone , a Specific Phosphodiesterase III Inhibitor , for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer . BACKGROUND We previously reported that patients with elevated preoperative B-type natriuretic peptide ( BNP ) levels have an increased risk for postoperative atrial fibrillation following lung cancer surgery . The present study evaluated whether the specific phosphodiesterase III inhibitor olprinone can reduce the incidence of postoperative atrial fibrillation in patients with elevated BNP levels undergoing pulmonary resection for lung cancer . METHODS A prospective randomized study was conducted with 40 patients who had elevated preoperative BNP levels ( ≥ 30 pg/mL ) and underwent scheduled lung cancer surgery . All patients were in sinus rhythm at surgery . Low-dose olprinone or placebo was continuously infused for 24 h and started just before anesthesia induction . The primary end point was the incidence of postoperative atrial fibrillation . The secondary end points were perioperative hemodynamics and levels of BNP , WBC counts , and C-reactive protein . RESULTS The incidence of postoperative atrial fibrillation was significantly lower in the olprinone group than in the placebo group ( 10 % vs 60 % , P < .001 ) . Patients in the olprinone group showed significantly lower BNP , WBC counts , and C-reactive protein levels after surgery . CONCLUSIONS Continuous infusion of olprinone during lung cancer surgery was safe and reduced the incidence of postoperative atrial fibrillation following pulmonary resection in patients with elevated preoperative BNP levels . TRIAL REGISTRY Japan Primary Registries Network ; No . : JPRN-UMIN2404 ; URL : http : //www.umin.ac.jp/ctr/ . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A Double-Blind Placebo-Controlled Study of the Effects of Olprinone , a Specific Phosphodiesterase III Inhibitor , for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer . BACKGROUND We previously reported that patients with elevated preoperative B-type natriuretic peptide ( BNP ) levels have an increased risk for postoperative atrial fibrillation following lung cancer surgery . The present study evaluated whether the specific phosphodiesterase III inhibitor olprinone can reduce the incidence of postoperative atrial fibrillation in patients with elevated BNP levels undergoing pulmonary resection for lung cancer . METHODS A prospective randomized study was conducted with 40 patients who had elevated preoperative BNP levels ( ≥ 30 pg/mL ) and underwent scheduled lung cancer surgery . All patients were in sinus rhythm at surgery . Low-dose olprinone or placebo was continuously infused for 24 h and started just before anesthesia induction . The primary end point was the incidence of postoperative atrial fibrillation . The secondary end points were perioperative hemodynamics and levels of BNP , WBC counts , and C-reactive protein . RESULTS The incidence of postoperative atrial fibrillation was significantly lower in the olprinone group than in the placebo group ( 10 % vs 60 % , P < .001 ) . Patients in the olprinone group showed significantly lower BNP , WBC counts , and C-reactive protein levels after surgery . CONCLUSIONS Continuous infusion of olprinone during lung cancer surgery was safe and reduced the incidence of postoperative atrial fibrillation following pulmonary resection in patients with elevated preoperative BNP levels . TRIAL REGISTRY Japan Primary Registries Network ; No . : JPRN-UMIN2404 ; URL : http : //www.umin.ac.jp/ctr/ .	[ "A", "Double", "-", "Blind", "Placebo", "-", "Controlled", "Study", "of", "the", "Effects", "of", "Olprinone", ",", "a", "Specific", "Phosphodiesterase", "III", "Inhibitor", ",", "for", "Preventing", "Postoperative", "Atrial", "Fibrillation", "in", "Patients", "Undergoing", "Pulmonary", "Resection", "for", "Lung", "Cancer", ".", "BACKGROUND", "We", "previously", "reported", "that", "patients", "with", "elevated", "preoperative", "B", "-", "type", "natriuretic", "peptide", "(", "BNP", ")", "levels", "have", "an", "increased", "risk", "for", "postoperative", "atrial", "fibrillation", "following", "lung", "cancer", "surgery", ".", "The", "present", "study", "evaluated", "whether", "the", "specific", "phosphodiesterase", "III", "inhibitor", "olprinone", "can", "reduce", "the", "incidence", "of", "postoperative", "atrial", "fibrillation", "in", "patients", "with", "elevated", "BNP", "levels", "undergoing", "pulmonary", "resection", "for", "lung", "cancer", ".", "METHODS", "A", "prospective", "randomized", "study", "was", "conducted", "with", "40", "patients", "who", "had", "elevated", "preoperative", "BNP", "levels", "(", "≥", "30", "pg", "/", "mL", ")", "and", "underwent", "scheduled", "lung", "cancer", "surgery", ".", "All", "patients", "were", "in", "sinus", "rhythm", "at", "surgery", ".", "Low", "-", "dose", "olprinone", "or", "placebo", "was", "continuously", "infused", "for", "24", "h", "and", "started", "just", "before", "anesthesia", "induction", ".", "The", "primary", "end", "point", "was", "the", "incidence", "of", "postoperative", "atrial", "fibrillation", ".", "The", "secondary", "end", "points", "were", "perioperative", "hemodynamics", "and", "levels", "of", "BNP", ",", "WBC", "counts", ",", "and", "C", "-", "reactive", "protein", ".", "RESULTS", "The", "incidence", "of", "postoperative", "atrial", "fibrillation", "was", "significantly", "lower", "in", "the", "olprinone", "group", "than", "in", "the", "placebo", "group", "(", "10", "%", "vs", "60", "%", ",", "P", "<", ".001", ")", ".", "Patients", "in", "the", "olprinone", "group", "showed", "significantly", "lower", "BNP", ",", "WBC", "counts", ",", "and", "C", "-", "reactive", "protein", "levels", "after", "surgery", ".", "CONCLUSIONS", "Continuous", "infusion", "of", "olprinone", "during", "lung", "cancer", "surgery", "was", "safe", "and", "reduced", "the", "incidence", "of", "postoperative", "atrial", "fibrillation", "following", "pulmonary", "resection", "in", "patients", "with", "elevated", "preoperative", "BNP", "levels", ".", "TRIAL", "REGISTRY", "Japan", "Primary", "Registries", "Network", ";", "No", ".", ":", "JPRN", "-", "UMIN2404", ";", "URL", ":", "http", ":", "//www.umin.ac.jp", "/", "ctr/", "." ]	[ "Intervention_Control", "Intervention_Pharmacological" ]
ESEs is a DNA, SR is a protein-family, U2AF35 is a protein, U2AF is a protein-complex, U2AF65 is a protein, Py tract is a DNA	1.0alpha7.train.279_task0	Sentence: To further investigate a possible role for ESEs in U2AF35-dependent splicing, an experiment was designed to test a critical tenet of the recruitment model for exon enhancer function: SR proteins bound to the enhancer sequence establish protein-protein interactions with U2AF35 that increase the local concentration of the U2AF heterodimer and facilitate U2AF65 binding to the Py tract (13). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-complex, DNA, protein-family, protein	[ "O", "O", "O", "O", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-protein-complex", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "I-DNA", "O", "O", "O", "O" ]	To further investigate a possible role for ESEs in U2AF35-dependent splicing, an experiment was designed to test a critical tenet of the recruitment model for exon enhancer function: SR proteins bound to the enhancer sequence establish protein-protein interactions with U2AF35 that increase the local concentration of the U2AF heterodimer and facilitate U2AF65 binding to the Py tract (13).	[ "To", "further", "investigate", "a", "possible", "role", "for", "ESEs", "in", "U2AF35-dependent", "splicing", ",", "an", "experiment", "was", "designed", "to", "test", "a", "critical", "tenet", "of", "the", "recruitment", "model", "for", "exon", "enhancer", "function", ":", "SR", "proteins", "bound", "to", "the", "enhancer", "sequence", "establish", "protein", "-", "protein", "interactions", "with", "U2AF35", "that", "increase", "the", "local", "concentration", "of", "the", "U2AF", "heterodimer", "and", "facilitate", "U2AF65", "binding", "to", "the", "Py", "tract", "(", "13", ")", "." ]	[ "DNA", "protein", "protein-complex", "protein-family" ]
ESEs is a DNA, SR is a protein-family, U2AF35 is a protein, U2AF is a protein-complex, U2AF65 is a protein, Py tract is a DNA	1.0alpha7.train.279_task1	Sentence: To further investigate a possible role for ESEs in U2AF35-dependent splicing, an experiment was designed to test a critical tenet of the recruitment model for exon enhancer function: SR proteins bound to the enhancer sequence establish protein-protein interactions with U2AF35 that increase the local concentration of the U2AF heterodimer and facilitate U2AF65 binding to the Py tract (13). Instructions: please typing these entity words according to sentence: ESEs, SR, U2AF35, U2AF, U2AF65, Py tract Options: protein-complex, DNA, protein-family, protein	[ "O", "O", "O", "O", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-protein-complex", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "I-DNA", "O", "O", "O", "O" ]	To further investigate a possible role for ESEs in U2AF35-dependent splicing, an experiment was designed to test a critical tenet of the recruitment model for exon enhancer function: SR proteins bound to the enhancer sequence establish protein-protein interactions with U2AF35 that increase the local concentration of the U2AF heterodimer and facilitate U2AF65 binding to the Py tract (13).	[ "To", "further", "investigate", "a", "possible", "role", "for", "ESEs", "in", "U2AF35-dependent", "splicing", ",", "an", "experiment", "was", "designed", "to", "test", "a", "critical", "tenet", "of", "the", "recruitment", "model", "for", "exon", "enhancer", "function", ":", "SR", "proteins", "bound", "to", "the", "enhancer", "sequence", "establish", "protein", "-", "protein", "interactions", "with", "U2AF35", "that", "increase", "the", "local", "concentration", "of", "the", "U2AF", "heterodimer", "and", "facilitate", "U2AF65", "binding", "to", "the", "Py", "tract", "(", "13", ")", "." ]	[ "DNA", "protein", "protein-complex", "protein-family" ]
ESEs, SR, U2AF35, U2AF, U2AF65, Py tract	1.0alpha7.train.279_task2	Sentence: To further investigate a possible role for ESEs in U2AF35-dependent splicing, an experiment was designed to test a critical tenet of the recruitment model for exon enhancer function: SR proteins bound to the enhancer sequence establish protein-protein interactions with U2AF35 that increase the local concentration of the U2AF heterodimer and facilitate U2AF65 binding to the Py tract (13). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-protein-complex", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "I-DNA", "O", "O", "O", "O" ]	To further investigate a possible role for ESEs in U2AF35-dependent splicing, an experiment was designed to test a critical tenet of the recruitment model for exon enhancer function: SR proteins bound to the enhancer sequence establish protein-protein interactions with U2AF35 that increase the local concentration of the U2AF heterodimer and facilitate U2AF65 binding to the Py tract (13).	[ "To", "further", "investigate", "a", "possible", "role", "for", "ESEs", "in", "U2AF35-dependent", "splicing", ",", "an", "experiment", "was", "designed", "to", "test", "a", "critical", "tenet", "of", "the", "recruitment", "model", "for", "exon", "enhancer", "function", ":", "SR", "proteins", "bound", "to", "the", "enhancer", "sequence", "establish", "protein", "-", "protein", "interactions", "with", "U2AF35", "that", "increase", "the", "local", "concentration", "of", "the", "U2AF", "heterodimer", "and", "facilitate", "U2AF65", "binding", "to", "the", "Py", "tract", "(", "13", ")", "." ]	[ "DNA", "protein", "protein-complex", "protein-family" ]
Haloperidol is a CHEMICAL, ribosomal protein S6 is a GENE-Y, dopamine- and cAMP - regulated phosphoprotein of 32 kDa is a GENE-Y, protein phosphatase-1 is a GENE-N	23643747_task0	Sentence: Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL	[ "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O" ]	Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.	[ "Haloperidol", "promotes", "mTORC1-dependent", "phosphorylation", "of", "ribosomal", "protein", "S6", "via", "dopamine-", "and", "cAMP", "-", "regulated", "phosphoprotein", "of", "32", "kDa", "and", "inhibition", "of", "protein", "phosphatase-1", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Haloperidol is a CHEMICAL, ribosomal protein S6 is a GENE-Y, dopamine- and cAMP - regulated phosphoprotein of 32 kDa is a GENE-Y, protein phosphatase-1 is a GENE-N	23643747_task1	Sentence: Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1. Instructions: please typing these entity words according to sentence: Haloperidol, ribosomal protein S6, dopamine- and cAMP - regulated phosphoprotein of 32 kDa, protein phosphatase-1 Options: GENE-N, GENE-Y, CHEMICAL	[ "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O" ]	Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.	[ "Haloperidol", "promotes", "mTORC1-dependent", "phosphorylation", "of", "ribosomal", "protein", "S6", "via", "dopamine-", "and", "cAMP", "-", "regulated", "phosphoprotein", "of", "32", "kDa", "and", "inhibition", "of", "protein", "phosphatase-1", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Haloperidol, ribosomal protein S6, dopamine- and cAMP - regulated phosphoprotein of 32 kDa, protein phosphatase-1	23643747_task2	Sentence: Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1. Instructions: please extract entity words from the input sentence	[ "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O" ]	Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.	[ "Haloperidol", "promotes", "mTORC1-dependent", "phosphorylation", "of", "ribosomal", "protein", "S6", "via", "dopamine-", "and", "cAMP", "-", "regulated", "phosphoprotein", "of", "32", "kDa", "and", "inhibition", "of", "protein", "phosphatase-1", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Copper is a CHEMICAL, Bis(l - histidinato)cadmium Dihydrate is a CHEMICAL	23530765_task0	Sentence: Electron Paramagnetic Resonance Spectroscopic Study of Copper Hopping in Doped Bis(l-histidinato)cadmium Dihydrate. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O" ]	Electron Paramagnetic Resonance Spectroscopic Study of Copper Hopping in Doped Bis(l-histidinato)cadmium Dihydrate.	[ "Electron", "Paramagnetic", "Resonance", "Spectroscopic", "Study", "of", "Copper", "Hopping", "in", "Doped", "Bis(l", "-", "histidinato)cadmium", "Dihydrate", "." ]	[ "CHEMICAL" ]
Copper is a CHEMICAL, Bis(l - histidinato)cadmium Dihydrate is a CHEMICAL	23530765_task1	Sentence: Electron Paramagnetic Resonance Spectroscopic Study of Copper Hopping in Doped Bis(l-histidinato)cadmium Dihydrate. Instructions: please typing these entity words according to sentence: Copper, Bis(l - histidinato)cadmium Dihydrate Options: CHEMICAL	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O" ]	Electron Paramagnetic Resonance Spectroscopic Study of Copper Hopping in Doped Bis(l-histidinato)cadmium Dihydrate.	[ "Electron", "Paramagnetic", "Resonance", "Spectroscopic", "Study", "of", "Copper", "Hopping", "in", "Doped", "Bis(l", "-", "histidinato)cadmium", "Dihydrate", "." ]	[ "CHEMICAL" ]
Copper, Bis(l - histidinato)cadmium Dihydrate	23530765_task2	Sentence: Electron Paramagnetic Resonance Spectroscopic Study of Copper Hopping in Doped Bis(l-histidinato)cadmium Dihydrate. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O" ]	Electron Paramagnetic Resonance Spectroscopic Study of Copper Hopping in Doped Bis(l-histidinato)cadmium Dihydrate.	[ "Electron", "Paramagnetic", "Resonance", "Spectroscopic", "Study", "of", "Copper", "Hopping", "in", "Doped", "Bis(l", "-", "histidinato)cadmium", "Dihydrate", "." ]	[ "CHEMICAL" ]
Tenascin is an umlsterm, Plattenepithelkarzinome is an umlsterm, Tumoren is an umlsterm, Zellen is an umlsterm, Tenascin is an umlsterm, Tumorstadium is an umlsterm, In - situ - Hybridisierung is an umlsterm, Nativgeweben is an umlsterm, Lymphknotenmetastasen is an umlsterm, Tumorzellkulturen is an umlsterm, Normalschleimhaut is an umlsterm, Tenascin is an umlsterm, Tumoren is an umlsterm, tumorumgebenden is an umlsterm, Gewebeschnitt is an umlsterm, Proteinanalyse is an umlsterm, Tumorzellkulturen is an umlsterm, Tumorzellen is an umlsterm, selbst is an umlsterm, Tenascin is an umlsterm, Tumorproliferation is an umlsterm, Tenascin is an umlsterm, Kopf - Hals - Tumoren is an umlsterm, gezielte is an umlsterm, Therapie is an umlsterm	HNO.90470723.ger.abstr_task0	Sentence: Tenascin , ein Glykoprotein der extrazellulaeren Matrix ( EZM ) , ist aufgrund seiner proliferations- und migrationsassoziierten Expression ein Zielmolekuel in der intralaesionalen Glioblastomtherapie . Ob dieses Konzept auf Plattenepithelkarzinome des oberen Aerodigestivtraktes uebertragbar ist , haengt wesentlich vom Tenascinexpressionsmuster in diesen Tumoren ab . Unser Ziel war es zu klaeren , von welchen Zellen und wie selektiv Tenascin exprimiert wird und ob ein Zusammenhang mit dem Tumorstadium besteht . Die Tenascinexpression wurde immunhistochemisch und ueber In-situ-Hybridisierung an Nativgeweben von Primaertumoren und Lymphknotenmetastasen ( n=39) sowie an Tumorzellkulturen ( n=15) untersucht . Die so erhaltenen Expressionsmuster wurden denen der Normalschleimhaut gegenuebergestellt . Tenascin wurde in Tumoren verstaerkt exprimiert und war in der gesamten tumorumgebenden EZM lokalisiert . Die mRNA-Analyse am Gewebeschnitt und die Proteinanalyse der Tumorzellkulturen ergab , dass die Tumorzellen selbst Tenascin synthetisierten . Ein Zusammenhang von Tenascinexpression und TNM-Stadium oder Tumorproliferation war nicht nachweisbar . Unsere Ergebnisse zeigen , dass Tenascin in Kopf-Hals-Tumoren selektiv exprimiert wird und sich fuer eine gezielte , onkologische Therapie anbietet . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]	Tenascin , ein Glykoprotein der extrazellulaeren Matrix ( EZM ) , ist aufgrund seiner proliferations- und migrationsassoziierten Expression ein Zielmolekuel in der intralaesionalen Glioblastomtherapie . Ob dieses Konzept auf Plattenepithelkarzinome des oberen Aerodigestivtraktes uebertragbar ist , haengt wesentlich vom Tenascinexpressionsmuster in diesen Tumoren ab . Unser Ziel war es zu klaeren , von welchen Zellen und wie selektiv Tenascin exprimiert wird und ob ein Zusammenhang mit dem Tumorstadium besteht . Die Tenascinexpression wurde immunhistochemisch und ueber In-situ-Hybridisierung an Nativgeweben von Primaertumoren und Lymphknotenmetastasen ( n=39) sowie an Tumorzellkulturen ( n=15) untersucht . Die so erhaltenen Expressionsmuster wurden denen der Normalschleimhaut gegenuebergestellt . Tenascin wurde in Tumoren verstaerkt exprimiert und war in der gesamten tumorumgebenden EZM lokalisiert . Die mRNA-Analyse am Gewebeschnitt und die Proteinanalyse der Tumorzellkulturen ergab , dass die Tumorzellen selbst Tenascin synthetisierten . Ein Zusammenhang von Tenascinexpression und TNM-Stadium oder Tumorproliferation war nicht nachweisbar . Unsere Ergebnisse zeigen , dass Tenascin in Kopf-Hals-Tumoren selektiv exprimiert wird und sich fuer eine gezielte , onkologische Therapie anbietet .	[ "Tenascin", ",", "ein", "Glykoprotein", "der", "extrazellulaeren", "Matrix", "(", "EZM", ")", ",", "ist", "aufgrund", "seiner", "proliferations-", "und", "migrationsassoziierten", "Expression", "ein", "Zielmolekuel", "in", "der", "intralaesionalen", "Glioblastomtherapie", ".", "Ob", "dieses", "Konzept", "auf", "Plattenepithelkarzinome", "des", "oberen", "Aerodigestivtraktes", "uebertragbar", "ist", ",", "haengt", "wesentlich", "vom", "Tenascinexpressionsmuster", "in", "diesen", "Tumoren", "ab", ".", "Unser", "Ziel", "war", "es", "zu", "klaeren", ",", "von", "welchen", "Zellen", "und", "wie", "selektiv", "Tenascin", "exprimiert", "wird", "und", "ob", "ein", "Zusammenhang", "mit", "dem", "Tumorstadium", "besteht", ".", "Die", "Tenascinexpression", "wurde", "immunhistochemisch", "und", "ueber", "In", "-", "situ", "-", "Hybridisierung", "an", "Nativgeweben", "von", "Primaertumoren", "und", "Lymphknotenmetastasen", "(", "n=39", ")", "sowie", "an", "Tumorzellkulturen", "(", "n=15", ")", "untersucht", ".", "Die", "so", "erhaltenen", "Expressionsmuster", "wurden", "denen", "der", "Normalschleimhaut", "gegenuebergestellt", ".", "Tenascin", "wurde", "in", "Tumoren", "verstaerkt", "exprimiert", "und", "war", "in", "der", "gesamten", "tumorumgebenden", "EZM", "lokalisiert", ".", "Die", "mRNA", "-", "Analyse", "am", "Gewebeschnitt", "und", "die", "Proteinanalyse", "der", "Tumorzellkulturen", "ergab", ",", "dass", "die", "Tumorzellen", "selbst", "Tenascin", "synthetisierten", ".", "Ein", "Zusammenhang", "von", "Tenascinexpression", "und", "TNM", "-", "Stadium", "oder", "Tumorproliferation", "war", "nicht", "nachweisbar", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "Tenascin", "in", "Kopf", "-", "Hals", "-", "Tumoren", "selektiv", "exprimiert", "wird", "und", "sich", "fuer", "eine", "gezielte", ",", "onkologische", "Therapie", "anbietet", "." ]	[ "umlsterm" ]
Tenascin is an umlsterm, Plattenepithelkarzinome is an umlsterm, Tumoren is an umlsterm, Zellen is an umlsterm, Tenascin is an umlsterm, Tumorstadium is an umlsterm, In - situ - Hybridisierung is an umlsterm, Nativgeweben is an umlsterm, Lymphknotenmetastasen is an umlsterm, Tumorzellkulturen is an umlsterm, Normalschleimhaut is an umlsterm, Tenascin is an umlsterm, Tumoren is an umlsterm, tumorumgebenden is an umlsterm, Gewebeschnitt is an umlsterm, Proteinanalyse is an umlsterm, Tumorzellkulturen is an umlsterm, Tumorzellen is an umlsterm, selbst is an umlsterm, Tenascin is an umlsterm, Tumorproliferation is an umlsterm, Tenascin is an umlsterm, Kopf - Hals - Tumoren is an umlsterm, gezielte is an umlsterm, Therapie is an umlsterm	HNO.90470723.ger.abstr_task1	Sentence: Tenascin , ein Glykoprotein der extrazellulaeren Matrix ( EZM ) , ist aufgrund seiner proliferations- und migrationsassoziierten Expression ein Zielmolekuel in der intralaesionalen Glioblastomtherapie . Ob dieses Konzept auf Plattenepithelkarzinome des oberen Aerodigestivtraktes uebertragbar ist , haengt wesentlich vom Tenascinexpressionsmuster in diesen Tumoren ab . Unser Ziel war es zu klaeren , von welchen Zellen und wie selektiv Tenascin exprimiert wird und ob ein Zusammenhang mit dem Tumorstadium besteht . Die Tenascinexpression wurde immunhistochemisch und ueber In-situ-Hybridisierung an Nativgeweben von Primaertumoren und Lymphknotenmetastasen ( n=39) sowie an Tumorzellkulturen ( n=15) untersucht . Die so erhaltenen Expressionsmuster wurden denen der Normalschleimhaut gegenuebergestellt . Tenascin wurde in Tumoren verstaerkt exprimiert und war in der gesamten tumorumgebenden EZM lokalisiert . Die mRNA-Analyse am Gewebeschnitt und die Proteinanalyse der Tumorzellkulturen ergab , dass die Tumorzellen selbst Tenascin synthetisierten . Ein Zusammenhang von Tenascinexpression und TNM-Stadium oder Tumorproliferation war nicht nachweisbar . Unsere Ergebnisse zeigen , dass Tenascin in Kopf-Hals-Tumoren selektiv exprimiert wird und sich fuer eine gezielte , onkologische Therapie anbietet . Instructions: please typing these entity words according to sentence: Tenascin, Plattenepithelkarzinome, Tumoren, Zellen, Tenascin, Tumorstadium, In - situ - Hybridisierung, Nativgeweben, Lymphknotenmetastasen, Tumorzellkulturen, Normalschleimhaut, Tenascin, Tumoren, tumorumgebenden, Gewebeschnitt, Proteinanalyse, Tumorzellkulturen, Tumorzellen, selbst, Tenascin, Tumorproliferation, Tenascin, Kopf - Hals - Tumoren, gezielte, Therapie Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]	Tenascin , ein Glykoprotein der extrazellulaeren Matrix ( EZM ) , ist aufgrund seiner proliferations- und migrationsassoziierten Expression ein Zielmolekuel in der intralaesionalen Glioblastomtherapie . Ob dieses Konzept auf Plattenepithelkarzinome des oberen Aerodigestivtraktes uebertragbar ist , haengt wesentlich vom Tenascinexpressionsmuster in diesen Tumoren ab . Unser Ziel war es zu klaeren , von welchen Zellen und wie selektiv Tenascin exprimiert wird und ob ein Zusammenhang mit dem Tumorstadium besteht . Die Tenascinexpression wurde immunhistochemisch und ueber In-situ-Hybridisierung an Nativgeweben von Primaertumoren und Lymphknotenmetastasen ( n=39) sowie an Tumorzellkulturen ( n=15) untersucht . Die so erhaltenen Expressionsmuster wurden denen der Normalschleimhaut gegenuebergestellt . Tenascin wurde in Tumoren verstaerkt exprimiert und war in der gesamten tumorumgebenden EZM lokalisiert . Die mRNA-Analyse am Gewebeschnitt und die Proteinanalyse der Tumorzellkulturen ergab , dass die Tumorzellen selbst Tenascin synthetisierten . Ein Zusammenhang von Tenascinexpression und TNM-Stadium oder Tumorproliferation war nicht nachweisbar . Unsere Ergebnisse zeigen , dass Tenascin in Kopf-Hals-Tumoren selektiv exprimiert wird und sich fuer eine gezielte , onkologische Therapie anbietet .	[ "Tenascin", ",", "ein", "Glykoprotein", "der", "extrazellulaeren", "Matrix", "(", "EZM", ")", ",", "ist", "aufgrund", "seiner", "proliferations-", "und", "migrationsassoziierten", "Expression", "ein", "Zielmolekuel", "in", "der", "intralaesionalen", "Glioblastomtherapie", ".", "Ob", "dieses", "Konzept", "auf", "Plattenepithelkarzinome", "des", "oberen", "Aerodigestivtraktes", "uebertragbar", "ist", ",", "haengt", "wesentlich", "vom", "Tenascinexpressionsmuster", "in", "diesen", "Tumoren", "ab", ".", "Unser", "Ziel", "war", "es", "zu", "klaeren", ",", "von", "welchen", "Zellen", "und", "wie", "selektiv", "Tenascin", "exprimiert", "wird", "und", "ob", "ein", "Zusammenhang", "mit", "dem", "Tumorstadium", "besteht", ".", "Die", "Tenascinexpression", "wurde", "immunhistochemisch", "und", "ueber", "In", "-", "situ", "-", "Hybridisierung", "an", "Nativgeweben", "von", "Primaertumoren", "und", "Lymphknotenmetastasen", "(", "n=39", ")", "sowie", "an", "Tumorzellkulturen", "(", "n=15", ")", "untersucht", ".", "Die", "so", "erhaltenen", "Expressionsmuster", "wurden", "denen", "der", "Normalschleimhaut", "gegenuebergestellt", ".", "Tenascin", "wurde", "in", "Tumoren", "verstaerkt", "exprimiert", "und", "war", "in", "der", "gesamten", "tumorumgebenden", "EZM", "lokalisiert", ".", "Die", "mRNA", "-", "Analyse", "am", "Gewebeschnitt", "und", "die", "Proteinanalyse", "der", "Tumorzellkulturen", "ergab", ",", "dass", "die", "Tumorzellen", "selbst", "Tenascin", "synthetisierten", ".", "Ein", "Zusammenhang", "von", "Tenascinexpression", "und", "TNM", "-", "Stadium", "oder", "Tumorproliferation", "war", "nicht", "nachweisbar", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "Tenascin", "in", "Kopf", "-", "Hals", "-", "Tumoren", "selektiv", "exprimiert", "wird", "und", "sich", "fuer", "eine", "gezielte", ",", "onkologische", "Therapie", "anbietet", "." ]	[ "umlsterm" ]
Tenascin, Plattenepithelkarzinome, Tumoren, Zellen, Tenascin, Tumorstadium, In - situ - Hybridisierung, Nativgeweben, Lymphknotenmetastasen, Tumorzellkulturen, Normalschleimhaut, Tenascin, Tumoren, tumorumgebenden, Gewebeschnitt, Proteinanalyse, Tumorzellkulturen, Tumorzellen, selbst, Tenascin, Tumorproliferation, Tenascin, Kopf - Hals - Tumoren, gezielte, Therapie	HNO.90470723.ger.abstr_task2	Sentence: Tenascin , ein Glykoprotein der extrazellulaeren Matrix ( EZM ) , ist aufgrund seiner proliferations- und migrationsassoziierten Expression ein Zielmolekuel in der intralaesionalen Glioblastomtherapie . Ob dieses Konzept auf Plattenepithelkarzinome des oberen Aerodigestivtraktes uebertragbar ist , haengt wesentlich vom Tenascinexpressionsmuster in diesen Tumoren ab . Unser Ziel war es zu klaeren , von welchen Zellen und wie selektiv Tenascin exprimiert wird und ob ein Zusammenhang mit dem Tumorstadium besteht . Die Tenascinexpression wurde immunhistochemisch und ueber In-situ-Hybridisierung an Nativgeweben von Primaertumoren und Lymphknotenmetastasen ( n=39) sowie an Tumorzellkulturen ( n=15) untersucht . Die so erhaltenen Expressionsmuster wurden denen der Normalschleimhaut gegenuebergestellt . Tenascin wurde in Tumoren verstaerkt exprimiert und war in der gesamten tumorumgebenden EZM lokalisiert . Die mRNA-Analyse am Gewebeschnitt und die Proteinanalyse der Tumorzellkulturen ergab , dass die Tumorzellen selbst Tenascin synthetisierten . Ein Zusammenhang von Tenascinexpression und TNM-Stadium oder Tumorproliferation war nicht nachweisbar . Unsere Ergebnisse zeigen , dass Tenascin in Kopf-Hals-Tumoren selektiv exprimiert wird und sich fuer eine gezielte , onkologische Therapie anbietet . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]	Tenascin , ein Glykoprotein der extrazellulaeren Matrix ( EZM ) , ist aufgrund seiner proliferations- und migrationsassoziierten Expression ein Zielmolekuel in der intralaesionalen Glioblastomtherapie . Ob dieses Konzept auf Plattenepithelkarzinome des oberen Aerodigestivtraktes uebertragbar ist , haengt wesentlich vom Tenascinexpressionsmuster in diesen Tumoren ab . Unser Ziel war es zu klaeren , von welchen Zellen und wie selektiv Tenascin exprimiert wird und ob ein Zusammenhang mit dem Tumorstadium besteht . Die Tenascinexpression wurde immunhistochemisch und ueber In-situ-Hybridisierung an Nativgeweben von Primaertumoren und Lymphknotenmetastasen ( n=39) sowie an Tumorzellkulturen ( n=15) untersucht . Die so erhaltenen Expressionsmuster wurden denen der Normalschleimhaut gegenuebergestellt . Tenascin wurde in Tumoren verstaerkt exprimiert und war in der gesamten tumorumgebenden EZM lokalisiert . Die mRNA-Analyse am Gewebeschnitt und die Proteinanalyse der Tumorzellkulturen ergab , dass die Tumorzellen selbst Tenascin synthetisierten . Ein Zusammenhang von Tenascinexpression und TNM-Stadium oder Tumorproliferation war nicht nachweisbar . Unsere Ergebnisse zeigen , dass Tenascin in Kopf-Hals-Tumoren selektiv exprimiert wird und sich fuer eine gezielte , onkologische Therapie anbietet .	[ "Tenascin", ",", "ein", "Glykoprotein", "der", "extrazellulaeren", "Matrix", "(", "EZM", ")", ",", "ist", "aufgrund", "seiner", "proliferations-", "und", "migrationsassoziierten", "Expression", "ein", "Zielmolekuel", "in", "der", "intralaesionalen", "Glioblastomtherapie", ".", "Ob", "dieses", "Konzept", "auf", "Plattenepithelkarzinome", "des", "oberen", "Aerodigestivtraktes", "uebertragbar", "ist", ",", "haengt", "wesentlich", "vom", "Tenascinexpressionsmuster", "in", "diesen", "Tumoren", "ab", ".", "Unser", "Ziel", "war", "es", "zu", "klaeren", ",", "von", "welchen", "Zellen", "und", "wie", "selektiv", "Tenascin", "exprimiert", "wird", "und", "ob", "ein", "Zusammenhang", "mit", "dem", "Tumorstadium", "besteht", ".", "Die", "Tenascinexpression", "wurde", "immunhistochemisch", "und", "ueber", "In", "-", "situ", "-", "Hybridisierung", "an", "Nativgeweben", "von", "Primaertumoren", "und", "Lymphknotenmetastasen", "(", "n=39", ")", "sowie", "an", "Tumorzellkulturen", "(", "n=15", ")", "untersucht", ".", "Die", "so", "erhaltenen", "Expressionsmuster", "wurden", "denen", "der", "Normalschleimhaut", "gegenuebergestellt", ".", "Tenascin", "wurde", "in", "Tumoren", "verstaerkt", "exprimiert", "und", "war", "in", "der", "gesamten", "tumorumgebenden", "EZM", "lokalisiert", ".", "Die", "mRNA", "-", "Analyse", "am", "Gewebeschnitt", "und", "die", "Proteinanalyse", "der", "Tumorzellkulturen", "ergab", ",", "dass", "die", "Tumorzellen", "selbst", "Tenascin", "synthetisierten", ".", "Ein", "Zusammenhang", "von", "Tenascinexpression", "und", "TNM", "-", "Stadium", "oder", "Tumorproliferation", "war", "nicht", "nachweisbar", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "Tenascin", "in", "Kopf", "-", "Hals", "-", "Tumoren", "selektiv", "exprimiert", "wird", "und", "sich", "fuer", "eine", "gezielte", ",", "onkologische", "Therapie", "anbietet", "." ]	[ "umlsterm" ]
transducer is an umlsterm, cochlea is an umlsterm, amplifier is an umlsterm, CAI is an umlsterm, treatment is an umlsterm, hearing loss is an umlsterm, implantation is an umlsterm, mastoid is an umlsterm, University is an umlsterm, cochlea is an umlsterm, amplifier is an umlsterm, transducer is an umlsterm, patients is an umlsterm, future is an umlsterm, fit is an umlsterm, CAI is an umlsterm, mastoid is an umlsterm, X - ray is an umlsterm, CT scans is an umlsterm, cadaver is an umlsterm, temporal bone is an umlsterm, mastoid is an umlsterm, CT scans is an umlsterm, water is an umlsterm, determination is an umlsterm, CAI is an umlsterm, temporal bones is an umlsterm, X - ray is an umlsterm, evaluation is an umlsterm	HNO.80460220.eng.abstr_task0	Sentence: Recently , the transducer and microphone of a cochlea amplifier implant ( CAI ) for the treatment of sensorineural cochlear hearing loss have been developed further for implantation into the mastoid cavity . At present , the University of Tuebingen implantable cochlea amplifier consists of an implantable microphone and an implantable piezoelectric transducer . It has been implanted into the first patients . Successful future application of this new implant depends on the suitable fit of the CAI within a patient's mastoid cavity . Using conventional X-ray and CT scans , we analyzed 50 cadaver specimens of the temporal bone before total mastoidectomy . After total mastoidectomy , the volume of the mastoid cavity was measured using CT scans and water volume determination . Finally , the CAI was implanted into those temporal bones that were large enough to house it . Our results demonstrate that the degree of pneumatization in the conventional Schueller X-ray is already a good parameter for preoperative evaluation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Recently , the transducer and microphone of a cochlea amplifier implant ( CAI ) for the treatment of sensorineural cochlear hearing loss have been developed further for implantation into the mastoid cavity . At present , the University of Tuebingen implantable cochlea amplifier consists of an implantable microphone and an implantable piezoelectric transducer . It has been implanted into the first patients . Successful future application of this new implant depends on the suitable fit of the CAI within a patient's mastoid cavity . Using conventional X-ray and CT scans , we analyzed 50 cadaver specimens of the temporal bone before total mastoidectomy . After total mastoidectomy , the volume of the mastoid cavity was measured using CT scans and water volume determination . Finally , the CAI was implanted into those temporal bones that were large enough to house it . Our results demonstrate that the degree of pneumatization in the conventional Schueller X-ray is already a good parameter for preoperative evaluation .	[ "Recently", ",", "the", "transducer", "and", "microphone", "of", "a", "cochlea", "amplifier", "implant", "(", "CAI", ")", "for", "the", "treatment", "of", "sensorineural", "cochlear", "hearing", "loss", "have", "been", "developed", "further", "for", "implantation", "into", "the", "mastoid", "cavity", ".", "At", "present", ",", "the", "University", "of", "Tuebingen", "implantable", "cochlea", "amplifier", "consists", "of", "an", "implantable", "microphone", "and", "an", "implantable", "piezoelectric", "transducer", ".", "It", "has", "been", "implanted", "into", "the", "first", "patients", ".", "Successful", "future", "application", "of", "this", "new", "implant", "depends", "on", "the", "suitable", "fit", "of", "the", "CAI", "within", "a", "patient", "'s", "mastoid", "cavity", ".", "Using", "conventional", "X", "-", "ray", "and", "CT", "scans", ",", "we", "analyzed", "50", "cadaver", "specimens", "of", "the", "temporal", "bone", "before", "total", "mastoidectomy", ".", "After", "total", "mastoidectomy", ",", "the", "volume", "of", "the", "mastoid", "cavity", "was", "measured", "using", "CT", "scans", "and", "water", "volume", "determination", ".", "Finally", ",", "the", "CAI", "was", "implanted", "into", "those", "temporal", "bones", "that", "were", "large", "enough", "to", "house", "it", ".", "Our", "results", "demonstrate", "that", "the", "degree", "of", "pneumatization", "in", "the", "conventional", "Schueller", "X", "-", "ray", "is", "already", "a", "good", "parameter", "for", "preoperative", "evaluation", "." ]	[ "umlsterm" ]
transducer is an umlsterm, cochlea is an umlsterm, amplifier is an umlsterm, CAI is an umlsterm, treatment is an umlsterm, hearing loss is an umlsterm, implantation is an umlsterm, mastoid is an umlsterm, University is an umlsterm, cochlea is an umlsterm, amplifier is an umlsterm, transducer is an umlsterm, patients is an umlsterm, future is an umlsterm, fit is an umlsterm, CAI is an umlsterm, mastoid is an umlsterm, X - ray is an umlsterm, CT scans is an umlsterm, cadaver is an umlsterm, temporal bone is an umlsterm, mastoid is an umlsterm, CT scans is an umlsterm, water is an umlsterm, determination is an umlsterm, CAI is an umlsterm, temporal bones is an umlsterm, X - ray is an umlsterm, evaluation is an umlsterm	HNO.80460220.eng.abstr_task1	Sentence: Recently , the transducer and microphone of a cochlea amplifier implant ( CAI ) for the treatment of sensorineural cochlear hearing loss have been developed further for implantation into the mastoid cavity . At present , the University of Tuebingen implantable cochlea amplifier consists of an implantable microphone and an implantable piezoelectric transducer . It has been implanted into the first patients . Successful future application of this new implant depends on the suitable fit of the CAI within a patient's mastoid cavity . Using conventional X-ray and CT scans , we analyzed 50 cadaver specimens of the temporal bone before total mastoidectomy . After total mastoidectomy , the volume of the mastoid cavity was measured using CT scans and water volume determination . Finally , the CAI was implanted into those temporal bones that were large enough to house it . Our results demonstrate that the degree of pneumatization in the conventional Schueller X-ray is already a good parameter for preoperative evaluation . Instructions: please typing these entity words according to sentence: transducer, cochlea, amplifier, CAI, treatment, hearing loss, implantation, mastoid, University, cochlea, amplifier, transducer, patients, future, fit, CAI, mastoid, X - ray, CT scans, cadaver, temporal bone, mastoid, CT scans, water, determination, CAI, temporal bones, X - ray, evaluation Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Recently , the transducer and microphone of a cochlea amplifier implant ( CAI ) for the treatment of sensorineural cochlear hearing loss have been developed further for implantation into the mastoid cavity . At present , the University of Tuebingen implantable cochlea amplifier consists of an implantable microphone and an implantable piezoelectric transducer . It has been implanted into the first patients . Successful future application of this new implant depends on the suitable fit of the CAI within a patient's mastoid cavity . Using conventional X-ray and CT scans , we analyzed 50 cadaver specimens of the temporal bone before total mastoidectomy . After total mastoidectomy , the volume of the mastoid cavity was measured using CT scans and water volume determination . Finally , the CAI was implanted into those temporal bones that were large enough to house it . Our results demonstrate that the degree of pneumatization in the conventional Schueller X-ray is already a good parameter for preoperative evaluation .	[ "Recently", ",", "the", "transducer", "and", "microphone", "of", "a", "cochlea", "amplifier", "implant", "(", "CAI", ")", "for", "the", "treatment", "of", "sensorineural", "cochlear", "hearing", "loss", "have", "been", "developed", "further", "for", "implantation", "into", "the", "mastoid", "cavity", ".", "At", "present", ",", "the", "University", "of", "Tuebingen", "implantable", "cochlea", "amplifier", "consists", "of", "an", "implantable", "microphone", "and", "an", "implantable", "piezoelectric", "transducer", ".", "It", "has", "been", "implanted", "into", "the", "first", "patients", ".", "Successful", "future", "application", "of", "this", "new", "implant", "depends", "on", "the", "suitable", "fit", "of", "the", "CAI", "within", "a", "patient", "'s", "mastoid", "cavity", ".", "Using", "conventional", "X", "-", "ray", "and", "CT", "scans", ",", "we", "analyzed", "50", "cadaver", "specimens", "of", "the", "temporal", "bone", "before", "total", "mastoidectomy", ".", "After", "total", "mastoidectomy", ",", "the", "volume", "of", "the", "mastoid", "cavity", "was", "measured", "using", "CT", "scans", "and", "water", "volume", "determination", ".", "Finally", ",", "the", "CAI", "was", "implanted", "into", "those", "temporal", "bones", "that", "were", "large", "enough", "to", "house", "it", ".", "Our", "results", "demonstrate", "that", "the", "degree", "of", "pneumatization", "in", "the", "conventional", "Schueller", "X", "-", "ray", "is", "already", "a", "good", "parameter", "for", "preoperative", "evaluation", "." ]	[ "umlsterm" ]
transducer, cochlea, amplifier, CAI, treatment, hearing loss, implantation, mastoid, University, cochlea, amplifier, transducer, patients, future, fit, CAI, mastoid, X - ray, CT scans, cadaver, temporal bone, mastoid, CT scans, water, determination, CAI, temporal bones, X - ray, evaluation	HNO.80460220.eng.abstr_task2	Sentence: Recently , the transducer and microphone of a cochlea amplifier implant ( CAI ) for the treatment of sensorineural cochlear hearing loss have been developed further for implantation into the mastoid cavity . At present , the University of Tuebingen implantable cochlea amplifier consists of an implantable microphone and an implantable piezoelectric transducer . It has been implanted into the first patients . Successful future application of this new implant depends on the suitable fit of the CAI within a patient's mastoid cavity . Using conventional X-ray and CT scans , we analyzed 50 cadaver specimens of the temporal bone before total mastoidectomy . After total mastoidectomy , the volume of the mastoid cavity was measured using CT scans and water volume determination . Finally , the CAI was implanted into those temporal bones that were large enough to house it . Our results demonstrate that the degree of pneumatization in the conventional Schueller X-ray is already a good parameter for preoperative evaluation . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Recently , the transducer and microphone of a cochlea amplifier implant ( CAI ) for the treatment of sensorineural cochlear hearing loss have been developed further for implantation into the mastoid cavity . At present , the University of Tuebingen implantable cochlea amplifier consists of an implantable microphone and an implantable piezoelectric transducer . It has been implanted into the first patients . Successful future application of this new implant depends on the suitable fit of the CAI within a patient's mastoid cavity . Using conventional X-ray and CT scans , we analyzed 50 cadaver specimens of the temporal bone before total mastoidectomy . After total mastoidectomy , the volume of the mastoid cavity was measured using CT scans and water volume determination . Finally , the CAI was implanted into those temporal bones that were large enough to house it . Our results demonstrate that the degree of pneumatization in the conventional Schueller X-ray is already a good parameter for preoperative evaluation .	[ "Recently", ",", "the", "transducer", "and", "microphone", "of", "a", "cochlea", "amplifier", "implant", "(", "CAI", ")", "for", "the", "treatment", "of", "sensorineural", "cochlear", "hearing", "loss", "have", "been", "developed", "further", "for", "implantation", "into", "the", "mastoid", "cavity", ".", "At", "present", ",", "the", "University", "of", "Tuebingen", "implantable", "cochlea", "amplifier", "consists", "of", "an", "implantable", "microphone", "and", "an", "implantable", "piezoelectric", "transducer", ".", "It", "has", "been", "implanted", "into", "the", "first", "patients", ".", "Successful", "future", "application", "of", "this", "new", "implant", "depends", "on", "the", "suitable", "fit", "of", "the", "CAI", "within", "a", "patient", "'s", "mastoid", "cavity", ".", "Using", "conventional", "X", "-", "ray", "and", "CT", "scans", ",", "we", "analyzed", "50", "cadaver", "specimens", "of", "the", "temporal", "bone", "before", "total", "mastoidectomy", ".", "After", "total", "mastoidectomy", ",", "the", "volume", "of", "the", "mastoid", "cavity", "was", "measured", "using", "CT", "scans", "and", "water", "volume", "determination", ".", "Finally", ",", "the", "CAI", "was", "implanted", "into", "those", "temporal", "bones", "that", "were", "large", "enough", "to", "house", "it", ".", "Our", "results", "demonstrate", "that", "the", "degree", "of", "pneumatization", "in", "the", "conventional", "Schueller", "X", "-", "ray", "is", "already", "a", "good", "parameter", "for", "preoperative", "evaluation", "." ]	[ "umlsterm" ]
p120cas is a Individual_protein, protein tyrosine kinase is a Individual_protein, E - cadherin is a Individual_protein, alpha - catenin is a Individual_protein, beta - catenin is a Individual_protein, plakoglobin is a Individual_protein	750_task0	Sentence: The p120cas gene encodes a protein tyrosine kinase substrate that associates with the cell-cell adhesion protein complex containing E-cadherin and its cytoplasmic cofactors alpha-catenin, beta-catenin, and plakoglobin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein	[ "O", "B-Individual_protein", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "B-Individual_protein", "O" ]	The p120cas gene encodes a protein tyrosine kinase substrate that associates with the cell-cell adhesion protein complex containing E-cadherin and its cytoplasmic cofactors alpha-catenin, beta-catenin, and plakoglobin.	[ "The", "p120cas", "gene", "encodes", "a", "protein", "tyrosine", "kinase", "substrate", "that", "associates", "with", "the", "cell", "-", "cell", "adhesion", "protein", "complex", "containing", "E", "-", "cadherin", "and", "its", "cytoplasmic", "cofactors", "alpha", "-", "catenin", ",", "beta", "-", "catenin", ",", "and", "plakoglobin", "." ]	[ "Individual_protein" ]
p120cas is a Individual_protein, protein tyrosine kinase is a Individual_protein, E - cadherin is a Individual_protein, alpha - catenin is a Individual_protein, beta - catenin is a Individual_protein, plakoglobin is a Individual_protein	750_task1	Sentence: The p120cas gene encodes a protein tyrosine kinase substrate that associates with the cell-cell adhesion protein complex containing E-cadherin and its cytoplasmic cofactors alpha-catenin, beta-catenin, and plakoglobin. Instructions: please typing these entity words according to sentence: p120cas, protein tyrosine kinase, E - cadherin, alpha - catenin, beta - catenin, plakoglobin Options: Individual_protein	[ "O", "B-Individual_protein", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "B-Individual_protein", "O" ]	The p120cas gene encodes a protein tyrosine kinase substrate that associates with the cell-cell adhesion protein complex containing E-cadherin and its cytoplasmic cofactors alpha-catenin, beta-catenin, and plakoglobin.	[ "The", "p120cas", "gene", "encodes", "a", "protein", "tyrosine", "kinase", "substrate", "that", "associates", "with", "the", "cell", "-", "cell", "adhesion", "protein", "complex", "containing", "E", "-", "cadherin", "and", "its", "cytoplasmic", "cofactors", "alpha", "-", "catenin", ",", "beta", "-", "catenin", ",", "and", "plakoglobin", "." ]	[ "Individual_protein" ]
p120cas, protein tyrosine kinase, E - cadherin, alpha - catenin, beta - catenin, plakoglobin	750_task2	Sentence: The p120cas gene encodes a protein tyrosine kinase substrate that associates with the cell-cell adhesion protein complex containing E-cadherin and its cytoplasmic cofactors alpha-catenin, beta-catenin, and plakoglobin. Instructions: please extract entity words from the input sentence	[ "O", "B-Individual_protein", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "B-Individual_protein", "O" ]	The p120cas gene encodes a protein tyrosine kinase substrate that associates with the cell-cell adhesion protein complex containing E-cadherin and its cytoplasmic cofactors alpha-catenin, beta-catenin, and plakoglobin.	[ "The", "p120cas", "gene", "encodes", "a", "protein", "tyrosine", "kinase", "substrate", "that", "associates", "with", "the", "cell", "-", "cell", "adhesion", "protein", "complex", "containing", "E", "-", "cadherin", "and", "its", "cytoplasmic", "cofactors", "alpha", "-", "catenin", ",", "beta", "-", "catenin", ",", "and", "plakoglobin", "." ]	[ "Individual_protein" ]
profilin is a Individual_protein, actin is a Individual_protein, profilin is a Individual_protein	349_task0	Sentence: Interestingly, profilin overproduction can compensate for the deleterious effects of too much actin in a profilin concentration-dependent manner. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein	[ "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O" ]	Interestingly, profilin overproduction can compensate for the deleterious effects of too much actin in a profilin concentration-dependent manner.	[ "Interestingly", ",", "profilin", "overproduction", "can", "compensate", "for", "the", "deleterious", "effects", "of", "too", "much", "actin", "in", "a", "profilin", "concentration", "-", "dependent", "manner", "." ]	[ "Individual_protein" ]
profilin is a Individual_protein, actin is a Individual_protein, profilin is a Individual_protein	349_task1	Sentence: Interestingly, profilin overproduction can compensate for the deleterious effects of too much actin in a profilin concentration-dependent manner. Instructions: please typing these entity words according to sentence: profilin, actin, profilin Options: Individual_protein	[ "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O" ]	Interestingly, profilin overproduction can compensate for the deleterious effects of too much actin in a profilin concentration-dependent manner.	[ "Interestingly", ",", "profilin", "overproduction", "can", "compensate", "for", "the", "deleterious", "effects", "of", "too", "much", "actin", "in", "a", "profilin", "concentration", "-", "dependent", "manner", "." ]	[ "Individual_protein" ]
profilin, actin, profilin	349_task2	Sentence: Interestingly, profilin overproduction can compensate for the deleterious effects of too much actin in a profilin concentration-dependent manner. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O" ]	Interestingly, profilin overproduction can compensate for the deleterious effects of too much actin in a profilin concentration-dependent manner.	[ "Interestingly", ",", "profilin", "overproduction", "can", "compensate", "for", "the", "deleterious", "effects", "of", "too", "much", "actin", "in", "a", "profilin", "concentration", "-", "dependent", "manner", "." ]	[ "Individual_protein" ]
efficacy and safety is a Outcome_Other, fluticasone propionate powder is a Intervention_Pharmacological, placebo is a Intervention_Control, moderate asthma is a Participant_Condition, Fluticasone propionate is a Intervention_Pharmacological, inhaled fluticasone propionate powder is a Intervention_Pharmacological, moderate asthma previously treated with an inhaled corticosteroid is a Participant_Condition, 342 is a Participant_Sample-size, adolescent and adult is a Participant_Age, forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted is a Participant_Condition, beclomethasone dipropionate is a Intervention_Pharmacological, triamcinolone acetonide is a Intervention_Pharmacological, mean increase from baseline to endpoint in FEV1 is a Outcome_Physical, remaining in the study over time is a Outcome_Other, exacerbating asthma is a Outcome_Physical, Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma is a Outcome_Physical, serious drug - related adverse events is a Outcome_Adverse-effects, well - tolerated and significantly is a Outcome_Other, improved lung function is a Outcome_Physical	89727_task0	Sentence: Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma . BACKGROUND Fluticasone propionate , an inhaled corticosteroid with negligible systemic bioavailability via the oral route , is efficacious in the treatment of asthma when administered via metered-dose inhaler . OBJECTIVE To evaluate the efficacy and safety of inhaled fluticasone propionate powder in patients with moderate asthma previously treated with an inhaled corticosteroid . METHODS This was a randomized , double-blind , placebo-controlled , parallel-group , multicenter study of 342 adolescent and adult patients with moderate asthma [ forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted ] treated previously by beclomethasone dipropionate or triamcinolone acetonide . Patients received fluticasone propionate powder 50 micrograms , 100 micrograms , 250 micrograms , or placebo via a breath-actuated inhalation device , the Diskhaler , twice daily for 12 weeks . RESULTS Patients in the fluticasone propionate groups experienced a mean increase from baseline to endpoint in FEV1 ranging from 0.43 L to 0.47 L. Patients in the placebo group experienced a mean decrease from baseline of 0.22 L ( P < .001 ) . The probability of patients remaining in the study over time without developing signs of exacerbating asthma was significantly greater in the fluticasone propionate groups than in the placebo group ( P = .001 ) . Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma requiring treatment also improved significantly with all fluticasone propionate treatment regimens compared with placebo ( P < .001 ) . There were no statistically significant differences at endpoint among the three fluticasone propionate groups . No serious drug-related adverse events occurred . CONCLUSIONS Fluticasone propionate powder ( 50 , 100 , and 250 micrograms ) was well-tolerated and significantly improved lung function in patients with moderate asthma . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Control", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O" ]	Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma . BACKGROUND Fluticasone propionate , an inhaled corticosteroid with negligible systemic bioavailability via the oral route , is efficacious in the treatment of asthma when administered via metered-dose inhaler . OBJECTIVE To evaluate the efficacy and safety of inhaled fluticasone propionate powder in patients with moderate asthma previously treated with an inhaled corticosteroid . METHODS This was a randomized , double-blind , placebo-controlled , parallel-group , multicenter study of 342 adolescent and adult patients with moderate asthma [ forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted ] treated previously by beclomethasone dipropionate or triamcinolone acetonide . Patients received fluticasone propionate powder 50 micrograms , 100 micrograms , 250 micrograms , or placebo via a breath-actuated inhalation device , the Diskhaler , twice daily for 12 weeks . RESULTS Patients in the fluticasone propionate groups experienced a mean increase from baseline to endpoint in FEV1 ranging from 0.43 L to 0.47 L. Patients in the placebo group experienced a mean decrease from baseline of 0.22 L ( P < .001 ) . The probability of patients remaining in the study over time without developing signs of exacerbating asthma was significantly greater in the fluticasone propionate groups than in the placebo group ( P = .001 ) . Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma requiring treatment also improved significantly with all fluticasone propionate treatment regimens compared with placebo ( P < .001 ) . There were no statistically significant differences at endpoint among the three fluticasone propionate groups . No serious drug-related adverse events occurred . CONCLUSIONS Fluticasone propionate powder ( 50 , 100 , and 250 micrograms ) was well-tolerated and significantly improved lung function in patients with moderate asthma .	[ "Comparative", "efficacy", "and", "safety", "of", "twice", "daily", "fluticasone", "propionate", "powder", "versus", "placebo", "in", "the", "treatment", "of", "moderate", "asthma", ".", "BACKGROUND", "Fluticasone", "propionate", ",", "an", "inhaled", "corticosteroid", "with", "negligible", "systemic", "bioavailability", "via", "the", "oral", "route", ",", "is", "efficacious", "in", "the", "treatment", "of", "asthma", "when", "administered", "via", "metered", "-", "dose", "inhaler", ".", "OBJECTIVE", "To", "evaluate", "the", "efficacy", "and", "safety", "of", "inhaled", "fluticasone", "propionate", "powder", "in", "patients", "with", "moderate", "asthma", "previously", "treated", "with", "an", "inhaled", "corticosteroid", ".", "METHODS", "This", "was", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "parallel", "-", "group", ",", "multicenter", "study", "of", "342", "adolescent", "and", "adult", "patients", "with", "moderate", "asthma", "[", "forced", "expiratory", "volume", "in", "1", "second", "(", "FEV1", ")", "between", "50", "%", "and", "80", "%", "of", "predicted", "]", "treated", "previously", "by", "beclomethasone", "dipropionate", "or", "triamcinolone", "acetonide", ".", "Patients", "received", "fluticasone", "propionate", "powder", "50", "micrograms", ",", "100", "micrograms", ",", "250", "micrograms", ",", "or", "placebo", "via", "a", "breath", "-", "actuated", "inhalation", "device", ",", "the", "Diskhaler", ",", "twice", "daily", "for", "12", "weeks", ".", "RESULTS", "Patients", "in", "the", "fluticasone", "propionate", "groups", "experienced", "a", "mean", "increase", "from", "baseline", "to", "endpoint", "in", "FEV1", "ranging", "from", "0.43", "L", "to", "0.47", "L.", "Patients", "in", "the", "placebo", "group", "experienced", "a", "mean", "decrease", "from", "baseline", "of", "0.22", "L", "(", "P", "<", ".001", ")", ".", "The", "probability", "of", "patients", "remaining", "in", "the", "study", "over", "time", "without", "developing", "signs", "of", "exacerbating", "asthma", "was", "significantly", "greater", "in", "the", "fluticasone", "propionate", "groups", "than", "in", "the", "placebo", "group", "(", "P", "=", ".001", ")", ".", "Asthma", "symptom", "scores", ",", "supplemental", "rescue", "albuterol", "use", ",", "and", "number", "of", "nighttime", "awakenings", "due", "to", "asthma", "requiring", "treatment", "also", "improved", "significantly", "with", "all", "fluticasone", "propionate", "treatment", "regimens", "compared", "with", "placebo", "(", "P", "<", ".001", ")", ".", "There", "were", "no", "statistically", "significant", "differences", "at", "endpoint", "among", "the", "three", "fluticasone", "propionate", "groups", ".", "No", "serious", "drug", "-", "related", "adverse", "events", "occurred", ".", "CONCLUSIONS", "Fluticasone", "propionate", "powder", "(", "50", ",", "100", ",", "and", "250", "micrograms", ")", "was", "well", "-", "tolerated", "and", "significantly", "improved", "lung", "function", "in", "patients", "with", "moderate", "asthma", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Adverse-effects", "Outcome_Other", "Participant_Age", "Intervention_Control", "Participant_Sample-size" ]
efficacy and safety is a Outcome_Other, fluticasone propionate powder is a Intervention_Pharmacological, placebo is a Intervention_Control, moderate asthma is a Participant_Condition, Fluticasone propionate is a Intervention_Pharmacological, inhaled fluticasone propionate powder is a Intervention_Pharmacological, moderate asthma previously treated with an inhaled corticosteroid is a Participant_Condition, 342 is a Participant_Sample-size, adolescent and adult is a Participant_Age, forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted is a Participant_Condition, beclomethasone dipropionate is a Intervention_Pharmacological, triamcinolone acetonide is a Intervention_Pharmacological, mean increase from baseline to endpoint in FEV1 is a Outcome_Physical, remaining in the study over time is a Outcome_Other, exacerbating asthma is a Outcome_Physical, Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma is a Outcome_Physical, serious drug - related adverse events is a Outcome_Adverse-effects, well - tolerated and significantly is a Outcome_Other, improved lung function is a Outcome_Physical	89727_task1	Sentence: Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma . BACKGROUND Fluticasone propionate , an inhaled corticosteroid with negligible systemic bioavailability via the oral route , is efficacious in the treatment of asthma when administered via metered-dose inhaler . OBJECTIVE To evaluate the efficacy and safety of inhaled fluticasone propionate powder in patients with moderate asthma previously treated with an inhaled corticosteroid . METHODS This was a randomized , double-blind , placebo-controlled , parallel-group , multicenter study of 342 adolescent and adult patients with moderate asthma [ forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted ] treated previously by beclomethasone dipropionate or triamcinolone acetonide . Patients received fluticasone propionate powder 50 micrograms , 100 micrograms , 250 micrograms , or placebo via a breath-actuated inhalation device , the Diskhaler , twice daily for 12 weeks . RESULTS Patients in the fluticasone propionate groups experienced a mean increase from baseline to endpoint in FEV1 ranging from 0.43 L to 0.47 L. Patients in the placebo group experienced a mean decrease from baseline of 0.22 L ( P < .001 ) . The probability of patients remaining in the study over time without developing signs of exacerbating asthma was significantly greater in the fluticasone propionate groups than in the placebo group ( P = .001 ) . Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma requiring treatment also improved significantly with all fluticasone propionate treatment regimens compared with placebo ( P < .001 ) . There were no statistically significant differences at endpoint among the three fluticasone propionate groups . No serious drug-related adverse events occurred . CONCLUSIONS Fluticasone propionate powder ( 50 , 100 , and 250 micrograms ) was well-tolerated and significantly improved lung function in patients with moderate asthma . Instructions: please typing these entity words according to sentence: efficacy and safety, fluticasone propionate powder, placebo, moderate asthma, Fluticasone propionate, inhaled fluticasone propionate powder, moderate asthma previously treated with an inhaled corticosteroid, 342, adolescent and adult, forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted, beclomethasone dipropionate, triamcinolone acetonide, mean increase from baseline to endpoint in FEV1, remaining in the study over time, exacerbating asthma, Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma, serious drug - related adverse events, well - tolerated and significantly, improved lung function Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Control", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O" ]	Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma . BACKGROUND Fluticasone propionate , an inhaled corticosteroid with negligible systemic bioavailability via the oral route , is efficacious in the treatment of asthma when administered via metered-dose inhaler . OBJECTIVE To evaluate the efficacy and safety of inhaled fluticasone propionate powder in patients with moderate asthma previously treated with an inhaled corticosteroid . METHODS This was a randomized , double-blind , placebo-controlled , parallel-group , multicenter study of 342 adolescent and adult patients with moderate asthma [ forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted ] treated previously by beclomethasone dipropionate or triamcinolone acetonide . Patients received fluticasone propionate powder 50 micrograms , 100 micrograms , 250 micrograms , or placebo via a breath-actuated inhalation device , the Diskhaler , twice daily for 12 weeks . RESULTS Patients in the fluticasone propionate groups experienced a mean increase from baseline to endpoint in FEV1 ranging from 0.43 L to 0.47 L. Patients in the placebo group experienced a mean decrease from baseline of 0.22 L ( P < .001 ) . The probability of patients remaining in the study over time without developing signs of exacerbating asthma was significantly greater in the fluticasone propionate groups than in the placebo group ( P = .001 ) . Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma requiring treatment also improved significantly with all fluticasone propionate treatment regimens compared with placebo ( P < .001 ) . There were no statistically significant differences at endpoint among the three fluticasone propionate groups . No serious drug-related adverse events occurred . CONCLUSIONS Fluticasone propionate powder ( 50 , 100 , and 250 micrograms ) was well-tolerated and significantly improved lung function in patients with moderate asthma .	[ "Comparative", "efficacy", "and", "safety", "of", "twice", "daily", "fluticasone", "propionate", "powder", "versus", "placebo", "in", "the", "treatment", "of", "moderate", "asthma", ".", "BACKGROUND", "Fluticasone", "propionate", ",", "an", "inhaled", "corticosteroid", "with", "negligible", "systemic", "bioavailability", "via", "the", "oral", "route", ",", "is", "efficacious", "in", "the", "treatment", "of", "asthma", "when", "administered", "via", "metered", "-", "dose", "inhaler", ".", "OBJECTIVE", "To", "evaluate", "the", "efficacy", "and", "safety", "of", "inhaled", "fluticasone", "propionate", "powder", "in", "patients", "with", "moderate", "asthma", "previously", "treated", "with", "an", "inhaled", "corticosteroid", ".", "METHODS", "This", "was", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "parallel", "-", "group", ",", "multicenter", "study", "of", "342", "adolescent", "and", "adult", "patients", "with", "moderate", "asthma", "[", "forced", "expiratory", "volume", "in", "1", "second", "(", "FEV1", ")", "between", "50", "%", "and", "80", "%", "of", "predicted", "]", "treated", "previously", "by", "beclomethasone", "dipropionate", "or", "triamcinolone", "acetonide", ".", "Patients", "received", "fluticasone", "propionate", "powder", "50", "micrograms", ",", "100", "micrograms", ",", "250", "micrograms", ",", "or", "placebo", "via", "a", "breath", "-", "actuated", "inhalation", "device", ",", "the", "Diskhaler", ",", "twice", "daily", "for", "12", "weeks", ".", "RESULTS", "Patients", "in", "the", "fluticasone", "propionate", "groups", "experienced", "a", "mean", "increase", "from", "baseline", "to", "endpoint", "in", "FEV1", "ranging", "from", "0.43", "L", "to", "0.47", "L.", "Patients", "in", "the", "placebo", "group", "experienced", "a", "mean", "decrease", "from", "baseline", "of", "0.22", "L", "(", "P", "<", ".001", ")", ".", "The", "probability", "of", "patients", "remaining", "in", "the", "study", "over", "time", "without", "developing", "signs", "of", "exacerbating", "asthma", "was", "significantly", "greater", "in", "the", "fluticasone", "propionate", "groups", "than", "in", "the", "placebo", "group", "(", "P", "=", ".001", ")", ".", "Asthma", "symptom", "scores", ",", "supplemental", "rescue", "albuterol", "use", ",", "and", "number", "of", "nighttime", "awakenings", "due", "to", "asthma", "requiring", "treatment", "also", "improved", "significantly", "with", "all", "fluticasone", "propionate", "treatment", "regimens", "compared", "with", "placebo", "(", "P", "<", ".001", ")", ".", "There", "were", "no", "statistically", "significant", "differences", "at", "endpoint", "among", "the", "three", "fluticasone", "propionate", "groups", ".", "No", "serious", "drug", "-", "related", "adverse", "events", "occurred", ".", "CONCLUSIONS", "Fluticasone", "propionate", "powder", "(", "50", ",", "100", ",", "and", "250", "micrograms", ")", "was", "well", "-", "tolerated", "and", "significantly", "improved", "lung", "function", "in", "patients", "with", "moderate", "asthma", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Adverse-effects", "Outcome_Other", "Participant_Age", "Intervention_Control", "Participant_Sample-size" ]
efficacy and safety, fluticasone propionate powder, placebo, moderate asthma, Fluticasone propionate, inhaled fluticasone propionate powder, moderate asthma previously treated with an inhaled corticosteroid, 342, adolescent and adult, forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted, beclomethasone dipropionate, triamcinolone acetonide, mean increase from baseline to endpoint in FEV1, remaining in the study over time, exacerbating asthma, Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma, serious drug - related adverse events, well - tolerated and significantly, improved lung function	89727_task2	Sentence: Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma . BACKGROUND Fluticasone propionate , an inhaled corticosteroid with negligible systemic bioavailability via the oral route , is efficacious in the treatment of asthma when administered via metered-dose inhaler . OBJECTIVE To evaluate the efficacy and safety of inhaled fluticasone propionate powder in patients with moderate asthma previously treated with an inhaled corticosteroid . METHODS This was a randomized , double-blind , placebo-controlled , parallel-group , multicenter study of 342 adolescent and adult patients with moderate asthma [ forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted ] treated previously by beclomethasone dipropionate or triamcinolone acetonide . Patients received fluticasone propionate powder 50 micrograms , 100 micrograms , 250 micrograms , or placebo via a breath-actuated inhalation device , the Diskhaler , twice daily for 12 weeks . RESULTS Patients in the fluticasone propionate groups experienced a mean increase from baseline to endpoint in FEV1 ranging from 0.43 L to 0.47 L. Patients in the placebo group experienced a mean decrease from baseline of 0.22 L ( P < .001 ) . The probability of patients remaining in the study over time without developing signs of exacerbating asthma was significantly greater in the fluticasone propionate groups than in the placebo group ( P = .001 ) . Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma requiring treatment also improved significantly with all fluticasone propionate treatment regimens compared with placebo ( P < .001 ) . There were no statistically significant differences at endpoint among the three fluticasone propionate groups . No serious drug-related adverse events occurred . CONCLUSIONS Fluticasone propionate powder ( 50 , 100 , and 250 micrograms ) was well-tolerated and significantly improved lung function in patients with moderate asthma . Instructions: please extract entity words from the input sentence	[ "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Control", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O" ]	Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma . BACKGROUND Fluticasone propionate , an inhaled corticosteroid with negligible systemic bioavailability via the oral route , is efficacious in the treatment of asthma when administered via metered-dose inhaler . OBJECTIVE To evaluate the efficacy and safety of inhaled fluticasone propionate powder in patients with moderate asthma previously treated with an inhaled corticosteroid . METHODS This was a randomized , double-blind , placebo-controlled , parallel-group , multicenter study of 342 adolescent and adult patients with moderate asthma [ forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted ] treated previously by beclomethasone dipropionate or triamcinolone acetonide . Patients received fluticasone propionate powder 50 micrograms , 100 micrograms , 250 micrograms , or placebo via a breath-actuated inhalation device , the Diskhaler , twice daily for 12 weeks . RESULTS Patients in the fluticasone propionate groups experienced a mean increase from baseline to endpoint in FEV1 ranging from 0.43 L to 0.47 L. Patients in the placebo group experienced a mean decrease from baseline of 0.22 L ( P < .001 ) . The probability of patients remaining in the study over time without developing signs of exacerbating asthma was significantly greater in the fluticasone propionate groups than in the placebo group ( P = .001 ) . Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma requiring treatment also improved significantly with all fluticasone propionate treatment regimens compared with placebo ( P < .001 ) . There were no statistically significant differences at endpoint among the three fluticasone propionate groups . No serious drug-related adverse events occurred . CONCLUSIONS Fluticasone propionate powder ( 50 , 100 , and 250 micrograms ) was well-tolerated and significantly improved lung function in patients with moderate asthma .	[ "Comparative", "efficacy", "and", "safety", "of", "twice", "daily", "fluticasone", "propionate", "powder", "versus", "placebo", "in", "the", "treatment", "of", "moderate", "asthma", ".", "BACKGROUND", "Fluticasone", "propionate", ",", "an", "inhaled", "corticosteroid", "with", "negligible", "systemic", "bioavailability", "via", "the", "oral", "route", ",", "is", "efficacious", "in", "the", "treatment", "of", "asthma", "when", "administered", "via", "metered", "-", "dose", "inhaler", ".", "OBJECTIVE", "To", "evaluate", "the", "efficacy", "and", "safety", "of", "inhaled", "fluticasone", "propionate", "powder", "in", "patients", "with", "moderate", "asthma", "previously", "treated", "with", "an", "inhaled", "corticosteroid", ".", "METHODS", "This", "was", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "parallel", "-", "group", ",", "multicenter", "study", "of", "342", "adolescent", "and", "adult", "patients", "with", "moderate", "asthma", "[", "forced", "expiratory", "volume", "in", "1", "second", "(", "FEV1", ")", "between", "50", "%", "and", "80", "%", "of", "predicted", "]", "treated", "previously", "by", "beclomethasone", "dipropionate", "or", "triamcinolone", "acetonide", ".", "Patients", "received", "fluticasone", "propionate", "powder", "50", "micrograms", ",", "100", "micrograms", ",", "250", "micrograms", ",", "or", "placebo", "via", "a", "breath", "-", "actuated", "inhalation", "device", ",", "the", "Diskhaler", ",", "twice", "daily", "for", "12", "weeks", ".", "RESULTS", "Patients", "in", "the", "fluticasone", "propionate", "groups", "experienced", "a", "mean", "increase", "from", "baseline", "to", "endpoint", "in", "FEV1", "ranging", "from", "0.43", "L", "to", "0.47", "L.", "Patients", "in", "the", "placebo", "group", "experienced", "a", "mean", "decrease", "from", "baseline", "of", "0.22", "L", "(", "P", "<", ".001", ")", ".", "The", "probability", "of", "patients", "remaining", "in", "the", "study", "over", "time", "without", "developing", "signs", "of", "exacerbating", "asthma", "was", "significantly", "greater", "in", "the", "fluticasone", "propionate", "groups", "than", "in", "the", "placebo", "group", "(", "P", "=", ".001", ")", ".", "Asthma", "symptom", "scores", ",", "supplemental", "rescue", "albuterol", "use", ",", "and", "number", "of", "nighttime", "awakenings", "due", "to", "asthma", "requiring", "treatment", "also", "improved", "significantly", "with", "all", "fluticasone", "propionate", "treatment", "regimens", "compared", "with", "placebo", "(", "P", "<", ".001", ")", ".", "There", "were", "no", "statistically", "significant", "differences", "at", "endpoint", "among", "the", "three", "fluticasone", "propionate", "groups", ".", "No", "serious", "drug", "-", "related", "adverse", "events", "occurred", ".", "CONCLUSIONS", "Fluticasone", "propionate", "powder", "(", "50", ",", "100", ",", "and", "250", "micrograms", ")", "was", "well", "-", "tolerated", "and", "significantly", "improved", "lung", "function", "in", "patients", "with", "moderate", "asthma", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Adverse-effects", "Outcome_Other", "Participant_Age", "Intervention_Control", "Participant_Sample-size" ]
IL-4 receptor alpha - chain cytoplasmic domain is a protein_domain_or_region, JAK-1 is a protein_molecule, STAT6 is a protein_molecule, IL-4-specific gene expression is an other_name	61724_task0	Sentence: The IL-4 receptor alpha-chain cytoplasmic domain is sufficient for activation of JAK-1 and STAT6 and the induction of IL-4-specific gene expression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_name, protein_domain_or_region, protein_molecule	[ "O", "B-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "O", "O", "O", "O", "O", "B-protein_molecule", "O", "B-protein_molecule", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]	The IL-4 receptor alpha-chain cytoplasmic domain is sufficient for activation of JAK-1 and STAT6 and the induction of IL-4-specific gene expression.	[ "The", "IL-4", "receptor", "alpha", "-", "chain", "cytoplasmic", "domain", "is", "sufficient", "for", "activation", "of", "JAK-1", "and", "STAT6", "and", "the", "induction", "of", "IL-4-specific", "gene", "expression", "." ]	[ "protein_domain_or_region", "(AND protein_domain_or_region protein_domain_or_region)", "protein_molecule", "other_name", "RNA_family_or_group", "cell_line", "protein_subunit", "protein_family_or_group", "DNA_family_or_group", "", "amino_acid_monomer", "protein_complex" ]
IL-4 receptor alpha - chain cytoplasmic domain is a protein_domain_or_region, JAK-1 is a protein_molecule, STAT6 is a protein_molecule, IL-4-specific gene expression is an other_name	61724_task1	Sentence: The IL-4 receptor alpha-chain cytoplasmic domain is sufficient for activation of JAK-1 and STAT6 and the induction of IL-4-specific gene expression. Instructions: please typing these entity words according to sentence: IL-4 receptor alpha - chain cytoplasmic domain, JAK-1, STAT6, IL-4-specific gene expression Options: other_name, protein_domain_or_region, protein_molecule	[ "O", "B-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "O", "O", "O", "O", "O", "B-protein_molecule", "O", "B-protein_molecule", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]	The IL-4 receptor alpha-chain cytoplasmic domain is sufficient for activation of JAK-1 and STAT6 and the induction of IL-4-specific gene expression.	[ "The", "IL-4", "receptor", "alpha", "-", "chain", "cytoplasmic", "domain", "is", "sufficient", "for", "activation", "of", "JAK-1", "and", "STAT6", "and", "the", "induction", "of", "IL-4-specific", "gene", "expression", "." ]	[ "protein_domain_or_region", "(AND protein_domain_or_region protein_domain_or_region)", "protein_molecule", "other_name", "RNA_family_or_group", "cell_line", "protein_subunit", "protein_family_or_group", "DNA_family_or_group", "", "amino_acid_monomer", "protein_complex" ]
IL-4 receptor alpha - chain cytoplasmic domain, JAK-1, STAT6, IL-4-specific gene expression	61724_task2	Sentence: The IL-4 receptor alpha-chain cytoplasmic domain is sufficient for activation of JAK-1 and STAT6 and the induction of IL-4-specific gene expression. Instructions: please extract entity words from the input sentence	[ "O", "B-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "O", "O", "O", "O", "O", "B-protein_molecule", "O", "B-protein_molecule", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]	The IL-4 receptor alpha-chain cytoplasmic domain is sufficient for activation of JAK-1 and STAT6 and the induction of IL-4-specific gene expression.	[ "The", "IL-4", "receptor", "alpha", "-", "chain", "cytoplasmic", "domain", "is", "sufficient", "for", "activation", "of", "JAK-1", "and", "STAT6", "and", "the", "induction", "of", "IL-4-specific", "gene", "expression", "." ]	[ "protein_domain_or_region", "(AND protein_domain_or_region protein_domain_or_region)", "protein_molecule", "other_name", "RNA_family_or_group", "cell_line", "protein_subunit", "protein_family_or_group", "DNA_family_or_group", "", "amino_acid_monomer", "protein_complex" ]
PS is a chemical	1.0alpha7.train.879_task0	Sentence: The effect is thought to arise through the non-specific binding of transcription factors with the PS backbone [ 2. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: chemical	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "O", "O", "O", "O" ]	The effect is thought to arise through the non-specific binding of transcription factors with the PS backbone [ 2.	[ "The", "effect", "is", "thought", "to", "arise", "through", "the", "non", "-", "specific", "binding", "of", " ", "transcription", "factors", "with", "the", " ", "PS", "backbone", "[", "2", "." ]	[ "chemical" ]
PS is a chemical	1.0alpha7.train.879_task1	Sentence: The effect is thought to arise through the non-specific binding of transcription factors with the PS backbone [ 2. Instructions: please typing these entity words according to sentence: PS Options: chemical	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "O", "O", "O", "O" ]	The effect is thought to arise through the non-specific binding of transcription factors with the PS backbone [ 2.	[ "The", "effect", "is", "thought", "to", "arise", "through", "the", "non", "-", "specific", "binding", "of", " ", "transcription", "factors", "with", "the", " ", "PS", "backbone", "[", "2", "." ]	[ "chemical" ]
PS	1.0alpha7.train.879_task2	Sentence: The effect is thought to arise through the non-specific binding of transcription factors with the PS backbone [ 2. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "O", "O", "O", "O" ]	The effect is thought to arise through the non-specific binding of transcription factors with the PS backbone [ 2.	[ "The", "effect", "is", "thought", "to", "arise", "through", "the", "non", "-", "specific", "binding", "of", " ", "transcription", "factors", "with", "the", " ", "PS", "backbone", "[", "2", "." ]	[ "chemical" ]
Menschen is an umlsterm	DerOpthalmologe.00970784.ger.abstr_task0	Sentence: Hintergrund . Eine Makulopathie bei jungen Menschen stellt differentialdiagnostisch eine Herausforderung dar . Neben hereditaeren Makuladystrophien und erworbenen Makuladegenerationen kommen seltener auch systemische Erkrankungen als Ursache in Betracht . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Hintergrund . Eine Makulopathie bei jungen Menschen stellt differentialdiagnostisch eine Herausforderung dar . Neben hereditaeren Makuladystrophien und erworbenen Makuladegenerationen kommen seltener auch systemische Erkrankungen als Ursache in Betracht .	[ "Hintergrund", ".", "Eine", "Makulopathie", "bei", "jungen", "Menschen", "stellt", "differentialdiagnostisch", "eine", "Herausforderung", "dar", ".", "Neben", "hereditaeren", "Makuladystrophien", "und", "erworbenen", "Makuladegenerationen", "kommen", "seltener", "auch", "systemische", "Erkrankungen", "als", "Ursache", "in", "Betracht", "." ]	[ "umlsterm" ]
Menschen is an umlsterm	DerOpthalmologe.00970784.ger.abstr_task1	Sentence: Hintergrund . Eine Makulopathie bei jungen Menschen stellt differentialdiagnostisch eine Herausforderung dar . Neben hereditaeren Makuladystrophien und erworbenen Makuladegenerationen kommen seltener auch systemische Erkrankungen als Ursache in Betracht . Instructions: please typing these entity words according to sentence: Menschen Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Hintergrund . Eine Makulopathie bei jungen Menschen stellt differentialdiagnostisch eine Herausforderung dar . Neben hereditaeren Makuladystrophien und erworbenen Makuladegenerationen kommen seltener auch systemische Erkrankungen als Ursache in Betracht .	[ "Hintergrund", ".", "Eine", "Makulopathie", "bei", "jungen", "Menschen", "stellt", "differentialdiagnostisch", "eine", "Herausforderung", "dar", ".", "Neben", "hereditaeren", "Makuladystrophien", "und", "erworbenen", "Makuladegenerationen", "kommen", "seltener", "auch", "systemische", "Erkrankungen", "als", "Ursache", "in", "Betracht", "." ]	[ "umlsterm" ]
Menschen	DerOpthalmologe.00970784.ger.abstr_task2	Sentence: Hintergrund . Eine Makulopathie bei jungen Menschen stellt differentialdiagnostisch eine Herausforderung dar . Neben hereditaeren Makuladystrophien und erworbenen Makuladegenerationen kommen seltener auch systemische Erkrankungen als Ursache in Betracht . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Hintergrund . Eine Makulopathie bei jungen Menschen stellt differentialdiagnostisch eine Herausforderung dar . Neben hereditaeren Makuladystrophien und erworbenen Makuladegenerationen kommen seltener auch systemische Erkrankungen als Ursache in Betracht .	[ "Hintergrund", ".", "Eine", "Makulopathie", "bei", "jungen", "Menschen", "stellt", "differentialdiagnostisch", "eine", "Herausforderung", "dar", ".", "Neben", "hereditaeren", "Makuladystrophien", "und", "erworbenen", "Makuladegenerationen", "kommen", "seltener", "auch", "systemische", "Erkrankungen", "als", "Ursache", "in", "Betracht", "." ]	[ "umlsterm" ]
Sarkoidose is an umlsterm, Gewebereaktion is an umlsterm, Aetiologie is an umlsterm, Therapie is an umlsterm, Interferonen is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Interferon - alpha is an umlsterm, Sarkoidose is an umlsterm, Interferontherapie is an umlsterm	DerHautarzt.70480482.ger.abstr_task0	Sentence: Die Sarkoidose ist eine granulomatoese Gewebereaktion ungeklaerter Aetiologie . Ueber eine Induktion dieser Erkrankung als Folge einer Therapie mit Interferonen liegen bisher nur Einzelberichte vor . Wir stellen 3 Patienten vor , die unter bzw. nach einer Therapie mit Interferon-alpha eine Sarkoidose entwickelten . Ein moeglicher kausaler Zusammenhang mit der Interferontherapie wird diskutiert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Die Sarkoidose ist eine granulomatoese Gewebereaktion ungeklaerter Aetiologie . Ueber eine Induktion dieser Erkrankung als Folge einer Therapie mit Interferonen liegen bisher nur Einzelberichte vor . Wir stellen 3 Patienten vor , die unter bzw. nach einer Therapie mit Interferon-alpha eine Sarkoidose entwickelten . Ein moeglicher kausaler Zusammenhang mit der Interferontherapie wird diskutiert .	[ "Die", "Sarkoidose", "ist", "eine", "granulomatoese", "Gewebereaktion", "ungeklaerter", "Aetiologie", ".", "Ueber", "eine", "Induktion", "dieser", "Erkrankung", "als", "Folge", "einer", "Therapie", "mit", "Interferonen", "liegen", "bisher", "nur", "Einzelberichte", "vor", ".", "Wir", "stellen", "3", "Patienten", "vor", ",", "die", "unter", "bzw", ".", "nach", "einer", "Therapie", "mit", "Interferon", "-", "alpha", "eine", "Sarkoidose", "entwickelten", ".", "Ein", "moeglicher", "kausaler", "Zusammenhang", "mit", "der", "Interferontherapie", "wird", "diskutiert", "." ]	[ "umlsterm" ]
Sarkoidose is an umlsterm, Gewebereaktion is an umlsterm, Aetiologie is an umlsterm, Therapie is an umlsterm, Interferonen is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Interferon - alpha is an umlsterm, Sarkoidose is an umlsterm, Interferontherapie is an umlsterm	DerHautarzt.70480482.ger.abstr_task1	Sentence: Die Sarkoidose ist eine granulomatoese Gewebereaktion ungeklaerter Aetiologie . Ueber eine Induktion dieser Erkrankung als Folge einer Therapie mit Interferonen liegen bisher nur Einzelberichte vor . Wir stellen 3 Patienten vor , die unter bzw. nach einer Therapie mit Interferon-alpha eine Sarkoidose entwickelten . Ein moeglicher kausaler Zusammenhang mit der Interferontherapie wird diskutiert . Instructions: please typing these entity words according to sentence: Sarkoidose, Gewebereaktion, Aetiologie, Therapie, Interferonen, Patienten, Therapie, Interferon - alpha, Sarkoidose, Interferontherapie Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Die Sarkoidose ist eine granulomatoese Gewebereaktion ungeklaerter Aetiologie . Ueber eine Induktion dieser Erkrankung als Folge einer Therapie mit Interferonen liegen bisher nur Einzelberichte vor . Wir stellen 3 Patienten vor , die unter bzw. nach einer Therapie mit Interferon-alpha eine Sarkoidose entwickelten . Ein moeglicher kausaler Zusammenhang mit der Interferontherapie wird diskutiert .	[ "Die", "Sarkoidose", "ist", "eine", "granulomatoese", "Gewebereaktion", "ungeklaerter", "Aetiologie", ".", "Ueber", "eine", "Induktion", "dieser", "Erkrankung", "als", "Folge", "einer", "Therapie", "mit", "Interferonen", "liegen", "bisher", "nur", "Einzelberichte", "vor", ".", "Wir", "stellen", "3", "Patienten", "vor", ",", "die", "unter", "bzw", ".", "nach", "einer", "Therapie", "mit", "Interferon", "-", "alpha", "eine", "Sarkoidose", "entwickelten", ".", "Ein", "moeglicher", "kausaler", "Zusammenhang", "mit", "der", "Interferontherapie", "wird", "diskutiert", "." ]	[ "umlsterm" ]
Sarkoidose, Gewebereaktion, Aetiologie, Therapie, Interferonen, Patienten, Therapie, Interferon - alpha, Sarkoidose, Interferontherapie	DerHautarzt.70480482.ger.abstr_task2	Sentence: Die Sarkoidose ist eine granulomatoese Gewebereaktion ungeklaerter Aetiologie . Ueber eine Induktion dieser Erkrankung als Folge einer Therapie mit Interferonen liegen bisher nur Einzelberichte vor . Wir stellen 3 Patienten vor , die unter bzw. nach einer Therapie mit Interferon-alpha eine Sarkoidose entwickelten . Ein moeglicher kausaler Zusammenhang mit der Interferontherapie wird diskutiert . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Die Sarkoidose ist eine granulomatoese Gewebereaktion ungeklaerter Aetiologie . Ueber eine Induktion dieser Erkrankung als Folge einer Therapie mit Interferonen liegen bisher nur Einzelberichte vor . Wir stellen 3 Patienten vor , die unter bzw. nach einer Therapie mit Interferon-alpha eine Sarkoidose entwickelten . Ein moeglicher kausaler Zusammenhang mit der Interferontherapie wird diskutiert .	[ "Die", "Sarkoidose", "ist", "eine", "granulomatoese", "Gewebereaktion", "ungeklaerter", "Aetiologie", ".", "Ueber", "eine", "Induktion", "dieser", "Erkrankung", "als", "Folge", "einer", "Therapie", "mit", "Interferonen", "liegen", "bisher", "nur", "Einzelberichte", "vor", ".", "Wir", "stellen", "3", "Patienten", "vor", ",", "die", "unter", "bzw", ".", "nach", "einer", "Therapie", "mit", "Interferon", "-", "alpha", "eine", "Sarkoidose", "entwickelten", ".", "Ein", "moeglicher", "kausaler", "Zusammenhang", "mit", "der", "Interferontherapie", "wird", "diskutiert", "." ]	[ "umlsterm" ]
PRA is a Measurement, > 50 % is a Value, DSA is a Measurement, > 1500 MFI is a Value, Retransplantation is a Condition, planning to is a Mood, mycophenolate is a Drug, instead of is a Negation, everolimus is a Drug, planning for is a Mood, follow - up is a Procedure, another center is a Visit	NCT03088280_exc_task0	Sentence: PRA > 50% DSA > 1500 MFI Retransplantation Patients who are planning to receive mycophenolate instead of everolimus Patients who have planning for follow-up in another center Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Value, Visit, Procedure, Negation, Measurement, Mood, Drug	[ "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "O", "O", "O", "O", "B-Mood", "I-Mood", "O", "B-Drug", "B-Negation", "I-Negation", "B-Drug", "O", "O", "O", "O", "B-Mood", "I-Mood", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Visit", "I-Visit", "O" ]	PRA > 50% DSA > 1500 MFI Retransplantation Patients who are planning to receive mycophenolate instead of everolimus Patients who have planning for follow-up in another center	[ "PRA", ">", "50", "%", "\n", "DSA", ">", "1500", "MFI", "\n", "Retransplantation", "\n", "Patients", "who", "are", "planning", "to", "receive", "mycophenolate", "instead", "of", "everolimus", "\n", "Patients", "who", "have", "planning", "for", "follow", "-", "up", "in", "another", "center", "\n" ]	[ "Condition", "Visit", "Drug", "Mood", "Value", "Negation", "Procedure", "Measurement" ]
PRA is a Measurement, > 50 % is a Value, DSA is a Measurement, > 1500 MFI is a Value, Retransplantation is a Condition, planning to is a Mood, mycophenolate is a Drug, instead of is a Negation, everolimus is a Drug, planning for is a Mood, follow - up is a Procedure, another center is a Visit	NCT03088280_exc_task1	Sentence: PRA > 50% DSA > 1500 MFI Retransplantation Patients who are planning to receive mycophenolate instead of everolimus Patients who have planning for follow-up in another center Instructions: please typing these entity words according to sentence: PRA, > 50 %, DSA, > 1500 MFI, Retransplantation, planning to, mycophenolate, instead of, everolimus, planning for, follow - up, another center Options: Condition, Value, Visit, Procedure, Negation, Measurement, Mood, Drug	[ "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "O", "O", "O", "O", "B-Mood", "I-Mood", "O", "B-Drug", "B-Negation", "I-Negation", "B-Drug", "O", "O", "O", "O", "B-Mood", "I-Mood", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Visit", "I-Visit", "O" ]	PRA > 50% DSA > 1500 MFI Retransplantation Patients who are planning to receive mycophenolate instead of everolimus Patients who have planning for follow-up in another center	[ "PRA", ">", "50", "%", "\n", "DSA", ">", "1500", "MFI", "\n", "Retransplantation", "\n", "Patients", "who", "are", "planning", "to", "receive", "mycophenolate", "instead", "of", "everolimus", "\n", "Patients", "who", "have", "planning", "for", "follow", "-", "up", "in", "another", "center", "\n" ]	[ "Condition", "Visit", "Drug", "Mood", "Value", "Negation", "Procedure", "Measurement" ]
PRA, > 50 %, DSA, > 1500 MFI, Retransplantation, planning to, mycophenolate, instead of, everolimus, planning for, follow - up, another center	NCT03088280_exc_task2	Sentence: PRA > 50% DSA > 1500 MFI Retransplantation Patients who are planning to receive mycophenolate instead of everolimus Patients who have planning for follow-up in another center Instructions: please extract entity words from the input sentence	[ "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "O", "O", "O", "O", "B-Mood", "I-Mood", "O", "B-Drug", "B-Negation", "I-Negation", "B-Drug", "O", "O", "O", "O", "B-Mood", "I-Mood", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Visit", "I-Visit", "O" ]	PRA > 50% DSA > 1500 MFI Retransplantation Patients who are planning to receive mycophenolate instead of everolimus Patients who have planning for follow-up in another center	[ "PRA", ">", "50", "%", "\n", "DSA", ">", "1500", "MFI", "\n", "Retransplantation", "\n", "Patients", "who", "are", "planning", "to", "receive", "mycophenolate", "instead", "of", "everolimus", "\n", "Patients", "who", "have", "planning", "for", "follow", "-", "up", "in", "another", "center", "\n" ]	[ "Condition", "Visit", "Drug", "Mood", "Value", "Negation", "Procedure", "Measurement" ]
weisse is an umlsterm, Piedra is an umlsterm, Menschen is an umlsterm, Tiere is an umlsterm, Hefe is an umlsterm, Trichosporon is an umlsterm, Infektion is an umlsterm	DerHautarzt.60470638.ger.abstr_task0	Sentence: Die weisse Piedra ist eine seltene Haarerkrankung des Menschen und bestimmter Tiere durch die weitverbreitete Hefe der Gattung Trichosporon . Klinisch ist die Infektion durch weissliche , weiche und leicht abstreifbare Belaege an den Haarschaeften charakterisiert ; an umschriebenen Stellen koennen die Schaefte jedoch auch durch Invasion der Erreger zerstoert werden . Prinzipiell koennen alle Koerperhaare befallen sein ; mit 95% am weitaus haeufigsten ist jedoch die Genitalbehaarung betroffen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die weisse Piedra ist eine seltene Haarerkrankung des Menschen und bestimmter Tiere durch die weitverbreitete Hefe der Gattung Trichosporon . Klinisch ist die Infektion durch weissliche , weiche und leicht abstreifbare Belaege an den Haarschaeften charakterisiert ; an umschriebenen Stellen koennen die Schaefte jedoch auch durch Invasion der Erreger zerstoert werden . Prinzipiell koennen alle Koerperhaare befallen sein ; mit 95% am weitaus haeufigsten ist jedoch die Genitalbehaarung betroffen .	[ "Die", "weisse", "Piedra", "ist", "eine", "seltene", "Haarerkrankung", "des", "Menschen", "und", "bestimmter", "Tiere", "durch", "die", "weitverbreitete", "Hefe", "der", "Gattung", "Trichosporon", ".", "Klinisch", "ist", "die", "Infektion", "durch", "weissliche", ",", "weiche", "und", "leicht", "abstreifbare", "Belaege", "an", "den", "Haarschaeften", "charakterisiert", ";", "an", "umschriebenen", "Stellen", "koennen", "die", "Schaefte", "jedoch", "auch", "durch", "Invasion", "der", "Erreger", "zerstoert", "werden", ".", "Prinzipiell", "koennen", "alle", "Koerperhaare", "befallen", "sein", ";", "mit", "95", "%", "am", "weitaus", "haeufigsten", "ist", "jedoch", "die", "Genitalbehaarung", "betroffen", "." ]	[ "umlsterm" ]
weisse is an umlsterm, Piedra is an umlsterm, Menschen is an umlsterm, Tiere is an umlsterm, Hefe is an umlsterm, Trichosporon is an umlsterm, Infektion is an umlsterm	DerHautarzt.60470638.ger.abstr_task1	Sentence: Die weisse Piedra ist eine seltene Haarerkrankung des Menschen und bestimmter Tiere durch die weitverbreitete Hefe der Gattung Trichosporon . Klinisch ist die Infektion durch weissliche , weiche und leicht abstreifbare Belaege an den Haarschaeften charakterisiert ; an umschriebenen Stellen koennen die Schaefte jedoch auch durch Invasion der Erreger zerstoert werden . Prinzipiell koennen alle Koerperhaare befallen sein ; mit 95% am weitaus haeufigsten ist jedoch die Genitalbehaarung betroffen . Instructions: please typing these entity words according to sentence: weisse, Piedra, Menschen, Tiere, Hefe, Trichosporon, Infektion Options: umlsterm	[ "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die weisse Piedra ist eine seltene Haarerkrankung des Menschen und bestimmter Tiere durch die weitverbreitete Hefe der Gattung Trichosporon . Klinisch ist die Infektion durch weissliche , weiche und leicht abstreifbare Belaege an den Haarschaeften charakterisiert ; an umschriebenen Stellen koennen die Schaefte jedoch auch durch Invasion der Erreger zerstoert werden . Prinzipiell koennen alle Koerperhaare befallen sein ; mit 95% am weitaus haeufigsten ist jedoch die Genitalbehaarung betroffen .	[ "Die", "weisse", "Piedra", "ist", "eine", "seltene", "Haarerkrankung", "des", "Menschen", "und", "bestimmter", "Tiere", "durch", "die", "weitverbreitete", "Hefe", "der", "Gattung", "Trichosporon", ".", "Klinisch", "ist", "die", "Infektion", "durch", "weissliche", ",", "weiche", "und", "leicht", "abstreifbare", "Belaege", "an", "den", "Haarschaeften", "charakterisiert", ";", "an", "umschriebenen", "Stellen", "koennen", "die", "Schaefte", "jedoch", "auch", "durch", "Invasion", "der", "Erreger", "zerstoert", "werden", ".", "Prinzipiell", "koennen", "alle", "Koerperhaare", "befallen", "sein", ";", "mit", "95", "%", "am", "weitaus", "haeufigsten", "ist", "jedoch", "die", "Genitalbehaarung", "betroffen", "." ]	[ "umlsterm" ]
weisse, Piedra, Menschen, Tiere, Hefe, Trichosporon, Infektion	DerHautarzt.60470638.ger.abstr_task2	Sentence: Die weisse Piedra ist eine seltene Haarerkrankung des Menschen und bestimmter Tiere durch die weitverbreitete Hefe der Gattung Trichosporon . Klinisch ist die Infektion durch weissliche , weiche und leicht abstreifbare Belaege an den Haarschaeften charakterisiert ; an umschriebenen Stellen koennen die Schaefte jedoch auch durch Invasion der Erreger zerstoert werden . Prinzipiell koennen alle Koerperhaare befallen sein ; mit 95% am weitaus haeufigsten ist jedoch die Genitalbehaarung betroffen . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die weisse Piedra ist eine seltene Haarerkrankung des Menschen und bestimmter Tiere durch die weitverbreitete Hefe der Gattung Trichosporon . Klinisch ist die Infektion durch weissliche , weiche und leicht abstreifbare Belaege an den Haarschaeften charakterisiert ; an umschriebenen Stellen koennen die Schaefte jedoch auch durch Invasion der Erreger zerstoert werden . Prinzipiell koennen alle Koerperhaare befallen sein ; mit 95% am weitaus haeufigsten ist jedoch die Genitalbehaarung betroffen .	[ "Die", "weisse", "Piedra", "ist", "eine", "seltene", "Haarerkrankung", "des", "Menschen", "und", "bestimmter", "Tiere", "durch", "die", "weitverbreitete", "Hefe", "der", "Gattung", "Trichosporon", ".", "Klinisch", "ist", "die", "Infektion", "durch", "weissliche", ",", "weiche", "und", "leicht", "abstreifbare", "Belaege", "an", "den", "Haarschaeften", "charakterisiert", ";", "an", "umschriebenen", "Stellen", "koennen", "die", "Schaefte", "jedoch", "auch", "durch", "Invasion", "der", "Erreger", "zerstoert", "werden", ".", "Prinzipiell", "koennen", "alle", "Koerperhaare", "befallen", "sein", ";", "mit", "95", "%", "am", "weitaus", "haeufigsten", "ist", "jedoch", "die", "Genitalbehaarung", "betroffen", "." ]	[ "umlsterm" ]
Pathologie is an umlsterm, Eignung is an umlsterm, Diagnostik is an umlsterm, Pathologie is an umlsterm, Makuladegeneration is an umlsterm, aelteren Menschen is an umlsterm	DerOpthalmologe.90960166.ger.abstr_task0	Sentence: Hintergrund : Kleine Areale retinaler Pathologie koennen , insbesondere im Anfangsstadium , schwer zu diagnostizieren sein . Das multifokale Elektroretinogramm ( MF-ERG ) bietet seit kurzem die Moeglichkeit der topographischen retinalen Funktionspruefung . Die Eignung des MF-ERGs in der Diagnostik fokaler retinaler Pathologie soll am Beispiel der altersabhaengigen Makuladegeneration ( AMD ) geprueft werden . Die AMD , die in 75 % bilateral verlaeuft , ist die haeufigste Ursache einer Beeintraechtigung des zentralen Sehvermoegens bei aelteren Menschen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Hintergrund : Kleine Areale retinaler Pathologie koennen , insbesondere im Anfangsstadium , schwer zu diagnostizieren sein . Das multifokale Elektroretinogramm ( MF-ERG ) bietet seit kurzem die Moeglichkeit der topographischen retinalen Funktionspruefung . Die Eignung des MF-ERGs in der Diagnostik fokaler retinaler Pathologie soll am Beispiel der altersabhaengigen Makuladegeneration ( AMD ) geprueft werden . Die AMD , die in 75 % bilateral verlaeuft , ist die haeufigste Ursache einer Beeintraechtigung des zentralen Sehvermoegens bei aelteren Menschen .	[ "Hintergrund", ":", "Kleine", "Areale", "retinaler", "Pathologie", "koennen", ",", "insbesondere", "im", "Anfangsstadium", ",", "schwer", "zu", "diagnostizieren", "sein", ".", "Das", "multifokale", "Elektroretinogramm", "(", "MF", "-", "ERG", ")", "bietet", "seit", "kurzem", "die", "Moeglichkeit", "der", "topographischen", "retinalen", "Funktionspruefung", ".", "Die", "Eignung", "des", "MF", "-", "ERGs", "in", "der", "Diagnostik", "fokaler", "retinaler", "Pathologie", "soll", "am", "Beispiel", "der", "altersabhaengigen", "Makuladegeneration", "(", "AMD", ")", "geprueft", "werden", ".", "Die", "AMD", ",", "die", "in", "75", "%", "bilateral", "verlaeuft", ",", "ist", "die", "haeufigste", "Ursache", "einer", "Beeintraechtigung", "des", "zentralen", "Sehvermoegens", "bei", "aelteren", "Menschen", "." ]	[ "umlsterm" ]
Pathologie is an umlsterm, Eignung is an umlsterm, Diagnostik is an umlsterm, Pathologie is an umlsterm, Makuladegeneration is an umlsterm, aelteren Menschen is an umlsterm	DerOpthalmologe.90960166.ger.abstr_task1	Sentence: Hintergrund : Kleine Areale retinaler Pathologie koennen , insbesondere im Anfangsstadium , schwer zu diagnostizieren sein . Das multifokale Elektroretinogramm ( MF-ERG ) bietet seit kurzem die Moeglichkeit der topographischen retinalen Funktionspruefung . Die Eignung des MF-ERGs in der Diagnostik fokaler retinaler Pathologie soll am Beispiel der altersabhaengigen Makuladegeneration ( AMD ) geprueft werden . Die AMD , die in 75 % bilateral verlaeuft , ist die haeufigste Ursache einer Beeintraechtigung des zentralen Sehvermoegens bei aelteren Menschen . Instructions: please typing these entity words according to sentence: Pathologie, Eignung, Diagnostik, Pathologie, Makuladegeneration, aelteren Menschen Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Hintergrund : Kleine Areale retinaler Pathologie koennen , insbesondere im Anfangsstadium , schwer zu diagnostizieren sein . Das multifokale Elektroretinogramm ( MF-ERG ) bietet seit kurzem die Moeglichkeit der topographischen retinalen Funktionspruefung . Die Eignung des MF-ERGs in der Diagnostik fokaler retinaler Pathologie soll am Beispiel der altersabhaengigen Makuladegeneration ( AMD ) geprueft werden . Die AMD , die in 75 % bilateral verlaeuft , ist die haeufigste Ursache einer Beeintraechtigung des zentralen Sehvermoegens bei aelteren Menschen .	[ "Hintergrund", ":", "Kleine", "Areale", "retinaler", "Pathologie", "koennen", ",", "insbesondere", "im", "Anfangsstadium", ",", "schwer", "zu", "diagnostizieren", "sein", ".", "Das", "multifokale", "Elektroretinogramm", "(", "MF", "-", "ERG", ")", "bietet", "seit", "kurzem", "die", "Moeglichkeit", "der", "topographischen", "retinalen", "Funktionspruefung", ".", "Die", "Eignung", "des", "MF", "-", "ERGs", "in", "der", "Diagnostik", "fokaler", "retinaler", "Pathologie", "soll", "am", "Beispiel", "der", "altersabhaengigen", "Makuladegeneration", "(", "AMD", ")", "geprueft", "werden", ".", "Die", "AMD", ",", "die", "in", "75", "%", "bilateral", "verlaeuft", ",", "ist", "die", "haeufigste", "Ursache", "einer", "Beeintraechtigung", "des", "zentralen", "Sehvermoegens", "bei", "aelteren", "Menschen", "." ]	[ "umlsterm" ]
Pathologie, Eignung, Diagnostik, Pathologie, Makuladegeneration, aelteren Menschen	DerOpthalmologe.90960166.ger.abstr_task2	Sentence: Hintergrund : Kleine Areale retinaler Pathologie koennen , insbesondere im Anfangsstadium , schwer zu diagnostizieren sein . Das multifokale Elektroretinogramm ( MF-ERG ) bietet seit kurzem die Moeglichkeit der topographischen retinalen Funktionspruefung . Die Eignung des MF-ERGs in der Diagnostik fokaler retinaler Pathologie soll am Beispiel der altersabhaengigen Makuladegeneration ( AMD ) geprueft werden . Die AMD , die in 75 % bilateral verlaeuft , ist die haeufigste Ursache einer Beeintraechtigung des zentralen Sehvermoegens bei aelteren Menschen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Hintergrund : Kleine Areale retinaler Pathologie koennen , insbesondere im Anfangsstadium , schwer zu diagnostizieren sein . Das multifokale Elektroretinogramm ( MF-ERG ) bietet seit kurzem die Moeglichkeit der topographischen retinalen Funktionspruefung . Die Eignung des MF-ERGs in der Diagnostik fokaler retinaler Pathologie soll am Beispiel der altersabhaengigen Makuladegeneration ( AMD ) geprueft werden . Die AMD , die in 75 % bilateral verlaeuft , ist die haeufigste Ursache einer Beeintraechtigung des zentralen Sehvermoegens bei aelteren Menschen .	[ "Hintergrund", ":", "Kleine", "Areale", "retinaler", "Pathologie", "koennen", ",", "insbesondere", "im", "Anfangsstadium", ",", "schwer", "zu", "diagnostizieren", "sein", ".", "Das", "multifokale", "Elektroretinogramm", "(", "MF", "-", "ERG", ")", "bietet", "seit", "kurzem", "die", "Moeglichkeit", "der", "topographischen", "retinalen", "Funktionspruefung", ".", "Die", "Eignung", "des", "MF", "-", "ERGs", "in", "der", "Diagnostik", "fokaler", "retinaler", "Pathologie", "soll", "am", "Beispiel", "der", "altersabhaengigen", "Makuladegeneration", "(", "AMD", ")", "geprueft", "werden", ".", "Die", "AMD", ",", "die", "in", "75", "%", "bilateral", "verlaeuft", ",", "ist", "die", "haeufigste", "Ursache", "einer", "Beeintraechtigung", "des", "zentralen", "Sehvermoegens", "bei", "aelteren", "Menschen", "." ]	[ "umlsterm" ]
Aromatase is a GENE-Y, Sulfatase is a GENE-Y, 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate is a CHEMICAL, 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate is a CHEMICAL, F is a CHEMICAL, Cl is a CHEMICAL, Br is a CHEMICAL, aromatase is a GENE-Y, sulfatase is a GENE-Y, halogen is a CHEMICAL, halogen is a CHEMICAL, halogen is a CHEMICAL, methylene is a CHEMICAL, difluoromethylene is a CHEMICAL, para - cyanophenyl is a CHEMICAL, triazolyl is a CHEMICAL, imidazolyl is a CHEMICAL, imidazole is a CHEMICAL, aromatase is a GENE-Y, steroid sulfatase is a GENE-Y, phenol is a CHEMICAL, aromatase is a GENE-Y	24173_task0	Sentence: Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs). Structure-activity relationship studies were performed on these compounds, and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms, replacement of the halogen with another group, replacement of the methylene linker with a difluoromethylene linker, replacement of the para-cyanophenyl ring with other ring structures, and replacement of the triazolyl group with an imidazolyl group. The most potent in vitro DASI discovered is an imidazole derivative with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5 nM, respectively. The parent phenol of this compound inhibits aromatase with an IC50 value of 0.028 nM in the same assay. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs). Structure-activity relationship studies were performed on these compounds, and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms, replacement of the halogen with another group, replacement of the methylene linker with a difluoromethylene linker, replacement of the para-cyanophenyl ring with other ring structures, and replacement of the triazolyl group with an imidazolyl group. The most potent in vitro DASI discovered is an imidazole derivative with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5 nM, respectively. The parent phenol of this compound inhibits aromatase with an IC50 value of 0.028 nM in the same assay.	[ "Synthesis", "and", "Structure", "-", "Activity", "Relationship", "Studies", "of", "Derivatives", "of", "the", "Dual", "Aromatase", "-", "Sulfatase", "Inhibitor", "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl", "sulfamate", ".", "\n", "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl", "sulfamate", "and", "its", "ortho", "-", "halogenated", "(", "F", ",", "Cl", ",", "Br", ")", "derivatives", "are", "first", "-", "generation", "dual", "aromatase", "and", "sulfatase", "inhibitors", "(", "DASIs", ")", ".", "Structure", "-", "activity", "relationship", "studies", "were", "performed", "on", "these", "compounds", ",", "and", "various", "modifications", "were", "made", "to", "their", "structures", "involving", "relocation", "of", "the", "halogen", "atom", ",", "introduction", "of", "more", "halogen", "atoms", ",", "replacement", "of", "the", "halogen", "with", "another", "group", ",", "replacement", "of", "the", "methylene", "linker", "with", "a", "difluoromethylene", "linker", ",", "replacement", "of", "the", "para", "-", "cyanophenyl", "ring", "with", "other", "ring", "structures", ",", "and", "replacement", "of", "the", "triazolyl", "group", "with", "an", "imidazolyl", "group", ".", "The", "most", "potent", "in", " ", "vitro", "DASI", "discovered", "is", "an", "imidazole", "derivative", "with", "IC50", "values", "against", "aromatase", "and", "steroid", "sulfatase", "in", "a", "JEG-3", "cell", "preparation", "of", "0.2", "and", "2.5", " ", "nM", ",", "respectively", ".", "The", "parent", "phenol", "of", "this", "compound", "inhibits", "aromatase", "with", "an", "IC50", "value", "of", "0.028", " ", "nM", "in", "the", "same", "assay", "." ]	[ "CHEMICAL", "GENE-Y" ]
Aromatase is a GENE-Y, Sulfatase is a GENE-Y, 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate is a CHEMICAL, 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate is a CHEMICAL, F is a CHEMICAL, Cl is a CHEMICAL, Br is a CHEMICAL, aromatase is a GENE-Y, sulfatase is a GENE-Y, halogen is a CHEMICAL, halogen is a CHEMICAL, halogen is a CHEMICAL, methylene is a CHEMICAL, difluoromethylene is a CHEMICAL, para - cyanophenyl is a CHEMICAL, triazolyl is a CHEMICAL, imidazolyl is a CHEMICAL, imidazole is a CHEMICAL, aromatase is a GENE-Y, steroid sulfatase is a GENE-Y, phenol is a CHEMICAL, aromatase is a GENE-Y	24173_task1	Sentence: Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs). Structure-activity relationship studies were performed on these compounds, and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms, replacement of the halogen with another group, replacement of the methylene linker with a difluoromethylene linker, replacement of the para-cyanophenyl ring with other ring structures, and replacement of the triazolyl group with an imidazolyl group. The most potent in vitro DASI discovered is an imidazole derivative with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5 nM, respectively. The parent phenol of this compound inhibits aromatase with an IC50 value of 0.028 nM in the same assay. Instructions: please typing these entity words according to sentence: Aromatase, Sulfatase, 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate, 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate, F, Cl, Br, aromatase, sulfatase, halogen, halogen, halogen, methylene, difluoromethylene, para - cyanophenyl, triazolyl, imidazolyl, imidazole, aromatase, steroid sulfatase, phenol, aromatase Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs). Structure-activity relationship studies were performed on these compounds, and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms, replacement of the halogen with another group, replacement of the methylene linker with a difluoromethylene linker, replacement of the para-cyanophenyl ring with other ring structures, and replacement of the triazolyl group with an imidazolyl group. The most potent in vitro DASI discovered is an imidazole derivative with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5 nM, respectively. The parent phenol of this compound inhibits aromatase with an IC50 value of 0.028 nM in the same assay.	[ "Synthesis", "and", "Structure", "-", "Activity", "Relationship", "Studies", "of", "Derivatives", "of", "the", "Dual", "Aromatase", "-", "Sulfatase", "Inhibitor", "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl", "sulfamate", ".", "\n", "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl", "sulfamate", "and", "its", "ortho", "-", "halogenated", "(", "F", ",", "Cl", ",", "Br", ")", "derivatives", "are", "first", "-", "generation", "dual", "aromatase", "and", "sulfatase", "inhibitors", "(", "DASIs", ")", ".", "Structure", "-", "activity", "relationship", "studies", "were", "performed", "on", "these", "compounds", ",", "and", "various", "modifications", "were", "made", "to", "their", "structures", "involving", "relocation", "of", "the", "halogen", "atom", ",", "introduction", "of", "more", "halogen", "atoms", ",", "replacement", "of", "the", "halogen", "with", "another", "group", ",", "replacement", "of", "the", "methylene", "linker", "with", "a", "difluoromethylene", "linker", ",", "replacement", "of", "the", "para", "-", "cyanophenyl", "ring", "with", "other", "ring", "structures", ",", "and", "replacement", "of", "the", "triazolyl", "group", "with", "an", "imidazolyl", "group", ".", "The", "most", "potent", "in", " ", "vitro", "DASI", "discovered", "is", "an", "imidazole", "derivative", "with", "IC50", "values", "against", "aromatase", "and", "steroid", "sulfatase", "in", "a", "JEG-3", "cell", "preparation", "of", "0.2", "and", "2.5", " ", "nM", ",", "respectively", ".", "The", "parent", "phenol", "of", "this", "compound", "inhibits", "aromatase", "with", "an", "IC50", "value", "of", "0.028", " ", "nM", "in", "the", "same", "assay", "." ]	[ "CHEMICAL", "GENE-Y" ]
Aromatase, Sulfatase, 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate, 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate, F, Cl, Br, aromatase, sulfatase, halogen, halogen, halogen, methylene, difluoromethylene, para - cyanophenyl, triazolyl, imidazolyl, imidazole, aromatase, steroid sulfatase, phenol, aromatase	24173_task2	Sentence: Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs). Structure-activity relationship studies were performed on these compounds, and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms, replacement of the halogen with another group, replacement of the methylene linker with a difluoromethylene linker, replacement of the para-cyanophenyl ring with other ring structures, and replacement of the triazolyl group with an imidazolyl group. The most potent in vitro DASI discovered is an imidazole derivative with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5 nM, respectively. The parent phenol of this compound inhibits aromatase with an IC50 value of 0.028 nM in the same assay. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs). Structure-activity relationship studies were performed on these compounds, and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms, replacement of the halogen with another group, replacement of the methylene linker with a difluoromethylene linker, replacement of the para-cyanophenyl ring with other ring structures, and replacement of the triazolyl group with an imidazolyl group. The most potent in vitro DASI discovered is an imidazole derivative with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5 nM, respectively. The parent phenol of this compound inhibits aromatase with an IC50 value of 0.028 nM in the same assay.	[ "Synthesis", "and", "Structure", "-", "Activity", "Relationship", "Studies", "of", "Derivatives", "of", "the", "Dual", "Aromatase", "-", "Sulfatase", "Inhibitor", "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl", "sulfamate", ".", "\n", "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl", "sulfamate", "and", "its", "ortho", "-", "halogenated", "(", "F", ",", "Cl", ",", "Br", ")", "derivatives", "are", "first", "-", "generation", "dual", "aromatase", "and", "sulfatase", "inhibitors", "(", "DASIs", ")", ".", "Structure", "-", "activity", "relationship", "studies", "were", "performed", "on", "these", "compounds", ",", "and", "various", "modifications", "were", "made", "to", "their", "structures", "involving", "relocation", "of", "the", "halogen", "atom", ",", "introduction", "of", "more", "halogen", "atoms", ",", "replacement", "of", "the", "halogen", "with", "another", "group", ",", "replacement", "of", "the", "methylene", "linker", "with", "a", "difluoromethylene", "linker", ",", "replacement", "of", "the", "para", "-", "cyanophenyl", "ring", "with", "other", "ring", "structures", ",", "and", "replacement", "of", "the", "triazolyl", "group", "with", "an", "imidazolyl", "group", ".", "The", "most", "potent", "in", " ", "vitro", "DASI", "discovered", "is", "an", "imidazole", "derivative", "with", "IC50", "values", "against", "aromatase", "and", "steroid", "sulfatase", "in", "a", "JEG-3", "cell", "preparation", "of", "0.2", "and", "2.5", " ", "nM", ",", "respectively", ".", "The", "parent", "phenol", "of", "this", "compound", "inhibits", "aromatase", "with", "an", "IC50", "value", "of", "0.028", " ", "nM", "in", "the", "same", "assay", "." ]	[ "CHEMICAL", "GENE-Y" ]
TACR1 is a gene	47_task0	Sentence: Fine mapping of the 2p11 dyslexia locus and exclusion of TACR1 as a candidate gene. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: gene	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "O", "O", "O", "O", "O" ]	Fine mapping of the 2p11 dyslexia locus and exclusion of TACR1 as a candidate gene.	[ "Fine", "mapping", "of", "the", "2p11", "dyslexia", "locus", "and", "exclusion", "of", " ", "TACR1", " ", "as", "a", "candidate", "gene", "." ]	[ "variant", "gene" ]
TACR1 is a gene	47_task1	Sentence: Fine mapping of the 2p11 dyslexia locus and exclusion of TACR1 as a candidate gene. Instructions: please typing these entity words according to sentence: TACR1 Options: gene	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "O", "O", "O", "O", "O" ]	Fine mapping of the 2p11 dyslexia locus and exclusion of TACR1 as a candidate gene.	[ "Fine", "mapping", "of", "the", "2p11", "dyslexia", "locus", "and", "exclusion", "of", " ", "TACR1", " ", "as", "a", "candidate", "gene", "." ]	[ "variant", "gene" ]

tolerance is a Outcome_Other, bronchoprotective effect is a Outcome_Physical, salmeterol / fluticasone is a Intervention_Pharmacological, salmeterol / fluticasone propionate is a Intervention_Pharmacological, early airway response ( EAR ) is a Outcome_Physical, placebo is a Intervention_Control, allergen challenge ( T1 ) is a Intervention_Pharmacological, single dose of salmeterol / fluticasone is a Intervention_Pharmacological, allergen challenge ( T2 ) is a Intervention_Pharmacological, allergen challenge ( T3 ) is a Intervention_Pharmacological, FEV1 is a Outcome_Physical, MaxDeltaFEV1 % is a Outcome_Physical, area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge is a Outcome_Physical, significantly greater is a Outcome_Other, No difference is a Outcome_Other, area under the curve is a Outcome_Physical, protected against EAR is a Outcome_Physical, protected against EAR . is a Outcome_Physical, tolerance to the protective effect is a Outcome_Physical

24706_task1

Sentence: Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge . In order to assess whether the administration of salmeterol/fluticasone propionate combination ( 50/250 mcg by Diskus ) for 1 week induces tolerance to the bronchoprotective effect of salmeterol on allergen challenge , a single-blind , cross-over study was carried out . We studied nine subjects ( eight men and one woman ; mean age+/-SD : 31.3+/-11.0 yr ) with mild intermittent allergic asthma , never treated with regular beta2-agonists or inhaled corticosteroids . In a previous allergen challenge all subjects had shown a positive early airway response ( EAR ) to allergen . They underwent allergen challenge after 1-week treatment with placebo and a single dose of placebo immediately before allergen challenge ( T1 ) , or 1-week treatment with placebo and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T2 ) , or 1-week treatment with salmeterol/fluticasone combination bid and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T3 ) . EAR was evaluated both as maximum decrease in FEV1 ( MaxDeltaFEV1 % ) after allergen challenge and as area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge protected by placebo ( T1 ) was significantly greater than MaxDeltaFEV1 % during allergen challenges protected by single dose of salmeterol/fluticasone ( T2 ) and by salmeterol/fluticasone 1-week treatment ( T3 ) . No difference was found in MaxDeltaFEV1 % between T2 and T3 . The same results were observed also after computing the area under the curve for each challenge . When individually considered , all subjects were protected against EAR ( protection index > or = 80 % ) at T2 , while at 3 seven out of nine subjects were still protected against EAR . In conclusion , the simultaneous administration of salmeterol and fluticasone in the same device prevents in almost 80 % of examined subjects the development of tolerance to the protective effect of salmeterol on allergen challenge . This observation may contribute to explain the positive interaction between inhaled beta2-agonists and corticosteroids in the long-term treatment of asthma . Instructions: please typing these entity words according to sentence: tolerance, bronchoprotective effect, salmeterol / fluticasone, salmeterol / fluticasone propionate, early airway response ( EAR ), placebo, allergen challenge ( T1 ), single dose of salmeterol / fluticasone, allergen challenge ( T2 ), allergen challenge ( T3 ), FEV1, MaxDeltaFEV1 %, area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge, significantly greater, No difference, area under the curve, protected against EAR, protected against EAR ., tolerance to the protective effect Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Intervention_Control

[ "O", "B-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge . In order to assess whether the administration of salmeterol/fluticasone propionate combination ( 50/250 mcg by Diskus ) for 1 week induces tolerance to the bronchoprotective effect of salmeterol on allergen challenge , a single-blind , cross-over study was carried out . We studied nine subjects ( eight men and one woman ; mean age+/-SD : 31.3+/-11.0 yr ) with mild intermittent allergic asthma , never treated with regular beta2-agonists or inhaled corticosteroids . In a previous allergen challenge all subjects had shown a positive early airway response ( EAR ) to allergen . They underwent allergen challenge after 1-week treatment with placebo and a single dose of placebo immediately before allergen challenge ( T1 ) , or 1-week treatment with placebo and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T2 ) , or 1-week treatment with salmeterol/fluticasone combination bid and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T3 ) . EAR was evaluated both as maximum decrease in FEV1 ( MaxDeltaFEV1 % ) after allergen challenge and as area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge protected by placebo ( T1 ) was significantly greater than MaxDeltaFEV1 % during allergen challenges protected by single dose of salmeterol/fluticasone ( T2 ) and by salmeterol/fluticasone 1-week treatment ( T3 ) . No difference was found in MaxDeltaFEV1 % between T2 and T3 . The same results were observed also after computing the area under the curve for each challenge . When individually considered , all subjects were protected against EAR ( protection index > or = 80 % ) at T2 , while at 3 seven out of nine subjects were still protected against EAR . In conclusion , the simultaneous administration of salmeterol and fluticasone in the same device prevents in almost 80 % of examined subjects the development of tolerance to the protective effect of salmeterol on allergen challenge . This observation may contribute to explain the positive interaction between inhaled beta2-agonists and corticosteroids in the long-term treatment of asthma .

[ "Minimal", "tolerance", "to", "the", "bronchoprotective", "effect", "of", "inhaled", "salmeterol", "/", "fluticasone", "combination", "on", "allergene", "challenge", ".", "In", "order", "to", "assess", "whether", "the", "administration", "of", "salmeterol", "/", "fluticasone", "propionate", "combination", "(", "50/250", "mcg", "by", "Diskus", ")", "for", "1", "week", "induces", "tolerance", "to", "the", "bronchoprotective", "effect", "of", "salmeterol", "on", "allergen", "challenge", ",", "a", "single", "-", "blind", ",", "cross", "-", "over", "study", "was", "carried", "out", ".", "We", "studied", "nine", "subjects", "(", "eight", "men", "and", "one", "woman", ";", "mean", "age+/-SD", ":", "31.3+/-11.0", "yr", ")", "with", "mild", "intermittent", "allergic", "asthma", ",", "never", "treated", "with", "regular", "beta2-agonists", "or", "inhaled", "corticosteroids", ".", "In", "a", "previous", "allergen", "challenge", "all", "subjects", "had", "shown", "a", "positive", "early", "airway", "response", "(", "EAR", ")", "to", "allergen", ".", "They", "underwent", "allergen", "challenge", "after", "1-week", "treatment", "with", "placebo", "and", "a", "single", "dose", "of", "placebo", "immediately", "before", "allergen", "challenge", "(", "T1", ")", ",", "or", "1-week", "treatment", "with", "placebo", "and", "a", "single", "dose", "of", "salmeterol", "/", "fluticasone", "immediately", "before", "allergen", "challenge", "(", "T2", ")", ",", "or", "1-week", "treatment", "with", "salmeterol", "/", "fluticasone", "combination", "bid", "and", "a", "single", "dose", "of", "salmeterol", "/", "fluticasone", "immediately", "before", "allergen", "challenge", "(", "T3", ")", ".", "EAR", "was", "evaluated", "both", "as", "maximum", "decrease", "in", "FEV1", "(", "MaxDeltaFEV1", "%", ")", "after", "allergen", "challenge", "and", "as", "area", "under", "FEV1", "-time", "curve", ".", "MaxDeltaFEV1", "%", "during", "allergen", "challenge", "protected", "by", "placebo", "(", "T1", ")", "was", "significantly", "greater", "than", "MaxDeltaFEV1", "%", "during", "allergen", "challenges", "protected", "by", "single", "dose", "of", "salmeterol", "/", "fluticasone", "(", "T2", ")", "and", "by", "salmeterol", "/", "fluticasone", "1-week", "treatment", "(", "T3", ")", ".", "No", "difference", "was", "found", "in", "MaxDeltaFEV1", "%", "between", "T2", "and", "T3", ".", "The", "same", "results", "were", "observed", "also", "after", "computing", "the", "area", "under", "the", "curve", "for", "each", "challenge", ".", "When", "individually", "considered", ",", "all", "subjects", "were", "protected", "against", "EAR", "(", "protection", "index", ">", "or", "=", "80", "%", ")", "at", "T2", ",", "while", "at", "3", "seven", "out", "of", "nine", "subjects", "were", "still", "protected", "against", "EAR", ".", "In", "conclusion", ",", "the", "simultaneous", "administration", "of", "salmeterol", "and", "fluticasone", "in", "the", "same", "device", "prevents", "in", "almost", "80", "%", "of", "examined", "subjects", "the", "development", "of", "tolerance", "to", "the", "protective", "effect", "of", "salmeterol", "on", "allergen", "challenge", ".", "This", "observation", "may", "contribute", "to", "explain", "the", "positive", "interaction", "between", "inhaled", "beta2-agonists", "and", "corticosteroids", "in", "the", "long", "-", "term", "treatment", "of", "asthma", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Intervention_Control" ]

tolerance, bronchoprotective effect, salmeterol / fluticasone, salmeterol / fluticasone propionate, early airway response ( EAR ), placebo, allergen challenge ( T1 ), single dose of salmeterol / fluticasone, allergen challenge ( T2 ), allergen challenge ( T3 ), FEV1, MaxDeltaFEV1 %, area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge, significantly greater, No difference, area under the curve, protected against EAR, protected against EAR ., tolerance to the protective effect

24706_task2

Sentence: Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge . In order to assess whether the administration of salmeterol/fluticasone propionate combination ( 50/250 mcg by Diskus ) for 1 week induces tolerance to the bronchoprotective effect of salmeterol on allergen challenge , a single-blind , cross-over study was carried out . We studied nine subjects ( eight men and one woman ; mean age+/-SD : 31.3+/-11.0 yr ) with mild intermittent allergic asthma , never treated with regular beta2-agonists or inhaled corticosteroids . In a previous allergen challenge all subjects had shown a positive early airway response ( EAR ) to allergen . They underwent allergen challenge after 1-week treatment with placebo and a single dose of placebo immediately before allergen challenge ( T1 ) , or 1-week treatment with placebo and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T2 ) , or 1-week treatment with salmeterol/fluticasone combination bid and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T3 ) . EAR was evaluated both as maximum decrease in FEV1 ( MaxDeltaFEV1 % ) after allergen challenge and as area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge protected by placebo ( T1 ) was significantly greater than MaxDeltaFEV1 % during allergen challenges protected by single dose of salmeterol/fluticasone ( T2 ) and by salmeterol/fluticasone 1-week treatment ( T3 ) . No difference was found in MaxDeltaFEV1 % between T2 and T3 . The same results were observed also after computing the area under the curve for each challenge . When individually considered , all subjects were protected against EAR ( protection index > or = 80 % ) at T2 , while at 3 seven out of nine subjects were still protected against EAR . In conclusion , the simultaneous administration of salmeterol and fluticasone in the same device prevents in almost 80 % of examined subjects the development of tolerance to the protective effect of salmeterol on allergen challenge . This observation may contribute to explain the positive interaction between inhaled beta2-agonists and corticosteroids in the long-term treatment of asthma . Instructions: please extract entity words from the input sentence

[ "O", "B-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge . In order to assess whether the administration of salmeterol/fluticasone propionate combination ( 50/250 mcg by Diskus ) for 1 week induces tolerance to the bronchoprotective effect of salmeterol on allergen challenge , a single-blind , cross-over study was carried out . We studied nine subjects ( eight men and one woman ; mean age+/-SD : 31.3+/-11.0 yr ) with mild intermittent allergic asthma , never treated with regular beta2-agonists or inhaled corticosteroids . In a previous allergen challenge all subjects had shown a positive early airway response ( EAR ) to allergen . They underwent allergen challenge after 1-week treatment with placebo and a single dose of placebo immediately before allergen challenge ( T1 ) , or 1-week treatment with placebo and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T2 ) , or 1-week treatment with salmeterol/fluticasone combination bid and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T3 ) . EAR was evaluated both as maximum decrease in FEV1 ( MaxDeltaFEV1 % ) after allergen challenge and as area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge protected by placebo ( T1 ) was significantly greater than MaxDeltaFEV1 % during allergen challenges protected by single dose of salmeterol/fluticasone ( T2 ) and by salmeterol/fluticasone 1-week treatment ( T3 ) . No difference was found in MaxDeltaFEV1 % between T2 and T3 . The same results were observed also after computing the area under the curve for each challenge . When individually considered , all subjects were protected against EAR ( protection index > or = 80 % ) at T2 , while at 3 seven out of nine subjects were still protected against EAR . In conclusion , the simultaneous administration of salmeterol and fluticasone in the same device prevents in almost 80 % of examined subjects the development of tolerance to the protective effect of salmeterol on allergen challenge . This observation may contribute to explain the positive interaction between inhaled beta2-agonists and corticosteroids in the long-term treatment of asthma .

[ "Minimal", "tolerance", "to", "the", "bronchoprotective", "effect", "of", "inhaled", "salmeterol", "/", "fluticasone", "combination", "on", "allergene", "challenge", ".", "In", "order", "to", "assess", "whether", "the", "administration", "of", "salmeterol", "/", "fluticasone", "propionate", "combination", "(", "50/250", "mcg", "by", "Diskus", ")", "for", "1", "week", "induces", "tolerance", "to", "the", "bronchoprotective", "effect", "of", "salmeterol", "on", "allergen", "challenge", ",", "a", "single", "-", "blind", ",", "cross", "-", "over", "study", "was", "carried", "out", ".", "We", "studied", "nine", "subjects", "(", "eight", "men", "and", "one", "woman", ";", "mean", "age+/-SD", ":", "31.3+/-11.0", "yr", ")", "with", "mild", "intermittent", "allergic", "asthma", ",", "never", "treated", "with", "regular", "beta2-agonists", "or", "inhaled", "corticosteroids", ".", "In", "a", "previous", "allergen", "challenge", "all", "subjects", "had", "shown", "a", "positive", "early", "airway", "response", "(", "EAR", ")", "to", "allergen", ".", "They", "underwent", "allergen", "challenge", "after", "1-week", "treatment", "with", "placebo", "and", "a", "single", "dose", "of", "placebo", "immediately", "before", "allergen", "challenge", "(", "T1", ")", ",", "or", "1-week", "treatment", "with", "placebo", "and", "a", "single", "dose", "of", "salmeterol", "/", "fluticasone", "immediately", "before", "allergen", "challenge", "(", "T2", ")", ",", "or", "1-week", "treatment", "with", "salmeterol", "/", "fluticasone", "combination", "bid", "and", "a", "single", "dose", "of", "salmeterol", "/", "fluticasone", "immediately", "before", "allergen", "challenge", "(", "T3", ")", ".", "EAR", "was", "evaluated", "both", "as", "maximum", "decrease", "in", "FEV1", "(", "MaxDeltaFEV1", "%", ")", "after", "allergen", "challenge", "and", "as", "area", "under", "FEV1", "-time", "curve", ".", "MaxDeltaFEV1", "%", "during", "allergen", "challenge", "protected", "by", "placebo", "(", "T1", ")", "was", "significantly", "greater", "than", "MaxDeltaFEV1", "%", "during", "allergen", "challenges", "protected", "by", "single", "dose", "of", "salmeterol", "/", "fluticasone", "(", "T2", ")", "and", "by", "salmeterol", "/", "fluticasone", "1-week", "treatment", "(", "T3", ")", ".", "No", "difference", "was", "found", "in", "MaxDeltaFEV1", "%", "between", "T2", "and", "T3", ".", "The", "same", "results", "were", "observed", "also", "after", "computing", "the", "area", "under", "the", "curve", "for", "each", "challenge", ".", "When", "individually", "considered", ",", "all", "subjects", "were", "protected", "against", "EAR", "(", "protection", "index", ">", "or", "=", "80", "%", ")", "at", "T2", ",", "while", "at", "3", "seven", "out", "of", "nine", "subjects", "were", "still", "protected", "against", "EAR", ".", "In", "conclusion", ",", "the", "simultaneous", "administration", "of", "salmeterol", "and", "fluticasone", "in", "the", "same", "device", "prevents", "in", "almost", "80", "%", "of", "examined", "subjects", "the", "development", "of", "tolerance", "to", "the", "protective", "effect", "of", "salmeterol", "on", "allergen", "challenge", ".", "This", "observation", "may", "contribute", "to", "explain", "the", "positive", "interaction", "between", "inhaled", "beta2-agonists", "and", "corticosteroids", "in", "the", "long", "-", "term", "treatment", "of", "asthma", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Intervention_Control" ]

gaviscon preparation is a Intervention_Pharmacological, esophageal is a Outcome_Physical, functional dyspepsia is a Outcome_Physical, elderly patients with GERD ] is a Participant_Condition, Geviskon is a Intervention_Pharmacological, aluminum - magnesium antacids is a Intervention_Pharmacological, alginate product -- Geviskon forte dose of 10 ml is a Intervention_Pharmacological, aluminum - magnesium antacid drug at a dose of 1 sachet is a Intervention_Pharmacological, frequency is a Outcome_Physical, severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia is a Outcome_Physical, degree of esophageal mucosal injury is a Outcome_Physical, relief of heartburn , regurgitation , chronic cough , sore throat , and EBS . is a Outcome_Physical

49818_task0

Sentence: [ Using gaviscon preparation for relief of esophageal , extraesophageal syndromes and functional dyspepsia in elderly patients with GERD ] . OBJECTIVE To compare the clinical efficacy of alginate drug Geviskon and aluminum-magnesium antacids to relieve symptoms of esophageal , extraesophageal syndrome and functional dyspepsia at 3 and 7 days of study in patients with GERD elderly . MATERIALS AND METHODS An open , longitudinal , randomized , parallel-group . The study included 60 patients with " A " degree of ERD , consistently received in-patient treatment in the Municipal KGVV , mean age 79.0 +/- 6.8 years . During the first 12 hours of hospital stay by " sealed envelopes " them randomly divided into equal groups of comparison , given 3 times a day : alginate product -- Geviskon forte dose of 10 ml and aluminum-magnesium antacid drug at a dose of 1 sachet . Assess the frequency and severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia at 3 and 7 days of study on 5-point scale Likert . The degree of esophageal mucosal injury was determined during endoscopy before the study . RESULTS The technique of alginate compared with antacids provided significantly more complete and earlier effect on the relief of heartburn , regurgitation , chronic cough , sore throat , and EBS . Only Geviskon influenced the symptoms of PPD in patients with GERD . CONCLUSION The clinical features Geviskon the frequency and timing of relief of symptoms of esophageal , extraesophageal syndrome , functional dyspepsia with GERD in the older age groups is higher than that of antacids . Suspension Geviskon may be recommended in patients with middle and old age as an effective and safe symptomatic funds in the first days of exchange rate earlier generations of PPI therapy , as well as monotherapy -- to maintain remission . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition

[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

[ Using gaviscon preparation for relief of esophageal , extraesophageal syndromes and functional dyspepsia in elderly patients with GERD ] . OBJECTIVE To compare the clinical efficacy of alginate drug Geviskon and aluminum-magnesium antacids to relieve symptoms of esophageal , extraesophageal syndrome and functional dyspepsia at 3 and 7 days of study in patients with GERD elderly . MATERIALS AND METHODS An open , longitudinal , randomized , parallel-group . The study included 60 patients with " A " degree of ERD , consistently received in-patient treatment in the Municipal KGVV , mean age 79.0 +/- 6.8 years . During the first 12 hours of hospital stay by " sealed envelopes " them randomly divided into equal groups of comparison , given 3 times a day : alginate product -- Geviskon forte dose of 10 ml and aluminum-magnesium antacid drug at a dose of 1 sachet . Assess the frequency and severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia at 3 and 7 days of study on 5-point scale Likert . The degree of esophageal mucosal injury was determined during endoscopy before the study . RESULTS The technique of alginate compared with antacids provided significantly more complete and earlier effect on the relief of heartburn , regurgitation , chronic cough , sore throat , and EBS . Only Geviskon influenced the symptoms of PPD in patients with GERD . CONCLUSION The clinical features Geviskon the frequency and timing of relief of symptoms of esophageal , extraesophageal syndrome , functional dyspepsia with GERD in the older age groups is higher than that of antacids . Suspension Geviskon may be recommended in patients with middle and old age as an effective and safe symptomatic funds in the first days of exchange rate earlier generations of PPI therapy , as well as monotherapy -- to maintain remission .

[ "[", "Using", "gaviscon", "preparation", "for", "relief", "of", "esophageal", ",", "extraesophageal", "syndromes", "and", "functional", "dyspepsia", "in", "elderly", "patients", "with", "GERD", "]", ".", "OBJECTIVE", "To", "compare", "the", "clinical", "efficacy", "of", "alginate", "drug", "Geviskon", "and", "aluminum", "-", "magnesium", "antacids", "to", "relieve", "symptoms", "of", "esophageal", ",", "extraesophageal", "syndrome", "and", "functional", "dyspepsia", "at", "3", "and", "7", "days", "of", "study", "in", "patients", "with", "GERD", "elderly", ".", "MATERIALS", "AND", "METHODS", "An", "open", ",", "longitudinal", ",", "randomized", ",", "parallel", "-", "group", ".", "The", "study", "included", "60", "patients", "with", "\"", "A", "\"", "degree", "of", "ERD", ",", "consistently", "received", "in", "-", "patient", "treatment", "in", "the", "Municipal", "KGVV", ",", "mean", "age", "79.0", "+", "/-", "6.8", "years", ".", "During", "the", "first", "12", "hours", "of", "hospital", "stay", "by", "\"", "sealed", "envelopes", "\"", "them", "randomly", "divided", "into", "equal", "groups", "of", "comparison", ",", "given", "3", "times", "a", "day", ":", "alginate", "product", "--", "Geviskon", "forte", "dose", "of", "10", "ml", "and", "aluminum", "-", "magnesium", "antacid", "drug", "at", "a", "dose", "of", "1", "sachet", ".", "Assess", "the", "frequency", "and", "severity", "of", "esophageal", "symptoms", ",", "extraesophageal", "syndrome", ",", "functional", "dyspepsia", "at", "3", "and", "7", "days", "of", "study", "on", "5-point", "scale", "Likert", ".", "The", "degree", "of", "esophageal", "mucosal", "injury", "was", "determined", "during", "endoscopy", "before", "the", "study", ".", "RESULTS", "The", "technique", "of", "alginate", "compared", "with", "antacids", "provided", "significantly", "more", "complete", "and", "earlier", "effect", "on", "the", "relief", "of", "heartburn", ",", "regurgitation", ",", "chronic", "cough", ",", "sore", "throat", ",", "and", "EBS", ".", "Only", "Geviskon", "influenced", "the", "symptoms", "of", "PPD", "in", "patients", "with", "GERD", ".", "CONCLUSION", "The", "clinical", "features", "Geviskon", "the", "frequency", "and", "timing", "of", "relief", "of", "symptoms", "of", "esophageal", ",", "extraesophageal", "syndrome", ",", "functional", "dyspepsia", "with", "GERD", "in", "the", "older", "age", "groups", "is", "higher", "than", "that", "of", "antacids", ".", "Suspension", "Geviskon", "may", "be", "recommended", "in", "patients", "with", "middle", "and", "old", "age", "as", "an", "effective", "and", "safe", "symptomatic", "funds", "in", "the", "first", "days", "of", "exchange", "rate", "earlier", "generations", "of", "PPI", "therapy", ",", "as", "well", "as", "monotherapy", "--", "to", "maintain", "remission", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Condition" ]

gaviscon preparation is a Intervention_Pharmacological, esophageal is a Outcome_Physical, functional dyspepsia is a Outcome_Physical, elderly patients with GERD ] is a Participant_Condition, Geviskon is a Intervention_Pharmacological, aluminum - magnesium antacids is a Intervention_Pharmacological, alginate product -- Geviskon forte dose of 10 ml is a Intervention_Pharmacological, aluminum - magnesium antacid drug at a dose of 1 sachet is a Intervention_Pharmacological, frequency is a Outcome_Physical, severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia is a Outcome_Physical, degree of esophageal mucosal injury is a Outcome_Physical, relief of heartburn , regurgitation , chronic cough , sore throat , and EBS . is a Outcome_Physical

49818_task1

Sentence: [ Using gaviscon preparation for relief of esophageal , extraesophageal syndromes and functional dyspepsia in elderly patients with GERD ] . OBJECTIVE To compare the clinical efficacy of alginate drug Geviskon and aluminum-magnesium antacids to relieve symptoms of esophageal , extraesophageal syndrome and functional dyspepsia at 3 and 7 days of study in patients with GERD elderly . MATERIALS AND METHODS An open , longitudinal , randomized , parallel-group . The study included 60 patients with " A " degree of ERD , consistently received in-patient treatment in the Municipal KGVV , mean age 79.0 +/- 6.8 years . During the first 12 hours of hospital stay by " sealed envelopes " them randomly divided into equal groups of comparison , given 3 times a day : alginate product -- Geviskon forte dose of 10 ml and aluminum-magnesium antacid drug at a dose of 1 sachet . Assess the frequency and severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia at 3 and 7 days of study on 5-point scale Likert . The degree of esophageal mucosal injury was determined during endoscopy before the study . RESULTS The technique of alginate compared with antacids provided significantly more complete and earlier effect on the relief of heartburn , regurgitation , chronic cough , sore throat , and EBS . Only Geviskon influenced the symptoms of PPD in patients with GERD . CONCLUSION The clinical features Geviskon the frequency and timing of relief of symptoms of esophageal , extraesophageal syndrome , functional dyspepsia with GERD in the older age groups is higher than that of antacids . Suspension Geviskon may be recommended in patients with middle and old age as an effective and safe symptomatic funds in the first days of exchange rate earlier generations of PPI therapy , as well as monotherapy -- to maintain remission . Instructions: please typing these entity words according to sentence: gaviscon preparation, esophageal, functional dyspepsia, elderly patients with GERD ], Geviskon, aluminum - magnesium antacids, alginate product -- Geviskon forte dose of 10 ml, aluminum - magnesium antacid drug at a dose of 1 sachet, frequency, severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia, degree of esophageal mucosal injury, relief of heartburn , regurgitation , chronic cough , sore throat , and EBS . Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition

[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

[ Using gaviscon preparation for relief of esophageal , extraesophageal syndromes and functional dyspepsia in elderly patients with GERD ] . OBJECTIVE To compare the clinical efficacy of alginate drug Geviskon and aluminum-magnesium antacids to relieve symptoms of esophageal , extraesophageal syndrome and functional dyspepsia at 3 and 7 days of study in patients with GERD elderly . MATERIALS AND METHODS An open , longitudinal , randomized , parallel-group . The study included 60 patients with " A " degree of ERD , consistently received in-patient treatment in the Municipal KGVV , mean age 79.0 +/- 6.8 years . During the first 12 hours of hospital stay by " sealed envelopes " them randomly divided into equal groups of comparison , given 3 times a day : alginate product -- Geviskon forte dose of 10 ml and aluminum-magnesium antacid drug at a dose of 1 sachet . Assess the frequency and severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia at 3 and 7 days of study on 5-point scale Likert . The degree of esophageal mucosal injury was determined during endoscopy before the study . RESULTS The technique of alginate compared with antacids provided significantly more complete and earlier effect on the relief of heartburn , regurgitation , chronic cough , sore throat , and EBS . Only Geviskon influenced the symptoms of PPD in patients with GERD . CONCLUSION The clinical features Geviskon the frequency and timing of relief of symptoms of esophageal , extraesophageal syndrome , functional dyspepsia with GERD in the older age groups is higher than that of antacids . Suspension Geviskon may be recommended in patients with middle and old age as an effective and safe symptomatic funds in the first days of exchange rate earlier generations of PPI therapy , as well as monotherapy -- to maintain remission .

[ "[", "Using", "gaviscon", "preparation", "for", "relief", "of", "esophageal", ",", "extraesophageal", "syndromes", "and", "functional", "dyspepsia", "in", "elderly", "patients", "with", "GERD", "]", ".", "OBJECTIVE", "To", "compare", "the", "clinical", "efficacy", "of", "alginate", "drug", "Geviskon", "and", "aluminum", "-", "magnesium", "antacids", "to", "relieve", "symptoms", "of", "esophageal", ",", "extraesophageal", "syndrome", "and", "functional", "dyspepsia", "at", "3", "and", "7", "days", "of", "study", "in", "patients", "with", "GERD", "elderly", ".", "MATERIALS", "AND", "METHODS", "An", "open", ",", "longitudinal", ",", "randomized", ",", "parallel", "-", "group", ".", "The", "study", "included", "60", "patients", "with", "\"", "A", "\"", "degree", "of", "ERD", ",", "consistently", "received", "in", "-", "patient", "treatment", "in", "the", "Municipal", "KGVV", ",", "mean", "age", "79.0", "+", "/-", "6.8", "years", ".", "During", "the", "first", "12", "hours", "of", "hospital", "stay", "by", "\"", "sealed", "envelopes", "\"", "them", "randomly", "divided", "into", "equal", "groups", "of", "comparison", ",", "given", "3", "times", "a", "day", ":", "alginate", "product", "--", "Geviskon", "forte", "dose", "of", "10", "ml", "and", "aluminum", "-", "magnesium", "antacid", "drug", "at", "a", "dose", "of", "1", "sachet", ".", "Assess", "the", "frequency", "and", "severity", "of", "esophageal", "symptoms", ",", "extraesophageal", "syndrome", ",", "functional", "dyspepsia", "at", "3", "and", "7", "days", "of", "study", "on", "5-point", "scale", "Likert", ".", "The", "degree", "of", "esophageal", "mucosal", "injury", "was", "determined", "during", "endoscopy", "before", "the", "study", ".", "RESULTS", "The", "technique", "of", "alginate", "compared", "with", "antacids", "provided", "significantly", "more", "complete", "and", "earlier", "effect", "on", "the", "relief", "of", "heartburn", ",", "regurgitation", ",", "chronic", "cough", ",", "sore", "throat", ",", "and", "EBS", ".", "Only", "Geviskon", "influenced", "the", "symptoms", "of", "PPD", "in", "patients", "with", "GERD", ".", "CONCLUSION", "The", "clinical", "features", "Geviskon", "the", "frequency", "and", "timing", "of", "relief", "of", "symptoms", "of", "esophageal", ",", "extraesophageal", "syndrome", ",", "functional", "dyspepsia", "with", "GERD", "in", "the", "older", "age", "groups", "is", "higher", "than", "that", "of", "antacids", ".", "Suspension", "Geviskon", "may", "be", "recommended", "in", "patients", "with", "middle", "and", "old", "age", "as", "an", "effective", "and", "safe", "symptomatic", "funds", "in", "the", "first", "days", "of", "exchange", "rate", "earlier", "generations", "of", "PPI", "therapy", ",", "as", "well", "as", "monotherapy", "--", "to", "maintain", "remission", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Condition" ]

gaviscon preparation, esophageal, functional dyspepsia, elderly patients with GERD ], Geviskon, aluminum - magnesium antacids, alginate product -- Geviskon forte dose of 10 ml, aluminum - magnesium antacid drug at a dose of 1 sachet, frequency, severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia, degree of esophageal mucosal injury, relief of heartburn , regurgitation , chronic cough , sore throat , and EBS .

49818_task2

Sentence: [ Using gaviscon preparation for relief of esophageal , extraesophageal syndromes and functional dyspepsia in elderly patients with GERD ] . OBJECTIVE To compare the clinical efficacy of alginate drug Geviskon and aluminum-magnesium antacids to relieve symptoms of esophageal , extraesophageal syndrome and functional dyspepsia at 3 and 7 days of study in patients with GERD elderly . MATERIALS AND METHODS An open , longitudinal , randomized , parallel-group . The study included 60 patients with " A " degree of ERD , consistently received in-patient treatment in the Municipal KGVV , mean age 79.0 +/- 6.8 years . During the first 12 hours of hospital stay by " sealed envelopes " them randomly divided into equal groups of comparison , given 3 times a day : alginate product -- Geviskon forte dose of 10 ml and aluminum-magnesium antacid drug at a dose of 1 sachet . Assess the frequency and severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia at 3 and 7 days of study on 5-point scale Likert . The degree of esophageal mucosal injury was determined during endoscopy before the study . RESULTS The technique of alginate compared with antacids provided significantly more complete and earlier effect on the relief of heartburn , regurgitation , chronic cough , sore throat , and EBS . Only Geviskon influenced the symptoms of PPD in patients with GERD . CONCLUSION The clinical features Geviskon the frequency and timing of relief of symptoms of esophageal , extraesophageal syndrome , functional dyspepsia with GERD in the older age groups is higher than that of antacids . Suspension Geviskon may be recommended in patients with middle and old age as an effective and safe symptomatic funds in the first days of exchange rate earlier generations of PPI therapy , as well as monotherapy -- to maintain remission . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

[ Using gaviscon preparation for relief of esophageal , extraesophageal syndromes and functional dyspepsia in elderly patients with GERD ] . OBJECTIVE To compare the clinical efficacy of alginate drug Geviskon and aluminum-magnesium antacids to relieve symptoms of esophageal , extraesophageal syndrome and functional dyspepsia at 3 and 7 days of study in patients with GERD elderly . MATERIALS AND METHODS An open , longitudinal , randomized , parallel-group . The study included 60 patients with " A " degree of ERD , consistently received in-patient treatment in the Municipal KGVV , mean age 79.0 +/- 6.8 years . During the first 12 hours of hospital stay by " sealed envelopes " them randomly divided into equal groups of comparison , given 3 times a day : alginate product -- Geviskon forte dose of 10 ml and aluminum-magnesium antacid drug at a dose of 1 sachet . Assess the frequency and severity of esophageal symptoms , extraesophageal syndrome , functional dyspepsia at 3 and 7 days of study on 5-point scale Likert . The degree of esophageal mucosal injury was determined during endoscopy before the study . RESULTS The technique of alginate compared with antacids provided significantly more complete and earlier effect on the relief of heartburn , regurgitation , chronic cough , sore throat , and EBS . Only Geviskon influenced the symptoms of PPD in patients with GERD . CONCLUSION The clinical features Geviskon the frequency and timing of relief of symptoms of esophageal , extraesophageal syndrome , functional dyspepsia with GERD in the older age groups is higher than that of antacids . Suspension Geviskon may be recommended in patients with middle and old age as an effective and safe symptomatic funds in the first days of exchange rate earlier generations of PPI therapy , as well as monotherapy -- to maintain remission .

[ "[", "Using", "gaviscon", "preparation", "for", "relief", "of", "esophageal", ",", "extraesophageal", "syndromes", "and", "functional", "dyspepsia", "in", "elderly", "patients", "with", "GERD", "]", ".", "OBJECTIVE", "To", "compare", "the", "clinical", "efficacy", "of", "alginate", "drug", "Geviskon", "and", "aluminum", "-", "magnesium", "antacids", "to", "relieve", "symptoms", "of", "esophageal", ",", "extraesophageal", "syndrome", "and", "functional", "dyspepsia", "at", "3", "and", "7", "days", "of", "study", "in", "patients", "with", "GERD", "elderly", ".", "MATERIALS", "AND", "METHODS", "An", "open", ",", "longitudinal", ",", "randomized", ",", "parallel", "-", "group", ".", "The", "study", "included", "60", "patients", "with", "\"", "A", "\"", "degree", "of", "ERD", ",", "consistently", "received", "in", "-", "patient", "treatment", "in", "the", "Municipal", "KGVV", ",", "mean", "age", "79.0", "+", "/-", "6.8", "years", ".", "During", "the", "first", "12", "hours", "of", "hospital", "stay", "by", "\"", "sealed", "envelopes", "\"", "them", "randomly", "divided", "into", "equal", "groups", "of", "comparison", ",", "given", "3", "times", "a", "day", ":", "alginate", "product", "--", "Geviskon", "forte", "dose", "of", "10", "ml", "and", "aluminum", "-", "magnesium", "antacid", "drug", "at", "a", "dose", "of", "1", "sachet", ".", "Assess", "the", "frequency", "and", "severity", "of", "esophageal", "symptoms", ",", "extraesophageal", "syndrome", ",", "functional", "dyspepsia", "at", "3", "and", "7", "days", "of", "study", "on", "5-point", "scale", "Likert", ".", "The", "degree", "of", "esophageal", "mucosal", "injury", "was", "determined", "during", "endoscopy", "before", "the", "study", ".", "RESULTS", "The", "technique", "of", "alginate", "compared", "with", "antacids", "provided", "significantly", "more", "complete", "and", "earlier", "effect", "on", "the", "relief", "of", "heartburn", ",", "regurgitation", ",", "chronic", "cough", ",", "sore", "throat", ",", "and", "EBS", ".", "Only", "Geviskon", "influenced", "the", "symptoms", "of", "PPD", "in", "patients", "with", "GERD", ".", "CONCLUSION", "The", "clinical", "features", "Geviskon", "the", "frequency", "and", "timing", "of", "relief", "of", "symptoms", "of", "esophageal", ",", "extraesophageal", "syndrome", ",", "functional", "dyspepsia", "with", "GERD", "in", "the", "older", "age", "groups", "is", "higher", "than", "that", "of", "antacids", ".", "Suspension", "Geviskon", "may", "be", "recommended", "in", "patients", "with", "middle", "and", "old", "age", "as", "an", "effective", "and", "safe", "symptomatic", "funds", "in", "the", "first", "days", "of", "exchange", "rate", "earlier", "generations", "of", "PPI", "therapy", ",", "as", "well", "as", "monotherapy", "--", "to", "maintain", "remission", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Condition" ]

Elena is a NOMBRE_SUJETO_ASISTENCIA, Justo Pascual is a NOMBRE_SUJETO_ASISTENCIA, 7401311 is a ID_SUJETO_ASISTENCIA, 47 16203430 65 is a ID_ASEGURAMIENTO, Calle Joaquin Vidal , 12 is a CALLE, Guadalajara is a TERRITORIO, 19001 is a TERRITORIO, 13/06/1939 is a FECHAS, España is a PAIS, 76 años is a EDAD_SUJETO_ASISTENCIA, 26/11/2015 is a FECHAS, Gabriel de Arriba is a NOMBRE_PERSONAL_SANITARIO, 19 19 87402 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, 76 años is a EDAD_SUJETO_ASISTENCIA, Gabriel de Arriba is a NOMBRE_PERSONAL_SANITARIO, Hospital Universitario de Guadalajara is a HOSPITAL, Universidad de Alcalá is a INSTITUCION, garribad@senefro.org is a CORREO_ELECTRONICO

114_task0

Sentence: Datos del paciente. Nombre: Elena. Apellidos: Justo Pascual. NHC: 7401311. NASS: 47 16203430 65. Domicilio: Calle Joaquin Vidal, 12. Localidad/ Provincia: Guadalajara. CP: 19001. Datos asistenciales. Fecha de nacimiento: 13/06/1939. País de nacimiento: España. Edad: 76 años Sexo: H. Fecha de Ingreso: 26/11/2015. Médico: Gabriel de Arriba NºCol: 19 19 87402. Informe clínico del paciente: Mujer de 76 años con antecedente de diabetes mellitus tipo 2, dislipemia y síndrome depresivo. Estaba en tratamiento con metformina 850 mg/8 horas, escitalopram 20 mg/24h, mirtazapina 30 mg/24 horas y simvastatina 40 mg/24 horas. En una analítica realizada seis meses antes tenía una Cr de 0,81 mg/dl. Dos semanas antes del ingreso comenzó tratamiento con ibuprofeno (600 mg/8 horas) por lumbalgia. Una semana antes tuvo náuseas, vómitos y diarrea, por lo que acudió a urgencias. En la exploración tenía sequedad de piel y mucosas y en la analítica la Cr plasmática fue de 9 mg/dl, glucosa de 189 mg/dl, urea de 196 mg/dl, hemoglobina de 10,9 g/dl, sodio de 125 mEq/l, potasio de 8,6 mEq/l y ácido láctico de 6,3 mmol/l. En la gasometría arterial tenía pH de 7,23 y bicarbonato de 15 mEq/l. Se realizó una ecografía abdominal en la que aparecía una ureterohidronefrosis bilateral por neoplasia vesical. Ante la inestabilidad hemodinámica de la paciente se realizó hemodiálisis durante dos horas, teniendo posteriormente una Cr de 5,9 mg/dl, potasio de 6,1 mEq/l, pH de 7,39 y bicarbonato de 22 mEq/l. Posteriormente se colocó nefrostomía bilateral con mejoría de cuadro clínico y normalización de cifras analíticas con Cr de 1,1 mg/dl, pH de 7,31 y bicarbonato de 23 mEq/l. Responsable clínico: Dr. Gabriel de Arriba, Sección de Nefrología, Hospital Universitario de Guadalajara. Departamento de Medicina. Universidad de Alcalá E-mail: garribad@senefro.org Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, INSTITUCION, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Elena. Apellidos: Justo Pascual. NHC: 7401311. NASS: 47 16203430 65. Domicilio: Calle Joaquin Vidal, 12. Localidad/ Provincia: Guadalajara. CP: 19001. Datos asistenciales. Fecha de nacimiento: 13/06/1939. País de nacimiento: España. Edad: 76 años Sexo: H. Fecha de Ingreso: 26/11/2015. Médico: Gabriel de Arriba NºCol: 19 19 87402. Informe clínico del paciente: Mujer de 76 años con antecedente de diabetes mellitus tipo 2, dislipemia y síndrome depresivo. Estaba en tratamiento con metformina 850 mg/8 horas, escitalopram 20 mg/24h, mirtazapina 30 mg/24 horas y simvastatina 40 mg/24 horas. En una analítica realizada seis meses antes tenía una Cr de 0,81 mg/dl. Dos semanas antes del ingreso comenzó tratamiento con ibuprofeno (600 mg/8 horas) por lumbalgia. Una semana antes tuvo náuseas, vómitos y diarrea, por lo que acudió a urgencias. En la exploración tenía sequedad de piel y mucosas y en la analítica la Cr plasmática fue de 9 mg/dl, glucosa de 189 mg/dl, urea de 196 mg/dl, hemoglobina de 10,9 g/dl, sodio de 125 mEq/l, potasio de 8,6 mEq/l y ácido láctico de 6,3 mmol/l. En la gasometría arterial tenía pH de 7,23 y bicarbonato de 15 mEq/l. Se realizó una ecografía abdominal en la que aparecía una ureterohidronefrosis bilateral por neoplasia vesical. Ante la inestabilidad hemodinámica de la paciente se realizó hemodiálisis durante dos horas, teniendo posteriormente una Cr de 5,9 mg/dl, potasio de 6,1 mEq/l, pH de 7,39 y bicarbonato de 22 mEq/l. Posteriormente se colocó nefrostomía bilateral con mejoría de cuadro clínico y normalización de cifras analíticas con Cr de 1,1 mg/dl, pH de 7,31 y bicarbonato de 23 mEq/l. Responsable clínico: Dr. Gabriel de Arriba, Sección de Nefrología, Hospital Universitario de Guadalajara. Departamento de Medicina. Universidad de Alcalá E-mail: garribad@senefro.org

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Elena", ".", "\n", "Apellidos", ":", "Justo", "Pascual", ".", "\n", "NHC", ":", "7401311", ".", "\n", "NASS", ":", "47", "16203430", "65", ".", "\n", "Domicilio", ":", "Calle", "Joaquin", "Vidal", ",", "12", ".", "\n", "Localidad/", "Provincia", ":", "Guadalajara", ".", "\n", "CP", ":", "19001", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "13/06/1939", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "76", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "26/11/2015", ".", "\n", "Médico", ":", "Gabriel", "de", "Arriba", "NºCol", ":", "19", "19", "87402", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "76", "años", "con", "antecedente", "de", "diabetes", "mellitus", "tipo", "2", ",", "dislipemia", "y", "síndrome", "depresivo", ".", "Estaba", "en", "tratamiento", "con", "metformina", "850", "mg/8", "horas", ",", "escitalopram", "20", "mg/24h", ",", "mirtazapina", "30", "mg/24", "horas", "y", "simvastatina", "40", "mg/24", "horas", ".", "En", "una", "analítica", "realizada", "seis", "meses", "antes", "tenía", "una", "Cr", "de", "0,81", "mg", "/", "dl", ".", "\n", "Dos", "semanas", "antes", "del", "ingreso", "comenzó", "tratamiento", "con", "ibuprofeno", "(", "600", "mg/8", "horas", ")", "por", "lumbalgia", ".", "Una", "semana", "antes", "tuvo", "náuseas", ",", "vómitos", "y", "diarrea", ",", "por", "lo", "que", "acudió", "a", "urgencias", ".", "En", "la", "exploración", "tenía", "sequedad", "de", "piel", "y", "mucosas", "y", "en", "la", "analítica", "la", "Cr", "plasmática", "fue", "de", "9", "mg", "/", "dl", ",", "glucosa", "de", "189", "mg", "/", "dl", ",", "urea", "de", "196", "mg", "/", "dl", ",", "hemoglobina", "de", "10,9", "g", "/", "dl", ",", "sodio", "de", "125", "mEq", "/", "l", ",", "potasio", "de", "8,6", "mEq", "/", "l", "y", "ácido", "láctico", "de", "6,3", "mmol", "/", "l.", "En", "la", "gasometría", "arterial", "tenía", "pH", "de", "7,23", "y", "bicarbonato", "de", "15", "mEq", "/", "l.", "Se", "realizó", "una", "ecografía", "abdominal", "en", "la", "que", "aparecía", "una", "ureterohidronefrosis", "bilateral", "por", "neoplasia", "vesical", ".", "Ante", "la", "inestabilidad", "hemodinámica", "de", "la", "paciente", "se", "realizó", "hemodiálisis", "durante", "dos", "horas", ",", "teniendo", "posteriormente", "una", "Cr", "de", "5,9", "mg", "/", "dl", ",", "potasio", "de", "6,1", "mEq", "/", "l", ",", "pH", "de", "7,39", "y", "bicarbonato", "de", "22", "mEq", "/", "l.", "Posteriormente", "se", "colocó", "nefrostomía", "bilateral", "con", "mejoría", "de", "cuadro", "clínico", "y", "normalización", "de", "cifras", "analíticas", "con", "Cr", "de", "1,1", "mg", "/", "dl", ",", "pH", "de", "7,31", "y", "bicarbonato", "de", "23", "mEq", "/", "l.", "\n", "Responsable", "clínico", ":", "Dr", ".", "Gabriel", "de", "Arriba", ",", "Sección", "de", "Nefrología", ",", "Hospital", "Universitario", "de", "Guadalajara", ".", "Departamento", "de", "Medicina", ".", "Universidad", "de", "Alcalá", "E", "-", "mail", ":", "garribad@senefro.org", "\n" ]

[ "HOSPITAL", "CALLE", "INSTITUCION", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "TERRITORIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

Elena is a NOMBRE_SUJETO_ASISTENCIA, Justo Pascual is a NOMBRE_SUJETO_ASISTENCIA, 7401311 is a ID_SUJETO_ASISTENCIA, 47 16203430 65 is a ID_ASEGURAMIENTO, Calle Joaquin Vidal , 12 is a CALLE, Guadalajara is a TERRITORIO, 19001 is a TERRITORIO, 13/06/1939 is a FECHAS, España is a PAIS, 76 años is a EDAD_SUJETO_ASISTENCIA, 26/11/2015 is a FECHAS, Gabriel de Arriba is a NOMBRE_PERSONAL_SANITARIO, 19 19 87402 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, 76 años is a EDAD_SUJETO_ASISTENCIA, Gabriel de Arriba is a NOMBRE_PERSONAL_SANITARIO, Hospital Universitario de Guadalajara is a HOSPITAL, Universidad de Alcalá is a INSTITUCION, garribad@senefro.org is a CORREO_ELECTRONICO

114_task1

Sentence: Datos del paciente. Nombre: Elena. Apellidos: Justo Pascual. NHC: 7401311. NASS: 47 16203430 65. Domicilio: Calle Joaquin Vidal, 12. Localidad/ Provincia: Guadalajara. CP: 19001. Datos asistenciales. Fecha de nacimiento: 13/06/1939. País de nacimiento: España. Edad: 76 años Sexo: H. Fecha de Ingreso: 26/11/2015. Médico: Gabriel de Arriba NºCol: 19 19 87402. Informe clínico del paciente: Mujer de 76 años con antecedente de diabetes mellitus tipo 2, dislipemia y síndrome depresivo. Estaba en tratamiento con metformina 850 mg/8 horas, escitalopram 20 mg/24h, mirtazapina 30 mg/24 horas y simvastatina 40 mg/24 horas. En una analítica realizada seis meses antes tenía una Cr de 0,81 mg/dl. Dos semanas antes del ingreso comenzó tratamiento con ibuprofeno (600 mg/8 horas) por lumbalgia. Una semana antes tuvo náuseas, vómitos y diarrea, por lo que acudió a urgencias. En la exploración tenía sequedad de piel y mucosas y en la analítica la Cr plasmática fue de 9 mg/dl, glucosa de 189 mg/dl, urea de 196 mg/dl, hemoglobina de 10,9 g/dl, sodio de 125 mEq/l, potasio de 8,6 mEq/l y ácido láctico de 6,3 mmol/l. En la gasometría arterial tenía pH de 7,23 y bicarbonato de 15 mEq/l. Se realizó una ecografía abdominal en la que aparecía una ureterohidronefrosis bilateral por neoplasia vesical. Ante la inestabilidad hemodinámica de la paciente se realizó hemodiálisis durante dos horas, teniendo posteriormente una Cr de 5,9 mg/dl, potasio de 6,1 mEq/l, pH de 7,39 y bicarbonato de 22 mEq/l. Posteriormente se colocó nefrostomía bilateral con mejoría de cuadro clínico y normalización de cifras analíticas con Cr de 1,1 mg/dl, pH de 7,31 y bicarbonato de 23 mEq/l. Responsable clínico: Dr. Gabriel de Arriba, Sección de Nefrología, Hospital Universitario de Guadalajara. Departamento de Medicina. Universidad de Alcalá E-mail: garribad@senefro.org Instructions: please typing these entity words according to sentence: Elena, Justo Pascual, 7401311, 47 16203430 65, Calle Joaquin Vidal , 12, Guadalajara, 19001, 13/06/1939, España, 76 años, 26/11/2015, Gabriel de Arriba, 19 19 87402, Mujer, 76 años, Gabriel de Arriba, Hospital Universitario de Guadalajara, Universidad de Alcalá, garribad@senefro.org Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, INSTITUCION, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Elena. Apellidos: Justo Pascual. NHC: 7401311. NASS: 47 16203430 65. Domicilio: Calle Joaquin Vidal, 12. Localidad/ Provincia: Guadalajara. CP: 19001. Datos asistenciales. Fecha de nacimiento: 13/06/1939. País de nacimiento: España. Edad: 76 años Sexo: H. Fecha de Ingreso: 26/11/2015. Médico: Gabriel de Arriba NºCol: 19 19 87402. Informe clínico del paciente: Mujer de 76 años con antecedente de diabetes mellitus tipo 2, dislipemia y síndrome depresivo. Estaba en tratamiento con metformina 850 mg/8 horas, escitalopram 20 mg/24h, mirtazapina 30 mg/24 horas y simvastatina 40 mg/24 horas. En una analítica realizada seis meses antes tenía una Cr de 0,81 mg/dl. Dos semanas antes del ingreso comenzó tratamiento con ibuprofeno (600 mg/8 horas) por lumbalgia. Una semana antes tuvo náuseas, vómitos y diarrea, por lo que acudió a urgencias. En la exploración tenía sequedad de piel y mucosas y en la analítica la Cr plasmática fue de 9 mg/dl, glucosa de 189 mg/dl, urea de 196 mg/dl, hemoglobina de 10,9 g/dl, sodio de 125 mEq/l, potasio de 8,6 mEq/l y ácido láctico de 6,3 mmol/l. En la gasometría arterial tenía pH de 7,23 y bicarbonato de 15 mEq/l. Se realizó una ecografía abdominal en la que aparecía una ureterohidronefrosis bilateral por neoplasia vesical. Ante la inestabilidad hemodinámica de la paciente se realizó hemodiálisis durante dos horas, teniendo posteriormente una Cr de 5,9 mg/dl, potasio de 6,1 mEq/l, pH de 7,39 y bicarbonato de 22 mEq/l. Posteriormente se colocó nefrostomía bilateral con mejoría de cuadro clínico y normalización de cifras analíticas con Cr de 1,1 mg/dl, pH de 7,31 y bicarbonato de 23 mEq/l. Responsable clínico: Dr. Gabriel de Arriba, Sección de Nefrología, Hospital Universitario de Guadalajara. Departamento de Medicina. Universidad de Alcalá E-mail: garribad@senefro.org

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Elena", ".", "\n", "Apellidos", ":", "Justo", "Pascual", ".", "\n", "NHC", ":", "7401311", ".", "\n", "NASS", ":", "47", "16203430", "65", ".", "\n", "Domicilio", ":", "Calle", "Joaquin", "Vidal", ",", "12", ".", "\n", "Localidad/", "Provincia", ":", "Guadalajara", ".", "\n", "CP", ":", "19001", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "13/06/1939", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "76", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "26/11/2015", ".", "\n", "Médico", ":", "Gabriel", "de", "Arriba", "NºCol", ":", "19", "19", "87402", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "76", "años", "con", "antecedente", "de", "diabetes", "mellitus", "tipo", "2", ",", "dislipemia", "y", "síndrome", "depresivo", ".", "Estaba", "en", "tratamiento", "con", "metformina", "850", "mg/8", "horas", ",", "escitalopram", "20", "mg/24h", ",", "mirtazapina", "30", "mg/24", "horas", "y", "simvastatina", "40", "mg/24", "horas", ".", "En", "una", "analítica", "realizada", "seis", "meses", "antes", "tenía", "una", "Cr", "de", "0,81", "mg", "/", "dl", ".", "\n", "Dos", "semanas", "antes", "del", "ingreso", "comenzó", "tratamiento", "con", "ibuprofeno", "(", "600", "mg/8", "horas", ")", "por", "lumbalgia", ".", "Una", "semana", "antes", "tuvo", "náuseas", ",", "vómitos", "y", "diarrea", ",", "por", "lo", "que", "acudió", "a", "urgencias", ".", "En", "la", "exploración", "tenía", "sequedad", "de", "piel", "y", "mucosas", "y", "en", "la", "analítica", "la", "Cr", "plasmática", "fue", "de", "9", "mg", "/", "dl", ",", "glucosa", "de", "189", "mg", "/", "dl", ",", "urea", "de", "196", "mg", "/", "dl", ",", "hemoglobina", "de", "10,9", "g", "/", "dl", ",", "sodio", "de", "125", "mEq", "/", "l", ",", "potasio", "de", "8,6", "mEq", "/", "l", "y", "ácido", "láctico", "de", "6,3", "mmol", "/", "l.", "En", "la", "gasometría", "arterial", "tenía", "pH", "de", "7,23", "y", "bicarbonato", "de", "15", "mEq", "/", "l.", "Se", "realizó", "una", "ecografía", "abdominal", "en", "la", "que", "aparecía", "una", "ureterohidronefrosis", "bilateral", "por", "neoplasia", "vesical", ".", "Ante", "la", "inestabilidad", "hemodinámica", "de", "la", "paciente", "se", "realizó", "hemodiálisis", "durante", "dos", "horas", ",", "teniendo", "posteriormente", "una", "Cr", "de", "5,9", "mg", "/", "dl", ",", "potasio", "de", "6,1", "mEq", "/", "l", ",", "pH", "de", "7,39", "y", "bicarbonato", "de", "22", "mEq", "/", "l.", "Posteriormente", "se", "colocó", "nefrostomía", "bilateral", "con", "mejoría", "de", "cuadro", "clínico", "y", "normalización", "de", "cifras", "analíticas", "con", "Cr", "de", "1,1", "mg", "/", "dl", ",", "pH", "de", "7,31", "y", "bicarbonato", "de", "23", "mEq", "/", "l.", "\n", "Responsable", "clínico", ":", "Dr", ".", "Gabriel", "de", "Arriba", ",", "Sección", "de", "Nefrología", ",", "Hospital", "Universitario", "de", "Guadalajara", ".", "Departamento", "de", "Medicina", ".", "Universidad", "de", "Alcalá", "E", "-", "mail", ":", "garribad@senefro.org", "\n" ]

[ "HOSPITAL", "CALLE", "INSTITUCION", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "TERRITORIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

Elena, Justo Pascual, 7401311, 47 16203430 65, Calle Joaquin Vidal , 12, Guadalajara, 19001, 13/06/1939, España, 76 años, 26/11/2015, Gabriel de Arriba, 19 19 87402, Mujer, 76 años, Gabriel de Arriba, Hospital Universitario de Guadalajara, Universidad de Alcalá, garribad@senefro.org

114_task2

Sentence: Datos del paciente. Nombre: Elena. Apellidos: Justo Pascual. NHC: 7401311. NASS: 47 16203430 65. Domicilio: Calle Joaquin Vidal, 12. Localidad/ Provincia: Guadalajara. CP: 19001. Datos asistenciales. Fecha de nacimiento: 13/06/1939. País de nacimiento: España. Edad: 76 años Sexo: H. Fecha de Ingreso: 26/11/2015. Médico: Gabriel de Arriba NºCol: 19 19 87402. Informe clínico del paciente: Mujer de 76 años con antecedente de diabetes mellitus tipo 2, dislipemia y síndrome depresivo. Estaba en tratamiento con metformina 850 mg/8 horas, escitalopram 20 mg/24h, mirtazapina 30 mg/24 horas y simvastatina 40 mg/24 horas. En una analítica realizada seis meses antes tenía una Cr de 0,81 mg/dl. Dos semanas antes del ingreso comenzó tratamiento con ibuprofeno (600 mg/8 horas) por lumbalgia. Una semana antes tuvo náuseas, vómitos y diarrea, por lo que acudió a urgencias. En la exploración tenía sequedad de piel y mucosas y en la analítica la Cr plasmática fue de 9 mg/dl, glucosa de 189 mg/dl, urea de 196 mg/dl, hemoglobina de 10,9 g/dl, sodio de 125 mEq/l, potasio de 8,6 mEq/l y ácido láctico de 6,3 mmol/l. En la gasometría arterial tenía pH de 7,23 y bicarbonato de 15 mEq/l. Se realizó una ecografía abdominal en la que aparecía una ureterohidronefrosis bilateral por neoplasia vesical. Ante la inestabilidad hemodinámica de la paciente se realizó hemodiálisis durante dos horas, teniendo posteriormente una Cr de 5,9 mg/dl, potasio de 6,1 mEq/l, pH de 7,39 y bicarbonato de 22 mEq/l. Posteriormente se colocó nefrostomía bilateral con mejoría de cuadro clínico y normalización de cifras analíticas con Cr de 1,1 mg/dl, pH de 7,31 y bicarbonato de 23 mEq/l. Responsable clínico: Dr. Gabriel de Arriba, Sección de Nefrología, Hospital Universitario de Guadalajara. Departamento de Medicina. Universidad de Alcalá E-mail: garribad@senefro.org Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Elena. Apellidos: Justo Pascual. NHC: 7401311. NASS: 47 16203430 65. Domicilio: Calle Joaquin Vidal, 12. Localidad/ Provincia: Guadalajara. CP: 19001. Datos asistenciales. Fecha de nacimiento: 13/06/1939. País de nacimiento: España. Edad: 76 años Sexo: H. Fecha de Ingreso: 26/11/2015. Médico: Gabriel de Arriba NºCol: 19 19 87402. Informe clínico del paciente: Mujer de 76 años con antecedente de diabetes mellitus tipo 2, dislipemia y síndrome depresivo. Estaba en tratamiento con metformina 850 mg/8 horas, escitalopram 20 mg/24h, mirtazapina 30 mg/24 horas y simvastatina 40 mg/24 horas. En una analítica realizada seis meses antes tenía una Cr de 0,81 mg/dl. Dos semanas antes del ingreso comenzó tratamiento con ibuprofeno (600 mg/8 horas) por lumbalgia. Una semana antes tuvo náuseas, vómitos y diarrea, por lo que acudió a urgencias. En la exploración tenía sequedad de piel y mucosas y en la analítica la Cr plasmática fue de 9 mg/dl, glucosa de 189 mg/dl, urea de 196 mg/dl, hemoglobina de 10,9 g/dl, sodio de 125 mEq/l, potasio de 8,6 mEq/l y ácido láctico de 6,3 mmol/l. En la gasometría arterial tenía pH de 7,23 y bicarbonato de 15 mEq/l. Se realizó una ecografía abdominal en la que aparecía una ureterohidronefrosis bilateral por neoplasia vesical. Ante la inestabilidad hemodinámica de la paciente se realizó hemodiálisis durante dos horas, teniendo posteriormente una Cr de 5,9 mg/dl, potasio de 6,1 mEq/l, pH de 7,39 y bicarbonato de 22 mEq/l. Posteriormente se colocó nefrostomía bilateral con mejoría de cuadro clínico y normalización de cifras analíticas con Cr de 1,1 mg/dl, pH de 7,31 y bicarbonato de 23 mEq/l. Responsable clínico: Dr. Gabriel de Arriba, Sección de Nefrología, Hospital Universitario de Guadalajara. Departamento de Medicina. Universidad de Alcalá E-mail: garribad@senefro.org

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Elena", ".", "\n", "Apellidos", ":", "Justo", "Pascual", ".", "\n", "NHC", ":", "7401311", ".", "\n", "NASS", ":", "47", "16203430", "65", ".", "\n", "Domicilio", ":", "Calle", "Joaquin", "Vidal", ",", "12", ".", "\n", "Localidad/", "Provincia", ":", "Guadalajara", ".", "\n", "CP", ":", "19001", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "13/06/1939", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "76", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "26/11/2015", ".", "\n", "Médico", ":", "Gabriel", "de", "Arriba", "NºCol", ":", "19", "19", "87402", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "76", "años", "con", "antecedente", "de", "diabetes", "mellitus", "tipo", "2", ",", "dislipemia", "y", "síndrome", "depresivo", ".", "Estaba", "en", "tratamiento", "con", "metformina", "850", "mg/8", "horas", ",", "escitalopram", "20", "mg/24h", ",", "mirtazapina", "30", "mg/24", "horas", "y", "simvastatina", "40", "mg/24", "horas", ".", "En", "una", "analítica", "realizada", "seis", "meses", "antes", "tenía", "una", "Cr", "de", "0,81", "mg", "/", "dl", ".", "\n", "Dos", "semanas", "antes", "del", "ingreso", "comenzó", "tratamiento", "con", "ibuprofeno", "(", "600", "mg/8", "horas", ")", "por", "lumbalgia", ".", "Una", "semana", "antes", "tuvo", "náuseas", ",", "vómitos", "y", "diarrea", ",", "por", "lo", "que", "acudió", "a", "urgencias", ".", "En", "la", "exploración", "tenía", "sequedad", "de", "piel", "y", "mucosas", "y", "en", "la", "analítica", "la", "Cr", "plasmática", "fue", "de", "9", "mg", "/", "dl", ",", "glucosa", "de", "189", "mg", "/", "dl", ",", "urea", "de", "196", "mg", "/", "dl", ",", "hemoglobina", "de", "10,9", "g", "/", "dl", ",", "sodio", "de", "125", "mEq", "/", "l", ",", "potasio", "de", "8,6", "mEq", "/", "l", "y", "ácido", "láctico", "de", "6,3", "mmol", "/", "l.", "En", "la", "gasometría", "arterial", "tenía", "pH", "de", "7,23", "y", "bicarbonato", "de", "15", "mEq", "/", "l.", "Se", "realizó", "una", "ecografía", "abdominal", "en", "la", "que", "aparecía", "una", "ureterohidronefrosis", "bilateral", "por", "neoplasia", "vesical", ".", "Ante", "la", "inestabilidad", "hemodinámica", "de", "la", "paciente", "se", "realizó", "hemodiálisis", "durante", "dos", "horas", ",", "teniendo", "posteriormente", "una", "Cr", "de", "5,9", "mg", "/", "dl", ",", "potasio", "de", "6,1", "mEq", "/", "l", ",", "pH", "de", "7,39", "y", "bicarbonato", "de", "22", "mEq", "/", "l.", "Posteriormente", "se", "colocó", "nefrostomía", "bilateral", "con", "mejoría", "de", "cuadro", "clínico", "y", "normalización", "de", "cifras", "analíticas", "con", "Cr", "de", "1,1", "mg", "/", "dl", ",", "pH", "de", "7,31", "y", "bicarbonato", "de", "23", "mEq", "/", "l.", "\n", "Responsable", "clínico", ":", "Dr", ".", "Gabriel", "de", "Arriba", ",", "Sección", "de", "Nefrología", ",", "Hospital", "Universitario", "de", "Guadalajara", ".", "Departamento", "de", "Medicina", ".", "Universidad", "de", "Alcalá", "E", "-", "mail", ":", "garribad@senefro.org", "\n" ]

[ "HOSPITAL", "CALLE", "INSTITUCION", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "TERRITORIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

pleomorphic adenoma is an umlsterm, parotid gland is an umlsterm, tumour is an umlsterm, congenital is an umlsterm, tumours is an umlsterm, salivary glands is an umlsterm, tumour is an umlsterm, tumour is an umlsterm, birth is an umlsterm, cellular structures is an umlsterm, classification is an umlsterm, malignant tumour is an umlsterm, tissue is an umlsterm, embryogenesis is an umlsterm, cell is an umlsterm, cell is an umlsterm, cell is an umlsterm, Differential diagnosis is an umlsterm, pleomorphic adenoma is an umlsterm, congenital is an umlsterm, salivary gland is an umlsterm, tumours is an umlsterm, congenital is an umlsterm, basal cell adenoma is an umlsterm, hybrid is an umlsterm, basal cell adenoma is an umlsterm, adenoid cystic carcinoma is an umlsterm, salivary gland is an umlsterm, tumour is an umlsterm

DerPathologe.80190286.eng.abstr_task0

Sentence: Juvenile pleomorphic adenoma of the parotid gland represents an extremely rare tumour entity and is comparable to congenital tumours of the salivary glands concerning its embryonal structure . The clinical detection of the tumour in a 7-year-old girl does not exclude that the tumour had developed either earlier or immediately after the birth . The high cellularity and the evidence of primitive epithelial and myoepithelial cellular structures do not justify its classification as a malignant tumour . However the presence of embryonal tissue structures associated with the end of the third month of embryogenesis is characterized by more solid cell formations in partly verticillate arrangement . The absence of further differentiation into lobular structures and differentiated duct or acinic cell formations may be due to cell arrest . Differential diagnosis of juvenile pleomorphic adenoma must distinguished it from other congenital salivary gland tumours ( e.g. congenital basal cell adenoma , hybrid basal cell adenoma - adenoid cystic carcinoma , sialoblastoma , salivary gland anlage tumour ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O" ]

Juvenile pleomorphic adenoma of the parotid gland represents an extremely rare tumour entity and is comparable to congenital tumours of the salivary glands concerning its embryonal structure . The clinical detection of the tumour in a 7-year-old girl does not exclude that the tumour had developed either earlier or immediately after the birth . The high cellularity and the evidence of primitive epithelial and myoepithelial cellular structures do not justify its classification as a malignant tumour . However the presence of embryonal tissue structures associated with the end of the third month of embryogenesis is characterized by more solid cell formations in partly verticillate arrangement . The absence of further differentiation into lobular structures and differentiated duct or acinic cell formations may be due to cell arrest . Differential diagnosis of juvenile pleomorphic adenoma must distinguished it from other congenital salivary gland tumours ( e.g. congenital basal cell adenoma , hybrid basal cell adenoma - adenoid cystic carcinoma , sialoblastoma , salivary gland anlage tumour ) .

[ "Juvenile", "pleomorphic", "adenoma", "of", "the", "parotid", "gland", "represents", "an", "extremely", "rare", "tumour", "entity", "and", "is", "comparable", "to", "congenital", "tumours", "of", "the", "salivary", "glands", "concerning", "its", "embryonal", "structure", ".", "The", "clinical", "detection", "of", "the", "tumour", "in", "a", "7-year", "-", "old", "girl", "does", "not", "exclude", "that", "the", "tumour", "had", "developed", "either", "earlier", "or", "immediately", "after", "the", "birth", ".", "The", "high", "cellularity", "and", "the", "evidence", "of", "primitive", "epithelial", "and", "myoepithelial", "cellular", "structures", "do", "not", "justify", "its", "classification", "as", "a", "malignant", "tumour", ".", "However", "the", "presence", "of", "embryonal", "tissue", "structures", "associated", "with", "the", "end", "of", "the", "third", "month", "of", "embryogenesis", "is", "characterized", "by", "more", "solid", "cell", "formations", "in", "partly", "verticillate", "arrangement", ".", "The", "absence", "of", "further", "differentiation", "into", "lobular", "structures", "and", "differentiated", "duct", "or", "acinic", "cell", "formations", "may", "be", "due", "to", "cell", "arrest", ".", "Differential", "diagnosis", "of", "juvenile", "pleomorphic", "adenoma", "must", "distinguished", "it", "from", "other", "congenital", "salivary", "gland", "tumours", "(", "e.g", ".", "congenital", "basal", "cell", "adenoma", ",", "hybrid", "basal", "cell", "adenoma", "-", "adenoid", "cystic", "carcinoma", ",", "sialoblastoma", ",", "salivary", "gland", "anlage", "tumour", ")", "." ]

[ "umlsterm" ]

pleomorphic adenoma is an umlsterm, parotid gland is an umlsterm, tumour is an umlsterm, congenital is an umlsterm, tumours is an umlsterm, salivary glands is an umlsterm, tumour is an umlsterm, tumour is an umlsterm, birth is an umlsterm, cellular structures is an umlsterm, classification is an umlsterm, malignant tumour is an umlsterm, tissue is an umlsterm, embryogenesis is an umlsterm, cell is an umlsterm, cell is an umlsterm, cell is an umlsterm, Differential diagnosis is an umlsterm, pleomorphic adenoma is an umlsterm, congenital is an umlsterm, salivary gland is an umlsterm, tumours is an umlsterm, congenital is an umlsterm, basal cell adenoma is an umlsterm, hybrid is an umlsterm, basal cell adenoma is an umlsterm, adenoid cystic carcinoma is an umlsterm, salivary gland is an umlsterm, tumour is an umlsterm

DerPathologe.80190286.eng.abstr_task1

Sentence: Juvenile pleomorphic adenoma of the parotid gland represents an extremely rare tumour entity and is comparable to congenital tumours of the salivary glands concerning its embryonal structure . The clinical detection of the tumour in a 7-year-old girl does not exclude that the tumour had developed either earlier or immediately after the birth . The high cellularity and the evidence of primitive epithelial and myoepithelial cellular structures do not justify its classification as a malignant tumour . However the presence of embryonal tissue structures associated with the end of the third month of embryogenesis is characterized by more solid cell formations in partly verticillate arrangement . The absence of further differentiation into lobular structures and differentiated duct or acinic cell formations may be due to cell arrest . Differential diagnosis of juvenile pleomorphic adenoma must distinguished it from other congenital salivary gland tumours ( e.g. congenital basal cell adenoma , hybrid basal cell adenoma - adenoid cystic carcinoma , sialoblastoma , salivary gland anlage tumour ) . Instructions: please typing these entity words according to sentence: pleomorphic adenoma, parotid gland, tumour, congenital, tumours, salivary glands, tumour, tumour, birth, cellular structures, classification, malignant tumour, tissue, embryogenesis, cell, cell, cell, Differential diagnosis, pleomorphic adenoma, congenital, salivary gland, tumours, congenital, basal cell adenoma, hybrid, basal cell adenoma, adenoid cystic carcinoma, salivary gland, tumour Options: umlsterm

[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O" ]

Juvenile pleomorphic adenoma of the parotid gland represents an extremely rare tumour entity and is comparable to congenital tumours of the salivary glands concerning its embryonal structure . The clinical detection of the tumour in a 7-year-old girl does not exclude that the tumour had developed either earlier or immediately after the birth . The high cellularity and the evidence of primitive epithelial and myoepithelial cellular structures do not justify its classification as a malignant tumour . However the presence of embryonal tissue structures associated with the end of the third month of embryogenesis is characterized by more solid cell formations in partly verticillate arrangement . The absence of further differentiation into lobular structures and differentiated duct or acinic cell formations may be due to cell arrest . Differential diagnosis of juvenile pleomorphic adenoma must distinguished it from other congenital salivary gland tumours ( e.g. congenital basal cell adenoma , hybrid basal cell adenoma - adenoid cystic carcinoma , sialoblastoma , salivary gland anlage tumour ) .

[ "Juvenile", "pleomorphic", "adenoma", "of", "the", "parotid", "gland", "represents", "an", "extremely", "rare", "tumour", "entity", "and", "is", "comparable", "to", "congenital", "tumours", "of", "the", "salivary", "glands", "concerning", "its", "embryonal", "structure", ".", "The", "clinical", "detection", "of", "the", "tumour", "in", "a", "7-year", "-", "old", "girl", "does", "not", "exclude", "that", "the", "tumour", "had", "developed", "either", "earlier", "or", "immediately", "after", "the", "birth", ".", "The", "high", "cellularity", "and", "the", "evidence", "of", "primitive", "epithelial", "and", "myoepithelial", "cellular", "structures", "do", "not", "justify", "its", "classification", "as", "a", "malignant", "tumour", ".", "However", "the", "presence", "of", "embryonal", "tissue", "structures", "associated", "with", "the", "end", "of", "the", "third", "month", "of", "embryogenesis", "is", "characterized", "by", "more", "solid", "cell", "formations", "in", "partly", "verticillate", "arrangement", ".", "The", "absence", "of", "further", "differentiation", "into", "lobular", "structures", "and", "differentiated", "duct", "or", "acinic", "cell", "formations", "may", "be", "due", "to", "cell", "arrest", ".", "Differential", "diagnosis", "of", "juvenile", "pleomorphic", "adenoma", "must", "distinguished", "it", "from", "other", "congenital", "salivary", "gland", "tumours", "(", "e.g", ".", "congenital", "basal", "cell", "adenoma", ",", "hybrid", "basal", "cell", "adenoma", "-", "adenoid", "cystic", "carcinoma", ",", "sialoblastoma", ",", "salivary", "gland", "anlage", "tumour", ")", "." ]

[ "umlsterm" ]

pleomorphic adenoma, parotid gland, tumour, congenital, tumours, salivary glands, tumour, tumour, birth, cellular structures, classification, malignant tumour, tissue, embryogenesis, cell, cell, cell, Differential diagnosis, pleomorphic adenoma, congenital, salivary gland, tumours, congenital, basal cell adenoma, hybrid, basal cell adenoma, adenoid cystic carcinoma, salivary gland, tumour

DerPathologe.80190286.eng.abstr_task2

Sentence: Juvenile pleomorphic adenoma of the parotid gland represents an extremely rare tumour entity and is comparable to congenital tumours of the salivary glands concerning its embryonal structure . The clinical detection of the tumour in a 7-year-old girl does not exclude that the tumour had developed either earlier or immediately after the birth . The high cellularity and the evidence of primitive epithelial and myoepithelial cellular structures do not justify its classification as a malignant tumour . However the presence of embryonal tissue structures associated with the end of the third month of embryogenesis is characterized by more solid cell formations in partly verticillate arrangement . The absence of further differentiation into lobular structures and differentiated duct or acinic cell formations may be due to cell arrest . Differential diagnosis of juvenile pleomorphic adenoma must distinguished it from other congenital salivary gland tumours ( e.g. congenital basal cell adenoma , hybrid basal cell adenoma - adenoid cystic carcinoma , sialoblastoma , salivary gland anlage tumour ) . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O" ]

Juvenile pleomorphic adenoma of the parotid gland represents an extremely rare tumour entity and is comparable to congenital tumours of the salivary glands concerning its embryonal structure . The clinical detection of the tumour in a 7-year-old girl does not exclude that the tumour had developed either earlier or immediately after the birth . The high cellularity and the evidence of primitive epithelial and myoepithelial cellular structures do not justify its classification as a malignant tumour . However the presence of embryonal tissue structures associated with the end of the third month of embryogenesis is characterized by more solid cell formations in partly verticillate arrangement . The absence of further differentiation into lobular structures and differentiated duct or acinic cell formations may be due to cell arrest . Differential diagnosis of juvenile pleomorphic adenoma must distinguished it from other congenital salivary gland tumours ( e.g. congenital basal cell adenoma , hybrid basal cell adenoma - adenoid cystic carcinoma , sialoblastoma , salivary gland anlage tumour ) .

[ "Juvenile", "pleomorphic", "adenoma", "of", "the", "parotid", "gland", "represents", "an", "extremely", "rare", "tumour", "entity", "and", "is", "comparable", "to", "congenital", "tumours", "of", "the", "salivary", "glands", "concerning", "its", "embryonal", "structure", ".", "The", "clinical", "detection", "of", "the", "tumour", "in", "a", "7-year", "-", "old", "girl", "does", "not", "exclude", "that", "the", "tumour", "had", "developed", "either", "earlier", "or", "immediately", "after", "the", "birth", ".", "The", "high", "cellularity", "and", "the", "evidence", "of", "primitive", "epithelial", "and", "myoepithelial", "cellular", "structures", "do", "not", "justify", "its", "classification", "as", "a", "malignant", "tumour", ".", "However", "the", "presence", "of", "embryonal", "tissue", "structures", "associated", "with", "the", "end", "of", "the", "third", "month", "of", "embryogenesis", "is", "characterized", "by", "more", "solid", "cell", "formations", "in", "partly", "verticillate", "arrangement", ".", "The", "absence", "of", "further", "differentiation", "into", "lobular", "structures", "and", "differentiated", "duct", "or", "acinic", "cell", "formations", "may", "be", "due", "to", "cell", "arrest", ".", "Differential", "diagnosis", "of", "juvenile", "pleomorphic", "adenoma", "must", "distinguished", "it", "from", "other", "congenital", "salivary", "gland", "tumours", "(", "e.g", ".", "congenital", "basal", "cell", "adenoma", ",", "hybrid", "basal", "cell", "adenoma", "-", "adenoid", "cystic", "carcinoma", ",", "sialoblastoma", ",", "salivary", "gland", "anlage", "tumour", ")", "." ]

[ "umlsterm" ]

Elektronenstrahltomographie is an umlsterm, Herzdiagnostik is an umlsterm, Methoden is an umlsterm, Methode is an umlsterm, Diagnostik is an umlsterm, Stenosen is an umlsterm, Injektion is an umlsterm, Roentgenkontrastmittel is an umlsterm, Elektronenstrahltomographie is an umlsterm, Methoden is an umlsterm, Myokardperfusion is an umlsterm, Elektronenstrahltomographie is an umlsterm

ZfuerKardiologie.0089vii11.ger.abstr_task0

Sentence: Mit der Elektronenstrahltomographie steht ein nichtinvasives Schnittbildverfahren fuer die Herzdiagnostik zur Verfuegung , das insbesondere neue Einblicke in die Erkrankungen der Herzkranzgefaesse gestattet . Durch Quantifizierung koronararterieller Verkalkungen kann eine schnelle , wenig belastende und kostenguenstige Einschaetzung des koronaren Risikos geleistet werden , die bisherige Methoden an prognostischer Aussagekraft deutlich uebertrifft . Als Methode zur nichtinvasiven Diagnostik koronararterieller Stenosen unter periphervenoeser Injektion von Roentgenkontrastmittel erreicht die Elektronenstrahltomographie hoehere Testqualitaeten als bisher verfuegbare nichtinvasive Methoden . Die Quantifizierung der Myokardperfusion stellt insbesondere als Belastungsuntersuchung eine realistische Alternative zu anderen Perfusionsuntersuchungen dar . Die hohe zeitliche Aufloesung der Elektronenstrahltomographie gestattet ausserdem eine akkurate Erfassung der kardialen Bewegungsablaeufe . Zusaetzliche Indikationen bestehen in der Abklaerung kardialer Raumforderungen , perikardialer Erkrankungen sowie in der Untersuchung der grossen Gefaesse . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mit der Elektronenstrahltomographie steht ein nichtinvasives Schnittbildverfahren fuer die Herzdiagnostik zur Verfuegung , das insbesondere neue Einblicke in die Erkrankungen der Herzkranzgefaesse gestattet . Durch Quantifizierung koronararterieller Verkalkungen kann eine schnelle , wenig belastende und kostenguenstige Einschaetzung des koronaren Risikos geleistet werden , die bisherige Methoden an prognostischer Aussagekraft deutlich uebertrifft . Als Methode zur nichtinvasiven Diagnostik koronararterieller Stenosen unter periphervenoeser Injektion von Roentgenkontrastmittel erreicht die Elektronenstrahltomographie hoehere Testqualitaeten als bisher verfuegbare nichtinvasive Methoden . Die Quantifizierung der Myokardperfusion stellt insbesondere als Belastungsuntersuchung eine realistische Alternative zu anderen Perfusionsuntersuchungen dar . Die hohe zeitliche Aufloesung der Elektronenstrahltomographie gestattet ausserdem eine akkurate Erfassung der kardialen Bewegungsablaeufe . Zusaetzliche Indikationen bestehen in der Abklaerung kardialer Raumforderungen , perikardialer Erkrankungen sowie in der Untersuchung der grossen Gefaesse .

[ "Mit", "der", "Elektronenstrahltomographie", "steht", "ein", "nichtinvasives", "Schnittbildverfahren", "fuer", "die", "Herzdiagnostik", "zur", "Verfuegung", ",", "das", "insbesondere", "neue", "Einblicke", "in", "die", "Erkrankungen", "der", "Herzkranzgefaesse", "gestattet", ".", "Durch", "Quantifizierung", "koronararterieller", "Verkalkungen", "kann", "eine", "schnelle", ",", "wenig", "belastende", "und", "kostenguenstige", "Einschaetzung", "des", "koronaren", "Risikos", "geleistet", "werden", ",", "die", "bisherige", "Methoden", "an", "prognostischer", "Aussagekraft", "deutlich", "uebertrifft", ".", "Als", "Methode", "zur", "nichtinvasiven", "Diagnostik", "koronararterieller", "Stenosen", "unter", "periphervenoeser", "Injektion", "von", "Roentgenkontrastmittel", "erreicht", "die", "Elektronenstrahltomographie", "hoehere", "Testqualitaeten", "als", "bisher", "verfuegbare", "nichtinvasive", "Methoden", ".", "Die", "Quantifizierung", "der", "Myokardperfusion", "stellt", "insbesondere", "als", "Belastungsuntersuchung", "eine", "realistische", "Alternative", "zu", "anderen", "Perfusionsuntersuchungen", "dar", ".", "Die", "hohe", "zeitliche", "Aufloesung", "der", "Elektronenstrahltomographie", "gestattet", "ausserdem", "eine", "akkurate", "Erfassung", "der", "kardialen", "Bewegungsablaeufe", ".", "Zusaetzliche", "Indikationen", "bestehen", "in", "der", "Abklaerung", "kardialer", "Raumforderungen", ",", "perikardialer", "Erkrankungen", "sowie", "in", "der", "Untersuchung", "der", "grossen", "Gefaesse", "." ]

[ "umlsterm" ]

Elektronenstrahltomographie is an umlsterm, Herzdiagnostik is an umlsterm, Methoden is an umlsterm, Methode is an umlsterm, Diagnostik is an umlsterm, Stenosen is an umlsterm, Injektion is an umlsterm, Roentgenkontrastmittel is an umlsterm, Elektronenstrahltomographie is an umlsterm, Methoden is an umlsterm, Myokardperfusion is an umlsterm, Elektronenstrahltomographie is an umlsterm

ZfuerKardiologie.0089vii11.ger.abstr_task1

Sentence: Mit der Elektronenstrahltomographie steht ein nichtinvasives Schnittbildverfahren fuer die Herzdiagnostik zur Verfuegung , das insbesondere neue Einblicke in die Erkrankungen der Herzkranzgefaesse gestattet . Durch Quantifizierung koronararterieller Verkalkungen kann eine schnelle , wenig belastende und kostenguenstige Einschaetzung des koronaren Risikos geleistet werden , die bisherige Methoden an prognostischer Aussagekraft deutlich uebertrifft . Als Methode zur nichtinvasiven Diagnostik koronararterieller Stenosen unter periphervenoeser Injektion von Roentgenkontrastmittel erreicht die Elektronenstrahltomographie hoehere Testqualitaeten als bisher verfuegbare nichtinvasive Methoden . Die Quantifizierung der Myokardperfusion stellt insbesondere als Belastungsuntersuchung eine realistische Alternative zu anderen Perfusionsuntersuchungen dar . Die hohe zeitliche Aufloesung der Elektronenstrahltomographie gestattet ausserdem eine akkurate Erfassung der kardialen Bewegungsablaeufe . Zusaetzliche Indikationen bestehen in der Abklaerung kardialer Raumforderungen , perikardialer Erkrankungen sowie in der Untersuchung der grossen Gefaesse . Instructions: please typing these entity words according to sentence: Elektronenstrahltomographie, Herzdiagnostik, Methoden, Methode, Diagnostik, Stenosen, Injektion, Roentgenkontrastmittel, Elektronenstrahltomographie, Methoden, Myokardperfusion, Elektronenstrahltomographie Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mit der Elektronenstrahltomographie steht ein nichtinvasives Schnittbildverfahren fuer die Herzdiagnostik zur Verfuegung , das insbesondere neue Einblicke in die Erkrankungen der Herzkranzgefaesse gestattet . Durch Quantifizierung koronararterieller Verkalkungen kann eine schnelle , wenig belastende und kostenguenstige Einschaetzung des koronaren Risikos geleistet werden , die bisherige Methoden an prognostischer Aussagekraft deutlich uebertrifft . Als Methode zur nichtinvasiven Diagnostik koronararterieller Stenosen unter periphervenoeser Injektion von Roentgenkontrastmittel erreicht die Elektronenstrahltomographie hoehere Testqualitaeten als bisher verfuegbare nichtinvasive Methoden . Die Quantifizierung der Myokardperfusion stellt insbesondere als Belastungsuntersuchung eine realistische Alternative zu anderen Perfusionsuntersuchungen dar . Die hohe zeitliche Aufloesung der Elektronenstrahltomographie gestattet ausserdem eine akkurate Erfassung der kardialen Bewegungsablaeufe . Zusaetzliche Indikationen bestehen in der Abklaerung kardialer Raumforderungen , perikardialer Erkrankungen sowie in der Untersuchung der grossen Gefaesse .

[ "Mit", "der", "Elektronenstrahltomographie", "steht", "ein", "nichtinvasives", "Schnittbildverfahren", "fuer", "die", "Herzdiagnostik", "zur", "Verfuegung", ",", "das", "insbesondere", "neue", "Einblicke", "in", "die", "Erkrankungen", "der", "Herzkranzgefaesse", "gestattet", ".", "Durch", "Quantifizierung", "koronararterieller", "Verkalkungen", "kann", "eine", "schnelle", ",", "wenig", "belastende", "und", "kostenguenstige", "Einschaetzung", "des", "koronaren", "Risikos", "geleistet", "werden", ",", "die", "bisherige", "Methoden", "an", "prognostischer", "Aussagekraft", "deutlich", "uebertrifft", ".", "Als", "Methode", "zur", "nichtinvasiven", "Diagnostik", "koronararterieller", "Stenosen", "unter", "periphervenoeser", "Injektion", "von", "Roentgenkontrastmittel", "erreicht", "die", "Elektronenstrahltomographie", "hoehere", "Testqualitaeten", "als", "bisher", "verfuegbare", "nichtinvasive", "Methoden", ".", "Die", "Quantifizierung", "der", "Myokardperfusion", "stellt", "insbesondere", "als", "Belastungsuntersuchung", "eine", "realistische", "Alternative", "zu", "anderen", "Perfusionsuntersuchungen", "dar", ".", "Die", "hohe", "zeitliche", "Aufloesung", "der", "Elektronenstrahltomographie", "gestattet", "ausserdem", "eine", "akkurate", "Erfassung", "der", "kardialen", "Bewegungsablaeufe", ".", "Zusaetzliche", "Indikationen", "bestehen", "in", "der", "Abklaerung", "kardialer", "Raumforderungen", ",", "perikardialer", "Erkrankungen", "sowie", "in", "der", "Untersuchung", "der", "grossen", "Gefaesse", "." ]

[ "umlsterm" ]

Elektronenstrahltomographie, Herzdiagnostik, Methoden, Methode, Diagnostik, Stenosen, Injektion, Roentgenkontrastmittel, Elektronenstrahltomographie, Methoden, Myokardperfusion, Elektronenstrahltomographie

ZfuerKardiologie.0089vii11.ger.abstr_task2

Sentence: Mit der Elektronenstrahltomographie steht ein nichtinvasives Schnittbildverfahren fuer die Herzdiagnostik zur Verfuegung , das insbesondere neue Einblicke in die Erkrankungen der Herzkranzgefaesse gestattet . Durch Quantifizierung koronararterieller Verkalkungen kann eine schnelle , wenig belastende und kostenguenstige Einschaetzung des koronaren Risikos geleistet werden , die bisherige Methoden an prognostischer Aussagekraft deutlich uebertrifft . Als Methode zur nichtinvasiven Diagnostik koronararterieller Stenosen unter periphervenoeser Injektion von Roentgenkontrastmittel erreicht die Elektronenstrahltomographie hoehere Testqualitaeten als bisher verfuegbare nichtinvasive Methoden . Die Quantifizierung der Myokardperfusion stellt insbesondere als Belastungsuntersuchung eine realistische Alternative zu anderen Perfusionsuntersuchungen dar . Die hohe zeitliche Aufloesung der Elektronenstrahltomographie gestattet ausserdem eine akkurate Erfassung der kardialen Bewegungsablaeufe . Zusaetzliche Indikationen bestehen in der Abklaerung kardialer Raumforderungen , perikardialer Erkrankungen sowie in der Untersuchung der grossen Gefaesse . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mit der Elektronenstrahltomographie steht ein nichtinvasives Schnittbildverfahren fuer die Herzdiagnostik zur Verfuegung , das insbesondere neue Einblicke in die Erkrankungen der Herzkranzgefaesse gestattet . Durch Quantifizierung koronararterieller Verkalkungen kann eine schnelle , wenig belastende und kostenguenstige Einschaetzung des koronaren Risikos geleistet werden , die bisherige Methoden an prognostischer Aussagekraft deutlich uebertrifft . Als Methode zur nichtinvasiven Diagnostik koronararterieller Stenosen unter periphervenoeser Injektion von Roentgenkontrastmittel erreicht die Elektronenstrahltomographie hoehere Testqualitaeten als bisher verfuegbare nichtinvasive Methoden . Die Quantifizierung der Myokardperfusion stellt insbesondere als Belastungsuntersuchung eine realistische Alternative zu anderen Perfusionsuntersuchungen dar . Die hohe zeitliche Aufloesung der Elektronenstrahltomographie gestattet ausserdem eine akkurate Erfassung der kardialen Bewegungsablaeufe . Zusaetzliche Indikationen bestehen in der Abklaerung kardialer Raumforderungen , perikardialer Erkrankungen sowie in der Untersuchung der grossen Gefaesse .

[ "Mit", "der", "Elektronenstrahltomographie", "steht", "ein", "nichtinvasives", "Schnittbildverfahren", "fuer", "die", "Herzdiagnostik", "zur", "Verfuegung", ",", "das", "insbesondere", "neue", "Einblicke", "in", "die", "Erkrankungen", "der", "Herzkranzgefaesse", "gestattet", ".", "Durch", "Quantifizierung", "koronararterieller", "Verkalkungen", "kann", "eine", "schnelle", ",", "wenig", "belastende", "und", "kostenguenstige", "Einschaetzung", "des", "koronaren", "Risikos", "geleistet", "werden", ",", "die", "bisherige", "Methoden", "an", "prognostischer", "Aussagekraft", "deutlich", "uebertrifft", ".", "Als", "Methode", "zur", "nichtinvasiven", "Diagnostik", "koronararterieller", "Stenosen", "unter", "periphervenoeser", "Injektion", "von", "Roentgenkontrastmittel", "erreicht", "die", "Elektronenstrahltomographie", "hoehere", "Testqualitaeten", "als", "bisher", "verfuegbare", "nichtinvasive", "Methoden", ".", "Die", "Quantifizierung", "der", "Myokardperfusion", "stellt", "insbesondere", "als", "Belastungsuntersuchung", "eine", "realistische", "Alternative", "zu", "anderen", "Perfusionsuntersuchungen", "dar", ".", "Die", "hohe", "zeitliche", "Aufloesung", "der", "Elektronenstrahltomographie", "gestattet", "ausserdem", "eine", "akkurate", "Erfassung", "der", "kardialen", "Bewegungsablaeufe", ".", "Zusaetzliche", "Indikationen", "bestehen", "in", "der", "Abklaerung", "kardialer", "Raumforderungen", ",", "perikardialer", "Erkrankungen", "sowie", "in", "der", "Untersuchung", "der", "grossen", "Gefaesse", "." ]

[ "umlsterm" ]

interferon regulatory factor-1 is a protein_molecule, NF kappa B is a protein_molecule, Sp1 is a protein_molecule, transcription factors is a protein_family_or_group

100169_task0

Sentence: Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF kappa B, and Sp1 transcription factors. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_family_or_group, protein_molecule

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_molecule", "B-protein_family_or_group", "I-protein_family_or_group", "O" ]

Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF kappa B, and Sp1 transcription factors.

[ "Triggering", "of", "the", "human", "interleukin-6", "gene", "by", "interferon", "-", "gamma", "and", "tumor", "necrosis", "factor", "-", "alpha", "in", "monocytic", "cells", "involves", "cooperation", "between", "interferon", "regulatory", "factor-1", ",", "NF", "kappa", "B", ",", "and", "Sp1", "transcription", "factors", "." ]

[ "DNA_domain_or_region", "protein_molecule", "protein_complex", "protein_family_or_group", "other_name", "cell_type", "lipid" ]

interferon regulatory factor-1 is a protein_molecule, NF kappa B is a protein_molecule, Sp1 is a protein_molecule, transcription factors is a protein_family_or_group

100169_task1

Sentence: Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF kappa B, and Sp1 transcription factors. Instructions: please typing these entity words according to sentence: interferon regulatory factor-1, NF kappa B, Sp1, transcription factors Options: protein_family_or_group, protein_molecule

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_molecule", "B-protein_family_or_group", "I-protein_family_or_group", "O" ]

Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF kappa B, and Sp1 transcription factors.

[ "Triggering", "of", "the", "human", "interleukin-6", "gene", "by", "interferon", "-", "gamma", "and", "tumor", "necrosis", "factor", "-", "alpha", "in", "monocytic", "cells", "involves", "cooperation", "between", "interferon", "regulatory", "factor-1", ",", "NF", "kappa", "B", ",", "and", "Sp1", "transcription", "factors", "." ]

[ "DNA_domain_or_region", "protein_molecule", "protein_complex", "protein_family_or_group", "other_name", "cell_type", "lipid" ]

interferon regulatory factor-1, NF kappa B, Sp1, transcription factors

100169_task2

Sentence: Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF kappa B, and Sp1 transcription factors. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_molecule", "B-protein_family_or_group", "I-protein_family_or_group", "O" ]

Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF kappa B, and Sp1 transcription factors.

[ "Triggering", "of", "the", "human", "interleukin-6", "gene", "by", "interferon", "-", "gamma", "and", "tumor", "necrosis", "factor", "-", "alpha", "in", "monocytic", "cells", "involves", "cooperation", "between", "interferon", "regulatory", "factor-1", ",", "NF", "kappa", "B", ",", "and", "Sp1", "transcription", "factors", "." ]

[ "DNA_domain_or_region", "protein_molecule", "protein_complex", "protein_family_or_group", "other_name", "cell_type", "lipid" ]

HIV is a Condition, controlled is a Qualifier, at least 12 weeks is a Temporal, Viral load is a Measurement, < 200 copies is a Value, BMI is a Person, > 27 to 45 is a Value, DM type 2 is a Condition, A1-C is a Measurement, > 7 to 15 is a Value

NCT02743598_inc_task0

Sentence: HIV controlled on therapy for at least 12 weeks Viral load < 200 copies BMI >27 to 45 Diagnosis of DM type 2 with A1-C >7 to 15 Participants must be willing to comply with all study related procedures Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Person, Measurement

[ "B-Condition", "B-Qualifier", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

HIV controlled on therapy for at least 12 weeks Viral load < 200 copies BMI >27 to 45 Diagnosis of DM type 2 with A1-C >7 to 15 Participants must be willing to comply with all study related procedures

[ "HIV", "controlled", "on", "therapy", "for", "at", "least", "12", "weeks", "\n", "Viral", "load", "<", "200", "copies", "\n", "BMI", ">", "27", "to", "45", "\n", "Diagnosis", "of", "DM", "type", "2", "with", "A1-C", ">", "7", "to", "15", "\n", "Participants", "must", "be", "willing", "to", "comply", "with", "all", "study", "related", "procedures", "\n" ]

[ "Temporal", "Value", "Qualifier", "Measurement", "Condition", "Person" ]

HIV is a Condition, controlled is a Qualifier, at least 12 weeks is a Temporal, Viral load is a Measurement, < 200 copies is a Value, BMI is a Person, > 27 to 45 is a Value, DM type 2 is a Condition, A1-C is a Measurement, > 7 to 15 is a Value

NCT02743598_inc_task1

Sentence: HIV controlled on therapy for at least 12 weeks Viral load < 200 copies BMI >27 to 45 Diagnosis of DM type 2 with A1-C >7 to 15 Participants must be willing to comply with all study related procedures Instructions: please typing these entity words according to sentence: HIV, controlled, at least 12 weeks, Viral load, < 200 copies, BMI, > 27 to 45, DM type 2, A1-C, > 7 to 15 Options: Temporal, Condition, Qualifier, Value, Person, Measurement

[ "B-Condition", "B-Qualifier", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

HIV controlled on therapy for at least 12 weeks Viral load < 200 copies BMI >27 to 45 Diagnosis of DM type 2 with A1-C >7 to 15 Participants must be willing to comply with all study related procedures

[ "HIV", "controlled", "on", "therapy", "for", "at", "least", "12", "weeks", "\n", "Viral", "load", "<", "200", "copies", "\n", "BMI", ">", "27", "to", "45", "\n", "Diagnosis", "of", "DM", "type", "2", "with", "A1-C", ">", "7", "to", "15", "\n", "Participants", "must", "be", "willing", "to", "comply", "with", "all", "study", "related", "procedures", "\n" ]

[ "Temporal", "Value", "Qualifier", "Measurement", "Condition", "Person" ]

HIV, controlled, at least 12 weeks, Viral load, < 200 copies, BMI, > 27 to 45, DM type 2, A1-C, > 7 to 15

NCT02743598_inc_task2

Sentence: HIV controlled on therapy for at least 12 weeks Viral load < 200 copies BMI >27 to 45 Diagnosis of DM type 2 with A1-C >7 to 15 Participants must be willing to comply with all study related procedures Instructions: please extract entity words from the input sentence

[ "B-Condition", "B-Qualifier", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

HIV controlled on therapy for at least 12 weeks Viral load < 200 copies BMI >27 to 45 Diagnosis of DM type 2 with A1-C >7 to 15 Participants must be willing to comply with all study related procedures

[ "HIV", "controlled", "on", "therapy", "for", "at", "least", "12", "weeks", "\n", "Viral", "load", "<", "200", "copies", "\n", "BMI", ">", "27", "to", "45", "\n", "Diagnosis", "of", "DM", "type", "2", "with", "A1-C", ">", "7", "to", "15", "\n", "Participants", "must", "be", "willing", "to", "comply", "with", "all", "study", "related", "procedures", "\n" ]

[ "Temporal", "Value", "Qualifier", "Measurement", "Condition", "Person" ]

ST6GalNAc I is a Protein, ST6GalNAc I is a Protein, ST6GalNAc I is a Protein, ST6GalNAc I is a Protein, ST6GalNAc I is a Protein

172_task0

Sentence: ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Sialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Sialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells.

[ "ST6GalNAc", "I", "expression", "in", "MDA", "-", "MB-231", "breast", "cancer", "cells", "greatly", "modifies", "their", "O", "-", "glycosylation", "pattern", "and", "enhances", "their", "tumourigenicity", ".", "\n", "Sialyl", "-", "Tn", "is", "a", "carbohydrate", "antigen", "overexpressed", "in", "several", "epithelial", "cancers", ",", "including", "breast", "cancer", ",", "and", "usually", "associated", "with", "poor", "prognosis", ".", "Sialyl", "-", "Tn", "is", "synthesized", "by", "a", "CMP", "-", "Neu5Ac", ":", "GalNAcalpha2,6-sialyltransferase", ":", "CMP", "-", "Neu5Ac", ":", "R", "-", "GalNAcalpha1-O", "-", "Ser", "/", "Thr", "alpha2,6-sialyltransferase", "(", "EC", "2.4.99.3", ")", "(", "ST6GalNAc", "I", ")", ",", "which", "transfers", "a", "sialic", "acid", "residue", "in", "alpha2,6-linkage", "to", "the", "GalNAcalpha1-O", "-", "Ser", "/", "Thr", "structure", ".", "However", ",", "established", "breast", "cancer", "cell", "lines", "express", "neither", "ST6GalNAc", "I", "nor", "sialyl", "-", "Tn", ".", "We", "have", "previously", "shown", "that", "stable", "transfection", "of", "MDA", "-", "MB-231", ",", "a", "human", "breast", "cancer", "cell", "line", ",", "with", "ST6GalNAc", "I", "cDNA", "induces", "sialyl", "-", "Tn", "antigen", "(", "STn", ")", "expression", ".", "We", "report", "here", "the", "modifications", "of", "the", "O", "-", "glycosylation", "pattern", "of", "a", "MUC1-related", "recombinant", "protein", "secreted", "by", "MDA", "-", "MB-231", "sialyl", "-", "Tn", "positive", "cells", ".", "We", "also", "show", "that", "sialyl", "-", "Tn", "expression", "and", "concomitant", "changes", "in", "the", "overall", "O", "-", "glycan", "profiles", "induce", "a", "decrease", "of", "adhesion", "and", "an", "increase", "of", "migration", "of", "MDA", "-", "MB-231", ".", "Moreover", ",", "STn", "positive", "clones", "exhibit", "an", "increased", "tumour", "growth", "in", "severe", "combined", "immunodeficiency", "(", "SCID", ")", "mice", ".", "These", "observations", "suggest", "that", "modification", "of", "the", "O", "-", "glycosylation", "pattern", "induced", "by", "ST6GalNAc", "I", "expression", "are", "sufficient", "to", "enhance", "the", "tumourigenicity", "of", "MDA", "-", "MB-231", "breast", "cancer", "cells", ".", "\n" ]

[ "Protein" ]

ST6GalNAc I is a Protein, ST6GalNAc I is a Protein, ST6GalNAc I is a Protein, ST6GalNAc I is a Protein, ST6GalNAc I is a Protein

172_task1

Sentence: ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Sialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells. Instructions: please typing these entity words according to sentence: ST6GalNAc I, ST6GalNAc I, ST6GalNAc I, ST6GalNAc I, ST6GalNAc I Options: Protein

[ "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Sialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells.

[ "ST6GalNAc", "I", "expression", "in", "MDA", "-", "MB-231", "breast", "cancer", "cells", "greatly", "modifies", "their", "O", "-", "glycosylation", "pattern", "and", "enhances", "their", "tumourigenicity", ".", "\n", "Sialyl", "-", "Tn", "is", "a", "carbohydrate", "antigen", "overexpressed", "in", "several", "epithelial", "cancers", ",", "including", "breast", "cancer", ",", "and", "usually", "associated", "with", "poor", "prognosis", ".", "Sialyl", "-", "Tn", "is", "synthesized", "by", "a", "CMP", "-", "Neu5Ac", ":", "GalNAcalpha2,6-sialyltransferase", ":", "CMP", "-", "Neu5Ac", ":", "R", "-", "GalNAcalpha1-O", "-", "Ser", "/", "Thr", "alpha2,6-sialyltransferase", "(", "EC", "2.4.99.3", ")", "(", "ST6GalNAc", "I", ")", ",", "which", "transfers", "a", "sialic", "acid", "residue", "in", "alpha2,6-linkage", "to", "the", "GalNAcalpha1-O", "-", "Ser", "/", "Thr", "structure", ".", "However", ",", "established", "breast", "cancer", "cell", "lines", "express", "neither", "ST6GalNAc", "I", "nor", "sialyl", "-", "Tn", ".", "We", "have", "previously", "shown", "that", "stable", "transfection", "of", "MDA", "-", "MB-231", ",", "a", "human", "breast", "cancer", "cell", "line", ",", "with", "ST6GalNAc", "I", "cDNA", "induces", "sialyl", "-", "Tn", "antigen", "(", "STn", ")", "expression", ".", "We", "report", "here", "the", "modifications", "of", "the", "O", "-", "glycosylation", "pattern", "of", "a", "MUC1-related", "recombinant", "protein", "secreted", "by", "MDA", "-", "MB-231", "sialyl", "-", "Tn", "positive", "cells", ".", "We", "also", "show", "that", "sialyl", "-", "Tn", "expression", "and", "concomitant", "changes", "in", "the", "overall", "O", "-", "glycan", "profiles", "induce", "a", "decrease", "of", "adhesion", "and", "an", "increase", "of", "migration", "of", "MDA", "-", "MB-231", ".", "Moreover", ",", "STn", "positive", "clones", "exhibit", "an", "increased", "tumour", "growth", "in", "severe", "combined", "immunodeficiency", "(", "SCID", ")", "mice", ".", "These", "observations", "suggest", "that", "modification", "of", "the", "O", "-", "glycosylation", "pattern", "induced", "by", "ST6GalNAc", "I", "expression", "are", "sufficient", "to", "enhance", "the", "tumourigenicity", "of", "MDA", "-", "MB-231", "breast", "cancer", "cells", ".", "\n" ]

[ "Protein" ]

ST6GalNAc I, ST6GalNAc I, ST6GalNAc I, ST6GalNAc I, ST6GalNAc I

172_task2

Sentence: ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Sialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells. Instructions: please extract entity words from the input sentence

[ "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Sialyl-Tn is a carbohydrate antigen overexpressed in several epithelial cancers, including breast cancer, and usually associated with poor prognosis. Sialyl-Tn is synthesized by a CMP-Neu5Ac:GalNAcalpha2,6-sialyltransferase: CMP-Neu5Ac: R-GalNAcalpha1-O-Ser/Thr alpha2,6-sialyltransferase (EC 2.4.99.3) (ST6GalNAc I), which transfers a sialic acid residue in alpha2,6-linkage to the GalNAcalpha1-O-Ser/Thr structure. However, established breast cancer cell lines express neither ST6GalNAc I nor sialyl-Tn. We have previously shown that stable transfection of MDA-MB-231, a human breast cancer cell line, with ST6GalNAc I cDNA induces sialyl-Tn antigen (STn) expression. We report here the modifications of the O-glycosylation pattern of a MUC1-related recombinant protein secreted by MDA-MB-231 sialyl-Tn positive cells. We also show that sialyl-Tn expression and concomitant changes in the overall O-glycan profiles induce a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, STn positive clones exhibit an increased tumour growth in severe combined immunodeficiency (SCID) mice. These observations suggest that modification of the O-glycosylation pattern induced by ST6GalNAc I expression are sufficient to enhance the tumourigenicity of MDA-MB-231 breast cancer cells.

[ "ST6GalNAc", "I", "expression", "in", "MDA", "-", "MB-231", "breast", "cancer", "cells", "greatly", "modifies", "their", "O", "-", "glycosylation", "pattern", "and", "enhances", "their", "tumourigenicity", ".", "\n", "Sialyl", "-", "Tn", "is", "a", "carbohydrate", "antigen", "overexpressed", "in", "several", "epithelial", "cancers", ",", "including", "breast", "cancer", ",", "and", "usually", "associated", "with", "poor", "prognosis", ".", "Sialyl", "-", "Tn", "is", "synthesized", "by", "a", "CMP", "-", "Neu5Ac", ":", "GalNAcalpha2,6-sialyltransferase", ":", "CMP", "-", "Neu5Ac", ":", "R", "-", "GalNAcalpha1-O", "-", "Ser", "/", "Thr", "alpha2,6-sialyltransferase", "(", "EC", "2.4.99.3", ")", "(", "ST6GalNAc", "I", ")", ",", "which", "transfers", "a", "sialic", "acid", "residue", "in", "alpha2,6-linkage", "to", "the", "GalNAcalpha1-O", "-", "Ser", "/", "Thr", "structure", ".", "However", ",", "established", "breast", "cancer", "cell", "lines", "express", "neither", "ST6GalNAc", "I", "nor", "sialyl", "-", "Tn", ".", "We", "have", "previously", "shown", "that", "stable", "transfection", "of", "MDA", "-", "MB-231", ",", "a", "human", "breast", "cancer", "cell", "line", ",", "with", "ST6GalNAc", "I", "cDNA", "induces", "sialyl", "-", "Tn", "antigen", "(", "STn", ")", "expression", ".", "We", "report", "here", "the", "modifications", "of", "the", "O", "-", "glycosylation", "pattern", "of", "a", "MUC1-related", "recombinant", "protein", "secreted", "by", "MDA", "-", "MB-231", "sialyl", "-", "Tn", "positive", "cells", ".", "We", "also", "show", "that", "sialyl", "-", "Tn", "expression", "and", "concomitant", "changes", "in", "the", "overall", "O", "-", "glycan", "profiles", "induce", "a", "decrease", "of", "adhesion", "and", "an", "increase", "of", "migration", "of", "MDA", "-", "MB-231", ".", "Moreover", ",", "STn", "positive", "clones", "exhibit", "an", "increased", "tumour", "growth", "in", "severe", "combined", "immunodeficiency", "(", "SCID", ")", "mice", ".", "These", "observations", "suggest", "that", "modification", "of", "the", "O", "-", "glycosylation", "pattern", "induced", "by", "ST6GalNAc", "I", "expression", "are", "sufficient", "to", "enhance", "the", "tumourigenicity", "of", "MDA", "-", "MB-231", "breast", "cancer", "cells", ".", "\n" ]

[ "Protein" ]

Langzeitwirkungen is an umlsterm, ASS is an umlsterm, Dipyridamol is an umlsterm, Phenprocoumon is an umlsterm, Patienten is an umlsterm

ZfuerKardiologie.80870865.ger.abstr_task0

Sentence: In einer prospektiven randomisierten Studie wurden die plaettchenhemmenden Langzeitwirkungen von 50 mg Azetylsalizylsaeure ASS ) ( allein und in Kombination mit Dipyridamol ( 2x200 mg ) im Vergleich zu Phenprocoumon bei 42 Patienten nach ACB-OP untersucht . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

In einer prospektiven randomisierten Studie wurden die plaettchenhemmenden Langzeitwirkungen von 50 mg Azetylsalizylsaeure ASS ) ( allein und in Kombination mit Dipyridamol ( 2x200 mg ) im Vergleich zu Phenprocoumon bei 42 Patienten nach ACB-OP untersucht .

[ "In", "einer", "prospektiven", "randomisierten", "Studie", "wurden", "die", "plaettchenhemmenden", "Langzeitwirkungen", "von", "50", "mg", "Azetylsalizylsaeure", "ASS", ")", "(", "allein", "und", "in", "Kombination", "mit", "Dipyridamol", "(", "2x200", "mg", ")", "im", "Vergleich", "zu", "Phenprocoumon", "bei", "42", "Patienten", "nach", "ACB", "-", "OP", "untersucht", "." ]

[ "umlsterm" ]

Langzeitwirkungen is an umlsterm, ASS is an umlsterm, Dipyridamol is an umlsterm, Phenprocoumon is an umlsterm, Patienten is an umlsterm

ZfuerKardiologie.80870865.ger.abstr_task1

Sentence: In einer prospektiven randomisierten Studie wurden die plaettchenhemmenden Langzeitwirkungen von 50 mg Azetylsalizylsaeure ASS ) ( allein und in Kombination mit Dipyridamol ( 2x200 mg ) im Vergleich zu Phenprocoumon bei 42 Patienten nach ACB-OP untersucht . Instructions: please typing these entity words according to sentence: Langzeitwirkungen, ASS, Dipyridamol, Phenprocoumon, Patienten Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

In einer prospektiven randomisierten Studie wurden die plaettchenhemmenden Langzeitwirkungen von 50 mg Azetylsalizylsaeure ASS ) ( allein und in Kombination mit Dipyridamol ( 2x200 mg ) im Vergleich zu Phenprocoumon bei 42 Patienten nach ACB-OP untersucht .

[ "In", "einer", "prospektiven", "randomisierten", "Studie", "wurden", "die", "plaettchenhemmenden", "Langzeitwirkungen", "von", "50", "mg", "Azetylsalizylsaeure", "ASS", ")", "(", "allein", "und", "in", "Kombination", "mit", "Dipyridamol", "(", "2x200", "mg", ")", "im", "Vergleich", "zu", "Phenprocoumon", "bei", "42", "Patienten", "nach", "ACB", "-", "OP", "untersucht", "." ]

[ "umlsterm" ]

Langzeitwirkungen, ASS, Dipyridamol, Phenprocoumon, Patienten

ZfuerKardiologie.80870865.ger.abstr_task2

Sentence: In einer prospektiven randomisierten Studie wurden die plaettchenhemmenden Langzeitwirkungen von 50 mg Azetylsalizylsaeure ASS ) ( allein und in Kombination mit Dipyridamol ( 2x200 mg ) im Vergleich zu Phenprocoumon bei 42 Patienten nach ACB-OP untersucht . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

In einer prospektiven randomisierten Studie wurden die plaettchenhemmenden Langzeitwirkungen von 50 mg Azetylsalizylsaeure ASS ) ( allein und in Kombination mit Dipyridamol ( 2x200 mg ) im Vergleich zu Phenprocoumon bei 42 Patienten nach ACB-OP untersucht .

[ "In", "einer", "prospektiven", "randomisierten", "Studie", "wurden", "die", "plaettchenhemmenden", "Langzeitwirkungen", "von", "50", "mg", "Azetylsalizylsaeure", "ASS", ")", "(", "allein", "und", "in", "Kombination", "mit", "Dipyridamol", "(", "2x200", "mg", ")", "im", "Vergleich", "zu", "Phenprocoumon", "bei", "42", "Patienten", "nach", "ACB", "-", "OP", "untersucht", "." ]

[ "umlsterm" ]

hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, ovarian cancer cell is a Cell, LL-37 is a Gene_or_gene_product, human cationic antimicrobial protein 18 is a Gene_or_gene_product, hCAP-18 is a Gene_or_gene_product, cancer is a Pathological_formation, tissue is a Tissue, LL-37 is a Gene_or_gene_product, tumor is a Pathological_formation, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, ovarian tissue is a Tissue, LL-37 is a Gene_or_gene_product, ovarian cancer cells is a Cell, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, immune is a Cell, granulosa cells is a Cell, normal ovarian tissue is a Tissue, ovarian tumors is a Pathological_formation, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, tumor is a Cell, stromal cells is a Cell, immune cell is a Cell, microvessel is a Tissue, epithelial - derived ovarian tumors is a Pathological_formation, ovarian tumor tissue lysates is a Organism_substance, ovarian cancer cell lines is a Cell, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, ovarian cancer cell lines is a Cell, LL-37 is a Gene_or_gene_product, matrix metalloproteinase is a Gene_or_gene_product, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, ovarian tumors is a Pathological_formation, LL-37 is a Gene_or_gene_product, tumor cells is a Cell, immune cells is a Cell, ovarian cancer is a Pathological_formation

72_task0

Sentence: Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. The role of the pro-inflammatory peptide, LL-37, and its pro-form, human cationic antimicrobial protein 18 (hCAP-18), in cancer development and progression is poorly understood. In damaged and inflamed tissue, LL-37 functions as a chemoattractant, mitogen and pro-angiogenic factor suggesting that the peptide may potentiate tumor progression. The aim of this study was to characterize the distribution of hCAP-18/LL-37 in normal and cancerous ovarian tissue and to examine the effects of LL-37 on ovarian cancer cells. Expression of hCAP-18/LL-37 was localized to immune and granulosa cells of normal ovarian tissue. By contrast, ovarian tumors displayed significantly higher levels of hCAP-18/LL-37 where expression was observed in tumor and stromal cells. Protein expression was statistically compared to the degree of immune cell infiltration and microvessel density in epithelial-derived ovarian tumors and a significant correlation was observed for both. It was demonstrated that ovarian tumor tissue lysates and ovarian cancer cell lines express hCAP-18/LL-37. Treatment of ovarian cancer cell lines with recombinant LL-37 stimulated proliferation, chemotaxis, invasion and matrix metalloproteinase expression. These data demonstrate for the first time that hCAP-18/LL-37 is significantly overexpressed in ovarian tumors and suggest LL-37 may contribute to ovarian tumorigenesis through direct stimulation of tumor cells, initiation of angiogenesis and recruitment of immune cells. These data provide further evidence of the existing relationship between pro-inflammatory molecules and ovarian cancer progression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, Cell, Pathological_formation, Gene_or_gene_product, Organism_substance

[ "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Tissue", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "I-Organism_substance", "I-Organism_substance", "I-Organism_substance", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "O", "O", "O" ]

Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. The role of the pro-inflammatory peptide, LL-37, and its pro-form, human cationic antimicrobial protein 18 (hCAP-18), in cancer development and progression is poorly understood. In damaged and inflamed tissue, LL-37 functions as a chemoattractant, mitogen and pro-angiogenic factor suggesting that the peptide may potentiate tumor progression. The aim of this study was to characterize the distribution of hCAP-18/LL-37 in normal and cancerous ovarian tissue and to examine the effects of LL-37 on ovarian cancer cells. Expression of hCAP-18/LL-37 was localized to immune and granulosa cells of normal ovarian tissue. By contrast, ovarian tumors displayed significantly higher levels of hCAP-18/LL-37 where expression was observed in tumor and stromal cells. Protein expression was statistically compared to the degree of immune cell infiltration and microvessel density in epithelial-derived ovarian tumors and a significant correlation was observed for both. It was demonstrated that ovarian tumor tissue lysates and ovarian cancer cell lines express hCAP-18/LL-37. Treatment of ovarian cancer cell lines with recombinant LL-37 stimulated proliferation, chemotaxis, invasion and matrix metalloproteinase expression. These data demonstrate for the first time that hCAP-18/LL-37 is significantly overexpressed in ovarian tumors and suggest LL-37 may contribute to ovarian tumorigenesis through direct stimulation of tumor cells, initiation of angiogenesis and recruitment of immune cells. These data provide further evidence of the existing relationship between pro-inflammatory molecules and ovarian cancer progression.

[ "Ovarian", "cancers", "overexpress", "the", "antimicrobial", "protein", "hCAP-18", "and", "its", "derivative", "LL-37", "increases", "ovarian", "cancer", "cell", "proliferation", "and", "invasion", ".", "\n\n", "The", "role", "of", "the", "pro", "-", "inflammatory", "peptide", ",", "LL-37", ",", "and", "its", "pro", "-", "form", ",", "human", "cationic", "antimicrobial", "protein", "18", "(", "hCAP-18", ")", ",", "in", "cancer", "development", "and", "progression", "is", "poorly", "understood", ".", "In", "damaged", "and", "inflamed", "tissue", ",", "LL-37", "functions", "as", "a", "chemoattractant", ",", "mitogen", "and", "pro", "-", "angiogenic", "factor", "suggesting", "that", "the", "peptide", "may", "potentiate", "tumor", "progression", ".", "The", "aim", "of", "this", "study", "was", "to", "characterize", "the", "distribution", "of", "hCAP-18", "/", "LL-37", "in", "normal", "and", "cancerous", "ovarian", "tissue", "and", "to", "examine", "the", "effects", "of", "LL-37", "on", "ovarian", "cancer", "cells", ".", "Expression", "of", "hCAP-18", "/", "LL-37", "was", "localized", "to", "immune", "and", "granulosa", "cells", "of", "normal", "ovarian", "tissue", ".", "By", "contrast", ",", "ovarian", "tumors", "displayed", "significantly", "higher", "levels", "of", "hCAP-18", "/", "LL-37", "where", "expression", "was", "observed", "in", "tumor", "and", "stromal", "cells", ".", "Protein", "expression", "was", "statistically", "compared", "to", "the", "degree", "of", "immune", "cell", "infiltration", "and", "microvessel", "density", "in", "epithelial", "-", "derived", "ovarian", "tumors", "and", "a", "significant", "correlation", "was", "observed", "for", "both", ".", "It", "was", "demonstrated", "that", "ovarian", "tumor", "tissue", "lysates", "and", "ovarian", "cancer", "cell", "lines", "express", "hCAP-18", "/", "LL-37", ".", "Treatment", "of", "ovarian", "cancer", "cell", "lines", "with", "recombinant", "LL-37", "stimulated", "proliferation", ",", "chemotaxis", ",", "invasion", "and", "matrix", "metalloproteinase", "expression", ".", "These", "data", "demonstrate", "for", "the", "first", "time", "that", "hCAP-18", "/", "LL-37", "is", "significantly", "overexpressed", "in", "ovarian", "tumors", "and", "suggest", "LL-37", "may", "contribute", "to", "ovarian", "tumorigenesis", "through", "direct", "stimulation", "of", "tumor", "cells", ",", "initiation", "of", "angiogenesis", "and", "recruitment", "of", "immune", "cells", ".", "These", "data", "provide", "further", "evidence", "of", "the", "existing", "relationship", "between", "pro", "-", "inflammatory", "molecules", "and", "ovarian", "cancer", "progression", ".", "\n" ]

[ "Gene_or_gene_product", "Pathological_formation", "Organism_substance", "Cell", "Tissue" ]

hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, ovarian cancer cell is a Cell, LL-37 is a Gene_or_gene_product, human cationic antimicrobial protein 18 is a Gene_or_gene_product, hCAP-18 is a Gene_or_gene_product, cancer is a Pathological_formation, tissue is a Tissue, LL-37 is a Gene_or_gene_product, tumor is a Pathological_formation, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, ovarian tissue is a Tissue, LL-37 is a Gene_or_gene_product, ovarian cancer cells is a Cell, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, immune is a Cell, granulosa cells is a Cell, normal ovarian tissue is a Tissue, ovarian tumors is a Pathological_formation, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, tumor is a Cell, stromal cells is a Cell, immune cell is a Cell, microvessel is a Tissue, epithelial - derived ovarian tumors is a Pathological_formation, ovarian tumor tissue lysates is a Organism_substance, ovarian cancer cell lines is a Cell, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, ovarian cancer cell lines is a Cell, LL-37 is a Gene_or_gene_product, matrix metalloproteinase is a Gene_or_gene_product, hCAP-18 is a Gene_or_gene_product, LL-37 is a Gene_or_gene_product, ovarian tumors is a Pathological_formation, LL-37 is a Gene_or_gene_product, tumor cells is a Cell, immune cells is a Cell, ovarian cancer is a Pathological_formation

72_task1

Sentence: Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. The role of the pro-inflammatory peptide, LL-37, and its pro-form, human cationic antimicrobial protein 18 (hCAP-18), in cancer development and progression is poorly understood. In damaged and inflamed tissue, LL-37 functions as a chemoattractant, mitogen and pro-angiogenic factor suggesting that the peptide may potentiate tumor progression. The aim of this study was to characterize the distribution of hCAP-18/LL-37 in normal and cancerous ovarian tissue and to examine the effects of LL-37 on ovarian cancer cells. Expression of hCAP-18/LL-37 was localized to immune and granulosa cells of normal ovarian tissue. By contrast, ovarian tumors displayed significantly higher levels of hCAP-18/LL-37 where expression was observed in tumor and stromal cells. Protein expression was statistically compared to the degree of immune cell infiltration and microvessel density in epithelial-derived ovarian tumors and a significant correlation was observed for both. It was demonstrated that ovarian tumor tissue lysates and ovarian cancer cell lines express hCAP-18/LL-37. Treatment of ovarian cancer cell lines with recombinant LL-37 stimulated proliferation, chemotaxis, invasion and matrix metalloproteinase expression. These data demonstrate for the first time that hCAP-18/LL-37 is significantly overexpressed in ovarian tumors and suggest LL-37 may contribute to ovarian tumorigenesis through direct stimulation of tumor cells, initiation of angiogenesis and recruitment of immune cells. These data provide further evidence of the existing relationship between pro-inflammatory molecules and ovarian cancer progression. Instructions: please typing these entity words according to sentence: hCAP-18, LL-37, ovarian cancer cell, LL-37, human cationic antimicrobial protein 18, hCAP-18, cancer, tissue, LL-37, tumor, hCAP-18, LL-37, ovarian tissue, LL-37, ovarian cancer cells, hCAP-18, LL-37, immune, granulosa cells, normal ovarian tissue, ovarian tumors, hCAP-18, LL-37, tumor, stromal cells, immune cell, microvessel, epithelial - derived ovarian tumors, ovarian tumor tissue lysates, ovarian cancer cell lines, hCAP-18, LL-37, ovarian cancer cell lines, LL-37, matrix metalloproteinase, hCAP-18, LL-37, ovarian tumors, LL-37, tumor cells, immune cells, ovarian cancer Options: Tissue, Cell, Pathological_formation, Gene_or_gene_product, Organism_substance

[ "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Tissue", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "I-Organism_substance", "I-Organism_substance", "I-Organism_substance", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "O", "O", "O" ]

Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. The role of the pro-inflammatory peptide, LL-37, and its pro-form, human cationic antimicrobial protein 18 (hCAP-18), in cancer development and progression is poorly understood. In damaged and inflamed tissue, LL-37 functions as a chemoattractant, mitogen and pro-angiogenic factor suggesting that the peptide may potentiate tumor progression. The aim of this study was to characterize the distribution of hCAP-18/LL-37 in normal and cancerous ovarian tissue and to examine the effects of LL-37 on ovarian cancer cells. Expression of hCAP-18/LL-37 was localized to immune and granulosa cells of normal ovarian tissue. By contrast, ovarian tumors displayed significantly higher levels of hCAP-18/LL-37 where expression was observed in tumor and stromal cells. Protein expression was statistically compared to the degree of immune cell infiltration and microvessel density in epithelial-derived ovarian tumors and a significant correlation was observed for both. It was demonstrated that ovarian tumor tissue lysates and ovarian cancer cell lines express hCAP-18/LL-37. Treatment of ovarian cancer cell lines with recombinant LL-37 stimulated proliferation, chemotaxis, invasion and matrix metalloproteinase expression. These data demonstrate for the first time that hCAP-18/LL-37 is significantly overexpressed in ovarian tumors and suggest LL-37 may contribute to ovarian tumorigenesis through direct stimulation of tumor cells, initiation of angiogenesis and recruitment of immune cells. These data provide further evidence of the existing relationship between pro-inflammatory molecules and ovarian cancer progression.

[ "Ovarian", "cancers", "overexpress", "the", "antimicrobial", "protein", "hCAP-18", "and", "its", "derivative", "LL-37", "increases", "ovarian", "cancer", "cell", "proliferation", "and", "invasion", ".", "\n\n", "The", "role", "of", "the", "pro", "-", "inflammatory", "peptide", ",", "LL-37", ",", "and", "its", "pro", "-", "form", ",", "human", "cationic", "antimicrobial", "protein", "18", "(", "hCAP-18", ")", ",", "in", "cancer", "development", "and", "progression", "is", "poorly", "understood", ".", "In", "damaged", "and", "inflamed", "tissue", ",", "LL-37", "functions", "as", "a", "chemoattractant", ",", "mitogen", "and", "pro", "-", "angiogenic", "factor", "suggesting", "that", "the", "peptide", "may", "potentiate", "tumor", "progression", ".", "The", "aim", "of", "this", "study", "was", "to", "characterize", "the", "distribution", "of", "hCAP-18", "/", "LL-37", "in", "normal", "and", "cancerous", "ovarian", "tissue", "and", "to", "examine", "the", "effects", "of", "LL-37", "on", "ovarian", "cancer", "cells", ".", "Expression", "of", "hCAP-18", "/", "LL-37", "was", "localized", "to", "immune", "and", "granulosa", "cells", "of", "normal", "ovarian", "tissue", ".", "By", "contrast", ",", "ovarian", "tumors", "displayed", "significantly", "higher", "levels", "of", "hCAP-18", "/", "LL-37", "where", "expression", "was", "observed", "in", "tumor", "and", "stromal", "cells", ".", "Protein", "expression", "was", "statistically", "compared", "to", "the", "degree", "of", "immune", "cell", "infiltration", "and", "microvessel", "density", "in", "epithelial", "-", "derived", "ovarian", "tumors", "and", "a", "significant", "correlation", "was", "observed", "for", "both", ".", "It", "was", "demonstrated", "that", "ovarian", "tumor", "tissue", "lysates", "and", "ovarian", "cancer", "cell", "lines", "express", "hCAP-18", "/", "LL-37", ".", "Treatment", "of", "ovarian", "cancer", "cell", "lines", "with", "recombinant", "LL-37", "stimulated", "proliferation", ",", "chemotaxis", ",", "invasion", "and", "matrix", "metalloproteinase", "expression", ".", "These", "data", "demonstrate", "for", "the", "first", "time", "that", "hCAP-18", "/", "LL-37", "is", "significantly", "overexpressed", "in", "ovarian", "tumors", "and", "suggest", "LL-37", "may", "contribute", "to", "ovarian", "tumorigenesis", "through", "direct", "stimulation", "of", "tumor", "cells", ",", "initiation", "of", "angiogenesis", "and", "recruitment", "of", "immune", "cells", ".", "These", "data", "provide", "further", "evidence", "of", "the", "existing", "relationship", "between", "pro", "-", "inflammatory", "molecules", "and", "ovarian", "cancer", "progression", ".", "\n" ]

[ "Gene_or_gene_product", "Pathological_formation", "Organism_substance", "Cell", "Tissue" ]

hCAP-18, LL-37, ovarian cancer cell, LL-37, human cationic antimicrobial protein 18, hCAP-18, cancer, tissue, LL-37, tumor, hCAP-18, LL-37, ovarian tissue, LL-37, ovarian cancer cells, hCAP-18, LL-37, immune, granulosa cells, normal ovarian tissue, ovarian tumors, hCAP-18, LL-37, tumor, stromal cells, immune cell, microvessel, epithelial - derived ovarian tumors, ovarian tumor tissue lysates, ovarian cancer cell lines, hCAP-18, LL-37, ovarian cancer cell lines, LL-37, matrix metalloproteinase, hCAP-18, LL-37, ovarian tumors, LL-37, tumor cells, immune cells, ovarian cancer

72_task2

Sentence: Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. The role of the pro-inflammatory peptide, LL-37, and its pro-form, human cationic antimicrobial protein 18 (hCAP-18), in cancer development and progression is poorly understood. In damaged and inflamed tissue, LL-37 functions as a chemoattractant, mitogen and pro-angiogenic factor suggesting that the peptide may potentiate tumor progression. The aim of this study was to characterize the distribution of hCAP-18/LL-37 in normal and cancerous ovarian tissue and to examine the effects of LL-37 on ovarian cancer cells. Expression of hCAP-18/LL-37 was localized to immune and granulosa cells of normal ovarian tissue. By contrast, ovarian tumors displayed significantly higher levels of hCAP-18/LL-37 where expression was observed in tumor and stromal cells. Protein expression was statistically compared to the degree of immune cell infiltration and microvessel density in epithelial-derived ovarian tumors and a significant correlation was observed for both. It was demonstrated that ovarian tumor tissue lysates and ovarian cancer cell lines express hCAP-18/LL-37. Treatment of ovarian cancer cell lines with recombinant LL-37 stimulated proliferation, chemotaxis, invasion and matrix metalloproteinase expression. These data demonstrate for the first time that hCAP-18/LL-37 is significantly overexpressed in ovarian tumors and suggest LL-37 may contribute to ovarian tumorigenesis through direct stimulation of tumor cells, initiation of angiogenesis and recruitment of immune cells. These data provide further evidence of the existing relationship between pro-inflammatory molecules and ovarian cancer progression. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Tissue", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "I-Organism_substance", "I-Organism_substance", "I-Organism_substance", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "O", "O", "O" ]

Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. The role of the pro-inflammatory peptide, LL-37, and its pro-form, human cationic antimicrobial protein 18 (hCAP-18), in cancer development and progression is poorly understood. In damaged and inflamed tissue, LL-37 functions as a chemoattractant, mitogen and pro-angiogenic factor suggesting that the peptide may potentiate tumor progression. The aim of this study was to characterize the distribution of hCAP-18/LL-37 in normal and cancerous ovarian tissue and to examine the effects of LL-37 on ovarian cancer cells. Expression of hCAP-18/LL-37 was localized to immune and granulosa cells of normal ovarian tissue. By contrast, ovarian tumors displayed significantly higher levels of hCAP-18/LL-37 where expression was observed in tumor and stromal cells. Protein expression was statistically compared to the degree of immune cell infiltration and microvessel density in epithelial-derived ovarian tumors and a significant correlation was observed for both. It was demonstrated that ovarian tumor tissue lysates and ovarian cancer cell lines express hCAP-18/LL-37. Treatment of ovarian cancer cell lines with recombinant LL-37 stimulated proliferation, chemotaxis, invasion and matrix metalloproteinase expression. These data demonstrate for the first time that hCAP-18/LL-37 is significantly overexpressed in ovarian tumors and suggest LL-37 may contribute to ovarian tumorigenesis through direct stimulation of tumor cells, initiation of angiogenesis and recruitment of immune cells. These data provide further evidence of the existing relationship between pro-inflammatory molecules and ovarian cancer progression.

[ "Ovarian", "cancers", "overexpress", "the", "antimicrobial", "protein", "hCAP-18", "and", "its", "derivative", "LL-37", "increases", "ovarian", "cancer", "cell", "proliferation", "and", "invasion", ".", "\n\n", "The", "role", "of", "the", "pro", "-", "inflammatory", "peptide", ",", "LL-37", ",", "and", "its", "pro", "-", "form", ",", "human", "cationic", "antimicrobial", "protein", "18", "(", "hCAP-18", ")", ",", "in", "cancer", "development", "and", "progression", "is", "poorly", "understood", ".", "In", "damaged", "and", "inflamed", "tissue", ",", "LL-37", "functions", "as", "a", "chemoattractant", ",", "mitogen", "and", "pro", "-", "angiogenic", "factor", "suggesting", "that", "the", "peptide", "may", "potentiate", "tumor", "progression", ".", "The", "aim", "of", "this", "study", "was", "to", "characterize", "the", "distribution", "of", "hCAP-18", "/", "LL-37", "in", "normal", "and", "cancerous", "ovarian", "tissue", "and", "to", "examine", "the", "effects", "of", "LL-37", "on", "ovarian", "cancer", "cells", ".", "Expression", "of", "hCAP-18", "/", "LL-37", "was", "localized", "to", "immune", "and", "granulosa", "cells", "of", "normal", "ovarian", "tissue", ".", "By", "contrast", ",", "ovarian", "tumors", "displayed", "significantly", "higher", "levels", "of", "hCAP-18", "/", "LL-37", "where", "expression", "was", "observed", "in", "tumor", "and", "stromal", "cells", ".", "Protein", "expression", "was", "statistically", "compared", "to", "the", "degree", "of", "immune", "cell", "infiltration", "and", "microvessel", "density", "in", "epithelial", "-", "derived", "ovarian", "tumors", "and", "a", "significant", "correlation", "was", "observed", "for", "both", ".", "It", "was", "demonstrated", "that", "ovarian", "tumor", "tissue", "lysates", "and", "ovarian", "cancer", "cell", "lines", "express", "hCAP-18", "/", "LL-37", ".", "Treatment", "of", "ovarian", "cancer", "cell", "lines", "with", "recombinant", "LL-37", "stimulated", "proliferation", ",", "chemotaxis", ",", "invasion", "and", "matrix", "metalloproteinase", "expression", ".", "These", "data", "demonstrate", "for", "the", "first", "time", "that", "hCAP-18", "/", "LL-37", "is", "significantly", "overexpressed", "in", "ovarian", "tumors", "and", "suggest", "LL-37", "may", "contribute", "to", "ovarian", "tumorigenesis", "through", "direct", "stimulation", "of", "tumor", "cells", ",", "initiation", "of", "angiogenesis", "and", "recruitment", "of", "immune", "cells", ".", "These", "data", "provide", "further", "evidence", "of", "the", "existing", "relationship", "between", "pro", "-", "inflammatory", "molecules", "and", "ovarian", "cancer", "progression", ".", "\n" ]

[ "Gene_or_gene_product", "Pathological_formation", "Organism_substance", "Cell", "Tissue" ]

prospective study is an umlsterm, quality of life is an umlsterm, life is an umlsterm, satisfaction is an umlsterm, health is an umlsterm, time is an umlsterm, heart transplantation is an umlsterm, patients is an umlsterm, questionnaires is an umlsterm, heart is an umlsterm, transplant is an umlsterm, symptom is an umlsterm, quality of life is an umlsterm, assessment is an umlsterm, life quality is an umlsterm, life changes is an umlsterm, language is an umlsterm, age is an umlsterm, evaluation is an umlsterm, standard is an umlsterm, Quality of life is an umlsterm, patients is an umlsterm, congestive heart failure is an umlsterm, quality of life is an umlsterm, health status is an umlsterm, health status is an umlsterm, Quality of life is an umlsterm, health is an umlsterm, satisfaction is an umlsterm, health status is an umlsterm, recreational activities is an umlsterm, patients is an umlsterm, quality of life is an umlsterm, postoperative is an umlsterm, life is an umlsterm, patients is an umlsterm

ZfuerKardiologie.80870808.eng.abstr_task0

Sentence: This prospective study was designed to compare quality of life , life satisfaction , and subjective ratings of health before and at variable time intervals after heart transplantation ( HTx ) . 175 patients were included between February 1994 and December 1997. Every six months before and 1,5 , 3 , 6 , and 12 months after HTx , they received the following standardized and validated questionnaires : German SF 36 , heart failure and specific transplant symptom list , global quality of life assessment , Munich life quality dimension list , expected/experienced life changes after HTx , good command of the German language , and a minimum age of 18 years . During data evaluation , median ( Me ) , mean ( M ) , and standard deviation ( SD ) were created from individual parameters . Quality of life was rated as very poor by 84% of patients with congestive heart failure . Only 6 weeks after HTx , 74% rated their quality of life as significantly better . Before HTx 80% were very unsatisfied about their health status and 87% about physical performance . Six weeks after HTx , this parameter improved significantly and 76% were very satisfied about their health status and 50% about physical performance . While somatic changes expected before HTx corresponded well with experienced ones , psychological improvements were smaller than expected , but one year after HTx they were significant ( before : M=3.66; SD=0.9; Range ( R ) =3 . 78 vs 12 months postop : M=4.61; SD=0.6; R=2.67; p 0.05 ) . Quality of life correlated before HTx best with subjectively rated health ( r=0.61, p 0.01 ) and 6 months after with satisfaction about health status ( r=0.76, p 0.01 ) . Only in 25% were expected improvements fulfilled regarding sexual activity/satisfaction , professional situation , and recreational activities . 90% of posttransplant patients reported physical compaints , most by effects of immunsuppression , but were coping well . The study shows that already 6 weeks after successful HTx all quality of life parameters improved significantly . Despite some unfulfilled expectations and complaints , the postoperative life situation of HTx patients appeared significantly improved . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

This prospective study was designed to compare quality of life , life satisfaction , and subjective ratings of health before and at variable time intervals after heart transplantation ( HTx ) . 175 patients were included between February 1994 and December 1997. Every six months before and 1,5 , 3 , 6 , and 12 months after HTx , they received the following standardized and validated questionnaires : German SF 36 , heart failure and specific transplant symptom list , global quality of life assessment , Munich life quality dimension list , expected/experienced life changes after HTx , good command of the German language , and a minimum age of 18 years . During data evaluation , median ( Me ) , mean ( M ) , and standard deviation ( SD ) were created from individual parameters . Quality of life was rated as very poor by 84% of patients with congestive heart failure . Only 6 weeks after HTx , 74% rated their quality of life as significantly better . Before HTx 80% were very unsatisfied about their health status and 87% about physical performance . Six weeks after HTx , this parameter improved significantly and 76% were very satisfied about their health status and 50% about physical performance . While somatic changes expected before HTx corresponded well with experienced ones , psychological improvements were smaller than expected , but one year after HTx they were significant ( before : M=3.66; SD=0.9; Range ( R ) =3 . 78 vs 12 months postop : M=4.61; SD=0.6; R=2.67; p 0.05 ) . Quality of life correlated before HTx best with subjectively rated health ( r=0.61, p 0.01 ) and 6 months after with satisfaction about health status ( r=0.76, p 0.01 ) . Only in 25% were expected improvements fulfilled regarding sexual activity/satisfaction , professional situation , and recreational activities . 90% of posttransplant patients reported physical compaints , most by effects of immunsuppression , but were coping well . The study shows that already 6 weeks after successful HTx all quality of life parameters improved significantly . Despite some unfulfilled expectations and complaints , the postoperative life situation of HTx patients appeared significantly improved .

[ "This", "prospective", "study", "was", "designed", "to", "compare", "quality", "of", "life", ",", "life", "satisfaction", ",", "and", "subjective", "ratings", "of", "health", "before", "and", "at", "variable", "time", "intervals", "after", "heart", "transplantation", "(", "HTx", ")", ".", "175", "patients", "were", "included", "between", "February", "1994", "and", "December", "1997", ".", "Every", "six", "months", "before", "and", "1,5", ",", "3", ",", "6", ",", "and", "12", "months", "after", "HTx", ",", "they", "received", "the", "following", "standardized", "and", "validated", "questionnaires", ":", "German", "SF", "36", ",", "heart", "failure", "and", "specific", "transplant", "symptom", "list", ",", "global", "quality", "of", "life", "assessment", ",", "Munich", "life", "quality", "dimension", "list", ",", "expected", "/", "experienced", "life", "changes", "after", "HTx", ",", "good", "command", "of", "the", "German", "language", ",", "and", "a", "minimum", "age", "of", "18", "years", ".", "During", "data", "evaluation", ",", "median", "(", "Me", ")", ",", "mean", "(", "M", ")", ",", "and", "standard", "deviation", "(", "SD", ")", "were", "created", "from", "individual", "parameters", ".", "Quality", "of", "life", "was", "rated", "as", "very", "poor", "by", "84", "%", "of", "patients", "with", "congestive", "heart", "failure", ".", "Only", "6", "weeks", "after", "HTx", ",", "74", "%", "rated", "their", "quality", "of", "life", "as", "significantly", "better", ".", "Before", "HTx", "80", "%", "were", "very", "unsatisfied", "about", "their", "health", "status", "and", "87", "%", "about", "physical", "performance", ".", "Six", "weeks", "after", "HTx", ",", "this", "parameter", "improved", "significantly", "and", "76", "%", "were", "very", "satisfied", "about", "their", "health", "status", "and", "50", "%", "about", "physical", "performance", ".", "While", "somatic", "changes", "expected", "before", "HTx", "corresponded", "well", "with", "experienced", "ones", ",", "psychological", "improvements", "were", "smaller", "than", "expected", ",", "but", "one", "year", "after", "HTx", "they", "were", "significant", "(", "before", ":", "M=3.66", ";", "SD=0.9", ";", "Range", "(", "R", ")", "=3", ".", "78", "vs", "12", "months", "postop", ":", "M=4.61", ";", "SD=0.6", ";", "R=2.67", ";", "p", "0.05", ")", ".", "Quality", "of", "life", "correlated", "before", "HTx", "best", "with", "subjectively", "rated", "health", "(", "r=0.61", ",", "p", "0.01", ")", "and", "6", "months", "after", "with", "satisfaction", "about", "health", "status", "(", "r=0.76", ",", "p", "0.01", ")", ".", "Only", "in", "25", "%", "were", "expected", "improvements", "fulfilled", "regarding", "sexual", "activity", "/", "satisfaction", ",", "professional", "situation", ",", "and", "recreational", "activities", ".", "90", "%", "of", "posttransplant", "patients", "reported", "physical", "compaints", ",", "most", "by", "effects", "of", "immunsuppression", ",", "but", "were", "coping", "well", ".", "The", "study", "shows", "that", "already", "6", "weeks", "after", "successful", "HTx", "all", "quality", "of", "life", "parameters", "improved", "significantly", ".", "Despite", "some", "unfulfilled", "expectations", "and", "complaints", ",", "the", "postoperative", "life", "situation", "of", "HTx", "patients", "appeared", "significantly", "improved", "." ]

[ "umlsterm" ]

prospective study is an umlsterm, quality of life is an umlsterm, life is an umlsterm, satisfaction is an umlsterm, health is an umlsterm, time is an umlsterm, heart transplantation is an umlsterm, patients is an umlsterm, questionnaires is an umlsterm, heart is an umlsterm, transplant is an umlsterm, symptom is an umlsterm, quality of life is an umlsterm, assessment is an umlsterm, life quality is an umlsterm, life changes is an umlsterm, language is an umlsterm, age is an umlsterm, evaluation is an umlsterm, standard is an umlsterm, Quality of life is an umlsterm, patients is an umlsterm, congestive heart failure is an umlsterm, quality of life is an umlsterm, health status is an umlsterm, health status is an umlsterm, Quality of life is an umlsterm, health is an umlsterm, satisfaction is an umlsterm, health status is an umlsterm, recreational activities is an umlsterm, patients is an umlsterm, quality of life is an umlsterm, postoperative is an umlsterm, life is an umlsterm, patients is an umlsterm

ZfuerKardiologie.80870808.eng.abstr_task1

Sentence: This prospective study was designed to compare quality of life , life satisfaction , and subjective ratings of health before and at variable time intervals after heart transplantation ( HTx ) . 175 patients were included between February 1994 and December 1997. Every six months before and 1,5 , 3 , 6 , and 12 months after HTx , they received the following standardized and validated questionnaires : German SF 36 , heart failure and specific transplant symptom list , global quality of life assessment , Munich life quality dimension list , expected/experienced life changes after HTx , good command of the German language , and a minimum age of 18 years . During data evaluation , median ( Me ) , mean ( M ) , and standard deviation ( SD ) were created from individual parameters . Quality of life was rated as very poor by 84% of patients with congestive heart failure . Only 6 weeks after HTx , 74% rated their quality of life as significantly better . Before HTx 80% were very unsatisfied about their health status and 87% about physical performance . Six weeks after HTx , this parameter improved significantly and 76% were very satisfied about their health status and 50% about physical performance . While somatic changes expected before HTx corresponded well with experienced ones , psychological improvements were smaller than expected , but one year after HTx they were significant ( before : M=3.66; SD=0.9; Range ( R ) =3 . 78 vs 12 months postop : M=4.61; SD=0.6; R=2.67; p 0.05 ) . Quality of life correlated before HTx best with subjectively rated health ( r=0.61, p 0.01 ) and 6 months after with satisfaction about health status ( r=0.76, p 0.01 ) . Only in 25% were expected improvements fulfilled regarding sexual activity/satisfaction , professional situation , and recreational activities . 90% of posttransplant patients reported physical compaints , most by effects of immunsuppression , but were coping well . The study shows that already 6 weeks after successful HTx all quality of life parameters improved significantly . Despite some unfulfilled expectations and complaints , the postoperative life situation of HTx patients appeared significantly improved . Instructions: please typing these entity words according to sentence: prospective study, quality of life, life, satisfaction, health, time, heart transplantation, patients, questionnaires, heart, transplant, symptom, quality of life, assessment, life quality, life changes, language, age, evaluation, standard, Quality of life, patients, congestive heart failure, quality of life, health status, health status, Quality of life, health, satisfaction, health status, recreational activities, patients, quality of life, postoperative, life, patients Options: umlsterm

[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

This prospective study was designed to compare quality of life , life satisfaction , and subjective ratings of health before and at variable time intervals after heart transplantation ( HTx ) . 175 patients were included between February 1994 and December 1997. Every six months before and 1,5 , 3 , 6 , and 12 months after HTx , they received the following standardized and validated questionnaires : German SF 36 , heart failure and specific transplant symptom list , global quality of life assessment , Munich life quality dimension list , expected/experienced life changes after HTx , good command of the German language , and a minimum age of 18 years . During data evaluation , median ( Me ) , mean ( M ) , and standard deviation ( SD ) were created from individual parameters . Quality of life was rated as very poor by 84% of patients with congestive heart failure . Only 6 weeks after HTx , 74% rated their quality of life as significantly better . Before HTx 80% were very unsatisfied about their health status and 87% about physical performance . Six weeks after HTx , this parameter improved significantly and 76% were very satisfied about their health status and 50% about physical performance . While somatic changes expected before HTx corresponded well with experienced ones , psychological improvements were smaller than expected , but one year after HTx they were significant ( before : M=3.66; SD=0.9; Range ( R ) =3 . 78 vs 12 months postop : M=4.61; SD=0.6; R=2.67; p 0.05 ) . Quality of life correlated before HTx best with subjectively rated health ( r=0.61, p 0.01 ) and 6 months after with satisfaction about health status ( r=0.76, p 0.01 ) . Only in 25% were expected improvements fulfilled regarding sexual activity/satisfaction , professional situation , and recreational activities . 90% of posttransplant patients reported physical compaints , most by effects of immunsuppression , but were coping well . The study shows that already 6 weeks after successful HTx all quality of life parameters improved significantly . Despite some unfulfilled expectations and complaints , the postoperative life situation of HTx patients appeared significantly improved .

[ "This", "prospective", "study", "was", "designed", "to", "compare", "quality", "of", "life", ",", "life", "satisfaction", ",", "and", "subjective", "ratings", "of", "health", "before", "and", "at", "variable", "time", "intervals", "after", "heart", "transplantation", "(", "HTx", ")", ".", "175", "patients", "were", "included", "between", "February", "1994", "and", "December", "1997", ".", "Every", "six", "months", "before", "and", "1,5", ",", "3", ",", "6", ",", "and", "12", "months", "after", "HTx", ",", "they", "received", "the", "following", "standardized", "and", "validated", "questionnaires", ":", "German", "SF", "36", ",", "heart", "failure", "and", "specific", "transplant", "symptom", "list", ",", "global", "quality", "of", "life", "assessment", ",", "Munich", "life", "quality", "dimension", "list", ",", "expected", "/", "experienced", "life", "changes", "after", "HTx", ",", "good", "command", "of", "the", "German", "language", ",", "and", "a", "minimum", "age", "of", "18", "years", ".", "During", "data", "evaluation", ",", "median", "(", "Me", ")", ",", "mean", "(", "M", ")", ",", "and", "standard", "deviation", "(", "SD", ")", "were", "created", "from", "individual", "parameters", ".", "Quality", "of", "life", "was", "rated", "as", "very", "poor", "by", "84", "%", "of", "patients", "with", "congestive", "heart", "failure", ".", "Only", "6", "weeks", "after", "HTx", ",", "74", "%", "rated", "their", "quality", "of", "life", "as", "significantly", "better", ".", "Before", "HTx", "80", "%", "were", "very", "unsatisfied", "about", "their", "health", "status", "and", "87", "%", "about", "physical", "performance", ".", "Six", "weeks", "after", "HTx", ",", "this", "parameter", "improved", "significantly", "and", "76", "%", "were", "very", "satisfied", "about", "their", "health", "status", "and", "50", "%", "about", "physical", "performance", ".", "While", "somatic", "changes", "expected", "before", "HTx", "corresponded", "well", "with", "experienced", "ones", ",", "psychological", "improvements", "were", "smaller", "than", "expected", ",", "but", "one", "year", "after", "HTx", "they", "were", "significant", "(", "before", ":", "M=3.66", ";", "SD=0.9", ";", "Range", "(", "R", ")", "=3", ".", "78", "vs", "12", "months", "postop", ":", "M=4.61", ";", "SD=0.6", ";", "R=2.67", ";", "p", "0.05", ")", ".", "Quality", "of", "life", "correlated", "before", "HTx", "best", "with", "subjectively", "rated", "health", "(", "r=0.61", ",", "p", "0.01", ")", "and", "6", "months", "after", "with", "satisfaction", "about", "health", "status", "(", "r=0.76", ",", "p", "0.01", ")", ".", "Only", "in", "25", "%", "were", "expected", "improvements", "fulfilled", "regarding", "sexual", "activity", "/", "satisfaction", ",", "professional", "situation", ",", "and", "recreational", "activities", ".", "90", "%", "of", "posttransplant", "patients", "reported", "physical", "compaints", ",", "most", "by", "effects", "of", "immunsuppression", ",", "but", "were", "coping", "well", ".", "The", "study", "shows", "that", "already", "6", "weeks", "after", "successful", "HTx", "all", "quality", "of", "life", "parameters", "improved", "significantly", ".", "Despite", "some", "unfulfilled", "expectations", "and", "complaints", ",", "the", "postoperative", "life", "situation", "of", "HTx", "patients", "appeared", "significantly", "improved", "." ]

[ "umlsterm" ]

prospective study, quality of life, life, satisfaction, health, time, heart transplantation, patients, questionnaires, heart, transplant, symptom, quality of life, assessment, life quality, life changes, language, age, evaluation, standard, Quality of life, patients, congestive heart failure, quality of life, health status, health status, Quality of life, health, satisfaction, health status, recreational activities, patients, quality of life, postoperative, life, patients

ZfuerKardiologie.80870808.eng.abstr_task2

Sentence: This prospective study was designed to compare quality of life , life satisfaction , and subjective ratings of health before and at variable time intervals after heart transplantation ( HTx ) . 175 patients were included between February 1994 and December 1997. Every six months before and 1,5 , 3 , 6 , and 12 months after HTx , they received the following standardized and validated questionnaires : German SF 36 , heart failure and specific transplant symptom list , global quality of life assessment , Munich life quality dimension list , expected/experienced life changes after HTx , good command of the German language , and a minimum age of 18 years . During data evaluation , median ( Me ) , mean ( M ) , and standard deviation ( SD ) were created from individual parameters . Quality of life was rated as very poor by 84% of patients with congestive heart failure . Only 6 weeks after HTx , 74% rated their quality of life as significantly better . Before HTx 80% were very unsatisfied about their health status and 87% about physical performance . Six weeks after HTx , this parameter improved significantly and 76% were very satisfied about their health status and 50% about physical performance . While somatic changes expected before HTx corresponded well with experienced ones , psychological improvements were smaller than expected , but one year after HTx they were significant ( before : M=3.66; SD=0.9; Range ( R ) =3 . 78 vs 12 months postop : M=4.61; SD=0.6; R=2.67; p 0.05 ) . Quality of life correlated before HTx best with subjectively rated health ( r=0.61, p 0.01 ) and 6 months after with satisfaction about health status ( r=0.76, p 0.01 ) . Only in 25% were expected improvements fulfilled regarding sexual activity/satisfaction , professional situation , and recreational activities . 90% of posttransplant patients reported physical compaints , most by effects of immunsuppression , but were coping well . The study shows that already 6 weeks after successful HTx all quality of life parameters improved significantly . Despite some unfulfilled expectations and complaints , the postoperative life situation of HTx patients appeared significantly improved . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

This prospective study was designed to compare quality of life , life satisfaction , and subjective ratings of health before and at variable time intervals after heart transplantation ( HTx ) . 175 patients were included between February 1994 and December 1997. Every six months before and 1,5 , 3 , 6 , and 12 months after HTx , they received the following standardized and validated questionnaires : German SF 36 , heart failure and specific transplant symptom list , global quality of life assessment , Munich life quality dimension list , expected/experienced life changes after HTx , good command of the German language , and a minimum age of 18 years . During data evaluation , median ( Me ) , mean ( M ) , and standard deviation ( SD ) were created from individual parameters . Quality of life was rated as very poor by 84% of patients with congestive heart failure . Only 6 weeks after HTx , 74% rated their quality of life as significantly better . Before HTx 80% were very unsatisfied about their health status and 87% about physical performance . Six weeks after HTx , this parameter improved significantly and 76% were very satisfied about their health status and 50% about physical performance . While somatic changes expected before HTx corresponded well with experienced ones , psychological improvements were smaller than expected , but one year after HTx they were significant ( before : M=3.66; SD=0.9; Range ( R ) =3 . 78 vs 12 months postop : M=4.61; SD=0.6; R=2.67; p 0.05 ) . Quality of life correlated before HTx best with subjectively rated health ( r=0.61, p 0.01 ) and 6 months after with satisfaction about health status ( r=0.76, p 0.01 ) . Only in 25% were expected improvements fulfilled regarding sexual activity/satisfaction , professional situation , and recreational activities . 90% of posttransplant patients reported physical compaints , most by effects of immunsuppression , but were coping well . The study shows that already 6 weeks after successful HTx all quality of life parameters improved significantly . Despite some unfulfilled expectations and complaints , the postoperative life situation of HTx patients appeared significantly improved .

[ "This", "prospective", "study", "was", "designed", "to", "compare", "quality", "of", "life", ",", "life", "satisfaction", ",", "and", "subjective", "ratings", "of", "health", "before", "and", "at", "variable", "time", "intervals", "after", "heart", "transplantation", "(", "HTx", ")", ".", "175", "patients", "were", "included", "between", "February", "1994", "and", "December", "1997", ".", "Every", "six", "months", "before", "and", "1,5", ",", "3", ",", "6", ",", "and", "12", "months", "after", "HTx", ",", "they", "received", "the", "following", "standardized", "and", "validated", "questionnaires", ":", "German", "SF", "36", ",", "heart", "failure", "and", "specific", "transplant", "symptom", "list", ",", "global", "quality", "of", "life", "assessment", ",", "Munich", "life", "quality", "dimension", "list", ",", "expected", "/", "experienced", "life", "changes", "after", "HTx", ",", "good", "command", "of", "the", "German", "language", ",", "and", "a", "minimum", "age", "of", "18", "years", ".", "During", "data", "evaluation", ",", "median", "(", "Me", ")", ",", "mean", "(", "M", ")", ",", "and", "standard", "deviation", "(", "SD", ")", "were", "created", "from", "individual", "parameters", ".", "Quality", "of", "life", "was", "rated", "as", "very", "poor", "by", "84", "%", "of", "patients", "with", "congestive", "heart", "failure", ".", "Only", "6", "weeks", "after", "HTx", ",", "74", "%", "rated", "their", "quality", "of", "life", "as", "significantly", "better", ".", "Before", "HTx", "80", "%", "were", "very", "unsatisfied", "about", "their", "health", "status", "and", "87", "%", "about", "physical", "performance", ".", "Six", "weeks", "after", "HTx", ",", "this", "parameter", "improved", "significantly", "and", "76", "%", "were", "very", "satisfied", "about", "their", "health", "status", "and", "50", "%", "about", "physical", "performance", ".", "While", "somatic", "changes", "expected", "before", "HTx", "corresponded", "well", "with", "experienced", "ones", ",", "psychological", "improvements", "were", "smaller", "than", "expected", ",", "but", "one", "year", "after", "HTx", "they", "were", "significant", "(", "before", ":", "M=3.66", ";", "SD=0.9", ";", "Range", "(", "R", ")", "=3", ".", "78", "vs", "12", "months", "postop", ":", "M=4.61", ";", "SD=0.6", ";", "R=2.67", ";", "p", "0.05", ")", ".", "Quality", "of", "life", "correlated", "before", "HTx", "best", "with", "subjectively", "rated", "health", "(", "r=0.61", ",", "p", "0.01", ")", "and", "6", "months", "after", "with", "satisfaction", "about", "health", "status", "(", "r=0.76", ",", "p", "0.01", ")", ".", "Only", "in", "25", "%", "were", "expected", "improvements", "fulfilled", "regarding", "sexual", "activity", "/", "satisfaction", ",", "professional", "situation", ",", "and", "recreational", "activities", ".", "90", "%", "of", "posttransplant", "patients", "reported", "physical", "compaints", ",", "most", "by", "effects", "of", "immunsuppression", ",", "but", "were", "coping", "well", ".", "The", "study", "shows", "that", "already", "6", "weeks", "after", "successful", "HTx", "all", "quality", "of", "life", "parameters", "improved", "significantly", ".", "Despite", "some", "unfulfilled", "expectations", "and", "complaints", ",", "the", "postoperative", "life", "situation", "of", "HTx", "patients", "appeared", "significantly", "improved", "." ]

[ "umlsterm" ]

beta - lactam is a FAMILY, amoxicillin is a TRIVIAL, clavulanic acid is a TRIVIAL, CA is a ABBREVIATION, ticarcillin is a TRIVIAL, CA is a ABBREVIATION, amoxicillin is a TRIVIAL, sulbactam is a TRIVIAL, piperacillin is a TRIVIAL, tazobactam is a TRIVIAL, amoxicillin is a TRIVIAL, beta - lactam is a FAMILY, beta - lactam is a FAMILY, beta - lactam is a FAMILY, penicillins is a TRIVIAL, cephalothin is a TRIVIAL, beta - lactam is a FAMILY, piperacillin is a TRIVIAL, tazobactam is a TRIVIAL, amoxicillin is a TRIVIAL, cefoxitin is a TRIVIAL, cephalothin is a TRIVIAL, cefotaxime is a TRIVIAL, cefotaxime is a TRIVIAL, piperacillin is a TRIVIAL, tazobactam is a TRIVIAL, CA is a ABBREVIATION, amoxicillin is a TRIVIAL, ticarcillin is a TRIVIAL, sulbactam is a TRIVIAL, amoxicillin is a TRIVIAL, penicillins is a TRIVIAL, Piperacillin is a TRIVIAL

example-51_task0

Sentence: 8654448 Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents. The efficacy of the clinically available beta-lactam/beta-lactamase inhibitor combinations (amoxicillin/clavulanic acid (CA), ticarcillin/CA, amoxicillin/sulbactam, and piperacillin/tazobactam) was evaluated on amoxicillin-resistant Escherichia coli isolates having the main patterns of beta-lactam resistance. The patterns, which reflect the production of various beta-lactamase enzymes, were analyzed by a principal component analysis of susceptibility to 11 beta-lactam antibiotics or beta-lactam/beta-lactamase inhibitor combinations. Sixty-two percent of strains were not very susceptible to penicillins, cephalothin, or any beta-lactam/beta-lactamase inhibitor combinations except for piperacillin/tazobactam; these strains may represent high-level broad-spectrum beta-lactamase (so-called penicillinase) production phenotype or inhibitor-resistant TEM-like enzyme production phenotype. Of the strains, 14.7% were resistant to amoxicillin andticarcillin compatible with low-level broad-spectrum beta-lactamase production phenotype; 5.7% were cefoxitin resistant and were postulated to present a high-level cephalosporinase production phenotype; and 2.6% were resistant to cephalothin only, attributable to a low-level cephalosporinase production phenotype. Three percent of strains were intermediate or resistant to cefotaxime and may produce an extended-spectrum beta-lactamase, and the remaining strains (12 %), resistant to all tested antibiotics except for cefotaxime and piperacillin/tazobactam, were hypothesized to produce both broad-spectrum beta-lactamase plus cephalosporinase. The minimal inhibitory concentration (MIC) for these phenotype patterns indicated that combinations of CA plus amoxicillin or ticarcillin, or sulbactam plus amoxicillin, restored the activity of penicillins against phenotype 1 strains, whereas these combinations remained inactive against the other phenotype strains. Piperacillin plus tazobactamshowed the best in vitro effect against the strains of all resistance phenotypes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: FAMILY, TRIVIAL, ABBREVIATION

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "B-ABBREVIATION", "O", "O", "B-TRIVIAL", "O", "B-ABBREVIATION", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ABBREVIATION", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

8654448 Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents. The efficacy of the clinically available beta-lactam/beta-lactamase inhibitor combinations (amoxicillin/clavulanic acid (CA), ticarcillin/CA, amoxicillin/sulbactam, and piperacillin/tazobactam) was evaluated on amoxicillin-resistant Escherichia coli isolates having the main patterns of beta-lactam resistance. The patterns, which reflect the production of various beta-lactamase enzymes, were analyzed by a principal component analysis of susceptibility to 11 beta-lactam antibiotics or beta-lactam/beta-lactamase inhibitor combinations. Sixty-two percent of strains were not very susceptible to penicillins, cephalothin, or any beta-lactam/beta-lactamase inhibitor combinations except for piperacillin/tazobactam; these strains may represent high-level broad-spectrum beta-lactamase (so-called penicillinase) production phenotype or inhibitor-resistant TEM-like enzyme production phenotype. Of the strains, 14.7% were resistant to amoxicillin andticarcillin compatible with low-level broad-spectrum beta-lactamase production phenotype; 5.7% were cefoxitin resistant and were postulated to present a high-level cephalosporinase production phenotype; and 2.6% were resistant to cephalothin only, attributable to a low-level cephalosporinase production phenotype. Three percent of strains were intermediate or resistant to cefotaxime and may produce an extended-spectrum beta-lactamase, and the remaining strains (12 %), resistant to all tested antibiotics except for cefotaxime and piperacillin/tazobactam, were hypothesized to produce both broad-spectrum beta-lactamase plus cephalosporinase. The minimal inhibitory concentration (MIC) for these phenotype patterns indicated that combinations of CA plus amoxicillin or ticarcillin, or sulbactam plus amoxicillin, restored the activity of penicillins against phenotype 1 strains, whereas these combinations remained inactive against the other phenotype strains. Piperacillin plus tazobactamshowed the best in vitro effect against the strains of all resistance phenotypes.

[ "8654448", " ", "Activity", "of", "beta", "-", "lactamase", "inhibitor", "combinations", "on", "Escherichia", "coli", "isolates", "exhibiting", "various", "patterns", "of", "resistance", "to", "beta", "-", "lactam", "agents", ".", " ", "The", "efficacy", "of", "the", "clinically", "available", "beta", "-", "lactam", "/", "beta", "-", "lactamase", "inhibitor", "combinations", "(", "amoxicillin", "/", "clavulanic", "acid", "(", "CA", ")", ",", "ticarcillin", "/", "CA", ",", "amoxicillin", "/", "sulbactam", ",", "and", "piperacillin", "/", "tazobactam", ")", "was", "evaluated", "on", " ", "amoxicillin", "-", "resistant", "Escherichia", "coli", "isolates", "having", "the", "main", "patterns", "of", "beta", "-", "lactam", "resistance", ".", "The", "patterns", ",", "which", "reflect", "the", "production", "of", "various", "beta", "-", "lactamase", "enzymes", ",", "were", "analyzed", "by", "a", "principal", "component", "analysis", "of", "susceptibility", "to", "11", "beta", "-", "lactam", "antibiotics", "or", "beta", "-", "lactam", "/", "beta", "-", "lactamase", "inhibitor", "combinations", ".", "Sixty", "-", "two", "percent", "of", "strains", "were", "not", "very", "susceptible", "to", "penicillins", ",", "cephalothin", ",", "or", "any", "beta", "-", "lactam", "/", "beta", "-", "lactamase", "inhibitor", "combinations", "except", "for", "piperacillin", "/", "tazobactam", ";", "these", "strains", "may", "represent", "high", "-", "level", "broad", "-", "spectrum", "beta", "-", "lactamase", "(", "so", "-", "called", "penicillinase", ")", "production", "phenotype", "or", "inhibitor", "-", "resistant", "TEM", "-", "like", "enzyme", "production", "phenotype", ".", "Of", "the", "strains", ",", "14.7", "%", "were", "resistant", "to", "amoxicillin", "andticarcillin", " ", "compatible", "with", "low", "-", "level", "broad", "-", "spectrum", "beta", "-", "lactamase", "production", "phenotype", ";", "5.7", "%", "were", "cefoxitin", "resistant", "and", "were", "postulated", "to", "present", "a", "high", "-", "level", "cephalosporinase", "production", "phenotype", ";", "and", "2.6", "%", "were", "resistant", "to", "cephalothin", "only", ",", "attributable", "to", "a", "low", "-", "level", "cephalosporinase", "production", "phenotype", ".", "Three", "percent", "of", "strains", "were", "intermediate", "or", "resistant", "to", "cefotaxime", "and", "may", "produce", "an", "extended", "-", "spectrum", "beta", "-", "lactamase", ",", "and", "the", "remaining", "strains", "(", "12", "%", ")", ",", "resistant", "to", "all", "tested", "antibiotics", "except", "for", "cefotaxime", "and", "piperacillin", "/", "tazobactam", ",", "were", "hypothesized", "to", "produce", "both", "broad", "-", "spectrum", "beta", "-", "lactamase", "plus", "cephalosporinase", ".", "The", "minimal", "inhibitory", "concentration", "(", "MIC", ")", "for", "these", "phenotype", "patterns", "indicated", "that", "combinations", "of", "CA", "plus", "amoxicillin", "or", "ticarcillin", ",", "or", "sulbactam", "plus", "amoxicillin", ",", "restored", "the", "activity", "of", "penicillins", "against", "phenotype", "1", "strains", ",", "whereas", "these", "combinations", "remained", "inactive", "against", "the", "other", "phenotype", "strains", ".", "Piperacillin", "plus", "tazobactamshowed", " ", "the", "best", "in", "vitro", "effect", "against", "the", "strains", "of", "all", "resistance", "phenotypes", "." ]

[ "TRIVIAL", "FAMILY", "ABBREVIATION" ]

beta - lactam is a FAMILY, amoxicillin is a TRIVIAL, clavulanic acid is a TRIVIAL, CA is a ABBREVIATION, ticarcillin is a TRIVIAL, CA is a ABBREVIATION, amoxicillin is a TRIVIAL, sulbactam is a TRIVIAL, piperacillin is a TRIVIAL, tazobactam is a TRIVIAL, amoxicillin is a TRIVIAL, beta - lactam is a FAMILY, beta - lactam is a FAMILY, beta - lactam is a FAMILY, penicillins is a TRIVIAL, cephalothin is a TRIVIAL, beta - lactam is a FAMILY, piperacillin is a TRIVIAL, tazobactam is a TRIVIAL, amoxicillin is a TRIVIAL, cefoxitin is a TRIVIAL, cephalothin is a TRIVIAL, cefotaxime is a TRIVIAL, cefotaxime is a TRIVIAL, piperacillin is a TRIVIAL, tazobactam is a TRIVIAL, CA is a ABBREVIATION, amoxicillin is a TRIVIAL, ticarcillin is a TRIVIAL, sulbactam is a TRIVIAL, amoxicillin is a TRIVIAL, penicillins is a TRIVIAL, Piperacillin is a TRIVIAL

example-51_task1

Sentence: 8654448 Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents. The efficacy of the clinically available beta-lactam/beta-lactamase inhibitor combinations (amoxicillin/clavulanic acid (CA), ticarcillin/CA, amoxicillin/sulbactam, and piperacillin/tazobactam) was evaluated on amoxicillin-resistant Escherichia coli isolates having the main patterns of beta-lactam resistance. The patterns, which reflect the production of various beta-lactamase enzymes, were analyzed by a principal component analysis of susceptibility to 11 beta-lactam antibiotics or beta-lactam/beta-lactamase inhibitor combinations. Sixty-two percent of strains were not very susceptible to penicillins, cephalothin, or any beta-lactam/beta-lactamase inhibitor combinations except for piperacillin/tazobactam; these strains may represent high-level broad-spectrum beta-lactamase (so-called penicillinase) production phenotype or inhibitor-resistant TEM-like enzyme production phenotype. Of the strains, 14.7% were resistant to amoxicillin andticarcillin compatible with low-level broad-spectrum beta-lactamase production phenotype; 5.7% were cefoxitin resistant and were postulated to present a high-level cephalosporinase production phenotype; and 2.6% were resistant to cephalothin only, attributable to a low-level cephalosporinase production phenotype. Three percent of strains were intermediate or resistant to cefotaxime and may produce an extended-spectrum beta-lactamase, and the remaining strains (12 %), resistant to all tested antibiotics except for cefotaxime and piperacillin/tazobactam, were hypothesized to produce both broad-spectrum beta-lactamase plus cephalosporinase. The minimal inhibitory concentration (MIC) for these phenotype patterns indicated that combinations of CA plus amoxicillin or ticarcillin, or sulbactam plus amoxicillin, restored the activity of penicillins against phenotype 1 strains, whereas these combinations remained inactive against the other phenotype strains. Piperacillin plus tazobactamshowed the best in vitro effect against the strains of all resistance phenotypes. Instructions: please typing these entity words according to sentence: beta - lactam, amoxicillin, clavulanic acid, CA, ticarcillin, CA, amoxicillin, sulbactam, piperacillin, tazobactam, amoxicillin, beta - lactam, beta - lactam, beta - lactam, penicillins, cephalothin, beta - lactam, piperacillin, tazobactam, amoxicillin, cefoxitin, cephalothin, cefotaxime, cefotaxime, piperacillin, tazobactam, CA, amoxicillin, ticarcillin, sulbactam, amoxicillin, penicillins, Piperacillin Options: FAMILY, TRIVIAL, ABBREVIATION

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "B-ABBREVIATION", "O", "O", "B-TRIVIAL", "O", "B-ABBREVIATION", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ABBREVIATION", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

8654448 Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents. The efficacy of the clinically available beta-lactam/beta-lactamase inhibitor combinations (amoxicillin/clavulanic acid (CA), ticarcillin/CA, amoxicillin/sulbactam, and piperacillin/tazobactam) was evaluated on amoxicillin-resistant Escherichia coli isolates having the main patterns of beta-lactam resistance. The patterns, which reflect the production of various beta-lactamase enzymes, were analyzed by a principal component analysis of susceptibility to 11 beta-lactam antibiotics or beta-lactam/beta-lactamase inhibitor combinations. Sixty-two percent of strains were not very susceptible to penicillins, cephalothin, or any beta-lactam/beta-lactamase inhibitor combinations except for piperacillin/tazobactam; these strains may represent high-level broad-spectrum beta-lactamase (so-called penicillinase) production phenotype or inhibitor-resistant TEM-like enzyme production phenotype. Of the strains, 14.7% were resistant to amoxicillin andticarcillin compatible with low-level broad-spectrum beta-lactamase production phenotype; 5.7% were cefoxitin resistant and were postulated to present a high-level cephalosporinase production phenotype; and 2.6% were resistant to cephalothin only, attributable to a low-level cephalosporinase production phenotype. Three percent of strains were intermediate or resistant to cefotaxime and may produce an extended-spectrum beta-lactamase, and the remaining strains (12 %), resistant to all tested antibiotics except for cefotaxime and piperacillin/tazobactam, were hypothesized to produce both broad-spectrum beta-lactamase plus cephalosporinase. The minimal inhibitory concentration (MIC) for these phenotype patterns indicated that combinations of CA plus amoxicillin or ticarcillin, or sulbactam plus amoxicillin, restored the activity of penicillins against phenotype 1 strains, whereas these combinations remained inactive against the other phenotype strains. Piperacillin plus tazobactamshowed the best in vitro effect against the strains of all resistance phenotypes.

[ "8654448", " ", "Activity", "of", "beta", "-", "lactamase", "inhibitor", "combinations", "on", "Escherichia", "coli", "isolates", "exhibiting", "various", "patterns", "of", "resistance", "to", "beta", "-", "lactam", "agents", ".", " ", "The", "efficacy", "of", "the", "clinically", "available", "beta", "-", "lactam", "/", "beta", "-", "lactamase", "inhibitor", "combinations", "(", "amoxicillin", "/", "clavulanic", "acid", "(", "CA", ")", ",", "ticarcillin", "/", "CA", ",", "amoxicillin", "/", "sulbactam", ",", "and", "piperacillin", "/", "tazobactam", ")", "was", "evaluated", "on", " ", "amoxicillin", "-", "resistant", "Escherichia", "coli", "isolates", "having", "the", "main", "patterns", "of", "beta", "-", "lactam", "resistance", ".", "The", "patterns", ",", "which", "reflect", "the", "production", "of", "various", "beta", "-", "lactamase", "enzymes", ",", "were", "analyzed", "by", "a", "principal", "component", "analysis", "of", "susceptibility", "to", "11", "beta", "-", "lactam", "antibiotics", "or", "beta", "-", "lactam", "/", "beta", "-", "lactamase", "inhibitor", "combinations", ".", "Sixty", "-", "two", "percent", "of", "strains", "were", "not", "very", "susceptible", "to", "penicillins", ",", "cephalothin", ",", "or", "any", "beta", "-", "lactam", "/", "beta", "-", "lactamase", "inhibitor", "combinations", "except", "for", "piperacillin", "/", "tazobactam", ";", "these", "strains", "may", "represent", "high", "-", "level", "broad", "-", "spectrum", "beta", "-", "lactamase", "(", "so", "-", "called", "penicillinase", ")", "production", "phenotype", "or", "inhibitor", "-", "resistant", "TEM", "-", "like", "enzyme", "production", "phenotype", ".", "Of", "the", "strains", ",", "14.7", "%", "were", "resistant", "to", "amoxicillin", "andticarcillin", " ", "compatible", "with", "low", "-", "level", "broad", "-", "spectrum", "beta", "-", "lactamase", "production", "phenotype", ";", "5.7", "%", "were", "cefoxitin", "resistant", "and", "were", "postulated", "to", "present", "a", "high", "-", "level", "cephalosporinase", "production", "phenotype", ";", "and", "2.6", "%", "were", "resistant", "to", "cephalothin", "only", ",", "attributable", "to", "a", "low", "-", "level", "cephalosporinase", "production", "phenotype", ".", "Three", "percent", "of", "strains", "were", "intermediate", "or", "resistant", "to", "cefotaxime", "and", "may", "produce", "an", "extended", "-", "spectrum", "beta", "-", "lactamase", ",", "and", "the", "remaining", "strains", "(", "12", "%", ")", ",", "resistant", "to", "all", "tested", "antibiotics", "except", "for", "cefotaxime", "and", "piperacillin", "/", "tazobactam", ",", "were", "hypothesized", "to", "produce", "both", "broad", "-", "spectrum", "beta", "-", "lactamase", "plus", "cephalosporinase", ".", "The", "minimal", "inhibitory", "concentration", "(", "MIC", ")", "for", "these", "phenotype", "patterns", "indicated", "that", "combinations", "of", "CA", "plus", "amoxicillin", "or", "ticarcillin", ",", "or", "sulbactam", "plus", "amoxicillin", ",", "restored", "the", "activity", "of", "penicillins", "against", "phenotype", "1", "strains", ",", "whereas", "these", "combinations", "remained", "inactive", "against", "the", "other", "phenotype", "strains", ".", "Piperacillin", "plus", "tazobactamshowed", " ", "the", "best", "in", "vitro", "effect", "against", "the", "strains", "of", "all", "resistance", "phenotypes", "." ]

[ "TRIVIAL", "FAMILY", "ABBREVIATION" ]

beta - lactam, amoxicillin, clavulanic acid, CA, ticarcillin, CA, amoxicillin, sulbactam, piperacillin, tazobactam, amoxicillin, beta - lactam, beta - lactam, beta - lactam, penicillins, cephalothin, beta - lactam, piperacillin, tazobactam, amoxicillin, cefoxitin, cephalothin, cefotaxime, cefotaxime, piperacillin, tazobactam, CA, amoxicillin, ticarcillin, sulbactam, amoxicillin, penicillins, Piperacillin

example-51_task2

Sentence: 8654448 Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents. The efficacy of the clinically available beta-lactam/beta-lactamase inhibitor combinations (amoxicillin/clavulanic acid (CA), ticarcillin/CA, amoxicillin/sulbactam, and piperacillin/tazobactam) was evaluated on amoxicillin-resistant Escherichia coli isolates having the main patterns of beta-lactam resistance. The patterns, which reflect the production of various beta-lactamase enzymes, were analyzed by a principal component analysis of susceptibility to 11 beta-lactam antibiotics or beta-lactam/beta-lactamase inhibitor combinations. Sixty-two percent of strains were not very susceptible to penicillins, cephalothin, or any beta-lactam/beta-lactamase inhibitor combinations except for piperacillin/tazobactam; these strains may represent high-level broad-spectrum beta-lactamase (so-called penicillinase) production phenotype or inhibitor-resistant TEM-like enzyme production phenotype. Of the strains, 14.7% were resistant to amoxicillin andticarcillin compatible with low-level broad-spectrum beta-lactamase production phenotype; 5.7% were cefoxitin resistant and were postulated to present a high-level cephalosporinase production phenotype; and 2.6% were resistant to cephalothin only, attributable to a low-level cephalosporinase production phenotype. Three percent of strains were intermediate or resistant to cefotaxime and may produce an extended-spectrum beta-lactamase, and the remaining strains (12 %), resistant to all tested antibiotics except for cefotaxime and piperacillin/tazobactam, were hypothesized to produce both broad-spectrum beta-lactamase plus cephalosporinase. The minimal inhibitory concentration (MIC) for these phenotype patterns indicated that combinations of CA plus amoxicillin or ticarcillin, or sulbactam plus amoxicillin, restored the activity of penicillins against phenotype 1 strains, whereas these combinations remained inactive against the other phenotype strains. Piperacillin plus tazobactamshowed the best in vitro effect against the strains of all resistance phenotypes. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "B-ABBREVIATION", "O", "O", "B-TRIVIAL", "O", "B-ABBREVIATION", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "B-FAMILY", "I-FAMILY", "I-FAMILY", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ABBREVIATION", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "B-TRIVIAL", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

8654448 Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents. The efficacy of the clinically available beta-lactam/beta-lactamase inhibitor combinations (amoxicillin/clavulanic acid (CA), ticarcillin/CA, amoxicillin/sulbactam, and piperacillin/tazobactam) was evaluated on amoxicillin-resistant Escherichia coli isolates having the main patterns of beta-lactam resistance. The patterns, which reflect the production of various beta-lactamase enzymes, were analyzed by a principal component analysis of susceptibility to 11 beta-lactam antibiotics or beta-lactam/beta-lactamase inhibitor combinations. Sixty-two percent of strains were not very susceptible to penicillins, cephalothin, or any beta-lactam/beta-lactamase inhibitor combinations except for piperacillin/tazobactam; these strains may represent high-level broad-spectrum beta-lactamase (so-called penicillinase) production phenotype or inhibitor-resistant TEM-like enzyme production phenotype. Of the strains, 14.7% were resistant to amoxicillin andticarcillin compatible with low-level broad-spectrum beta-lactamase production phenotype; 5.7% were cefoxitin resistant and were postulated to present a high-level cephalosporinase production phenotype; and 2.6% were resistant to cephalothin only, attributable to a low-level cephalosporinase production phenotype. Three percent of strains were intermediate or resistant to cefotaxime and may produce an extended-spectrum beta-lactamase, and the remaining strains (12 %), resistant to all tested antibiotics except for cefotaxime and piperacillin/tazobactam, were hypothesized to produce both broad-spectrum beta-lactamase plus cephalosporinase. The minimal inhibitory concentration (MIC) for these phenotype patterns indicated that combinations of CA plus amoxicillin or ticarcillin, or sulbactam plus amoxicillin, restored the activity of penicillins against phenotype 1 strains, whereas these combinations remained inactive against the other phenotype strains. Piperacillin plus tazobactamshowed the best in vitro effect against the strains of all resistance phenotypes.

[ "8654448", " ", "Activity", "of", "beta", "-", "lactamase", "inhibitor", "combinations", "on", "Escherichia", "coli", "isolates", "exhibiting", "various", "patterns", "of", "resistance", "to", "beta", "-", "lactam", "agents", ".", " ", "The", "efficacy", "of", "the", "clinically", "available", "beta", "-", "lactam", "/", "beta", "-", "lactamase", "inhibitor", "combinations", "(", "amoxicillin", "/", "clavulanic", "acid", "(", "CA", ")", ",", "ticarcillin", "/", "CA", ",", "amoxicillin", "/", "sulbactam", ",", "and", "piperacillin", "/", "tazobactam", ")", "was", "evaluated", "on", " ", "amoxicillin", "-", "resistant", "Escherichia", "coli", "isolates", "having", "the", "main", "patterns", "of", "beta", "-", "lactam", "resistance", ".", "The", "patterns", ",", "which", "reflect", "the", "production", "of", "various", "beta", "-", "lactamase", "enzymes", ",", "were", "analyzed", "by", "a", "principal", "component", "analysis", "of", "susceptibility", "to", "11", "beta", "-", "lactam", "antibiotics", "or", "beta", "-", "lactam", "/", "beta", "-", "lactamase", "inhibitor", "combinations", ".", "Sixty", "-", "two", "percent", "of", "strains", "were", "not", "very", "susceptible", "to", "penicillins", ",", "cephalothin", ",", "or", "any", "beta", "-", "lactam", "/", "beta", "-", "lactamase", "inhibitor", "combinations", "except", "for", "piperacillin", "/", "tazobactam", ";", "these", "strains", "may", "represent", "high", "-", "level", "broad", "-", "spectrum", "beta", "-", "lactamase", "(", "so", "-", "called", "penicillinase", ")", "production", "phenotype", "or", "inhibitor", "-", "resistant", "TEM", "-", "like", "enzyme", "production", "phenotype", ".", "Of", "the", "strains", ",", "14.7", "%", "were", "resistant", "to", "amoxicillin", "andticarcillin", " ", "compatible", "with", "low", "-", "level", "broad", "-", "spectrum", "beta", "-", "lactamase", "production", "phenotype", ";", "5.7", "%", "were", "cefoxitin", "resistant", "and", "were", "postulated", "to", "present", "a", "high", "-", "level", "cephalosporinase", "production", "phenotype", ";", "and", "2.6", "%", "were", "resistant", "to", "cephalothin", "only", ",", "attributable", "to", "a", "low", "-", "level", "cephalosporinase", "production", "phenotype", ".", "Three", "percent", "of", "strains", "were", "intermediate", "or", "resistant", "to", "cefotaxime", "and", "may", "produce", "an", "extended", "-", "spectrum", "beta", "-", "lactamase", ",", "and", "the", "remaining", "strains", "(", "12", "%", ")", ",", "resistant", "to", "all", "tested", "antibiotics", "except", "for", "cefotaxime", "and", "piperacillin", "/", "tazobactam", ",", "were", "hypothesized", "to", "produce", "both", "broad", "-", "spectrum", "beta", "-", "lactamase", "plus", "cephalosporinase", ".", "The", "minimal", "inhibitory", "concentration", "(", "MIC", ")", "for", "these", "phenotype", "patterns", "indicated", "that", "combinations", "of", "CA", "plus", "amoxicillin", "or", "ticarcillin", ",", "or", "sulbactam", "plus", "amoxicillin", ",", "restored", "the", "activity", "of", "penicillins", "against", "phenotype", "1", "strains", ",", "whereas", "these", "combinations", "remained", "inactive", "against", "the", "other", "phenotype", "strains", ".", "Piperacillin", "plus", "tazobactamshowed", " ", "the", "best", "in", "vitro", "effect", "against", "the", "strains", "of", "all", "resistance", "phenotypes", "." ]

[ "TRIVIAL", "FAMILY", "ABBREVIATION" ]

MRI signal hyperintensities is a Outcome_Physical, and is a Outcome_Mental, failure to remit is a Outcome_Physical, antidepressant treatment is a Intervention_Pharmacological, . is a Outcome_Mental, remission is a Outcome_Physical, total lesion volume is a Outcome_Physical, geriatric depression is a Participant_Condition, lesion volume by region of interest ( ROI ) is a Outcome_Physical, Thirty - eight is a Participant_Sample-size, baseline MRIs is a Intervention_Physical, sertraline is a Intervention_Pharmacological, nortriptyline is a Intervention_Pharmacological, late - life depression is a Participant_Condition, DWMH is a Outcome_Physical, , and is a Outcome_Mental, PVH volumes is a Outcome_Physical, Remission from depression is a Outcome_Mental, Hamilton Rating Scale for Depression score is a Outcome_Mental

51155_task0

Sentence: MRI signal hyperintensities and failure to remit following antidepressant treatment . BACKGROUND MRI signal hyperintensities predict poor remission to antidepressant treatment . Previous studies using volumetrics in outpatient samples have relied on total lesion volume . The purpose of this study was to test whether remission from geriatric depression depends on lesion volume by region of interest ( ROI ) . METHOD Thirty-eight patients received baseline MRIs as part of a larger 12-week , randomized clinical trial comparing sertraline and nortriptyline in the treatment of late-life depression . MRIcro was used to quantify MRI-hyperintensity volume into total hyperintensity , deep white matter hyperintensity ( DWMH ) , and periventricular hyperintensity ( PVH ) volumes . High versus low total , DWMH , and PVH volumes were defined based on the highest quartile of their respective distributions . Remission from depression was defined as a 24-item Hamilton Rating Scale for Depression score ≤ 7 for two consecutive weeks . RESULTS Patients classified as having high DWMH were 7.14 times more likely not to remit following antidepressant treatment compared to patients classified as having low DWMH ( p=0.02 ) . Similar odds ratios were obtained for PVH ( OR=4.17 , p=0.16 ) and total volumes ( OR=5.00 , p=0.05 ) . Importantly , adjusting for age did not change the magnitude of these effects . LIMITATIONS A small and predominantly White sample . CONCLUSIONS This is the first study to test whether remission from geriatric depression depends on lesion volume by ROI in an outpatient sample . The pattern of remission rates and odds ratios was similar when patients were classified as having high DWMH , PVH or total volume suggesting that lesion location may not be critical . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Mental

[ "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Mental", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

MRI signal hyperintensities and failure to remit following antidepressant treatment . BACKGROUND MRI signal hyperintensities predict poor remission to antidepressant treatment . Previous studies using volumetrics in outpatient samples have relied on total lesion volume . The purpose of this study was to test whether remission from geriatric depression depends on lesion volume by region of interest ( ROI ) . METHOD Thirty-eight patients received baseline MRIs as part of a larger 12-week , randomized clinical trial comparing sertraline and nortriptyline in the treatment of late-life depression . MRIcro was used to quantify MRI-hyperintensity volume into total hyperintensity , deep white matter hyperintensity ( DWMH ) , and periventricular hyperintensity ( PVH ) volumes . High versus low total , DWMH , and PVH volumes were defined based on the highest quartile of their respective distributions . Remission from depression was defined as a 24-item Hamilton Rating Scale for Depression score ≤ 7 for two consecutive weeks . RESULTS Patients classified as having high DWMH were 7.14 times more likely not to remit following antidepressant treatment compared to patients classified as having low DWMH ( p=0.02 ) . Similar odds ratios were obtained for PVH ( OR=4.17 , p=0.16 ) and total volumes ( OR=5.00 , p=0.05 ) . Importantly , adjusting for age did not change the magnitude of these effects . LIMITATIONS A small and predominantly White sample . CONCLUSIONS This is the first study to test whether remission from geriatric depression depends on lesion volume by ROI in an outpatient sample . The pattern of remission rates and odds ratios was similar when patients were classified as having high DWMH , PVH or total volume suggesting that lesion location may not be critical .

[ "MRI", "signal", "hyperintensities", "and", "failure", "to", "remit", "following", "antidepressant", "treatment", ".", "BACKGROUND", "MRI", "signal", "hyperintensities", "predict", "poor", "remission", "to", "antidepressant", "treatment", ".", "Previous", "studies", "using", "volumetrics", "in", "outpatient", "samples", "have", "relied", "on", "total", "lesion", "volume", ".", "The", "purpose", "of", "this", "study", "was", "to", "test", "whether", "remission", "from", "geriatric", "depression", "depends", "on", "lesion", "volume", "by", "region", "of", "interest", "(", "ROI", ")", ".", "METHOD", "Thirty", "-", "eight", "patients", "received", "baseline", "MRIs", "as", "part", "of", "a", "larger", "12-week", ",", "randomized", "clinical", "trial", "comparing", "sertraline", "and", "nortriptyline", "in", "the", "treatment", "of", "late", "-", "life", "depression", ".", "MRIcro", "was", "used", "to", "quantify", "MRI", "-", "hyperintensity", "volume", "into", "total", "hyperintensity", ",", "deep", "white", "matter", "hyperintensity", "(", "DWMH", ")", ",", "and", "periventricular", "hyperintensity", "(", "PVH", ")", "volumes", ".", "High", "versus", "low", "total", ",", "DWMH", ",", "and", "PVH", "volumes", "were", "defined", "based", "on", "the", "highest", "quartile", "of", "their", "respective", "distributions", ".", "Remission", "from", "depression", "was", "defined", "as", "a", "24-item", "Hamilton", "Rating", "Scale", "for", "Depression", "score", "≤", "7", "for", "two", "consecutive", "weeks", ".", "RESULTS", "Patients", "classified", "as", "having", "high", "DWMH", "were", "7.14", "times", "more", "likely", "not", "to", "remit", "following", "antidepressant", "treatment", "compared", "to", "patients", "classified", "as", "having", "low", "DWMH", "(", "p=0.02", ")", ".", "Similar", "odds", "ratios", "were", "obtained", "for", "PVH", "(", "OR=4.17", ",", "p=0.16", ")", "and", "total", "volumes", "(", "OR=5.00", ",", "p=0.05", ")", ".", "Importantly", ",", "adjusting", "for", "age", "did", "not", "change", "the", "magnitude", "of", "these", "effects", ".", "LIMITATIONS", "A", "small", "and", "predominantly", "White", "sample", ".", "CONCLUSIONS", "This", "is", "the", "first", "study", "to", "test", "whether", "remission", "from", "geriatric", "depression", "depends", "on", "lesion", "volume", "by", "ROI", "in", "an", "outpatient", "sample", ".", "The", "pattern", "of", "remission", "rates", "and", "odds", "ratios", "was", "similar", "when", "patients", "were", "classified", "as", "having", "high", "DWMH", ",", "PVH", "or", "total", "volume", "suggesting", "that", "lesion", "location", "may", "not", "be", "critical", "." ]

[ "Outcome_Physical", "Outcome_Mental", "Intervention_Pharmacological", "Participant_Condition", "Intervention_Physical", "Participant_Sample-size" ]

MRI signal hyperintensities is a Outcome_Physical, and is a Outcome_Mental, failure to remit is a Outcome_Physical, antidepressant treatment is a Intervention_Pharmacological, . is a Outcome_Mental, remission is a Outcome_Physical, total lesion volume is a Outcome_Physical, geriatric depression is a Participant_Condition, lesion volume by region of interest ( ROI ) is a Outcome_Physical, Thirty - eight is a Participant_Sample-size, baseline MRIs is a Intervention_Physical, sertraline is a Intervention_Pharmacological, nortriptyline is a Intervention_Pharmacological, late - life depression is a Participant_Condition, DWMH is a Outcome_Physical, , and is a Outcome_Mental, PVH volumes is a Outcome_Physical, Remission from depression is a Outcome_Mental, Hamilton Rating Scale for Depression score is a Outcome_Mental

51155_task1

Sentence: MRI signal hyperintensities and failure to remit following antidepressant treatment . BACKGROUND MRI signal hyperintensities predict poor remission to antidepressant treatment . Previous studies using volumetrics in outpatient samples have relied on total lesion volume . The purpose of this study was to test whether remission from geriatric depression depends on lesion volume by region of interest ( ROI ) . METHOD Thirty-eight patients received baseline MRIs as part of a larger 12-week , randomized clinical trial comparing sertraline and nortriptyline in the treatment of late-life depression . MRIcro was used to quantify MRI-hyperintensity volume into total hyperintensity , deep white matter hyperintensity ( DWMH ) , and periventricular hyperintensity ( PVH ) volumes . High versus low total , DWMH , and PVH volumes were defined based on the highest quartile of their respective distributions . Remission from depression was defined as a 24-item Hamilton Rating Scale for Depression score ≤ 7 for two consecutive weeks . RESULTS Patients classified as having high DWMH were 7.14 times more likely not to remit following antidepressant treatment compared to patients classified as having low DWMH ( p=0.02 ) . Similar odds ratios were obtained for PVH ( OR=4.17 , p=0.16 ) and total volumes ( OR=5.00 , p=0.05 ) . Importantly , adjusting for age did not change the magnitude of these effects . LIMITATIONS A small and predominantly White sample . CONCLUSIONS This is the first study to test whether remission from geriatric depression depends on lesion volume by ROI in an outpatient sample . The pattern of remission rates and odds ratios was similar when patients were classified as having high DWMH , PVH or total volume suggesting that lesion location may not be critical . Instructions: please typing these entity words according to sentence: MRI signal hyperintensities, and, failure to remit, antidepressant treatment, ., remission, total lesion volume, geriatric depression, lesion volume by region of interest ( ROI ), Thirty - eight, baseline MRIs, sertraline, nortriptyline, late - life depression, DWMH, , and, PVH volumes, Remission from depression, Hamilton Rating Scale for Depression score Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Mental

[ "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Mental", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

MRI signal hyperintensities and failure to remit following antidepressant treatment . BACKGROUND MRI signal hyperintensities predict poor remission to antidepressant treatment . Previous studies using volumetrics in outpatient samples have relied on total lesion volume . The purpose of this study was to test whether remission from geriatric depression depends on lesion volume by region of interest ( ROI ) . METHOD Thirty-eight patients received baseline MRIs as part of a larger 12-week , randomized clinical trial comparing sertraline and nortriptyline in the treatment of late-life depression . MRIcro was used to quantify MRI-hyperintensity volume into total hyperintensity , deep white matter hyperintensity ( DWMH ) , and periventricular hyperintensity ( PVH ) volumes . High versus low total , DWMH , and PVH volumes were defined based on the highest quartile of their respective distributions . Remission from depression was defined as a 24-item Hamilton Rating Scale for Depression score ≤ 7 for two consecutive weeks . RESULTS Patients classified as having high DWMH were 7.14 times more likely not to remit following antidepressant treatment compared to patients classified as having low DWMH ( p=0.02 ) . Similar odds ratios were obtained for PVH ( OR=4.17 , p=0.16 ) and total volumes ( OR=5.00 , p=0.05 ) . Importantly , adjusting for age did not change the magnitude of these effects . LIMITATIONS A small and predominantly White sample . CONCLUSIONS This is the first study to test whether remission from geriatric depression depends on lesion volume by ROI in an outpatient sample . The pattern of remission rates and odds ratios was similar when patients were classified as having high DWMH , PVH or total volume suggesting that lesion location may not be critical .

[ "MRI", "signal", "hyperintensities", "and", "failure", "to", "remit", "following", "antidepressant", "treatment", ".", "BACKGROUND", "MRI", "signal", "hyperintensities", "predict", "poor", "remission", "to", "antidepressant", "treatment", ".", "Previous", "studies", "using", "volumetrics", "in", "outpatient", "samples", "have", "relied", "on", "total", "lesion", "volume", ".", "The", "purpose", "of", "this", "study", "was", "to", "test", "whether", "remission", "from", "geriatric", "depression", "depends", "on", "lesion", "volume", "by", "region", "of", "interest", "(", "ROI", ")", ".", "METHOD", "Thirty", "-", "eight", "patients", "received", "baseline", "MRIs", "as", "part", "of", "a", "larger", "12-week", ",", "randomized", "clinical", "trial", "comparing", "sertraline", "and", "nortriptyline", "in", "the", "treatment", "of", "late", "-", "life", "depression", ".", "MRIcro", "was", "used", "to", "quantify", "MRI", "-", "hyperintensity", "volume", "into", "total", "hyperintensity", ",", "deep", "white", "matter", "hyperintensity", "(", "DWMH", ")", ",", "and", "periventricular", "hyperintensity", "(", "PVH", ")", "volumes", ".", "High", "versus", "low", "total", ",", "DWMH", ",", "and", "PVH", "volumes", "were", "defined", "based", "on", "the", "highest", "quartile", "of", "their", "respective", "distributions", ".", "Remission", "from", "depression", "was", "defined", "as", "a", "24-item", "Hamilton", "Rating", "Scale", "for", "Depression", "score", "≤", "7", "for", "two", "consecutive", "weeks", ".", "RESULTS", "Patients", "classified", "as", "having", "high", "DWMH", "were", "7.14", "times", "more", "likely", "not", "to", "remit", "following", "antidepressant", "treatment", "compared", "to", "patients", "classified", "as", "having", "low", "DWMH", "(", "p=0.02", ")", ".", "Similar", "odds", "ratios", "were", "obtained", "for", "PVH", "(", "OR=4.17", ",", "p=0.16", ")", "and", "total", "volumes", "(", "OR=5.00", ",", "p=0.05", ")", ".", "Importantly", ",", "adjusting", "for", "age", "did", "not", "change", "the", "magnitude", "of", "these", "effects", ".", "LIMITATIONS", "A", "small", "and", "predominantly", "White", "sample", ".", "CONCLUSIONS", "This", "is", "the", "first", "study", "to", "test", "whether", "remission", "from", "geriatric", "depression", "depends", "on", "lesion", "volume", "by", "ROI", "in", "an", "outpatient", "sample", ".", "The", "pattern", "of", "remission", "rates", "and", "odds", "ratios", "was", "similar", "when", "patients", "were", "classified", "as", "having", "high", "DWMH", ",", "PVH", "or", "total", "volume", "suggesting", "that", "lesion", "location", "may", "not", "be", "critical", "." ]

[ "Outcome_Physical", "Outcome_Mental", "Intervention_Pharmacological", "Participant_Condition", "Intervention_Physical", "Participant_Sample-size" ]

MRI signal hyperintensities, and, failure to remit, antidepressant treatment, ., remission, total lesion volume, geriatric depression, lesion volume by region of interest ( ROI ), Thirty - eight, baseline MRIs, sertraline, nortriptyline, late - life depression, DWMH, , and, PVH volumes, Remission from depression, Hamilton Rating Scale for Depression score

51155_task2

Sentence: MRI signal hyperintensities and failure to remit following antidepressant treatment . BACKGROUND MRI signal hyperintensities predict poor remission to antidepressant treatment . Previous studies using volumetrics in outpatient samples have relied on total lesion volume . The purpose of this study was to test whether remission from geriatric depression depends on lesion volume by region of interest ( ROI ) . METHOD Thirty-eight patients received baseline MRIs as part of a larger 12-week , randomized clinical trial comparing sertraline and nortriptyline in the treatment of late-life depression . MRIcro was used to quantify MRI-hyperintensity volume into total hyperintensity , deep white matter hyperintensity ( DWMH ) , and periventricular hyperintensity ( PVH ) volumes . High versus low total , DWMH , and PVH volumes were defined based on the highest quartile of their respective distributions . Remission from depression was defined as a 24-item Hamilton Rating Scale for Depression score ≤ 7 for two consecutive weeks . RESULTS Patients classified as having high DWMH were 7.14 times more likely not to remit following antidepressant treatment compared to patients classified as having low DWMH ( p=0.02 ) . Similar odds ratios were obtained for PVH ( OR=4.17 , p=0.16 ) and total volumes ( OR=5.00 , p=0.05 ) . Importantly , adjusting for age did not change the magnitude of these effects . LIMITATIONS A small and predominantly White sample . CONCLUSIONS This is the first study to test whether remission from geriatric depression depends on lesion volume by ROI in an outpatient sample . The pattern of remission rates and odds ratios was similar when patients were classified as having high DWMH , PVH or total volume suggesting that lesion location may not be critical . Instructions: please extract entity words from the input sentence

[ "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Mental", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

MRI signal hyperintensities and failure to remit following antidepressant treatment . BACKGROUND MRI signal hyperintensities predict poor remission to antidepressant treatment . Previous studies using volumetrics in outpatient samples have relied on total lesion volume . The purpose of this study was to test whether remission from geriatric depression depends on lesion volume by region of interest ( ROI ) . METHOD Thirty-eight patients received baseline MRIs as part of a larger 12-week , randomized clinical trial comparing sertraline and nortriptyline in the treatment of late-life depression . MRIcro was used to quantify MRI-hyperintensity volume into total hyperintensity , deep white matter hyperintensity ( DWMH ) , and periventricular hyperintensity ( PVH ) volumes . High versus low total , DWMH , and PVH volumes were defined based on the highest quartile of their respective distributions . Remission from depression was defined as a 24-item Hamilton Rating Scale for Depression score ≤ 7 for two consecutive weeks . RESULTS Patients classified as having high DWMH were 7.14 times more likely not to remit following antidepressant treatment compared to patients classified as having low DWMH ( p=0.02 ) . Similar odds ratios were obtained for PVH ( OR=4.17 , p=0.16 ) and total volumes ( OR=5.00 , p=0.05 ) . Importantly , adjusting for age did not change the magnitude of these effects . LIMITATIONS A small and predominantly White sample . CONCLUSIONS This is the first study to test whether remission from geriatric depression depends on lesion volume by ROI in an outpatient sample . The pattern of remission rates and odds ratios was similar when patients were classified as having high DWMH , PVH or total volume suggesting that lesion location may not be critical .

[ "MRI", "signal", "hyperintensities", "and", "failure", "to", "remit", "following", "antidepressant", "treatment", ".", "BACKGROUND", "MRI", "signal", "hyperintensities", "predict", "poor", "remission", "to", "antidepressant", "treatment", ".", "Previous", "studies", "using", "volumetrics", "in", "outpatient", "samples", "have", "relied", "on", "total", "lesion", "volume", ".", "The", "purpose", "of", "this", "study", "was", "to", "test", "whether", "remission", "from", "geriatric", "depression", "depends", "on", "lesion", "volume", "by", "region", "of", "interest", "(", "ROI", ")", ".", "METHOD", "Thirty", "-", "eight", "patients", "received", "baseline", "MRIs", "as", "part", "of", "a", "larger", "12-week", ",", "randomized", "clinical", "trial", "comparing", "sertraline", "and", "nortriptyline", "in", "the", "treatment", "of", "late", "-", "life", "depression", ".", "MRIcro", "was", "used", "to", "quantify", "MRI", "-", "hyperintensity", "volume", "into", "total", "hyperintensity", ",", "deep", "white", "matter", "hyperintensity", "(", "DWMH", ")", ",", "and", "periventricular", "hyperintensity", "(", "PVH", ")", "volumes", ".", "High", "versus", "low", "total", ",", "DWMH", ",", "and", "PVH", "volumes", "were", "defined", "based", "on", "the", "highest", "quartile", "of", "their", "respective", "distributions", ".", "Remission", "from", "depression", "was", "defined", "as", "a", "24-item", "Hamilton", "Rating", "Scale", "for", "Depression", "score", "≤", "7", "for", "two", "consecutive", "weeks", ".", "RESULTS", "Patients", "classified", "as", "having", "high", "DWMH", "were", "7.14", "times", "more", "likely", "not", "to", "remit", "following", "antidepressant", "treatment", "compared", "to", "patients", "classified", "as", "having", "low", "DWMH", "(", "p=0.02", ")", ".", "Similar", "odds", "ratios", "were", "obtained", "for", "PVH", "(", "OR=4.17", ",", "p=0.16", ")", "and", "total", "volumes", "(", "OR=5.00", ",", "p=0.05", ")", ".", "Importantly", ",", "adjusting", "for", "age", "did", "not", "change", "the", "magnitude", "of", "these", "effects", ".", "LIMITATIONS", "A", "small", "and", "predominantly", "White", "sample", ".", "CONCLUSIONS", "This", "is", "the", "first", "study", "to", "test", "whether", "remission", "from", "geriatric", "depression", "depends", "on", "lesion", "volume", "by", "ROI", "in", "an", "outpatient", "sample", ".", "The", "pattern", "of", "remission", "rates", "and", "odds", "ratios", "was", "similar", "when", "patients", "were", "classified", "as", "having", "high", "DWMH", ",", "PVH", "or", "total", "volume", "suggesting", "that", "lesion", "location", "may", "not", "be", "critical", "." ]

[ "Outcome_Physical", "Outcome_Mental", "Intervention_Pharmacological", "Participant_Condition", "Intervention_Physical", "Participant_Sample-size" ]

mouse carbonic anhydrase V is a GENE-Y, The carbonic anhydrase V is a GENE-Y, amino is a CHEMICAL, amino acids is a CHEMICAL, carbonic anhydrase ( CA ) V is a GENE-Y, CA V is a GENE-Y, CO2 is a CHEMICAL, mouse CA V is a GENE-Y, CA I is a GENE-Y, acetazolamide is a CHEMICAL, ethoxzolamide is a CHEMICAL, cyanate is a CHEMICAL, CA V is a GENE-Y, CA II is a GENE-Y, Mouse CA V is a GENE-Y, histidine is a CHEMICAL, CA V is a GENE-Y, Tyr64 - ->His is a GENE-N, CA V is a GENE-Y, tyrosine is a CHEMICAL

27984_task0

Sentence: Catalytic properties of mouse carbonic anhydrase V. A cDNA encoding the mouse carbonic anhydrase V gene was isolated by reverse transcription and polymerase chain reaction from BALB/c mouse liver mRNA. Vectors containing the full coding sequence as well as two different NH2-terminal truncated genes expressed enzymatically active protein in Escherichia coli. The carbonic anhydrase V produced by a vector containing the full coding sequence, which includes a possible NH2-terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several amino-terminal ends. The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 amino acids, yielding a protein equivalent to a carbonic anhydrase (CA) V isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions. These latter two forms of CA V had identical steady-state constants for the hydration of CO2, with maximal values of kcat/Km at 3 x 10(7) M-1 s-1 and kcat at 3 x 10(5) s-1 with an apparent pKa for catalysis of 7.4 determined from kcat/Km. In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II. Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway. Investigation of a site-specific mutant of CA V containing the replacement Tyr64-->His showed that the unique kinetic properties of CA V are not due to the presence of tyrosine at position 64. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O" ]

Catalytic properties of mouse carbonic anhydrase V. A cDNA encoding the mouse carbonic anhydrase V gene was isolated by reverse transcription and polymerase chain reaction from BALB/c mouse liver mRNA. Vectors containing the full coding sequence as well as two different NH2-terminal truncated genes expressed enzymatically active protein in Escherichia coli. The carbonic anhydrase V produced by a vector containing the full coding sequence, which includes a possible NH2-terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several amino-terminal ends. The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 amino acids, yielding a protein equivalent to a carbonic anhydrase (CA) V isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions. These latter two forms of CA V had identical steady-state constants for the hydration of CO2, with maximal values of kcat/Km at 3 x 10(7) M-1 s-1 and kcat at 3 x 10(5) s-1 with an apparent pKa for catalysis of 7.4 determined from kcat/Km. In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II. Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway. Investigation of a site-specific mutant of CA V containing the replacement Tyr64-->His showed that the unique kinetic properties of CA V are not due to the presence of tyrosine at position 64.

[ "Catalytic", "properties", "of", "mouse", "carbonic", "anhydrase", "V.", "\n", "A", "cDNA", "encoding", "the", "mouse", "carbonic", "anhydrase", "V", "gene", "was", "isolated", "by", "reverse", "transcription", "and", "polymerase", "chain", "reaction", "from", "BALB", "/", "c", "mouse", "liver", "mRNA", ".", "Vectors", "containing", "the", "full", "coding", "sequence", "as", "well", "as", "two", "different", "NH2-terminal", "truncated", "genes", "expressed", "enzymatically", "active", "protein", "in", "Escherichia", "coli", ".", "The", "carbonic", "anhydrase", "V", "produced", "by", "a", "vector", "containing", "the", "full", "coding", "sequence", ",", "which", "includes", "a", "possible", "NH2-terminal", "mitochondrial", "targeting", "signal", ",", "was", "proteolytically", "processed", "by", "E.", "coli", "and", "contained", "several", "amino", "-", "terminal", "ends", ".", "The", "two", "NH2-terminal", "truncated", "vectors", "deleted", ",", "respectively", ",", "1", ")", "the", "29-amino", "acid", "putative", "targeting", "sequence", "and", "2", ")", "51", "amino", "acids", ",", "yielding", "a", "protein", "equivalent", "to", "a", "carbonic", "anhydrase", "(", "CA", ")", "V", "isolated", "from", "mouse", "liver", "mitochondria", ";", "and", "both", "vectors", "produced", "homogeneous", "protein", "fractions", ".", "These", "latter", "two", "forms", "of", "CA", "V", "had", "identical", "steady", "-", "state", "constants", "for", "the", "hydration", "of", "CO2", ",", "with", "maximal", "values", "of", "kcat", "/", "Km", "at", "3", "x", "10(7", ")", "M-1", "s-1", "and", "kcat", "at", "3", "x", "10(5", ")", "s-1", "with", "an", "apparent", "pKa", "for", "catalysis", "of", "7.4", "determined", "from", "kcat", "/", "Km", ".", "In", "catalytic", "properties", ",", "mouse", "CA", "V", "is", "closest", "to", "CA", "I", ";", "however", ",", "in", "inhibition", "by", "acetazolamide", ",", "ethoxzolamide", ",", "and", "cyanate", ",", "CA", "V", "is", "very", "similar", "to", "CA", "II", ".", "Mouse", "CA", "V", "has", "a", "tyrosine", "at", "position", "64", ",", "where", "the", "highly", "active", "isozyme", "II", "has", "histidine", "serving", "as", "a", "proton", "shuttle", "in", "the", "catalytic", "pathway", ".", "Investigation", "of", "a", "site", "-", "specific", "mutant", "of", "CA", "V", "containing", "the", "replacement", "Tyr64", "-", "->His", "showed", "that", "the", "unique", "kinetic", "properties", "of", "CA", "V", "are", "not", "due", "to", "the", "presence", "of", "tyrosine", "at", "position", "64", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

mouse carbonic anhydrase V is a GENE-Y, The carbonic anhydrase V is a GENE-Y, amino is a CHEMICAL, amino acids is a CHEMICAL, carbonic anhydrase ( CA ) V is a GENE-Y, CA V is a GENE-Y, CO2 is a CHEMICAL, mouse CA V is a GENE-Y, CA I is a GENE-Y, acetazolamide is a CHEMICAL, ethoxzolamide is a CHEMICAL, cyanate is a CHEMICAL, CA V is a GENE-Y, CA II is a GENE-Y, Mouse CA V is a GENE-Y, histidine is a CHEMICAL, CA V is a GENE-Y, Tyr64 - ->His is a GENE-N, CA V is a GENE-Y, tyrosine is a CHEMICAL

27984_task1

Sentence: Catalytic properties of mouse carbonic anhydrase V. A cDNA encoding the mouse carbonic anhydrase V gene was isolated by reverse transcription and polymerase chain reaction from BALB/c mouse liver mRNA. Vectors containing the full coding sequence as well as two different NH2-terminal truncated genes expressed enzymatically active protein in Escherichia coli. The carbonic anhydrase V produced by a vector containing the full coding sequence, which includes a possible NH2-terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several amino-terminal ends. The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 amino acids, yielding a protein equivalent to a carbonic anhydrase (CA) V isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions. These latter two forms of CA V had identical steady-state constants for the hydration of CO2, with maximal values of kcat/Km at 3 x 10(7) M-1 s-1 and kcat at 3 x 10(5) s-1 with an apparent pKa for catalysis of 7.4 determined from kcat/Km. In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II. Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway. Investigation of a site-specific mutant of CA V containing the replacement Tyr64-->His showed that the unique kinetic properties of CA V are not due to the presence of tyrosine at position 64. Instructions: please typing these entity words according to sentence: mouse carbonic anhydrase V, The carbonic anhydrase V, amino, amino acids, carbonic anhydrase ( CA ) V, CA V, CO2, mouse CA V, CA I, acetazolamide, ethoxzolamide, cyanate, CA V, CA II, Mouse CA V, histidine, CA V, Tyr64 - ->His, CA V, tyrosine Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O" ]

Catalytic properties of mouse carbonic anhydrase V. A cDNA encoding the mouse carbonic anhydrase V gene was isolated by reverse transcription and polymerase chain reaction from BALB/c mouse liver mRNA. Vectors containing the full coding sequence as well as two different NH2-terminal truncated genes expressed enzymatically active protein in Escherichia coli. The carbonic anhydrase V produced by a vector containing the full coding sequence, which includes a possible NH2-terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several amino-terminal ends. The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 amino acids, yielding a protein equivalent to a carbonic anhydrase (CA) V isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions. These latter two forms of CA V had identical steady-state constants for the hydration of CO2, with maximal values of kcat/Km at 3 x 10(7) M-1 s-1 and kcat at 3 x 10(5) s-1 with an apparent pKa for catalysis of 7.4 determined from kcat/Km. In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II. Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway. Investigation of a site-specific mutant of CA V containing the replacement Tyr64-->His showed that the unique kinetic properties of CA V are not due to the presence of tyrosine at position 64.

[ "Catalytic", "properties", "of", "mouse", "carbonic", "anhydrase", "V.", "\n", "A", "cDNA", "encoding", "the", "mouse", "carbonic", "anhydrase", "V", "gene", "was", "isolated", "by", "reverse", "transcription", "and", "polymerase", "chain", "reaction", "from", "BALB", "/", "c", "mouse", "liver", "mRNA", ".", "Vectors", "containing", "the", "full", "coding", "sequence", "as", "well", "as", "two", "different", "NH2-terminal", "truncated", "genes", "expressed", "enzymatically", "active", "protein", "in", "Escherichia", "coli", ".", "The", "carbonic", "anhydrase", "V", "produced", "by", "a", "vector", "containing", "the", "full", "coding", "sequence", ",", "which", "includes", "a", "possible", "NH2-terminal", "mitochondrial", "targeting", "signal", ",", "was", "proteolytically", "processed", "by", "E.", "coli", "and", "contained", "several", "amino", "-", "terminal", "ends", ".", "The", "two", "NH2-terminal", "truncated", "vectors", "deleted", ",", "respectively", ",", "1", ")", "the", "29-amino", "acid", "putative", "targeting", "sequence", "and", "2", ")", "51", "amino", "acids", ",", "yielding", "a", "protein", "equivalent", "to", "a", "carbonic", "anhydrase", "(", "CA", ")", "V", "isolated", "from", "mouse", "liver", "mitochondria", ";", "and", "both", "vectors", "produced", "homogeneous", "protein", "fractions", ".", "These", "latter", "two", "forms", "of", "CA", "V", "had", "identical", "steady", "-", "state", "constants", "for", "the", "hydration", "of", "CO2", ",", "with", "maximal", "values", "of", "kcat", "/", "Km", "at", "3", "x", "10(7", ")", "M-1", "s-1", "and", "kcat", "at", "3", "x", "10(5", ")", "s-1", "with", "an", "apparent", "pKa", "for", "catalysis", "of", "7.4", "determined", "from", "kcat", "/", "Km", ".", "In", "catalytic", "properties", ",", "mouse", "CA", "V", "is", "closest", "to", "CA", "I", ";", "however", ",", "in", "inhibition", "by", "acetazolamide", ",", "ethoxzolamide", ",", "and", "cyanate", ",", "CA", "V", "is", "very", "similar", "to", "CA", "II", ".", "Mouse", "CA", "V", "has", "a", "tyrosine", "at", "position", "64", ",", "where", "the", "highly", "active", "isozyme", "II", "has", "histidine", "serving", "as", "a", "proton", "shuttle", "in", "the", "catalytic", "pathway", ".", "Investigation", "of", "a", "site", "-", "specific", "mutant", "of", "CA", "V", "containing", "the", "replacement", "Tyr64", "-", "->His", "showed", "that", "the", "unique", "kinetic", "properties", "of", "CA", "V", "are", "not", "due", "to", "the", "presence", "of", "tyrosine", "at", "position", "64", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

mouse carbonic anhydrase V, The carbonic anhydrase V, amino, amino acids, carbonic anhydrase ( CA ) V, CA V, CO2, mouse CA V, CA I, acetazolamide, ethoxzolamide, cyanate, CA V, CA II, Mouse CA V, histidine, CA V, Tyr64 - ->His, CA V, tyrosine

27984_task2

Sentence: Catalytic properties of mouse carbonic anhydrase V. A cDNA encoding the mouse carbonic anhydrase V gene was isolated by reverse transcription and polymerase chain reaction from BALB/c mouse liver mRNA. Vectors containing the full coding sequence as well as two different NH2-terminal truncated genes expressed enzymatically active protein in Escherichia coli. The carbonic anhydrase V produced by a vector containing the full coding sequence, which includes a possible NH2-terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several amino-terminal ends. The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 amino acids, yielding a protein equivalent to a carbonic anhydrase (CA) V isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions. These latter two forms of CA V had identical steady-state constants for the hydration of CO2, with maximal values of kcat/Km at 3 x 10(7) M-1 s-1 and kcat at 3 x 10(5) s-1 with an apparent pKa for catalysis of 7.4 determined from kcat/Km. In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II. Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway. Investigation of a site-specific mutant of CA V containing the replacement Tyr64-->His showed that the unique kinetic properties of CA V are not due to the presence of tyrosine at position 64. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O" ]

Catalytic properties of mouse carbonic anhydrase V. A cDNA encoding the mouse carbonic anhydrase V gene was isolated by reverse transcription and polymerase chain reaction from BALB/c mouse liver mRNA. Vectors containing the full coding sequence as well as two different NH2-terminal truncated genes expressed enzymatically active protein in Escherichia coli. The carbonic anhydrase V produced by a vector containing the full coding sequence, which includes a possible NH2-terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several amino-terminal ends. The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 amino acids, yielding a protein equivalent to a carbonic anhydrase (CA) V isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions. These latter two forms of CA V had identical steady-state constants for the hydration of CO2, with maximal values of kcat/Km at 3 x 10(7) M-1 s-1 and kcat at 3 x 10(5) s-1 with an apparent pKa for catalysis of 7.4 determined from kcat/Km. In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II. Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway. Investigation of a site-specific mutant of CA V containing the replacement Tyr64-->His showed that the unique kinetic properties of CA V are not due to the presence of tyrosine at position 64.

[ "Catalytic", "properties", "of", "mouse", "carbonic", "anhydrase", "V.", "\n", "A", "cDNA", "encoding", "the", "mouse", "carbonic", "anhydrase", "V", "gene", "was", "isolated", "by", "reverse", "transcription", "and", "polymerase", "chain", "reaction", "from", "BALB", "/", "c", "mouse", "liver", "mRNA", ".", "Vectors", "containing", "the", "full", "coding", "sequence", "as", "well", "as", "two", "different", "NH2-terminal", "truncated", "genes", "expressed", "enzymatically", "active", "protein", "in", "Escherichia", "coli", ".", "The", "carbonic", "anhydrase", "V", "produced", "by", "a", "vector", "containing", "the", "full", "coding", "sequence", ",", "which", "includes", "a", "possible", "NH2-terminal", "mitochondrial", "targeting", "signal", ",", "was", "proteolytically", "processed", "by", "E.", "coli", "and", "contained", "several", "amino", "-", "terminal", "ends", ".", "The", "two", "NH2-terminal", "truncated", "vectors", "deleted", ",", "respectively", ",", "1", ")", "the", "29-amino", "acid", "putative", "targeting", "sequence", "and", "2", ")", "51", "amino", "acids", ",", "yielding", "a", "protein", "equivalent", "to", "a", "carbonic", "anhydrase", "(", "CA", ")", "V", "isolated", "from", "mouse", "liver", "mitochondria", ";", "and", "both", "vectors", "produced", "homogeneous", "protein", "fractions", ".", "These", "latter", "two", "forms", "of", "CA", "V", "had", "identical", "steady", "-", "state", "constants", "for", "the", "hydration", "of", "CO2", ",", "with", "maximal", "values", "of", "kcat", "/", "Km", "at", "3", "x", "10(7", ")", "M-1", "s-1", "and", "kcat", "at", "3", "x", "10(5", ")", "s-1", "with", "an", "apparent", "pKa", "for", "catalysis", "of", "7.4", "determined", "from", "kcat", "/", "Km", ".", "In", "catalytic", "properties", ",", "mouse", "CA", "V", "is", "closest", "to", "CA", "I", ";", "however", ",", "in", "inhibition", "by", "acetazolamide", ",", "ethoxzolamide", ",", "and", "cyanate", ",", "CA", "V", "is", "very", "similar", "to", "CA", "II", ".", "Mouse", "CA", "V", "has", "a", "tyrosine", "at", "position", "64", ",", "where", "the", "highly", "active", "isozyme", "II", "has", "histidine", "serving", "as", "a", "proton", "shuttle", "in", "the", "catalytic", "pathway", ".", "Investigation", "of", "a", "site", "-", "specific", "mutant", "of", "CA", "V", "containing", "the", "replacement", "Tyr64", "-", "->His", "showed", "that", "the", "unique", "kinetic", "properties", "of", "CA", "V", "are", "not", "due", "to", "the", "presence", "of", "tyrosine", "at", "position", "64", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

glucagon is a Intervention_Pharmacological, hyoscine N - butyl bromide is a Intervention_Pharmacological, endoscopic retrograde cholangiopancreatography is a Intervention_Physical, endoscopic retrograde cholangiopancreatography ( ERCP ) . is a Participant_Condition, basal blood sugar and amylase levels . is a Outcome_Physical, basal pulse and duodenal peristaltic rates is a Outcome_Physical, 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N - butyl bromide ( n = 36 ) is a Participant_Condition, Glucagon is a Intervention_Pharmacological, hyperglycemia is a Outcome_Physical, anticholinergic effect . is a Outcome_Physical, necessary interval for ERCP is a Outcome_Other, success rate for cholangiopancreatography is a Outcome_Other, hyperamylasemia nor pancreatitis is a Outcome_Physical, performance of ERCP is a Outcome_Other

81074_task0

Sentence: A randomized study comparing glucagon and hyoscine N-butyl bromide before endoscopic retrograde cholangiopancreatography . BACKGROUND This study tried to resolve whether glucagon is a better premedication for endoscopic retrograde cholangiopancreatography ( ERCP ) . METHODS We first measured the basal blood sugar and amylase levels . Then an endoscope was placed in the duodenum without premedication , and basal pulse and duodenal peristaltic rates were measured . ERCP began after studied subjects were randomly premedicated with either 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N-butyl bromide ( n = 36 ) intravenously . Ten minutes later the variables were measured again . RESULTS Glucagon elicited hyperglycemia whereas hyoscine N-butyl bromide manifested an anticholinergic effect . No difference was found between these two groups with regard to the necessary interval for ERCP ( 20.6 +/- 14.1 min versus 21.4 +/- 14.7 min ; NS ) or the success rate for cholangiopancreatography ( 92.1 % versus 91.7 % ; NS ) . Neither hyperamylasemia nor pancreatitis was preventable when glucagon was used . CONCLUSIONS The two premedications appear equally effective in the performance of ERCP . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Physical, Outcome_Other

[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]

A randomized study comparing glucagon and hyoscine N-butyl bromide before endoscopic retrograde cholangiopancreatography . BACKGROUND This study tried to resolve whether glucagon is a better premedication for endoscopic retrograde cholangiopancreatography ( ERCP ) . METHODS We first measured the basal blood sugar and amylase levels . Then an endoscope was placed in the duodenum without premedication , and basal pulse and duodenal peristaltic rates were measured . ERCP began after studied subjects were randomly premedicated with either 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N-butyl bromide ( n = 36 ) intravenously . Ten minutes later the variables were measured again . RESULTS Glucagon elicited hyperglycemia whereas hyoscine N-butyl bromide manifested an anticholinergic effect . No difference was found between these two groups with regard to the necessary interval for ERCP ( 20.6 +/- 14.1 min versus 21.4 +/- 14.7 min ; NS ) or the success rate for cholangiopancreatography ( 92.1 % versus 91.7 % ; NS ) . Neither hyperamylasemia nor pancreatitis was preventable when glucagon was used . CONCLUSIONS The two premedications appear equally effective in the performance of ERCP .

[ "A", "randomized", "study", "comparing", "glucagon", "and", "hyoscine", "N", "-", "butyl", "bromide", "before", "endoscopic", "retrograde", "cholangiopancreatography", ".", "BACKGROUND", "This", "study", "tried", "to", "resolve", "whether", "glucagon", "is", "a", "better", "premedication", "for", "endoscopic", "retrograde", "cholangiopancreatography", "(", "ERCP", ")", ".", "METHODS", "We", "first", "measured", "the", "basal", "blood", "sugar", "and", "amylase", "levels", ".", "Then", "an", "endoscope", "was", "placed", "in", "the", "duodenum", "without", "premedication", ",", "and", "basal", "pulse", "and", "duodenal", "peristaltic", "rates", "were", "measured", ".", "ERCP", "began", "after", "studied", "subjects", "were", "randomly", "premedicated", "with", "either", "1", "mg", "glucagon", "(", "n", "=", "38", ")", "or", "40", "mg", "hyoscine", "N", "-", "butyl", "bromide", "(", "n", "=", "36", ")", "intravenously", ".", "Ten", "minutes", "later", "the", "variables", "were", "measured", "again", ".", "RESULTS", "Glucagon", "elicited", "hyperglycemia", "whereas", "hyoscine", "N", "-", "butyl", "bromide", "manifested", "an", "anticholinergic", "effect", ".", "No", "difference", "was", "found", "between", "these", "two", "groups", "with", "regard", "to", "the", "necessary", "interval", "for", "ERCP", "(", "20.6", "+", "/-", "14.1", "min", "versus", "21.4", "+", "/-", "14.7", "min", ";", "NS", ")", "or", "the", "success", "rate", "for", "cholangiopancreatography", "(", "92.1", "%", "versus", "91.7", "%", ";", "NS", ")", ".", "Neither", "hyperamylasemia", "nor", "pancreatitis", "was", "preventable", "when", "glucagon", "was", "used", ".", "CONCLUSIONS", "The", "two", "premedications", "appear", "equally", "effective", "in", "the", "performance", "of", "ERCP", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Physical", "Outcome_Other", "Intervention_Pharmacological" ]

glucagon is a Intervention_Pharmacological, hyoscine N - butyl bromide is a Intervention_Pharmacological, endoscopic retrograde cholangiopancreatography is a Intervention_Physical, endoscopic retrograde cholangiopancreatography ( ERCP ) . is a Participant_Condition, basal blood sugar and amylase levels . is a Outcome_Physical, basal pulse and duodenal peristaltic rates is a Outcome_Physical, 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N - butyl bromide ( n = 36 ) is a Participant_Condition, Glucagon is a Intervention_Pharmacological, hyperglycemia is a Outcome_Physical, anticholinergic effect . is a Outcome_Physical, necessary interval for ERCP is a Outcome_Other, success rate for cholangiopancreatography is a Outcome_Other, hyperamylasemia nor pancreatitis is a Outcome_Physical, performance of ERCP is a Outcome_Other

81074_task1

Sentence: A randomized study comparing glucagon and hyoscine N-butyl bromide before endoscopic retrograde cholangiopancreatography . BACKGROUND This study tried to resolve whether glucagon is a better premedication for endoscopic retrograde cholangiopancreatography ( ERCP ) . METHODS We first measured the basal blood sugar and amylase levels . Then an endoscope was placed in the duodenum without premedication , and basal pulse and duodenal peristaltic rates were measured . ERCP began after studied subjects were randomly premedicated with either 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N-butyl bromide ( n = 36 ) intravenously . Ten minutes later the variables were measured again . RESULTS Glucagon elicited hyperglycemia whereas hyoscine N-butyl bromide manifested an anticholinergic effect . No difference was found between these two groups with regard to the necessary interval for ERCP ( 20.6 +/- 14.1 min versus 21.4 +/- 14.7 min ; NS ) or the success rate for cholangiopancreatography ( 92.1 % versus 91.7 % ; NS ) . Neither hyperamylasemia nor pancreatitis was preventable when glucagon was used . CONCLUSIONS The two premedications appear equally effective in the performance of ERCP . Instructions: please typing these entity words according to sentence: glucagon, hyoscine N - butyl bromide, endoscopic retrograde cholangiopancreatography, endoscopic retrograde cholangiopancreatography ( ERCP ) ., basal blood sugar and amylase levels ., basal pulse and duodenal peristaltic rates, 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N - butyl bromide ( n = 36 ), Glucagon, hyperglycemia, anticholinergic effect ., necessary interval for ERCP, success rate for cholangiopancreatography, hyperamylasemia nor pancreatitis, performance of ERCP Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Physical, Outcome_Other

[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]

A randomized study comparing glucagon and hyoscine N-butyl bromide before endoscopic retrograde cholangiopancreatography . BACKGROUND This study tried to resolve whether glucagon is a better premedication for endoscopic retrograde cholangiopancreatography ( ERCP ) . METHODS We first measured the basal blood sugar and amylase levels . Then an endoscope was placed in the duodenum without premedication , and basal pulse and duodenal peristaltic rates were measured . ERCP began after studied subjects were randomly premedicated with either 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N-butyl bromide ( n = 36 ) intravenously . Ten minutes later the variables were measured again . RESULTS Glucagon elicited hyperglycemia whereas hyoscine N-butyl bromide manifested an anticholinergic effect . No difference was found between these two groups with regard to the necessary interval for ERCP ( 20.6 +/- 14.1 min versus 21.4 +/- 14.7 min ; NS ) or the success rate for cholangiopancreatography ( 92.1 % versus 91.7 % ; NS ) . Neither hyperamylasemia nor pancreatitis was preventable when glucagon was used . CONCLUSIONS The two premedications appear equally effective in the performance of ERCP .

[ "A", "randomized", "study", "comparing", "glucagon", "and", "hyoscine", "N", "-", "butyl", "bromide", "before", "endoscopic", "retrograde", "cholangiopancreatography", ".", "BACKGROUND", "This", "study", "tried", "to", "resolve", "whether", "glucagon", "is", "a", "better", "premedication", "for", "endoscopic", "retrograde", "cholangiopancreatography", "(", "ERCP", ")", ".", "METHODS", "We", "first", "measured", "the", "basal", "blood", "sugar", "and", "amylase", "levels", ".", "Then", "an", "endoscope", "was", "placed", "in", "the", "duodenum", "without", "premedication", ",", "and", "basal", "pulse", "and", "duodenal", "peristaltic", "rates", "were", "measured", ".", "ERCP", "began", "after", "studied", "subjects", "were", "randomly", "premedicated", "with", "either", "1", "mg", "glucagon", "(", "n", "=", "38", ")", "or", "40", "mg", "hyoscine", "N", "-", "butyl", "bromide", "(", "n", "=", "36", ")", "intravenously", ".", "Ten", "minutes", "later", "the", "variables", "were", "measured", "again", ".", "RESULTS", "Glucagon", "elicited", "hyperglycemia", "whereas", "hyoscine", "N", "-", "butyl", "bromide", "manifested", "an", "anticholinergic", "effect", ".", "No", "difference", "was", "found", "between", "these", "two", "groups", "with", "regard", "to", "the", "necessary", "interval", "for", "ERCP", "(", "20.6", "+", "/-", "14.1", "min", "versus", "21.4", "+", "/-", "14.7", "min", ";", "NS", ")", "or", "the", "success", "rate", "for", "cholangiopancreatography", "(", "92.1", "%", "versus", "91.7", "%", ";", "NS", ")", ".", "Neither", "hyperamylasemia", "nor", "pancreatitis", "was", "preventable", "when", "glucagon", "was", "used", ".", "CONCLUSIONS", "The", "two", "premedications", "appear", "equally", "effective", "in", "the", "performance", "of", "ERCP", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Physical", "Outcome_Other", "Intervention_Pharmacological" ]

glucagon, hyoscine N - butyl bromide, endoscopic retrograde cholangiopancreatography, endoscopic retrograde cholangiopancreatography ( ERCP ) ., basal blood sugar and amylase levels ., basal pulse and duodenal peristaltic rates, 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N - butyl bromide ( n = 36 ), Glucagon, hyperglycemia, anticholinergic effect ., necessary interval for ERCP, success rate for cholangiopancreatography, hyperamylasemia nor pancreatitis, performance of ERCP

81074_task2

Sentence: A randomized study comparing glucagon and hyoscine N-butyl bromide before endoscopic retrograde cholangiopancreatography . BACKGROUND This study tried to resolve whether glucagon is a better premedication for endoscopic retrograde cholangiopancreatography ( ERCP ) . METHODS We first measured the basal blood sugar and amylase levels . Then an endoscope was placed in the duodenum without premedication , and basal pulse and duodenal peristaltic rates were measured . ERCP began after studied subjects were randomly premedicated with either 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N-butyl bromide ( n = 36 ) intravenously . Ten minutes later the variables were measured again . RESULTS Glucagon elicited hyperglycemia whereas hyoscine N-butyl bromide manifested an anticholinergic effect . No difference was found between these two groups with regard to the necessary interval for ERCP ( 20.6 +/- 14.1 min versus 21.4 +/- 14.7 min ; NS ) or the success rate for cholangiopancreatography ( 92.1 % versus 91.7 % ; NS ) . Neither hyperamylasemia nor pancreatitis was preventable when glucagon was used . CONCLUSIONS The two premedications appear equally effective in the performance of ERCP . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]

A randomized study comparing glucagon and hyoscine N-butyl bromide before endoscopic retrograde cholangiopancreatography . BACKGROUND This study tried to resolve whether glucagon is a better premedication for endoscopic retrograde cholangiopancreatography ( ERCP ) . METHODS We first measured the basal blood sugar and amylase levels . Then an endoscope was placed in the duodenum without premedication , and basal pulse and duodenal peristaltic rates were measured . ERCP began after studied subjects were randomly premedicated with either 1 mg glucagon ( n = 38 ) or 40 mg hyoscine N-butyl bromide ( n = 36 ) intravenously . Ten minutes later the variables were measured again . RESULTS Glucagon elicited hyperglycemia whereas hyoscine N-butyl bromide manifested an anticholinergic effect . No difference was found between these two groups with regard to the necessary interval for ERCP ( 20.6 +/- 14.1 min versus 21.4 +/- 14.7 min ; NS ) or the success rate for cholangiopancreatography ( 92.1 % versus 91.7 % ; NS ) . Neither hyperamylasemia nor pancreatitis was preventable when glucagon was used . CONCLUSIONS The two premedications appear equally effective in the performance of ERCP .

[ "A", "randomized", "study", "comparing", "glucagon", "and", "hyoscine", "N", "-", "butyl", "bromide", "before", "endoscopic", "retrograde", "cholangiopancreatography", ".", "BACKGROUND", "This", "study", "tried", "to", "resolve", "whether", "glucagon", "is", "a", "better", "premedication", "for", "endoscopic", "retrograde", "cholangiopancreatography", "(", "ERCP", ")", ".", "METHODS", "We", "first", "measured", "the", "basal", "blood", "sugar", "and", "amylase", "levels", ".", "Then", "an", "endoscope", "was", "placed", "in", "the", "duodenum", "without", "premedication", ",", "and", "basal", "pulse", "and", "duodenal", "peristaltic", "rates", "were", "measured", ".", "ERCP", "began", "after", "studied", "subjects", "were", "randomly", "premedicated", "with", "either", "1", "mg", "glucagon", "(", "n", "=", "38", ")", "or", "40", "mg", "hyoscine", "N", "-", "butyl", "bromide", "(", "n", "=", "36", ")", "intravenously", ".", "Ten", "minutes", "later", "the", "variables", "were", "measured", "again", ".", "RESULTS", "Glucagon", "elicited", "hyperglycemia", "whereas", "hyoscine", "N", "-", "butyl", "bromide", "manifested", "an", "anticholinergic", "effect", ".", "No", "difference", "was", "found", "between", "these", "two", "groups", "with", "regard", "to", "the", "necessary", "interval", "for", "ERCP", "(", "20.6", "+", "/-", "14.1", "min", "versus", "21.4", "+", "/-", "14.7", "min", ";", "NS", ")", "or", "the", "success", "rate", "for", "cholangiopancreatography", "(", "92.1", "%", "versus", "91.7", "%", ";", "NS", ")", ".", "Neither", "hyperamylasemia", "nor", "pancreatitis", "was", "preventable", "when", "glucagon", "was", "used", ".", "CONCLUSIONS", "The", "two", "premedications", "appear", "equally", "effective", "in", "the", "performance", "of", "ERCP", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Physical", "Outcome_Other", "Intervention_Pharmacological" ]

patients is an umlsterm, pancreatic is an umlsterm, carcinoma is an umlsterm, carcinoma is an umlsterm, pancreatitis is an umlsterm, role is an umlsterm, CA is an umlsterm, diagnosis is an umlsterm, head is an umlsterm, pancreas is an umlsterm, sensitivity is an umlsterm, pancreatic is an umlsterm, carcinoma is an umlsterm, carcinoma is an umlsterm, specificity is an umlsterm, Carcinoembryonic antigen is an umlsterm, patient is an umlsterm, tumor markers is an umlsterm, sensitivity is an umlsterm, specificity is an umlsterm, obstructive jaundice is an umlsterm, cancer is an umlsterm, patients is an umlsterm, pancreatitis is an umlsterm, CA is an umlsterm, prognosis is an umlsterm, patients is an umlsterm, tumor markers is an umlsterm

DerChirurg.60671007.eng.abstr_task0

Sentence: In 96 patients ( ductal pancreatic carcinoma , n = 34 ; periampullary carcinoma , n = 43 ; chronic pancreatitis , n = 19 ) the role of CA 19-9 in the diagnosis of lesions of the head of the pancreas were evaluated . The sensitivity for ductal pancreatic carcinoma was 73.3 % , for periampullary carcinoma 48.8 % , and specificity was 63.2 % . Carcinoembryonic antigen was elevated only in every fifth patient . Even when combining the two tumor markers no increase in sensitivity could be observed . The low specificity of 63 % , which decreased to 33 % in the case of obstructive jaundice , does not allow adequate preoperative differentiation between cancer patients and those with chronic pancreatitis . In cases of postoperatively elevated CA 19-9 level the prognosis is worse than in patients with normal tumor markers . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

In 96 patients ( ductal pancreatic carcinoma , n = 34 ; periampullary carcinoma , n = 43 ; chronic pancreatitis , n = 19 ) the role of CA 19-9 in the diagnosis of lesions of the head of the pancreas were evaluated . The sensitivity for ductal pancreatic carcinoma was 73.3 % , for periampullary carcinoma 48.8 % , and specificity was 63.2 % . Carcinoembryonic antigen was elevated only in every fifth patient . Even when combining the two tumor markers no increase in sensitivity could be observed . The low specificity of 63 % , which decreased to 33 % in the case of obstructive jaundice , does not allow adequate preoperative differentiation between cancer patients and those with chronic pancreatitis . In cases of postoperatively elevated CA 19-9 level the prognosis is worse than in patients with normal tumor markers .

[ "In", "96", "patients", "(", "ductal", "pancreatic", "carcinoma", ",", "n", "=", "34", ";", "periampullary", "carcinoma", ",", "n", "=", "43", ";", "chronic", "pancreatitis", ",", "n", "=", "19", ")", "the", "role", "of", "CA", "19", "-", "9", "in", "the", "diagnosis", "of", "lesions", "of", "the", "head", "of", "the", "pancreas", "were", "evaluated", ".", "The", "sensitivity", "for", "ductal", "pancreatic", "carcinoma", "was", "73.3", "%", ",", "for", "periampullary", "carcinoma", "48.8", "%", ",", "and", "specificity", "was", "63.2", "%", ".", "Carcinoembryonic", "antigen", "was", "elevated", "only", "in", "every", "fifth", "patient", ".", "Even", "when", "combining", "the", "two", "tumor", "markers", "no", "increase", "in", "sensitivity", "could", "be", "observed", ".", "The", "low", "specificity", "of", "63", "%", ",", "which", "decreased", "to", "33", "%", "in", "the", "case", "of", "obstructive", "jaundice", ",", "does", "not", "allow", "adequate", "preoperative", "differentiation", "between", "cancer", "patients", "and", "those", "with", "chronic", "pancreatitis", ".", "In", "cases", "of", "postoperatively", "elevated", "CA", "19", "-", "9", "level", "the", "prognosis", "is", "worse", "than", "in", "patients", "with", "normal", "tumor", "markers", "." ]

[ "umlsterm" ]

patients is an umlsterm, pancreatic is an umlsterm, carcinoma is an umlsterm, carcinoma is an umlsterm, pancreatitis is an umlsterm, role is an umlsterm, CA is an umlsterm, diagnosis is an umlsterm, head is an umlsterm, pancreas is an umlsterm, sensitivity is an umlsterm, pancreatic is an umlsterm, carcinoma is an umlsterm, carcinoma is an umlsterm, specificity is an umlsterm, Carcinoembryonic antigen is an umlsterm, patient is an umlsterm, tumor markers is an umlsterm, sensitivity is an umlsterm, specificity is an umlsterm, obstructive jaundice is an umlsterm, cancer is an umlsterm, patients is an umlsterm, pancreatitis is an umlsterm, CA is an umlsterm, prognosis is an umlsterm, patients is an umlsterm, tumor markers is an umlsterm

DerChirurg.60671007.eng.abstr_task1

Sentence: In 96 patients ( ductal pancreatic carcinoma , n = 34 ; periampullary carcinoma , n = 43 ; chronic pancreatitis , n = 19 ) the role of CA 19-9 in the diagnosis of lesions of the head of the pancreas were evaluated . The sensitivity for ductal pancreatic carcinoma was 73.3 % , for periampullary carcinoma 48.8 % , and specificity was 63.2 % . Carcinoembryonic antigen was elevated only in every fifth patient . Even when combining the two tumor markers no increase in sensitivity could be observed . The low specificity of 63 % , which decreased to 33 % in the case of obstructive jaundice , does not allow adequate preoperative differentiation between cancer patients and those with chronic pancreatitis . In cases of postoperatively elevated CA 19-9 level the prognosis is worse than in patients with normal tumor markers . Instructions: please typing these entity words according to sentence: patients, pancreatic, carcinoma, carcinoma, pancreatitis, role, CA, diagnosis, head, pancreas, sensitivity, pancreatic, carcinoma, carcinoma, specificity, Carcinoembryonic antigen, patient, tumor markers, sensitivity, specificity, obstructive jaundice, cancer, patients, pancreatitis, CA, prognosis, patients, tumor markers Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

In 96 patients ( ductal pancreatic carcinoma , n = 34 ; periampullary carcinoma , n = 43 ; chronic pancreatitis , n = 19 ) the role of CA 19-9 in the diagnosis of lesions of the head of the pancreas were evaluated . The sensitivity for ductal pancreatic carcinoma was 73.3 % , for periampullary carcinoma 48.8 % , and specificity was 63.2 % . Carcinoembryonic antigen was elevated only in every fifth patient . Even when combining the two tumor markers no increase in sensitivity could be observed . The low specificity of 63 % , which decreased to 33 % in the case of obstructive jaundice , does not allow adequate preoperative differentiation between cancer patients and those with chronic pancreatitis . In cases of postoperatively elevated CA 19-9 level the prognosis is worse than in patients with normal tumor markers .

[ "In", "96", "patients", "(", "ductal", "pancreatic", "carcinoma", ",", "n", "=", "34", ";", "periampullary", "carcinoma", ",", "n", "=", "43", ";", "chronic", "pancreatitis", ",", "n", "=", "19", ")", "the", "role", "of", "CA", "19", "-", "9", "in", "the", "diagnosis", "of", "lesions", "of", "the", "head", "of", "the", "pancreas", "were", "evaluated", ".", "The", "sensitivity", "for", "ductal", "pancreatic", "carcinoma", "was", "73.3", "%", ",", "for", "periampullary", "carcinoma", "48.8", "%", ",", "and", "specificity", "was", "63.2", "%", ".", "Carcinoembryonic", "antigen", "was", "elevated", "only", "in", "every", "fifth", "patient", ".", "Even", "when", "combining", "the", "two", "tumor", "markers", "no", "increase", "in", "sensitivity", "could", "be", "observed", ".", "The", "low", "specificity", "of", "63", "%", ",", "which", "decreased", "to", "33", "%", "in", "the", "case", "of", "obstructive", "jaundice", ",", "does", "not", "allow", "adequate", "preoperative", "differentiation", "between", "cancer", "patients", "and", "those", "with", "chronic", "pancreatitis", ".", "In", "cases", "of", "postoperatively", "elevated", "CA", "19", "-", "9", "level", "the", "prognosis", "is", "worse", "than", "in", "patients", "with", "normal", "tumor", "markers", "." ]

[ "umlsterm" ]

patients, pancreatic, carcinoma, carcinoma, pancreatitis, role, CA, diagnosis, head, pancreas, sensitivity, pancreatic, carcinoma, carcinoma, specificity, Carcinoembryonic antigen, patient, tumor markers, sensitivity, specificity, obstructive jaundice, cancer, patients, pancreatitis, CA, prognosis, patients, tumor markers

DerChirurg.60671007.eng.abstr_task2

Sentence: In 96 patients ( ductal pancreatic carcinoma , n = 34 ; periampullary carcinoma , n = 43 ; chronic pancreatitis , n = 19 ) the role of CA 19-9 in the diagnosis of lesions of the head of the pancreas were evaluated . The sensitivity for ductal pancreatic carcinoma was 73.3 % , for periampullary carcinoma 48.8 % , and specificity was 63.2 % . Carcinoembryonic antigen was elevated only in every fifth patient . Even when combining the two tumor markers no increase in sensitivity could be observed . The low specificity of 63 % , which decreased to 33 % in the case of obstructive jaundice , does not allow adequate preoperative differentiation between cancer patients and those with chronic pancreatitis . In cases of postoperatively elevated CA 19-9 level the prognosis is worse than in patients with normal tumor markers . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

In 96 patients ( ductal pancreatic carcinoma , n = 34 ; periampullary carcinoma , n = 43 ; chronic pancreatitis , n = 19 ) the role of CA 19-9 in the diagnosis of lesions of the head of the pancreas were evaluated . The sensitivity for ductal pancreatic carcinoma was 73.3 % , for periampullary carcinoma 48.8 % , and specificity was 63.2 % . Carcinoembryonic antigen was elevated only in every fifth patient . Even when combining the two tumor markers no increase in sensitivity could be observed . The low specificity of 63 % , which decreased to 33 % in the case of obstructive jaundice , does not allow adequate preoperative differentiation between cancer patients and those with chronic pancreatitis . In cases of postoperatively elevated CA 19-9 level the prognosis is worse than in patients with normal tumor markers .

[ "In", "96", "patients", "(", "ductal", "pancreatic", "carcinoma", ",", "n", "=", "34", ";", "periampullary", "carcinoma", ",", "n", "=", "43", ";", "chronic", "pancreatitis", ",", "n", "=", "19", ")", "the", "role", "of", "CA", "19", "-", "9", "in", "the", "diagnosis", "of", "lesions", "of", "the", "head", "of", "the", "pancreas", "were", "evaluated", ".", "The", "sensitivity", "for", "ductal", "pancreatic", "carcinoma", "was", "73.3", "%", ",", "for", "periampullary", "carcinoma", "48.8", "%", ",", "and", "specificity", "was", "63.2", "%", ".", "Carcinoembryonic", "antigen", "was", "elevated", "only", "in", "every", "fifth", "patient", ".", "Even", "when", "combining", "the", "two", "tumor", "markers", "no", "increase", "in", "sensitivity", "could", "be", "observed", ".", "The", "low", "specificity", "of", "63", "%", ",", "which", "decreased", "to", "33", "%", "in", "the", "case", "of", "obstructive", "jaundice", ",", "does", "not", "allow", "adequate", "preoperative", "differentiation", "between", "cancer", "patients", "and", "those", "with", "chronic", "pancreatitis", ".", "In", "cases", "of", "postoperatively", "elevated", "CA", "19", "-", "9", "level", "the", "prognosis", "is", "worse", "than", "in", "patients", "with", "normal", "tumor", "markers", "." ]

[ "umlsterm" ]

Placebo - Controlled is a Intervention_Control, Olprinone is a Intervention_Pharmacological, olprinone is a Intervention_Pharmacological

72165_task0

Sentence: A Double-Blind Placebo-Controlled Study of the Effects of Olprinone , a Specific Phosphodiesterase III Inhibitor , for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer . BACKGROUND We previously reported that patients with elevated preoperative B-type natriuretic peptide ( BNP ) levels have an increased risk for postoperative atrial fibrillation following lung cancer surgery . The present study evaluated whether the specific phosphodiesterase III inhibitor olprinone can reduce the incidence of postoperative atrial fibrillation in patients with elevated BNP levels undergoing pulmonary resection for lung cancer . METHODS A prospective randomized study was conducted with 40 patients who had elevated preoperative BNP levels ( ≥ 30 pg/mL ) and underwent scheduled lung cancer surgery . All patients were in sinus rhythm at surgery . Low-dose olprinone or placebo was continuously infused for 24 h and started just before anesthesia induction . The primary end point was the incidence of postoperative atrial fibrillation . The secondary end points were perioperative hemodynamics and levels of BNP , WBC counts , and C-reactive protein . RESULTS The incidence of postoperative atrial fibrillation was significantly lower in the olprinone group than in the placebo group ( 10 % vs 60 % , P < .001 ) . Patients in the olprinone group showed significantly lower BNP , WBC counts , and C-reactive protein levels after surgery . CONCLUSIONS Continuous infusion of olprinone during lung cancer surgery was safe and reduced the incidence of postoperative atrial fibrillation following pulmonary resection in patients with elevated preoperative BNP levels . TRIAL REGISTRY Japan Primary Registries Network ; No . : JPRN-UMIN2404 ; URL : http : //www.umin.ac.jp/ctr/ . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control

[ "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A Double-Blind Placebo-Controlled Study of the Effects of Olprinone , a Specific Phosphodiesterase III Inhibitor , for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer . BACKGROUND We previously reported that patients with elevated preoperative B-type natriuretic peptide ( BNP ) levels have an increased risk for postoperative atrial fibrillation following lung cancer surgery . The present study evaluated whether the specific phosphodiesterase III inhibitor olprinone can reduce the incidence of postoperative atrial fibrillation in patients with elevated BNP levels undergoing pulmonary resection for lung cancer . METHODS A prospective randomized study was conducted with 40 patients who had elevated preoperative BNP levels ( ≥ 30 pg/mL ) and underwent scheduled lung cancer surgery . All patients were in sinus rhythm at surgery . Low-dose olprinone or placebo was continuously infused for 24 h and started just before anesthesia induction . The primary end point was the incidence of postoperative atrial fibrillation . The secondary end points were perioperative hemodynamics and levels of BNP , WBC counts , and C-reactive protein . RESULTS The incidence of postoperative atrial fibrillation was significantly lower in the olprinone group than in the placebo group ( 10 % vs 60 % , P < .001 ) . Patients in the olprinone group showed significantly lower BNP , WBC counts , and C-reactive protein levels after surgery . CONCLUSIONS Continuous infusion of olprinone during lung cancer surgery was safe and reduced the incidence of postoperative atrial fibrillation following pulmonary resection in patients with elevated preoperative BNP levels . TRIAL REGISTRY Japan Primary Registries Network ; No . : JPRN-UMIN2404 ; URL : http : //www.umin.ac.jp/ctr/ .

[ "A", "Double", "-", "Blind", "Placebo", "-", "Controlled", "Study", "of", "the", "Effects", "of", "Olprinone", ",", "a", "Specific", "Phosphodiesterase", "III", "Inhibitor", ",", "for", "Preventing", "Postoperative", "Atrial", "Fibrillation", "in", "Patients", "Undergoing", "Pulmonary", "Resection", "for", "Lung", "Cancer", ".", "BACKGROUND", "We", "previously", "reported", "that", "patients", "with", "elevated", "preoperative", "B", "-", "type", "natriuretic", "peptide", "(", "BNP", ")", "levels", "have", "an", "increased", "risk", "for", "postoperative", "atrial", "fibrillation", "following", "lung", "cancer", "surgery", ".", "The", "present", "study", "evaluated", "whether", "the", "specific", "phosphodiesterase", "III", "inhibitor", "olprinone", "can", "reduce", "the", "incidence", "of", "postoperative", "atrial", "fibrillation", "in", "patients", "with", "elevated", "BNP", "levels", "undergoing", "pulmonary", "resection", "for", "lung", "cancer", ".", "METHODS", "A", "prospective", "randomized", "study", "was", "conducted", "with", "40", "patients", "who", "had", "elevated", "preoperative", "BNP", "levels", "(", "≥", "30", "pg", "/", "mL", ")", "and", "underwent", "scheduled", "lung", "cancer", "surgery", ".", "All", "patients", "were", "in", "sinus", "rhythm", "at", "surgery", ".", "Low", "-", "dose", "olprinone", "or", "placebo", "was", "continuously", "infused", "for", "24", "h", "and", "started", "just", "before", "anesthesia", "induction", ".", "The", "primary", "end", "point", "was", "the", "incidence", "of", "postoperative", "atrial", "fibrillation", ".", "The", "secondary", "end", "points", "were", "perioperative", "hemodynamics", "and", "levels", "of", "BNP", ",", "WBC", "counts", ",", "and", "C", "-", "reactive", "protein", ".", "RESULTS", "The", "incidence", "of", "postoperative", "atrial", "fibrillation", "was", "significantly", "lower", "in", "the", "olprinone", "group", "than", "in", "the", "placebo", "group", "(", "10", "%", "vs", "60", "%", ",", "P", "<", ".001", ")", ".", "Patients", "in", "the", "olprinone", "group", "showed", "significantly", "lower", "BNP", ",", "WBC", "counts", ",", "and", "C", "-", "reactive", "protein", "levels", "after", "surgery", ".", "CONCLUSIONS", "Continuous", "infusion", "of", "olprinone", "during", "lung", "cancer", "surgery", "was", "safe", "and", "reduced", "the", "incidence", "of", "postoperative", "atrial", "fibrillation", "following", "pulmonary", "resection", "in", "patients", "with", "elevated", "preoperative", "BNP", "levels", ".", "TRIAL", "REGISTRY", "Japan", "Primary", "Registries", "Network", ";", "No", ".", ":", "JPRN", "-", "UMIN2404", ";", "URL", ":", "http", ":", "//www.umin.ac.jp", "/", "ctr/", "." ]

[ "Intervention_Control", "Intervention_Pharmacological" ]

Placebo - Controlled is a Intervention_Control, Olprinone is a Intervention_Pharmacological, olprinone is a Intervention_Pharmacological

72165_task1

Sentence: A Double-Blind Placebo-Controlled Study of the Effects of Olprinone , a Specific Phosphodiesterase III Inhibitor , for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer . BACKGROUND We previously reported that patients with elevated preoperative B-type natriuretic peptide ( BNP ) levels have an increased risk for postoperative atrial fibrillation following lung cancer surgery . The present study evaluated whether the specific phosphodiesterase III inhibitor olprinone can reduce the incidence of postoperative atrial fibrillation in patients with elevated BNP levels undergoing pulmonary resection for lung cancer . METHODS A prospective randomized study was conducted with 40 patients who had elevated preoperative BNP levels ( ≥ 30 pg/mL ) and underwent scheduled lung cancer surgery . All patients were in sinus rhythm at surgery . Low-dose olprinone or placebo was continuously infused for 24 h and started just before anesthesia induction . The primary end point was the incidence of postoperative atrial fibrillation . The secondary end points were perioperative hemodynamics and levels of BNP , WBC counts , and C-reactive protein . RESULTS The incidence of postoperative atrial fibrillation was significantly lower in the olprinone group than in the placebo group ( 10 % vs 60 % , P < .001 ) . Patients in the olprinone group showed significantly lower BNP , WBC counts , and C-reactive protein levels after surgery . CONCLUSIONS Continuous infusion of olprinone during lung cancer surgery was safe and reduced the incidence of postoperative atrial fibrillation following pulmonary resection in patients with elevated preoperative BNP levels . TRIAL REGISTRY Japan Primary Registries Network ; No . : JPRN-UMIN2404 ; URL : http : //www.umin.ac.jp/ctr/ . Instructions: please typing these entity words according to sentence: Placebo - Controlled, Olprinone, olprinone Options: Intervention_Pharmacological, Intervention_Control

[ "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A Double-Blind Placebo-Controlled Study of the Effects of Olprinone , a Specific Phosphodiesterase III Inhibitor , for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer . BACKGROUND We previously reported that patients with elevated preoperative B-type natriuretic peptide ( BNP ) levels have an increased risk for postoperative atrial fibrillation following lung cancer surgery . The present study evaluated whether the specific phosphodiesterase III inhibitor olprinone can reduce the incidence of postoperative atrial fibrillation in patients with elevated BNP levels undergoing pulmonary resection for lung cancer . METHODS A prospective randomized study was conducted with 40 patients who had elevated preoperative BNP levels ( ≥ 30 pg/mL ) and underwent scheduled lung cancer surgery . All patients were in sinus rhythm at surgery . Low-dose olprinone or placebo was continuously infused for 24 h and started just before anesthesia induction . The primary end point was the incidence of postoperative atrial fibrillation . The secondary end points were perioperative hemodynamics and levels of BNP , WBC counts , and C-reactive protein . RESULTS The incidence of postoperative atrial fibrillation was significantly lower in the olprinone group than in the placebo group ( 10 % vs 60 % , P < .001 ) . Patients in the olprinone group showed significantly lower BNP , WBC counts , and C-reactive protein levels after surgery . CONCLUSIONS Continuous infusion of olprinone during lung cancer surgery was safe and reduced the incidence of postoperative atrial fibrillation following pulmonary resection in patients with elevated preoperative BNP levels . TRIAL REGISTRY Japan Primary Registries Network ; No . : JPRN-UMIN2404 ; URL : http : //www.umin.ac.jp/ctr/ .

[ "A", "Double", "-", "Blind", "Placebo", "-", "Controlled", "Study", "of", "the", "Effects", "of", "Olprinone", ",", "a", "Specific", "Phosphodiesterase", "III", "Inhibitor", ",", "for", "Preventing", "Postoperative", "Atrial", "Fibrillation", "in", "Patients", "Undergoing", "Pulmonary", "Resection", "for", "Lung", "Cancer", ".", "BACKGROUND", "We", "previously", "reported", "that", "patients", "with", "elevated", "preoperative", "B", "-", "type", "natriuretic", "peptide", "(", "BNP", ")", "levels", "have", "an", "increased", "risk", "for", "postoperative", "atrial", "fibrillation", "following", "lung", "cancer", "surgery", ".", "The", "present", "study", "evaluated", "whether", "the", "specific", "phosphodiesterase", "III", "inhibitor", "olprinone", "can", "reduce", "the", "incidence", "of", "postoperative", "atrial", "fibrillation", "in", "patients", "with", "elevated", "BNP", "levels", "undergoing", "pulmonary", "resection", "for", "lung", "cancer", ".", "METHODS", "A", "prospective", "randomized", "study", "was", "conducted", "with", "40", "patients", "who", "had", "elevated", "preoperative", "BNP", "levels", "(", "≥", "30", "pg", "/", "mL", ")", "and", "underwent", "scheduled", "lung", "cancer", "surgery", ".", "All", "patients", "were", "in", "sinus", "rhythm", "at", "surgery", ".", "Low", "-", "dose", "olprinone", "or", "placebo", "was", "continuously", "infused", "for", "24", "h", "and", "started", "just", "before", "anesthesia", "induction", ".", "The", "primary", "end", "point", "was", "the", "incidence", "of", "postoperative", "atrial", "fibrillation", ".", "The", "secondary", "end", "points", "were", "perioperative", "hemodynamics", "and", "levels", "of", "BNP", ",", "WBC", "counts", ",", "and", "C", "-", "reactive", "protein", ".", "RESULTS", "The", "incidence", "of", "postoperative", "atrial", "fibrillation", "was", "significantly", "lower", "in", "the", "olprinone", "group", "than", "in", "the", "placebo", "group", "(", "10", "%", "vs", "60", "%", ",", "P", "<", ".001", ")", ".", "Patients", "in", "the", "olprinone", "group", "showed", "significantly", "lower", "BNP", ",", "WBC", "counts", ",", "and", "C", "-", "reactive", "protein", "levels", "after", "surgery", ".", "CONCLUSIONS", "Continuous", "infusion", "of", "olprinone", "during", "lung", "cancer", "surgery", "was", "safe", "and", "reduced", "the", "incidence", "of", "postoperative", "atrial", "fibrillation", "following", "pulmonary", "resection", "in", "patients", "with", "elevated", "preoperative", "BNP", "levels", ".", "TRIAL", "REGISTRY", "Japan", "Primary", "Registries", "Network", ";", "No", ".", ":", "JPRN", "-", "UMIN2404", ";", "URL", ":", "http", ":", "//www.umin.ac.jp", "/", "ctr/", "." ]

[ "Intervention_Control", "Intervention_Pharmacological" ]

Placebo - Controlled, Olprinone, olprinone

72165_task2

Sentence: A Double-Blind Placebo-Controlled Study of the Effects of Olprinone , a Specific Phosphodiesterase III Inhibitor , for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer . BACKGROUND We previously reported that patients with elevated preoperative B-type natriuretic peptide ( BNP ) levels have an increased risk for postoperative atrial fibrillation following lung cancer surgery . The present study evaluated whether the specific phosphodiesterase III inhibitor olprinone can reduce the incidence of postoperative atrial fibrillation in patients with elevated BNP levels undergoing pulmonary resection for lung cancer . METHODS A prospective randomized study was conducted with 40 patients who had elevated preoperative BNP levels ( ≥ 30 pg/mL ) and underwent scheduled lung cancer surgery . All patients were in sinus rhythm at surgery . Low-dose olprinone or placebo was continuously infused for 24 h and started just before anesthesia induction . The primary end point was the incidence of postoperative atrial fibrillation . The secondary end points were perioperative hemodynamics and levels of BNP , WBC counts , and C-reactive protein . RESULTS The incidence of postoperative atrial fibrillation was significantly lower in the olprinone group than in the placebo group ( 10 % vs 60 % , P < .001 ) . Patients in the olprinone group showed significantly lower BNP , WBC counts , and C-reactive protein levels after surgery . CONCLUSIONS Continuous infusion of olprinone during lung cancer surgery was safe and reduced the incidence of postoperative atrial fibrillation following pulmonary resection in patients with elevated preoperative BNP levels . TRIAL REGISTRY Japan Primary Registries Network ; No . : JPRN-UMIN2404 ; URL : http : //www.umin.ac.jp/ctr/ . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A Double-Blind Placebo-Controlled Study of the Effects of Olprinone , a Specific Phosphodiesterase III Inhibitor , for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer . BACKGROUND We previously reported that patients with elevated preoperative B-type natriuretic peptide ( BNP ) levels have an increased risk for postoperative atrial fibrillation following lung cancer surgery . The present study evaluated whether the specific phosphodiesterase III inhibitor olprinone can reduce the incidence of postoperative atrial fibrillation in patients with elevated BNP levels undergoing pulmonary resection for lung cancer . METHODS A prospective randomized study was conducted with 40 patients who had elevated preoperative BNP levels ( ≥ 30 pg/mL ) and underwent scheduled lung cancer surgery . All patients were in sinus rhythm at surgery . Low-dose olprinone or placebo was continuously infused for 24 h and started just before anesthesia induction . The primary end point was the incidence of postoperative atrial fibrillation . The secondary end points were perioperative hemodynamics and levels of BNP , WBC counts , and C-reactive protein . RESULTS The incidence of postoperative atrial fibrillation was significantly lower in the olprinone group than in the placebo group ( 10 % vs 60 % , P < .001 ) . Patients in the olprinone group showed significantly lower BNP , WBC counts , and C-reactive protein levels after surgery . CONCLUSIONS Continuous infusion of olprinone during lung cancer surgery was safe and reduced the incidence of postoperative atrial fibrillation following pulmonary resection in patients with elevated preoperative BNP levels . TRIAL REGISTRY Japan Primary Registries Network ; No . : JPRN-UMIN2404 ; URL : http : //www.umin.ac.jp/ctr/ .

[ "A", "Double", "-", "Blind", "Placebo", "-", "Controlled", "Study", "of", "the", "Effects", "of", "Olprinone", ",", "a", "Specific", "Phosphodiesterase", "III", "Inhibitor", ",", "for", "Preventing", "Postoperative", "Atrial", "Fibrillation", "in", "Patients", "Undergoing", "Pulmonary", "Resection", "for", "Lung", "Cancer", ".", "BACKGROUND", "We", "previously", "reported", "that", "patients", "with", "elevated", "preoperative", "B", "-", "type", "natriuretic", "peptide", "(", "BNP", ")", "levels", "have", "an", "increased", "risk", "for", "postoperative", "atrial", "fibrillation", "following", "lung", "cancer", "surgery", ".", "The", "present", "study", "evaluated", "whether", "the", "specific", "phosphodiesterase", "III", "inhibitor", "olprinone", "can", "reduce", "the", "incidence", "of", "postoperative", "atrial", "fibrillation", "in", "patients", "with", "elevated", "BNP", "levels", "undergoing", "pulmonary", "resection", "for", "lung", "cancer", ".", "METHODS", "A", "prospective", "randomized", "study", "was", "conducted", "with", "40", "patients", "who", "had", "elevated", "preoperative", "BNP", "levels", "(", "≥", "30", "pg", "/", "mL", ")", "and", "underwent", "scheduled", "lung", "cancer", "surgery", ".", "All", "patients", "were", "in", "sinus", "rhythm", "at", "surgery", ".", "Low", "-", "dose", "olprinone", "or", "placebo", "was", "continuously", "infused", "for", "24", "h", "and", "started", "just", "before", "anesthesia", "induction", ".", "The", "primary", "end", "point", "was", "the", "incidence", "of", "postoperative", "atrial", "fibrillation", ".", "The", "secondary", "end", "points", "were", "perioperative", "hemodynamics", "and", "levels", "of", "BNP", ",", "WBC", "counts", ",", "and", "C", "-", "reactive", "protein", ".", "RESULTS", "The", "incidence", "of", "postoperative", "atrial", "fibrillation", "was", "significantly", "lower", "in", "the", "olprinone", "group", "than", "in", "the", "placebo", "group", "(", "10", "%", "vs", "60", "%", ",", "P", "<", ".001", ")", ".", "Patients", "in", "the", "olprinone", "group", "showed", "significantly", "lower", "BNP", ",", "WBC", "counts", ",", "and", "C", "-", "reactive", "protein", "levels", "after", "surgery", ".", "CONCLUSIONS", "Continuous", "infusion", "of", "olprinone", "during", "lung", "cancer", "surgery", "was", "safe", "and", "reduced", "the", "incidence", "of", "postoperative", "atrial", "fibrillation", "following", "pulmonary", "resection", "in", "patients", "with", "elevated", "preoperative", "BNP", "levels", ".", "TRIAL", "REGISTRY", "Japan", "Primary", "Registries", "Network", ";", "No", ".", ":", "JPRN", "-", "UMIN2404", ";", "URL", ":", "http", ":", "//www.umin.ac.jp", "/", "ctr/", "." ]

[ "Intervention_Control", "Intervention_Pharmacological" ]

ESEs is a DNA, SR is a protein-family, U2AF35 is a protein, U2AF is a protein-complex, U2AF65 is a protein, Py tract is a DNA

1.0alpha7.train.279_task0

Sentence: To further investigate a possible role for ESEs in U2AF35-dependent splicing, an experiment was designed to test a critical tenet of the recruitment model for exon enhancer function: SR proteins bound to the enhancer sequence establish protein-protein interactions with U2AF35 that increase the local concentration of the U2AF heterodimer and facilitate U2AF65 binding to the Py tract (13). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-complex, DNA, protein-family, protein

[ "O", "O", "O", "O", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-protein-complex", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "I-DNA", "O", "O", "O", "O" ]

To further investigate a possible role for ESEs in U2AF35-dependent splicing, an experiment was designed to test a critical tenet of the recruitment model for exon enhancer function: SR proteins bound to the enhancer sequence establish protein-protein interactions with U2AF35 that increase the local concentration of the U2AF heterodimer and facilitate U2AF65 binding to the Py tract (13).

[ "To", "further", "investigate", "a", "possible", "role", "for", "ESEs", "in", "U2AF35-dependent", "splicing", ",", "an", "experiment", "was", "designed", "to", "test", "a", "critical", "tenet", "of", "the", "recruitment", "model", "for", "exon", "enhancer", "function", ":", "SR", "proteins", "bound", "to", "the", "enhancer", "sequence", "establish", "protein", "-", "protein", "interactions", "with", "U2AF35", "that", "increase", "the", "local", "concentration", "of", "the", "U2AF", "heterodimer", "and", "facilitate", "U2AF65", "binding", "to", "the", "Py", "tract", "(", "13", ")", "." ]

[ "DNA", "protein", "protein-complex", "protein-family" ]

ESEs is a DNA, SR is a protein-family, U2AF35 is a protein, U2AF is a protein-complex, U2AF65 is a protein, Py tract is a DNA

1.0alpha7.train.279_task1

Sentence: To further investigate a possible role for ESEs in U2AF35-dependent splicing, an experiment was designed to test a critical tenet of the recruitment model for exon enhancer function: SR proteins bound to the enhancer sequence establish protein-protein interactions with U2AF35 that increase the local concentration of the U2AF heterodimer and facilitate U2AF65 binding to the Py tract (13). Instructions: please typing these entity words according to sentence: ESEs, SR, U2AF35, U2AF, U2AF65, Py tract Options: protein-complex, DNA, protein-family, protein

[ "O", "O", "O", "O", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-protein-complex", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "I-DNA", "O", "O", "O", "O" ]

To further investigate a possible role for ESEs in U2AF35-dependent splicing, an experiment was designed to test a critical tenet of the recruitment model for exon enhancer function: SR proteins bound to the enhancer sequence establish protein-protein interactions with U2AF35 that increase the local concentration of the U2AF heterodimer and facilitate U2AF65 binding to the Py tract (13).

[ "To", "further", "investigate", "a", "possible", "role", "for", "ESEs", "in", "U2AF35-dependent", "splicing", ",", "an", "experiment", "was", "designed", "to", "test", "a", "critical", "tenet", "of", "the", "recruitment", "model", "for", "exon", "enhancer", "function", ":", "SR", "proteins", "bound", "to", "the", "enhancer", "sequence", "establish", "protein", "-", "protein", "interactions", "with", "U2AF35", "that", "increase", "the", "local", "concentration", "of", "the", "U2AF", "heterodimer", "and", "facilitate", "U2AF65", "binding", "to", "the", "Py", "tract", "(", "13", ")", "." ]

[ "DNA", "protein", "protein-complex", "protein-family" ]

ESEs, SR, U2AF35, U2AF, U2AF65, Py tract

1.0alpha7.train.279_task2

Sentence: To further investigate a possible role for ESEs in U2AF35-dependent splicing, an experiment was designed to test a critical tenet of the recruitment model for exon enhancer function: SR proteins bound to the enhancer sequence establish protein-protein interactions with U2AF35 that increase the local concentration of the U2AF heterodimer and facilitate U2AF65 binding to the Py tract (13). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-protein-complex", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "I-DNA", "O", "O", "O", "O" ]

To further investigate a possible role for ESEs in U2AF35-dependent splicing, an experiment was designed to test a critical tenet of the recruitment model for exon enhancer function: SR proteins bound to the enhancer sequence establish protein-protein interactions with U2AF35 that increase the local concentration of the U2AF heterodimer and facilitate U2AF65 binding to the Py tract (13).

[ "To", "further", "investigate", "a", "possible", "role", "for", "ESEs", "in", "U2AF35-dependent", "splicing", ",", "an", "experiment", "was", "designed", "to", "test", "a", "critical", "tenet", "of", "the", "recruitment", "model", "for", "exon", "enhancer", "function", ":", "SR", "proteins", "bound", "to", "the", "enhancer", "sequence", "establish", "protein", "-", "protein", "interactions", "with", "U2AF35", "that", "increase", "the", "local", "concentration", "of", "the", "U2AF", "heterodimer", "and", "facilitate", "U2AF65", "binding", "to", "the", "Py", "tract", "(", "13", ")", "." ]

[ "DNA", "protein", "protein-complex", "protein-family" ]

Haloperidol is a CHEMICAL, ribosomal protein S6 is a GENE-Y, dopamine- and cAMP - regulated phosphoprotein of 32 kDa is a GENE-Y, protein phosphatase-1 is a GENE-N

23643747_task0

Sentence: Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL

[ "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O" ]

Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.

[ "Haloperidol", "promotes", "mTORC1-dependent", "phosphorylation", "of", "ribosomal", "protein", "S6", "via", "dopamine-", "and", "cAMP", "-", "regulated", "phosphoprotein", "of", "32", "kDa", "and", "inhibition", "of", "protein", "phosphatase-1", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

Haloperidol is a CHEMICAL, ribosomal protein S6 is a GENE-Y, dopamine- and cAMP - regulated phosphoprotein of 32 kDa is a GENE-Y, protein phosphatase-1 is a GENE-N

23643747_task1

Sentence: Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1. Instructions: please typing these entity words according to sentence: Haloperidol, ribosomal protein S6, dopamine- and cAMP - regulated phosphoprotein of 32 kDa, protein phosphatase-1 Options: GENE-N, GENE-Y, CHEMICAL

[ "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O" ]

Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.

[ "Haloperidol", "promotes", "mTORC1-dependent", "phosphorylation", "of", "ribosomal", "protein", "S6", "via", "dopamine-", "and", "cAMP", "-", "regulated", "phosphoprotein", "of", "32", "kDa", "and", "inhibition", "of", "protein", "phosphatase-1", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

Haloperidol, ribosomal protein S6, dopamine- and cAMP - regulated phosphoprotein of 32 kDa, protein phosphatase-1

23643747_task2

Sentence: Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1. Instructions: please extract entity words from the input sentence

[ "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O" ]

Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.

[ "Haloperidol", "promotes", "mTORC1-dependent", "phosphorylation", "of", "ribosomal", "protein", "S6", "via", "dopamine-", "and", "cAMP", "-", "regulated", "phosphoprotein", "of", "32", "kDa", "and", "inhibition", "of", "protein", "phosphatase-1", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

Copper is a CHEMICAL, Bis(l - histidinato)cadmium Dihydrate is a CHEMICAL

23530765_task0

Sentence: Electron Paramagnetic Resonance Spectroscopic Study of Copper Hopping in Doped Bis(l-histidinato)cadmium Dihydrate. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O" ]

Electron Paramagnetic Resonance Spectroscopic Study of Copper Hopping in Doped Bis(l-histidinato)cadmium Dihydrate.

[ "Electron", "Paramagnetic", "Resonance", "Spectroscopic", "Study", "of", "Copper", "Hopping", "in", "Doped", "Bis(l", "-", "histidinato)cadmium", "Dihydrate", "." ]

[ "CHEMICAL" ]

Copper is a CHEMICAL, Bis(l - histidinato)cadmium Dihydrate is a CHEMICAL

23530765_task1

Sentence: Electron Paramagnetic Resonance Spectroscopic Study of Copper Hopping in Doped Bis(l-histidinato)cadmium Dihydrate. Instructions: please typing these entity words according to sentence: Copper, Bis(l - histidinato)cadmium Dihydrate Options: CHEMICAL

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O" ]

Electron Paramagnetic Resonance Spectroscopic Study of Copper Hopping in Doped Bis(l-histidinato)cadmium Dihydrate.

[ "Electron", "Paramagnetic", "Resonance", "Spectroscopic", "Study", "of", "Copper", "Hopping", "in", "Doped", "Bis(l", "-", "histidinato)cadmium", "Dihydrate", "." ]

[ "CHEMICAL" ]

Copper, Bis(l - histidinato)cadmium Dihydrate

23530765_task2

Sentence: Electron Paramagnetic Resonance Spectroscopic Study of Copper Hopping in Doped Bis(l-histidinato)cadmium Dihydrate. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O" ]

Electron Paramagnetic Resonance Spectroscopic Study of Copper Hopping in Doped Bis(l-histidinato)cadmium Dihydrate.

[ "Electron", "Paramagnetic", "Resonance", "Spectroscopic", "Study", "of", "Copper", "Hopping", "in", "Doped", "Bis(l", "-", "histidinato)cadmium", "Dihydrate", "." ]

[ "CHEMICAL" ]

Tenascin is an umlsterm, Plattenepithelkarzinome is an umlsterm, Tumoren is an umlsterm, Zellen is an umlsterm, Tenascin is an umlsterm, Tumorstadium is an umlsterm, In - situ - Hybridisierung is an umlsterm, Nativgeweben is an umlsterm, Lymphknotenmetastasen is an umlsterm, Tumorzellkulturen is an umlsterm, Normalschleimhaut is an umlsterm, Tenascin is an umlsterm, Tumoren is an umlsterm, tumorumgebenden is an umlsterm, Gewebeschnitt is an umlsterm, Proteinanalyse is an umlsterm, Tumorzellkulturen is an umlsterm, Tumorzellen is an umlsterm, selbst is an umlsterm, Tenascin is an umlsterm, Tumorproliferation is an umlsterm, Tenascin is an umlsterm, Kopf - Hals - Tumoren is an umlsterm, gezielte is an umlsterm, Therapie is an umlsterm

HNO.90470723.ger.abstr_task0

Sentence: Tenascin , ein Glykoprotein der extrazellulaeren Matrix ( EZM ) , ist aufgrund seiner proliferations- und migrationsassoziierten Expression ein Zielmolekuel in der intralaesionalen Glioblastomtherapie . Ob dieses Konzept auf Plattenepithelkarzinome des oberen Aerodigestivtraktes uebertragbar ist , haengt wesentlich vom Tenascinexpressionsmuster in diesen Tumoren ab . Unser Ziel war es zu klaeren , von welchen Zellen und wie selektiv Tenascin exprimiert wird und ob ein Zusammenhang mit dem Tumorstadium besteht . Die Tenascinexpression wurde immunhistochemisch und ueber In-situ-Hybridisierung an Nativgeweben von Primaertumoren und Lymphknotenmetastasen ( n=39) sowie an Tumorzellkulturen ( n=15) untersucht . Die so erhaltenen Expressionsmuster wurden denen der Normalschleimhaut gegenuebergestellt . Tenascin wurde in Tumoren verstaerkt exprimiert und war in der gesamten tumorumgebenden EZM lokalisiert . Die mRNA-Analyse am Gewebeschnitt und die Proteinanalyse der Tumorzellkulturen ergab , dass die Tumorzellen selbst Tenascin synthetisierten . Ein Zusammenhang von Tenascinexpression und TNM-Stadium oder Tumorproliferation war nicht nachweisbar . Unsere Ergebnisse zeigen , dass Tenascin in Kopf-Hals-Tumoren selektiv exprimiert wird und sich fuer eine gezielte , onkologische Therapie anbietet . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]

Tenascin , ein Glykoprotein der extrazellulaeren Matrix ( EZM ) , ist aufgrund seiner proliferations- und migrationsassoziierten Expression ein Zielmolekuel in der intralaesionalen Glioblastomtherapie . Ob dieses Konzept auf Plattenepithelkarzinome des oberen Aerodigestivtraktes uebertragbar ist , haengt wesentlich vom Tenascinexpressionsmuster in diesen Tumoren ab . Unser Ziel war es zu klaeren , von welchen Zellen und wie selektiv Tenascin exprimiert wird und ob ein Zusammenhang mit dem Tumorstadium besteht . Die Tenascinexpression wurde immunhistochemisch und ueber In-situ-Hybridisierung an Nativgeweben von Primaertumoren und Lymphknotenmetastasen ( n=39) sowie an Tumorzellkulturen ( n=15) untersucht . Die so erhaltenen Expressionsmuster wurden denen der Normalschleimhaut gegenuebergestellt . Tenascin wurde in Tumoren verstaerkt exprimiert und war in der gesamten tumorumgebenden EZM lokalisiert . Die mRNA-Analyse am Gewebeschnitt und die Proteinanalyse der Tumorzellkulturen ergab , dass die Tumorzellen selbst Tenascin synthetisierten . Ein Zusammenhang von Tenascinexpression und TNM-Stadium oder Tumorproliferation war nicht nachweisbar . Unsere Ergebnisse zeigen , dass Tenascin in Kopf-Hals-Tumoren selektiv exprimiert wird und sich fuer eine gezielte , onkologische Therapie anbietet .

[ "Tenascin", ",", "ein", "Glykoprotein", "der", "extrazellulaeren", "Matrix", "(", "EZM", ")", ",", "ist", "aufgrund", "seiner", "proliferations-", "und", "migrationsassoziierten", "Expression", "ein", "Zielmolekuel", "in", "der", "intralaesionalen", "Glioblastomtherapie", ".", "Ob", "dieses", "Konzept", "auf", "Plattenepithelkarzinome", "des", "oberen", "Aerodigestivtraktes", "uebertragbar", "ist", ",", "haengt", "wesentlich", "vom", "Tenascinexpressionsmuster", "in", "diesen", "Tumoren", "ab", ".", "Unser", "Ziel", "war", "es", "zu", "klaeren", ",", "von", "welchen", "Zellen", "und", "wie", "selektiv", "Tenascin", "exprimiert", "wird", "und", "ob", "ein", "Zusammenhang", "mit", "dem", "Tumorstadium", "besteht", ".", "Die", "Tenascinexpression", "wurde", "immunhistochemisch", "und", "ueber", "In", "-", "situ", "-", "Hybridisierung", "an", "Nativgeweben", "von", "Primaertumoren", "und", "Lymphknotenmetastasen", "(", "n=39", ")", "sowie", "an", "Tumorzellkulturen", "(", "n=15", ")", "untersucht", ".", "Die", "so", "erhaltenen", "Expressionsmuster", "wurden", "denen", "der", "Normalschleimhaut", "gegenuebergestellt", ".", "Tenascin", "wurde", "in", "Tumoren", "verstaerkt", "exprimiert", "und", "war", "in", "der", "gesamten", "tumorumgebenden", "EZM", "lokalisiert", ".", "Die", "mRNA", "-", "Analyse", "am", "Gewebeschnitt", "und", "die", "Proteinanalyse", "der", "Tumorzellkulturen", "ergab", ",", "dass", "die", "Tumorzellen", "selbst", "Tenascin", "synthetisierten", ".", "Ein", "Zusammenhang", "von", "Tenascinexpression", "und", "TNM", "-", "Stadium", "oder", "Tumorproliferation", "war", "nicht", "nachweisbar", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "Tenascin", "in", "Kopf", "-", "Hals", "-", "Tumoren", "selektiv", "exprimiert", "wird", "und", "sich", "fuer", "eine", "gezielte", ",", "onkologische", "Therapie", "anbietet", "." ]

[ "umlsterm" ]

Tenascin is an umlsterm, Plattenepithelkarzinome is an umlsterm, Tumoren is an umlsterm, Zellen is an umlsterm, Tenascin is an umlsterm, Tumorstadium is an umlsterm, In - situ - Hybridisierung is an umlsterm, Nativgeweben is an umlsterm, Lymphknotenmetastasen is an umlsterm, Tumorzellkulturen is an umlsterm, Normalschleimhaut is an umlsterm, Tenascin is an umlsterm, Tumoren is an umlsterm, tumorumgebenden is an umlsterm, Gewebeschnitt is an umlsterm, Proteinanalyse is an umlsterm, Tumorzellkulturen is an umlsterm, Tumorzellen is an umlsterm, selbst is an umlsterm, Tenascin is an umlsterm, Tumorproliferation is an umlsterm, Tenascin is an umlsterm, Kopf - Hals - Tumoren is an umlsterm, gezielte is an umlsterm, Therapie is an umlsterm

HNO.90470723.ger.abstr_task1

Sentence: Tenascin , ein Glykoprotein der extrazellulaeren Matrix ( EZM ) , ist aufgrund seiner proliferations- und migrationsassoziierten Expression ein Zielmolekuel in der intralaesionalen Glioblastomtherapie . Ob dieses Konzept auf Plattenepithelkarzinome des oberen Aerodigestivtraktes uebertragbar ist , haengt wesentlich vom Tenascinexpressionsmuster in diesen Tumoren ab . Unser Ziel war es zu klaeren , von welchen Zellen und wie selektiv Tenascin exprimiert wird und ob ein Zusammenhang mit dem Tumorstadium besteht . Die Tenascinexpression wurde immunhistochemisch und ueber In-situ-Hybridisierung an Nativgeweben von Primaertumoren und Lymphknotenmetastasen ( n=39) sowie an Tumorzellkulturen ( n=15) untersucht . Die so erhaltenen Expressionsmuster wurden denen der Normalschleimhaut gegenuebergestellt . Tenascin wurde in Tumoren verstaerkt exprimiert und war in der gesamten tumorumgebenden EZM lokalisiert . Die mRNA-Analyse am Gewebeschnitt und die Proteinanalyse der Tumorzellkulturen ergab , dass die Tumorzellen selbst Tenascin synthetisierten . Ein Zusammenhang von Tenascinexpression und TNM-Stadium oder Tumorproliferation war nicht nachweisbar . Unsere Ergebnisse zeigen , dass Tenascin in Kopf-Hals-Tumoren selektiv exprimiert wird und sich fuer eine gezielte , onkologische Therapie anbietet . Instructions: please typing these entity words according to sentence: Tenascin, Plattenepithelkarzinome, Tumoren, Zellen, Tenascin, Tumorstadium, In - situ - Hybridisierung, Nativgeweben, Lymphknotenmetastasen, Tumorzellkulturen, Normalschleimhaut, Tenascin, Tumoren, tumorumgebenden, Gewebeschnitt, Proteinanalyse, Tumorzellkulturen, Tumorzellen, selbst, Tenascin, Tumorproliferation, Tenascin, Kopf - Hals - Tumoren, gezielte, Therapie Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]

Tenascin , ein Glykoprotein der extrazellulaeren Matrix ( EZM ) , ist aufgrund seiner proliferations- und migrationsassoziierten Expression ein Zielmolekuel in der intralaesionalen Glioblastomtherapie . Ob dieses Konzept auf Plattenepithelkarzinome des oberen Aerodigestivtraktes uebertragbar ist , haengt wesentlich vom Tenascinexpressionsmuster in diesen Tumoren ab . Unser Ziel war es zu klaeren , von welchen Zellen und wie selektiv Tenascin exprimiert wird und ob ein Zusammenhang mit dem Tumorstadium besteht . Die Tenascinexpression wurde immunhistochemisch und ueber In-situ-Hybridisierung an Nativgeweben von Primaertumoren und Lymphknotenmetastasen ( n=39) sowie an Tumorzellkulturen ( n=15) untersucht . Die so erhaltenen Expressionsmuster wurden denen der Normalschleimhaut gegenuebergestellt . Tenascin wurde in Tumoren verstaerkt exprimiert und war in der gesamten tumorumgebenden EZM lokalisiert . Die mRNA-Analyse am Gewebeschnitt und die Proteinanalyse der Tumorzellkulturen ergab , dass die Tumorzellen selbst Tenascin synthetisierten . Ein Zusammenhang von Tenascinexpression und TNM-Stadium oder Tumorproliferation war nicht nachweisbar . Unsere Ergebnisse zeigen , dass Tenascin in Kopf-Hals-Tumoren selektiv exprimiert wird und sich fuer eine gezielte , onkologische Therapie anbietet .

[ "Tenascin", ",", "ein", "Glykoprotein", "der", "extrazellulaeren", "Matrix", "(", "EZM", ")", ",", "ist", "aufgrund", "seiner", "proliferations-", "und", "migrationsassoziierten", "Expression", "ein", "Zielmolekuel", "in", "der", "intralaesionalen", "Glioblastomtherapie", ".", "Ob", "dieses", "Konzept", "auf", "Plattenepithelkarzinome", "des", "oberen", "Aerodigestivtraktes", "uebertragbar", "ist", ",", "haengt", "wesentlich", "vom", "Tenascinexpressionsmuster", "in", "diesen", "Tumoren", "ab", ".", "Unser", "Ziel", "war", "es", "zu", "klaeren", ",", "von", "welchen", "Zellen", "und", "wie", "selektiv", "Tenascin", "exprimiert", "wird", "und", "ob", "ein", "Zusammenhang", "mit", "dem", "Tumorstadium", "besteht", ".", "Die", "Tenascinexpression", "wurde", "immunhistochemisch", "und", "ueber", "In", "-", "situ", "-", "Hybridisierung", "an", "Nativgeweben", "von", "Primaertumoren", "und", "Lymphknotenmetastasen", "(", "n=39", ")", "sowie", "an", "Tumorzellkulturen", "(", "n=15", ")", "untersucht", ".", "Die", "so", "erhaltenen", "Expressionsmuster", "wurden", "denen", "der", "Normalschleimhaut", "gegenuebergestellt", ".", "Tenascin", "wurde", "in", "Tumoren", "verstaerkt", "exprimiert", "und", "war", "in", "der", "gesamten", "tumorumgebenden", "EZM", "lokalisiert", ".", "Die", "mRNA", "-", "Analyse", "am", "Gewebeschnitt", "und", "die", "Proteinanalyse", "der", "Tumorzellkulturen", "ergab", ",", "dass", "die", "Tumorzellen", "selbst", "Tenascin", "synthetisierten", ".", "Ein", "Zusammenhang", "von", "Tenascinexpression", "und", "TNM", "-", "Stadium", "oder", "Tumorproliferation", "war", "nicht", "nachweisbar", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "Tenascin", "in", "Kopf", "-", "Hals", "-", "Tumoren", "selektiv", "exprimiert", "wird", "und", "sich", "fuer", "eine", "gezielte", ",", "onkologische", "Therapie", "anbietet", "." ]

[ "umlsterm" ]

Tenascin, Plattenepithelkarzinome, Tumoren, Zellen, Tenascin, Tumorstadium, In - situ - Hybridisierung, Nativgeweben, Lymphknotenmetastasen, Tumorzellkulturen, Normalschleimhaut, Tenascin, Tumoren, tumorumgebenden, Gewebeschnitt, Proteinanalyse, Tumorzellkulturen, Tumorzellen, selbst, Tenascin, Tumorproliferation, Tenascin, Kopf - Hals - Tumoren, gezielte, Therapie

HNO.90470723.ger.abstr_task2

Sentence: Tenascin , ein Glykoprotein der extrazellulaeren Matrix ( EZM ) , ist aufgrund seiner proliferations- und migrationsassoziierten Expression ein Zielmolekuel in der intralaesionalen Glioblastomtherapie . Ob dieses Konzept auf Plattenepithelkarzinome des oberen Aerodigestivtraktes uebertragbar ist , haengt wesentlich vom Tenascinexpressionsmuster in diesen Tumoren ab . Unser Ziel war es zu klaeren , von welchen Zellen und wie selektiv Tenascin exprimiert wird und ob ein Zusammenhang mit dem Tumorstadium besteht . Die Tenascinexpression wurde immunhistochemisch und ueber In-situ-Hybridisierung an Nativgeweben von Primaertumoren und Lymphknotenmetastasen ( n=39) sowie an Tumorzellkulturen ( n=15) untersucht . Die so erhaltenen Expressionsmuster wurden denen der Normalschleimhaut gegenuebergestellt . Tenascin wurde in Tumoren verstaerkt exprimiert und war in der gesamten tumorumgebenden EZM lokalisiert . Die mRNA-Analyse am Gewebeschnitt und die Proteinanalyse der Tumorzellkulturen ergab , dass die Tumorzellen selbst Tenascin synthetisierten . Ein Zusammenhang von Tenascinexpression und TNM-Stadium oder Tumorproliferation war nicht nachweisbar . Unsere Ergebnisse zeigen , dass Tenascin in Kopf-Hals-Tumoren selektiv exprimiert wird und sich fuer eine gezielte , onkologische Therapie anbietet . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]

Tenascin , ein Glykoprotein der extrazellulaeren Matrix ( EZM ) , ist aufgrund seiner proliferations- und migrationsassoziierten Expression ein Zielmolekuel in der intralaesionalen Glioblastomtherapie . Ob dieses Konzept auf Plattenepithelkarzinome des oberen Aerodigestivtraktes uebertragbar ist , haengt wesentlich vom Tenascinexpressionsmuster in diesen Tumoren ab . Unser Ziel war es zu klaeren , von welchen Zellen und wie selektiv Tenascin exprimiert wird und ob ein Zusammenhang mit dem Tumorstadium besteht . Die Tenascinexpression wurde immunhistochemisch und ueber In-situ-Hybridisierung an Nativgeweben von Primaertumoren und Lymphknotenmetastasen ( n=39) sowie an Tumorzellkulturen ( n=15) untersucht . Die so erhaltenen Expressionsmuster wurden denen der Normalschleimhaut gegenuebergestellt . Tenascin wurde in Tumoren verstaerkt exprimiert und war in der gesamten tumorumgebenden EZM lokalisiert . Die mRNA-Analyse am Gewebeschnitt und die Proteinanalyse der Tumorzellkulturen ergab , dass die Tumorzellen selbst Tenascin synthetisierten . Ein Zusammenhang von Tenascinexpression und TNM-Stadium oder Tumorproliferation war nicht nachweisbar . Unsere Ergebnisse zeigen , dass Tenascin in Kopf-Hals-Tumoren selektiv exprimiert wird und sich fuer eine gezielte , onkologische Therapie anbietet .

[ "Tenascin", ",", "ein", "Glykoprotein", "der", "extrazellulaeren", "Matrix", "(", "EZM", ")", ",", "ist", "aufgrund", "seiner", "proliferations-", "und", "migrationsassoziierten", "Expression", "ein", "Zielmolekuel", "in", "der", "intralaesionalen", "Glioblastomtherapie", ".", "Ob", "dieses", "Konzept", "auf", "Plattenepithelkarzinome", "des", "oberen", "Aerodigestivtraktes", "uebertragbar", "ist", ",", "haengt", "wesentlich", "vom", "Tenascinexpressionsmuster", "in", "diesen", "Tumoren", "ab", ".", "Unser", "Ziel", "war", "es", "zu", "klaeren", ",", "von", "welchen", "Zellen", "und", "wie", "selektiv", "Tenascin", "exprimiert", "wird", "und", "ob", "ein", "Zusammenhang", "mit", "dem", "Tumorstadium", "besteht", ".", "Die", "Tenascinexpression", "wurde", "immunhistochemisch", "und", "ueber", "In", "-", "situ", "-", "Hybridisierung", "an", "Nativgeweben", "von", "Primaertumoren", "und", "Lymphknotenmetastasen", "(", "n=39", ")", "sowie", "an", "Tumorzellkulturen", "(", "n=15", ")", "untersucht", ".", "Die", "so", "erhaltenen", "Expressionsmuster", "wurden", "denen", "der", "Normalschleimhaut", "gegenuebergestellt", ".", "Tenascin", "wurde", "in", "Tumoren", "verstaerkt", "exprimiert", "und", "war", "in", "der", "gesamten", "tumorumgebenden", "EZM", "lokalisiert", ".", "Die", "mRNA", "-", "Analyse", "am", "Gewebeschnitt", "und", "die", "Proteinanalyse", "der", "Tumorzellkulturen", "ergab", ",", "dass", "die", "Tumorzellen", "selbst", "Tenascin", "synthetisierten", ".", "Ein", "Zusammenhang", "von", "Tenascinexpression", "und", "TNM", "-", "Stadium", "oder", "Tumorproliferation", "war", "nicht", "nachweisbar", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "Tenascin", "in", "Kopf", "-", "Hals", "-", "Tumoren", "selektiv", "exprimiert", "wird", "und", "sich", "fuer", "eine", "gezielte", ",", "onkologische", "Therapie", "anbietet", "." ]

[ "umlsterm" ]

transducer is an umlsterm, cochlea is an umlsterm, amplifier is an umlsterm, CAI is an umlsterm, treatment is an umlsterm, hearing loss is an umlsterm, implantation is an umlsterm, mastoid is an umlsterm, University is an umlsterm, cochlea is an umlsterm, amplifier is an umlsterm, transducer is an umlsterm, patients is an umlsterm, future is an umlsterm, fit is an umlsterm, CAI is an umlsterm, mastoid is an umlsterm, X - ray is an umlsterm, CT scans is an umlsterm, cadaver is an umlsterm, temporal bone is an umlsterm, mastoid is an umlsterm, CT scans is an umlsterm, water is an umlsterm, determination is an umlsterm, CAI is an umlsterm, temporal bones is an umlsterm, X - ray is an umlsterm, evaluation is an umlsterm

HNO.80460220.eng.abstr_task0

Sentence: Recently , the transducer and microphone of a cochlea amplifier implant ( CAI ) for the treatment of sensorineural cochlear hearing loss have been developed further for implantation into the mastoid cavity . At present , the University of Tuebingen implantable cochlea amplifier consists of an implantable microphone and an implantable piezoelectric transducer . It has been implanted into the first patients . Successful future application of this new implant depends on the suitable fit of the CAI within a patient's mastoid cavity . Using conventional X-ray and CT scans , we analyzed 50 cadaver specimens of the temporal bone before total mastoidectomy . After total mastoidectomy , the volume of the mastoid cavity was measured using CT scans and water volume determination . Finally , the CAI was implanted into those temporal bones that were large enough to house it . Our results demonstrate that the degree of pneumatization in the conventional Schueller X-ray is already a good parameter for preoperative evaluation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Recently , the transducer and microphone of a cochlea amplifier implant ( CAI ) for the treatment of sensorineural cochlear hearing loss have been developed further for implantation into the mastoid cavity . At present , the University of Tuebingen implantable cochlea amplifier consists of an implantable microphone and an implantable piezoelectric transducer . It has been implanted into the first patients . Successful future application of this new implant depends on the suitable fit of the CAI within a patient's mastoid cavity . Using conventional X-ray and CT scans , we analyzed 50 cadaver specimens of the temporal bone before total mastoidectomy . After total mastoidectomy , the volume of the mastoid cavity was measured using CT scans and water volume determination . Finally , the CAI was implanted into those temporal bones that were large enough to house it . Our results demonstrate that the degree of pneumatization in the conventional Schueller X-ray is already a good parameter for preoperative evaluation .

[ "Recently", ",", "the", "transducer", "and", "microphone", "of", "a", "cochlea", "amplifier", "implant", "(", "CAI", ")", "for", "the", "treatment", "of", "sensorineural", "cochlear", "hearing", "loss", "have", "been", "developed", "further", "for", "implantation", "into", "the", "mastoid", "cavity", ".", "At", "present", ",", "the", "University", "of", "Tuebingen", "implantable", "cochlea", "amplifier", "consists", "of", "an", "implantable", "microphone", "and", "an", "implantable", "piezoelectric", "transducer", ".", "It", "has", "been", "implanted", "into", "the", "first", "patients", ".", "Successful", "future", "application", "of", "this", "new", "implant", "depends", "on", "the", "suitable", "fit", "of", "the", "CAI", "within", "a", "patient", "'s", "mastoid", "cavity", ".", "Using", "conventional", "X", "-", "ray", "and", "CT", "scans", ",", "we", "analyzed", "50", "cadaver", "specimens", "of", "the", "temporal", "bone", "before", "total", "mastoidectomy", ".", "After", "total", "mastoidectomy", ",", "the", "volume", "of", "the", "mastoid", "cavity", "was", "measured", "using", "CT", "scans", "and", "water", "volume", "determination", ".", "Finally", ",", "the", "CAI", "was", "implanted", "into", "those", "temporal", "bones", "that", "were", "large", "enough", "to", "house", "it", ".", "Our", "results", "demonstrate", "that", "the", "degree", "of", "pneumatization", "in", "the", "conventional", "Schueller", "X", "-", "ray", "is", "already", "a", "good", "parameter", "for", "preoperative", "evaluation", "." ]

[ "umlsterm" ]

transducer is an umlsterm, cochlea is an umlsterm, amplifier is an umlsterm, CAI is an umlsterm, treatment is an umlsterm, hearing loss is an umlsterm, implantation is an umlsterm, mastoid is an umlsterm, University is an umlsterm, cochlea is an umlsterm, amplifier is an umlsterm, transducer is an umlsterm, patients is an umlsterm, future is an umlsterm, fit is an umlsterm, CAI is an umlsterm, mastoid is an umlsterm, X - ray is an umlsterm, CT scans is an umlsterm, cadaver is an umlsterm, temporal bone is an umlsterm, mastoid is an umlsterm, CT scans is an umlsterm, water is an umlsterm, determination is an umlsterm, CAI is an umlsterm, temporal bones is an umlsterm, X - ray is an umlsterm, evaluation is an umlsterm

HNO.80460220.eng.abstr_task1

Sentence: Recently , the transducer and microphone of a cochlea amplifier implant ( CAI ) for the treatment of sensorineural cochlear hearing loss have been developed further for implantation into the mastoid cavity . At present , the University of Tuebingen implantable cochlea amplifier consists of an implantable microphone and an implantable piezoelectric transducer . It has been implanted into the first patients . Successful future application of this new implant depends on the suitable fit of the CAI within a patient's mastoid cavity . Using conventional X-ray and CT scans , we analyzed 50 cadaver specimens of the temporal bone before total mastoidectomy . After total mastoidectomy , the volume of the mastoid cavity was measured using CT scans and water volume determination . Finally , the CAI was implanted into those temporal bones that were large enough to house it . Our results demonstrate that the degree of pneumatization in the conventional Schueller X-ray is already a good parameter for preoperative evaluation . Instructions: please typing these entity words according to sentence: transducer, cochlea, amplifier, CAI, treatment, hearing loss, implantation, mastoid, University, cochlea, amplifier, transducer, patients, future, fit, CAI, mastoid, X - ray, CT scans, cadaver, temporal bone, mastoid, CT scans, water, determination, CAI, temporal bones, X - ray, evaluation Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Recently , the transducer and microphone of a cochlea amplifier implant ( CAI ) for the treatment of sensorineural cochlear hearing loss have been developed further for implantation into the mastoid cavity . At present , the University of Tuebingen implantable cochlea amplifier consists of an implantable microphone and an implantable piezoelectric transducer . It has been implanted into the first patients . Successful future application of this new implant depends on the suitable fit of the CAI within a patient's mastoid cavity . Using conventional X-ray and CT scans , we analyzed 50 cadaver specimens of the temporal bone before total mastoidectomy . After total mastoidectomy , the volume of the mastoid cavity was measured using CT scans and water volume determination . Finally , the CAI was implanted into those temporal bones that were large enough to house it . Our results demonstrate that the degree of pneumatization in the conventional Schueller X-ray is already a good parameter for preoperative evaluation .

[ "Recently", ",", "the", "transducer", "and", "microphone", "of", "a", "cochlea", "amplifier", "implant", "(", "CAI", ")", "for", "the", "treatment", "of", "sensorineural", "cochlear", "hearing", "loss", "have", "been", "developed", "further", "for", "implantation", "into", "the", "mastoid", "cavity", ".", "At", "present", ",", "the", "University", "of", "Tuebingen", "implantable", "cochlea", "amplifier", "consists", "of", "an", "implantable", "microphone", "and", "an", "implantable", "piezoelectric", "transducer", ".", "It", "has", "been", "implanted", "into", "the", "first", "patients", ".", "Successful", "future", "application", "of", "this", "new", "implant", "depends", "on", "the", "suitable", "fit", "of", "the", "CAI", "within", "a", "patient", "'s", "mastoid", "cavity", ".", "Using", "conventional", "X", "-", "ray", "and", "CT", "scans", ",", "we", "analyzed", "50", "cadaver", "specimens", "of", "the", "temporal", "bone", "before", "total", "mastoidectomy", ".", "After", "total", "mastoidectomy", ",", "the", "volume", "of", "the", "mastoid", "cavity", "was", "measured", "using", "CT", "scans", "and", "water", "volume", "determination", ".", "Finally", ",", "the", "CAI", "was", "implanted", "into", "those", "temporal", "bones", "that", "were", "large", "enough", "to", "house", "it", ".", "Our", "results", "demonstrate", "that", "the", "degree", "of", "pneumatization", "in", "the", "conventional", "Schueller", "X", "-", "ray", "is", "already", "a", "good", "parameter", "for", "preoperative", "evaluation", "." ]

[ "umlsterm" ]

transducer, cochlea, amplifier, CAI, treatment, hearing loss, implantation, mastoid, University, cochlea, amplifier, transducer, patients, future, fit, CAI, mastoid, X - ray, CT scans, cadaver, temporal bone, mastoid, CT scans, water, determination, CAI, temporal bones, X - ray, evaluation

HNO.80460220.eng.abstr_task2

Sentence: Recently , the transducer and microphone of a cochlea amplifier implant ( CAI ) for the treatment of sensorineural cochlear hearing loss have been developed further for implantation into the mastoid cavity . At present , the University of Tuebingen implantable cochlea amplifier consists of an implantable microphone and an implantable piezoelectric transducer . It has been implanted into the first patients . Successful future application of this new implant depends on the suitable fit of the CAI within a patient's mastoid cavity . Using conventional X-ray and CT scans , we analyzed 50 cadaver specimens of the temporal bone before total mastoidectomy . After total mastoidectomy , the volume of the mastoid cavity was measured using CT scans and water volume determination . Finally , the CAI was implanted into those temporal bones that were large enough to house it . Our results demonstrate that the degree of pneumatization in the conventional Schueller X-ray is already a good parameter for preoperative evaluation . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Recently , the transducer and microphone of a cochlea amplifier implant ( CAI ) for the treatment of sensorineural cochlear hearing loss have been developed further for implantation into the mastoid cavity . At present , the University of Tuebingen implantable cochlea amplifier consists of an implantable microphone and an implantable piezoelectric transducer . It has been implanted into the first patients . Successful future application of this new implant depends on the suitable fit of the CAI within a patient's mastoid cavity . Using conventional X-ray and CT scans , we analyzed 50 cadaver specimens of the temporal bone before total mastoidectomy . After total mastoidectomy , the volume of the mastoid cavity was measured using CT scans and water volume determination . Finally , the CAI was implanted into those temporal bones that were large enough to house it . Our results demonstrate that the degree of pneumatization in the conventional Schueller X-ray is already a good parameter for preoperative evaluation .

[ "Recently", ",", "the", "transducer", "and", "microphone", "of", "a", "cochlea", "amplifier", "implant", "(", "CAI", ")", "for", "the", "treatment", "of", "sensorineural", "cochlear", "hearing", "loss", "have", "been", "developed", "further", "for", "implantation", "into", "the", "mastoid", "cavity", ".", "At", "present", ",", "the", "University", "of", "Tuebingen", "implantable", "cochlea", "amplifier", "consists", "of", "an", "implantable", "microphone", "and", "an", "implantable", "piezoelectric", "transducer", ".", "It", "has", "been", "implanted", "into", "the", "first", "patients", ".", "Successful", "future", "application", "of", "this", "new", "implant", "depends", "on", "the", "suitable", "fit", "of", "the", "CAI", "within", "a", "patient", "'s", "mastoid", "cavity", ".", "Using", "conventional", "X", "-", "ray", "and", "CT", "scans", ",", "we", "analyzed", "50", "cadaver", "specimens", "of", "the", "temporal", "bone", "before", "total", "mastoidectomy", ".", "After", "total", "mastoidectomy", ",", "the", "volume", "of", "the", "mastoid", "cavity", "was", "measured", "using", "CT", "scans", "and", "water", "volume", "determination", ".", "Finally", ",", "the", "CAI", "was", "implanted", "into", "those", "temporal", "bones", "that", "were", "large", "enough", "to", "house", "it", ".", "Our", "results", "demonstrate", "that", "the", "degree", "of", "pneumatization", "in", "the", "conventional", "Schueller", "X", "-", "ray", "is", "already", "a", "good", "parameter", "for", "preoperative", "evaluation", "." ]

[ "umlsterm" ]

p120cas is a Individual_protein, protein tyrosine kinase is a Individual_protein, E - cadherin is a Individual_protein, alpha - catenin is a Individual_protein, beta - catenin is a Individual_protein, plakoglobin is a Individual_protein

750_task0

Sentence: The p120cas gene encodes a protein tyrosine kinase substrate that associates with the cell-cell adhesion protein complex containing E-cadherin and its cytoplasmic cofactors alpha-catenin, beta-catenin, and plakoglobin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein

[ "O", "B-Individual_protein", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "B-Individual_protein", "O" ]

The p120cas gene encodes a protein tyrosine kinase substrate that associates with the cell-cell adhesion protein complex containing E-cadherin and its cytoplasmic cofactors alpha-catenin, beta-catenin, and plakoglobin.

[ "The", "p120cas", "gene", "encodes", "a", "protein", "tyrosine", "kinase", "substrate", "that", "associates", "with", "the", "cell", "-", "cell", "adhesion", "protein", "complex", "containing", "E", "-", "cadherin", "and", "its", "cytoplasmic", "cofactors", "alpha", "-", "catenin", ",", "beta", "-", "catenin", ",", "and", "plakoglobin", "." ]

[ "Individual_protein" ]

p120cas is a Individual_protein, protein tyrosine kinase is a Individual_protein, E - cadherin is a Individual_protein, alpha - catenin is a Individual_protein, beta - catenin is a Individual_protein, plakoglobin is a Individual_protein

750_task1

Sentence: The p120cas gene encodes a protein tyrosine kinase substrate that associates with the cell-cell adhesion protein complex containing E-cadherin and its cytoplasmic cofactors alpha-catenin, beta-catenin, and plakoglobin. Instructions: please typing these entity words according to sentence: p120cas, protein tyrosine kinase, E - cadherin, alpha - catenin, beta - catenin, plakoglobin Options: Individual_protein

[ "O", "B-Individual_protein", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "B-Individual_protein", "O" ]

The p120cas gene encodes a protein tyrosine kinase substrate that associates with the cell-cell adhesion protein complex containing E-cadherin and its cytoplasmic cofactors alpha-catenin, beta-catenin, and plakoglobin.

[ "The", "p120cas", "gene", "encodes", "a", "protein", "tyrosine", "kinase", "substrate", "that", "associates", "with", "the", "cell", "-", "cell", "adhesion", "protein", "complex", "containing", "E", "-", "cadherin", "and", "its", "cytoplasmic", "cofactors", "alpha", "-", "catenin", ",", "beta", "-", "catenin", ",", "and", "plakoglobin", "." ]

[ "Individual_protein" ]

p120cas, protein tyrosine kinase, E - cadherin, alpha - catenin, beta - catenin, plakoglobin

750_task2

Sentence: The p120cas gene encodes a protein tyrosine kinase substrate that associates with the cell-cell adhesion protein complex containing E-cadherin and its cytoplasmic cofactors alpha-catenin, beta-catenin, and plakoglobin. Instructions: please extract entity words from the input sentence

[ "O", "B-Individual_protein", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "B-Individual_protein", "O" ]

The p120cas gene encodes a protein tyrosine kinase substrate that associates with the cell-cell adhesion protein complex containing E-cadherin and its cytoplasmic cofactors alpha-catenin, beta-catenin, and plakoglobin.

[ "The", "p120cas", "gene", "encodes", "a", "protein", "tyrosine", "kinase", "substrate", "that", "associates", "with", "the", "cell", "-", "cell", "adhesion", "protein", "complex", "containing", "E", "-", "cadherin", "and", "its", "cytoplasmic", "cofactors", "alpha", "-", "catenin", ",", "beta", "-", "catenin", ",", "and", "plakoglobin", "." ]

[ "Individual_protein" ]

profilin is a Individual_protein, actin is a Individual_protein, profilin is a Individual_protein

349_task0

Sentence: Interestingly, profilin overproduction can compensate for the deleterious effects of too much actin in a profilin concentration-dependent manner. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein

[ "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O" ]

Interestingly, profilin overproduction can compensate for the deleterious effects of too much actin in a profilin concentration-dependent manner.

[ "Interestingly", ",", "profilin", "overproduction", "can", "compensate", "for", "the", "deleterious", "effects", "of", "too", "much", "actin", "in", "a", "profilin", "concentration", "-", "dependent", "manner", "." ]

[ "Individual_protein" ]

profilin is a Individual_protein, actin is a Individual_protein, profilin is a Individual_protein

349_task1

Sentence: Interestingly, profilin overproduction can compensate for the deleterious effects of too much actin in a profilin concentration-dependent manner. Instructions: please typing these entity words according to sentence: profilin, actin, profilin Options: Individual_protein

[ "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O" ]

Interestingly, profilin overproduction can compensate for the deleterious effects of too much actin in a profilin concentration-dependent manner.

[ "Interestingly", ",", "profilin", "overproduction", "can", "compensate", "for", "the", "deleterious", "effects", "of", "too", "much", "actin", "in", "a", "profilin", "concentration", "-", "dependent", "manner", "." ]

[ "Individual_protein" ]

profilin, actin, profilin

349_task2

Sentence: Interestingly, profilin overproduction can compensate for the deleterious effects of too much actin in a profilin concentration-dependent manner. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O" ]

Interestingly, profilin overproduction can compensate for the deleterious effects of too much actin in a profilin concentration-dependent manner.

[ "Interestingly", ",", "profilin", "overproduction", "can", "compensate", "for", "the", "deleterious", "effects", "of", "too", "much", "actin", "in", "a", "profilin", "concentration", "-", "dependent", "manner", "." ]

[ "Individual_protein" ]

efficacy and safety is a Outcome_Other, fluticasone propionate powder is a Intervention_Pharmacological, placebo is a Intervention_Control, moderate asthma is a Participant_Condition, Fluticasone propionate is a Intervention_Pharmacological, inhaled fluticasone propionate powder is a Intervention_Pharmacological, moderate asthma previously treated with an inhaled corticosteroid is a Participant_Condition, 342 is a Participant_Sample-size, adolescent and adult is a Participant_Age, forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted is a Participant_Condition, beclomethasone dipropionate is a Intervention_Pharmacological, triamcinolone acetonide is a Intervention_Pharmacological, mean increase from baseline to endpoint in FEV1 is a Outcome_Physical, remaining in the study over time is a Outcome_Other, exacerbating asthma is a Outcome_Physical, Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma is a Outcome_Physical, serious drug - related adverse events is a Outcome_Adverse-effects, well - tolerated and significantly is a Outcome_Other, improved lung function is a Outcome_Physical

89727_task0

Sentence: Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma . BACKGROUND Fluticasone propionate , an inhaled corticosteroid with negligible systemic bioavailability via the oral route , is efficacious in the treatment of asthma when administered via metered-dose inhaler . OBJECTIVE To evaluate the efficacy and safety of inhaled fluticasone propionate powder in patients with moderate asthma previously treated with an inhaled corticosteroid . METHODS This was a randomized , double-blind , placebo-controlled , parallel-group , multicenter study of 342 adolescent and adult patients with moderate asthma [ forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted ] treated previously by beclomethasone dipropionate or triamcinolone acetonide . Patients received fluticasone propionate powder 50 micrograms , 100 micrograms , 250 micrograms , or placebo via a breath-actuated inhalation device , the Diskhaler , twice daily for 12 weeks . RESULTS Patients in the fluticasone propionate groups experienced a mean increase from baseline to endpoint in FEV1 ranging from 0.43 L to 0.47 L. Patients in the placebo group experienced a mean decrease from baseline of 0.22 L ( P < .001 ) . The probability of patients remaining in the study over time without developing signs of exacerbating asthma was significantly greater in the fluticasone propionate groups than in the placebo group ( P = .001 ) . Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma requiring treatment also improved significantly with all fluticasone propionate treatment regimens compared with placebo ( P < .001 ) . There were no statistically significant differences at endpoint among the three fluticasone propionate groups . No serious drug-related adverse events occurred . CONCLUSIONS Fluticasone propionate powder ( 50 , 100 , and 250 micrograms ) was well-tolerated and significantly improved lung function in patients with moderate asthma . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Control", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O" ]

Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma . BACKGROUND Fluticasone propionate , an inhaled corticosteroid with negligible systemic bioavailability via the oral route , is efficacious in the treatment of asthma when administered via metered-dose inhaler . OBJECTIVE To evaluate the efficacy and safety of inhaled fluticasone propionate powder in patients with moderate asthma previously treated with an inhaled corticosteroid . METHODS This was a randomized , double-blind , placebo-controlled , parallel-group , multicenter study of 342 adolescent and adult patients with moderate asthma [ forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted ] treated previously by beclomethasone dipropionate or triamcinolone acetonide . Patients received fluticasone propionate powder 50 micrograms , 100 micrograms , 250 micrograms , or placebo via a breath-actuated inhalation device , the Diskhaler , twice daily for 12 weeks . RESULTS Patients in the fluticasone propionate groups experienced a mean increase from baseline to endpoint in FEV1 ranging from 0.43 L to 0.47 L. Patients in the placebo group experienced a mean decrease from baseline of 0.22 L ( P < .001 ) . The probability of patients remaining in the study over time without developing signs of exacerbating asthma was significantly greater in the fluticasone propionate groups than in the placebo group ( P = .001 ) . Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma requiring treatment also improved significantly with all fluticasone propionate treatment regimens compared with placebo ( P < .001 ) . There were no statistically significant differences at endpoint among the three fluticasone propionate groups . No serious drug-related adverse events occurred . CONCLUSIONS Fluticasone propionate powder ( 50 , 100 , and 250 micrograms ) was well-tolerated and significantly improved lung function in patients with moderate asthma .

[ "Comparative", "efficacy", "and", "safety", "of", "twice", "daily", "fluticasone", "propionate", "powder", "versus", "placebo", "in", "the", "treatment", "of", "moderate", "asthma", ".", "BACKGROUND", "Fluticasone", "propionate", ",", "an", "inhaled", "corticosteroid", "with", "negligible", "systemic", "bioavailability", "via", "the", "oral", "route", ",", "is", "efficacious", "in", "the", "treatment", "of", "asthma", "when", "administered", "via", "metered", "-", "dose", "inhaler", ".", "OBJECTIVE", "To", "evaluate", "the", "efficacy", "and", "safety", "of", "inhaled", "fluticasone", "propionate", "powder", "in", "patients", "with", "moderate", "asthma", "previously", "treated", "with", "an", "inhaled", "corticosteroid", ".", "METHODS", "This", "was", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "parallel", "-", "group", ",", "multicenter", "study", "of", "342", "adolescent", "and", "adult", "patients", "with", "moderate", "asthma", "[", "forced", "expiratory", "volume", "in", "1", "second", "(", "FEV1", ")", "between", "50", "%", "and", "80", "%", "of", "predicted", "]", "treated", "previously", "by", "beclomethasone", "dipropionate", "or", "triamcinolone", "acetonide", ".", "Patients", "received", "fluticasone", "propionate", "powder", "50", "micrograms", ",", "100", "micrograms", ",", "250", "micrograms", ",", "or", "placebo", "via", "a", "breath", "-", "actuated", "inhalation", "device", ",", "the", "Diskhaler", ",", "twice", "daily", "for", "12", "weeks", ".", "RESULTS", "Patients", "in", "the", "fluticasone", "propionate", "groups", "experienced", "a", "mean", "increase", "from", "baseline", "to", "endpoint", "in", "FEV1", "ranging", "from", "0.43", "L", "to", "0.47", "L.", "Patients", "in", "the", "placebo", "group", "experienced", "a", "mean", "decrease", "from", "baseline", "of", "0.22", "L", "(", "P", "<", ".001", ")", ".", "The", "probability", "of", "patients", "remaining", "in", "the", "study", "over", "time", "without", "developing", "signs", "of", "exacerbating", "asthma", "was", "significantly", "greater", "in", "the", "fluticasone", "propionate", "groups", "than", "in", "the", "placebo", "group", "(", "P", "=", ".001", ")", ".", "Asthma", "symptom", "scores", ",", "supplemental", "rescue", "albuterol", "use", ",", "and", "number", "of", "nighttime", "awakenings", "due", "to", "asthma", "requiring", "treatment", "also", "improved", "significantly", "with", "all", "fluticasone", "propionate", "treatment", "regimens", "compared", "with", "placebo", "(", "P", "<", ".001", ")", ".", "There", "were", "no", "statistically", "significant", "differences", "at", "endpoint", "among", "the", "three", "fluticasone", "propionate", "groups", ".", "No", "serious", "drug", "-", "related", "adverse", "events", "occurred", ".", "CONCLUSIONS", "Fluticasone", "propionate", "powder", "(", "50", ",", "100", ",", "and", "250", "micrograms", ")", "was", "well", "-", "tolerated", "and", "significantly", "improved", "lung", "function", "in", "patients", "with", "moderate", "asthma", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Adverse-effects", "Outcome_Other", "Participant_Age", "Intervention_Control", "Participant_Sample-size" ]

efficacy and safety is a Outcome_Other, fluticasone propionate powder is a Intervention_Pharmacological, placebo is a Intervention_Control, moderate asthma is a Participant_Condition, Fluticasone propionate is a Intervention_Pharmacological, inhaled fluticasone propionate powder is a Intervention_Pharmacological, moderate asthma previously treated with an inhaled corticosteroid is a Participant_Condition, 342 is a Participant_Sample-size, adolescent and adult is a Participant_Age, forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted is a Participant_Condition, beclomethasone dipropionate is a Intervention_Pharmacological, triamcinolone acetonide is a Intervention_Pharmacological, mean increase from baseline to endpoint in FEV1 is a Outcome_Physical, remaining in the study over time is a Outcome_Other, exacerbating asthma is a Outcome_Physical, Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma is a Outcome_Physical, serious drug - related adverse events is a Outcome_Adverse-effects, well - tolerated and significantly is a Outcome_Other, improved lung function is a Outcome_Physical

89727_task1

Sentence: Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma . BACKGROUND Fluticasone propionate , an inhaled corticosteroid with negligible systemic bioavailability via the oral route , is efficacious in the treatment of asthma when administered via metered-dose inhaler . OBJECTIVE To evaluate the efficacy and safety of inhaled fluticasone propionate powder in patients with moderate asthma previously treated with an inhaled corticosteroid . METHODS This was a randomized , double-blind , placebo-controlled , parallel-group , multicenter study of 342 adolescent and adult patients with moderate asthma [ forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted ] treated previously by beclomethasone dipropionate or triamcinolone acetonide . Patients received fluticasone propionate powder 50 micrograms , 100 micrograms , 250 micrograms , or placebo via a breath-actuated inhalation device , the Diskhaler , twice daily for 12 weeks . RESULTS Patients in the fluticasone propionate groups experienced a mean increase from baseline to endpoint in FEV1 ranging from 0.43 L to 0.47 L. Patients in the placebo group experienced a mean decrease from baseline of 0.22 L ( P < .001 ) . The probability of patients remaining in the study over time without developing signs of exacerbating asthma was significantly greater in the fluticasone propionate groups than in the placebo group ( P = .001 ) . Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma requiring treatment also improved significantly with all fluticasone propionate treatment regimens compared with placebo ( P < .001 ) . There were no statistically significant differences at endpoint among the three fluticasone propionate groups . No serious drug-related adverse events occurred . CONCLUSIONS Fluticasone propionate powder ( 50 , 100 , and 250 micrograms ) was well-tolerated and significantly improved lung function in patients with moderate asthma . Instructions: please typing these entity words according to sentence: efficacy and safety, fluticasone propionate powder, placebo, moderate asthma, Fluticasone propionate, inhaled fluticasone propionate powder, moderate asthma previously treated with an inhaled corticosteroid, 342, adolescent and adult, forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted, beclomethasone dipropionate, triamcinolone acetonide, mean increase from baseline to endpoint in FEV1, remaining in the study over time, exacerbating asthma, Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma, serious drug - related adverse events, well - tolerated and significantly, improved lung function Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Control", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O" ]

Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma . BACKGROUND Fluticasone propionate , an inhaled corticosteroid with negligible systemic bioavailability via the oral route , is efficacious in the treatment of asthma when administered via metered-dose inhaler . OBJECTIVE To evaluate the efficacy and safety of inhaled fluticasone propionate powder in patients with moderate asthma previously treated with an inhaled corticosteroid . METHODS This was a randomized , double-blind , placebo-controlled , parallel-group , multicenter study of 342 adolescent and adult patients with moderate asthma [ forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted ] treated previously by beclomethasone dipropionate or triamcinolone acetonide . Patients received fluticasone propionate powder 50 micrograms , 100 micrograms , 250 micrograms , or placebo via a breath-actuated inhalation device , the Diskhaler , twice daily for 12 weeks . RESULTS Patients in the fluticasone propionate groups experienced a mean increase from baseline to endpoint in FEV1 ranging from 0.43 L to 0.47 L. Patients in the placebo group experienced a mean decrease from baseline of 0.22 L ( P < .001 ) . The probability of patients remaining in the study over time without developing signs of exacerbating asthma was significantly greater in the fluticasone propionate groups than in the placebo group ( P = .001 ) . Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma requiring treatment also improved significantly with all fluticasone propionate treatment regimens compared with placebo ( P < .001 ) . There were no statistically significant differences at endpoint among the three fluticasone propionate groups . No serious drug-related adverse events occurred . CONCLUSIONS Fluticasone propionate powder ( 50 , 100 , and 250 micrograms ) was well-tolerated and significantly improved lung function in patients with moderate asthma .

[ "Comparative", "efficacy", "and", "safety", "of", "twice", "daily", "fluticasone", "propionate", "powder", "versus", "placebo", "in", "the", "treatment", "of", "moderate", "asthma", ".", "BACKGROUND", "Fluticasone", "propionate", ",", "an", "inhaled", "corticosteroid", "with", "negligible", "systemic", "bioavailability", "via", "the", "oral", "route", ",", "is", "efficacious", "in", "the", "treatment", "of", "asthma", "when", "administered", "via", "metered", "-", "dose", "inhaler", ".", "OBJECTIVE", "To", "evaluate", "the", "efficacy", "and", "safety", "of", "inhaled", "fluticasone", "propionate", "powder", "in", "patients", "with", "moderate", "asthma", "previously", "treated", "with", "an", "inhaled", "corticosteroid", ".", "METHODS", "This", "was", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "parallel", "-", "group", ",", "multicenter", "study", "of", "342", "adolescent", "and", "adult", "patients", "with", "moderate", "asthma", "[", "forced", "expiratory", "volume", "in", "1", "second", "(", "FEV1", ")", "between", "50", "%", "and", "80", "%", "of", "predicted", "]", "treated", "previously", "by", "beclomethasone", "dipropionate", "or", "triamcinolone", "acetonide", ".", "Patients", "received", "fluticasone", "propionate", "powder", "50", "micrograms", ",", "100", "micrograms", ",", "250", "micrograms", ",", "or", "placebo", "via", "a", "breath", "-", "actuated", "inhalation", "device", ",", "the", "Diskhaler", ",", "twice", "daily", "for", "12", "weeks", ".", "RESULTS", "Patients", "in", "the", "fluticasone", "propionate", "groups", "experienced", "a", "mean", "increase", "from", "baseline", "to", "endpoint", "in", "FEV1", "ranging", "from", "0.43", "L", "to", "0.47", "L.", "Patients", "in", "the", "placebo", "group", "experienced", "a", "mean", "decrease", "from", "baseline", "of", "0.22", "L", "(", "P", "<", ".001", ")", ".", "The", "probability", "of", "patients", "remaining", "in", "the", "study", "over", "time", "without", "developing", "signs", "of", "exacerbating", "asthma", "was", "significantly", "greater", "in", "the", "fluticasone", "propionate", "groups", "than", "in", "the", "placebo", "group", "(", "P", "=", ".001", ")", ".", "Asthma", "symptom", "scores", ",", "supplemental", "rescue", "albuterol", "use", ",", "and", "number", "of", "nighttime", "awakenings", "due", "to", "asthma", "requiring", "treatment", "also", "improved", "significantly", "with", "all", "fluticasone", "propionate", "treatment", "regimens", "compared", "with", "placebo", "(", "P", "<", ".001", ")", ".", "There", "were", "no", "statistically", "significant", "differences", "at", "endpoint", "among", "the", "three", "fluticasone", "propionate", "groups", ".", "No", "serious", "drug", "-", "related", "adverse", "events", "occurred", ".", "CONCLUSIONS", "Fluticasone", "propionate", "powder", "(", "50", ",", "100", ",", "and", "250", "micrograms", ")", "was", "well", "-", "tolerated", "and", "significantly", "improved", "lung", "function", "in", "patients", "with", "moderate", "asthma", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Adverse-effects", "Outcome_Other", "Participant_Age", "Intervention_Control", "Participant_Sample-size" ]

efficacy and safety, fluticasone propionate powder, placebo, moderate asthma, Fluticasone propionate, inhaled fluticasone propionate powder, moderate asthma previously treated with an inhaled corticosteroid, 342, adolescent and adult, forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted, beclomethasone dipropionate, triamcinolone acetonide, mean increase from baseline to endpoint in FEV1, remaining in the study over time, exacerbating asthma, Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma, serious drug - related adverse events, well - tolerated and significantly, improved lung function

89727_task2

Sentence: Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma . BACKGROUND Fluticasone propionate , an inhaled corticosteroid with negligible systemic bioavailability via the oral route , is efficacious in the treatment of asthma when administered via metered-dose inhaler . OBJECTIVE To evaluate the efficacy and safety of inhaled fluticasone propionate powder in patients with moderate asthma previously treated with an inhaled corticosteroid . METHODS This was a randomized , double-blind , placebo-controlled , parallel-group , multicenter study of 342 adolescent and adult patients with moderate asthma [ forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted ] treated previously by beclomethasone dipropionate or triamcinolone acetonide . Patients received fluticasone propionate powder 50 micrograms , 100 micrograms , 250 micrograms , or placebo via a breath-actuated inhalation device , the Diskhaler , twice daily for 12 weeks . RESULTS Patients in the fluticasone propionate groups experienced a mean increase from baseline to endpoint in FEV1 ranging from 0.43 L to 0.47 L. Patients in the placebo group experienced a mean decrease from baseline of 0.22 L ( P < .001 ) . The probability of patients remaining in the study over time without developing signs of exacerbating asthma was significantly greater in the fluticasone propionate groups than in the placebo group ( P = .001 ) . Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma requiring treatment also improved significantly with all fluticasone propionate treatment regimens compared with placebo ( P < .001 ) . There were no statistically significant differences at endpoint among the three fluticasone propionate groups . No serious drug-related adverse events occurred . CONCLUSIONS Fluticasone propionate powder ( 50 , 100 , and 250 micrograms ) was well-tolerated and significantly improved lung function in patients with moderate asthma . Instructions: please extract entity words from the input sentence

[ "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Control", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O" ]

Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma . BACKGROUND Fluticasone propionate , an inhaled corticosteroid with negligible systemic bioavailability via the oral route , is efficacious in the treatment of asthma when administered via metered-dose inhaler . OBJECTIVE To evaluate the efficacy and safety of inhaled fluticasone propionate powder in patients with moderate asthma previously treated with an inhaled corticosteroid . METHODS This was a randomized , double-blind , placebo-controlled , parallel-group , multicenter study of 342 adolescent and adult patients with moderate asthma [ forced expiratory volume in 1 second ( FEV1 ) between 50 % and 80 % of predicted ] treated previously by beclomethasone dipropionate or triamcinolone acetonide . Patients received fluticasone propionate powder 50 micrograms , 100 micrograms , 250 micrograms , or placebo via a breath-actuated inhalation device , the Diskhaler , twice daily for 12 weeks . RESULTS Patients in the fluticasone propionate groups experienced a mean increase from baseline to endpoint in FEV1 ranging from 0.43 L to 0.47 L. Patients in the placebo group experienced a mean decrease from baseline of 0.22 L ( P < .001 ) . The probability of patients remaining in the study over time without developing signs of exacerbating asthma was significantly greater in the fluticasone propionate groups than in the placebo group ( P = .001 ) . Asthma symptom scores , supplemental rescue albuterol use , and number of nighttime awakenings due to asthma requiring treatment also improved significantly with all fluticasone propionate treatment regimens compared with placebo ( P < .001 ) . There were no statistically significant differences at endpoint among the three fluticasone propionate groups . No serious drug-related adverse events occurred . CONCLUSIONS Fluticasone propionate powder ( 50 , 100 , and 250 micrograms ) was well-tolerated and significantly improved lung function in patients with moderate asthma .

[ "Comparative", "efficacy", "and", "safety", "of", "twice", "daily", "fluticasone", "propionate", "powder", "versus", "placebo", "in", "the", "treatment", "of", "moderate", "asthma", ".", "BACKGROUND", "Fluticasone", "propionate", ",", "an", "inhaled", "corticosteroid", "with", "negligible", "systemic", "bioavailability", "via", "the", "oral", "route", ",", "is", "efficacious", "in", "the", "treatment", "of", "asthma", "when", "administered", "via", "metered", "-", "dose", "inhaler", ".", "OBJECTIVE", "To", "evaluate", "the", "efficacy", "and", "safety", "of", "inhaled", "fluticasone", "propionate", "powder", "in", "patients", "with", "moderate", "asthma", "previously", "treated", "with", "an", "inhaled", "corticosteroid", ".", "METHODS", "This", "was", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "parallel", "-", "group", ",", "multicenter", "study", "of", "342", "adolescent", "and", "adult", "patients", "with", "moderate", "asthma", "[", "forced", "expiratory", "volume", "in", "1", "second", "(", "FEV1", ")", "between", "50", "%", "and", "80", "%", "of", "predicted", "]", "treated", "previously", "by", "beclomethasone", "dipropionate", "or", "triamcinolone", "acetonide", ".", "Patients", "received", "fluticasone", "propionate", "powder", "50", "micrograms", ",", "100", "micrograms", ",", "250", "micrograms", ",", "or", "placebo", "via", "a", "breath", "-", "actuated", "inhalation", "device", ",", "the", "Diskhaler", ",", "twice", "daily", "for", "12", "weeks", ".", "RESULTS", "Patients", "in", "the", "fluticasone", "propionate", "groups", "experienced", "a", "mean", "increase", "from", "baseline", "to", "endpoint", "in", "FEV1", "ranging", "from", "0.43", "L", "to", "0.47", "L.", "Patients", "in", "the", "placebo", "group", "experienced", "a", "mean", "decrease", "from", "baseline", "of", "0.22", "L", "(", "P", "<", ".001", ")", ".", "The", "probability", "of", "patients", "remaining", "in", "the", "study", "over", "time", "without", "developing", "signs", "of", "exacerbating", "asthma", "was", "significantly", "greater", "in", "the", "fluticasone", "propionate", "groups", "than", "in", "the", "placebo", "group", "(", "P", "=", ".001", ")", ".", "Asthma", "symptom", "scores", ",", "supplemental", "rescue", "albuterol", "use", ",", "and", "number", "of", "nighttime", "awakenings", "due", "to", "asthma", "requiring", "treatment", "also", "improved", "significantly", "with", "all", "fluticasone", "propionate", "treatment", "regimens", "compared", "with", "placebo", "(", "P", "<", ".001", ")", ".", "There", "were", "no", "statistically", "significant", "differences", "at", "endpoint", "among", "the", "three", "fluticasone", "propionate", "groups", ".", "No", "serious", "drug", "-", "related", "adverse", "events", "occurred", ".", "CONCLUSIONS", "Fluticasone", "propionate", "powder", "(", "50", ",", "100", ",", "and", "250", "micrograms", ")", "was", "well", "-", "tolerated", "and", "significantly", "improved", "lung", "function", "in", "patients", "with", "moderate", "asthma", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Adverse-effects", "Outcome_Other", "Participant_Age", "Intervention_Control", "Participant_Sample-size" ]

IL-4 receptor alpha - chain cytoplasmic domain is a protein_domain_or_region, JAK-1 is a protein_molecule, STAT6 is a protein_molecule, IL-4-specific gene expression is an other_name

61724_task0

Sentence: The IL-4 receptor alpha-chain cytoplasmic domain is sufficient for activation of JAK-1 and STAT6 and the induction of IL-4-specific gene expression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_name, protein_domain_or_region, protein_molecule

[ "O", "B-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "O", "O", "O", "O", "O", "B-protein_molecule", "O", "B-protein_molecule", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]

The IL-4 receptor alpha-chain cytoplasmic domain is sufficient for activation of JAK-1 and STAT6 and the induction of IL-4-specific gene expression.

[ "The", "IL-4", "receptor", "alpha", "-", "chain", "cytoplasmic", "domain", "is", "sufficient", "for", "activation", "of", "JAK-1", "and", "STAT6", "and", "the", "induction", "of", "IL-4-specific", "gene", "expression", "." ]

[ "protein_domain_or_region", "(AND protein_domain_or_region protein_domain_or_region)", "protein_molecule", "other_name", "RNA_family_or_group", "cell_line", "protein_subunit", "protein_family_or_group", "DNA_family_or_group", "", "amino_acid_monomer", "protein_complex" ]

IL-4 receptor alpha - chain cytoplasmic domain is a protein_domain_or_region, JAK-1 is a protein_molecule, STAT6 is a protein_molecule, IL-4-specific gene expression is an other_name

61724_task1

Sentence: The IL-4 receptor alpha-chain cytoplasmic domain is sufficient for activation of JAK-1 and STAT6 and the induction of IL-4-specific gene expression. Instructions: please typing these entity words according to sentence: IL-4 receptor alpha - chain cytoplasmic domain, JAK-1, STAT6, IL-4-specific gene expression Options: other_name, protein_domain_or_region, protein_molecule

[ "O", "B-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "O", "O", "O", "O", "O", "B-protein_molecule", "O", "B-protein_molecule", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]

The IL-4 receptor alpha-chain cytoplasmic domain is sufficient for activation of JAK-1 and STAT6 and the induction of IL-4-specific gene expression.

[ "The", "IL-4", "receptor", "alpha", "-", "chain", "cytoplasmic", "domain", "is", "sufficient", "for", "activation", "of", "JAK-1", "and", "STAT6", "and", "the", "induction", "of", "IL-4-specific", "gene", "expression", "." ]

[ "protein_domain_or_region", "(AND protein_domain_or_region protein_domain_or_region)", "protein_molecule", "other_name", "RNA_family_or_group", "cell_line", "protein_subunit", "protein_family_or_group", "DNA_family_or_group", "", "amino_acid_monomer", "protein_complex" ]

IL-4 receptor alpha - chain cytoplasmic domain, JAK-1, STAT6, IL-4-specific gene expression

61724_task2

Sentence: The IL-4 receptor alpha-chain cytoplasmic domain is sufficient for activation of JAK-1 and STAT6 and the induction of IL-4-specific gene expression. Instructions: please extract entity words from the input sentence

[ "O", "B-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "I-protein_domain_or_region", "O", "O", "O", "O", "O", "B-protein_molecule", "O", "B-protein_molecule", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]

The IL-4 receptor alpha-chain cytoplasmic domain is sufficient for activation of JAK-1 and STAT6 and the induction of IL-4-specific gene expression.

[ "The", "IL-4", "receptor", "alpha", "-", "chain", "cytoplasmic", "domain", "is", "sufficient", "for", "activation", "of", "JAK-1", "and", "STAT6", "and", "the", "induction", "of", "IL-4-specific", "gene", "expression", "." ]

[ "protein_domain_or_region", "(AND protein_domain_or_region protein_domain_or_region)", "protein_molecule", "other_name", "RNA_family_or_group", "cell_line", "protein_subunit", "protein_family_or_group", "DNA_family_or_group", "", "amino_acid_monomer", "protein_complex" ]

PS is a chemical

1.0alpha7.train.879_task0

Sentence: The effect is thought to arise through the non-specific binding of transcription factors with the PS backbone [ 2. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: chemical

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "O", "O", "O", "O" ]

The effect is thought to arise through the non-specific binding of transcription factors with the PS backbone [ 2.

[ "The", "effect", "is", "thought", "to", "arise", "through", "the", "non", "-", "specific", "binding", "of", " ", "transcription", "factors", "with", "the", " ", "PS", "backbone", "[", "2", "." ]

[ "chemical" ]

PS is a chemical

1.0alpha7.train.879_task1

Sentence: The effect is thought to arise through the non-specific binding of transcription factors with the PS backbone [ 2. Instructions: please typing these entity words according to sentence: PS Options: chemical

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "O", "O", "O", "O" ]

The effect is thought to arise through the non-specific binding of transcription factors with the PS backbone [ 2.

[ "The", "effect", "is", "thought", "to", "arise", "through", "the", "non", "-", "specific", "binding", "of", " ", "transcription", "factors", "with", "the", " ", "PS", "backbone", "[", "2", "." ]

[ "chemical" ]

PS

1.0alpha7.train.879_task2

Sentence: The effect is thought to arise through the non-specific binding of transcription factors with the PS backbone [ 2. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "O", "O", "O", "O" ]

The effect is thought to arise through the non-specific binding of transcription factors with the PS backbone [ 2.

[ "The", "effect", "is", "thought", "to", "arise", "through", "the", "non", "-", "specific", "binding", "of", " ", "transcription", "factors", "with", "the", " ", "PS", "backbone", "[", "2", "." ]

[ "chemical" ]

Menschen is an umlsterm

DerOpthalmologe.00970784.ger.abstr_task0

Sentence: Hintergrund . Eine Makulopathie bei jungen Menschen stellt differentialdiagnostisch eine Herausforderung dar . Neben hereditaeren Makuladystrophien und erworbenen Makuladegenerationen kommen seltener auch systemische Erkrankungen als Ursache in Betracht . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Hintergrund . Eine Makulopathie bei jungen Menschen stellt differentialdiagnostisch eine Herausforderung dar . Neben hereditaeren Makuladystrophien und erworbenen Makuladegenerationen kommen seltener auch systemische Erkrankungen als Ursache in Betracht .

[ "Hintergrund", ".", "Eine", "Makulopathie", "bei", "jungen", "Menschen", "stellt", "differentialdiagnostisch", "eine", "Herausforderung", "dar", ".", "Neben", "hereditaeren", "Makuladystrophien", "und", "erworbenen", "Makuladegenerationen", "kommen", "seltener", "auch", "systemische", "Erkrankungen", "als", "Ursache", "in", "Betracht", "." ]

[ "umlsterm" ]

Menschen is an umlsterm

DerOpthalmologe.00970784.ger.abstr_task1

Sentence: Hintergrund . Eine Makulopathie bei jungen Menschen stellt differentialdiagnostisch eine Herausforderung dar . Neben hereditaeren Makuladystrophien und erworbenen Makuladegenerationen kommen seltener auch systemische Erkrankungen als Ursache in Betracht . Instructions: please typing these entity words according to sentence: Menschen Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Hintergrund . Eine Makulopathie bei jungen Menschen stellt differentialdiagnostisch eine Herausforderung dar . Neben hereditaeren Makuladystrophien und erworbenen Makuladegenerationen kommen seltener auch systemische Erkrankungen als Ursache in Betracht .

[ "Hintergrund", ".", "Eine", "Makulopathie", "bei", "jungen", "Menschen", "stellt", "differentialdiagnostisch", "eine", "Herausforderung", "dar", ".", "Neben", "hereditaeren", "Makuladystrophien", "und", "erworbenen", "Makuladegenerationen", "kommen", "seltener", "auch", "systemische", "Erkrankungen", "als", "Ursache", "in", "Betracht", "." ]

[ "umlsterm" ]

Menschen

DerOpthalmologe.00970784.ger.abstr_task2

Sentence: Hintergrund . Eine Makulopathie bei jungen Menschen stellt differentialdiagnostisch eine Herausforderung dar . Neben hereditaeren Makuladystrophien und erworbenen Makuladegenerationen kommen seltener auch systemische Erkrankungen als Ursache in Betracht . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Hintergrund . Eine Makulopathie bei jungen Menschen stellt differentialdiagnostisch eine Herausforderung dar . Neben hereditaeren Makuladystrophien und erworbenen Makuladegenerationen kommen seltener auch systemische Erkrankungen als Ursache in Betracht .

[ "Hintergrund", ".", "Eine", "Makulopathie", "bei", "jungen", "Menschen", "stellt", "differentialdiagnostisch", "eine", "Herausforderung", "dar", ".", "Neben", "hereditaeren", "Makuladystrophien", "und", "erworbenen", "Makuladegenerationen", "kommen", "seltener", "auch", "systemische", "Erkrankungen", "als", "Ursache", "in", "Betracht", "." ]

[ "umlsterm" ]

Sarkoidose is an umlsterm, Gewebereaktion is an umlsterm, Aetiologie is an umlsterm, Therapie is an umlsterm, Interferonen is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Interferon - alpha is an umlsterm, Sarkoidose is an umlsterm, Interferontherapie is an umlsterm

DerHautarzt.70480482.ger.abstr_task0

Sentence: Die Sarkoidose ist eine granulomatoese Gewebereaktion ungeklaerter Aetiologie . Ueber eine Induktion dieser Erkrankung als Folge einer Therapie mit Interferonen liegen bisher nur Einzelberichte vor . Wir stellen 3 Patienten vor , die unter bzw. nach einer Therapie mit Interferon-alpha eine Sarkoidose entwickelten . Ein moeglicher kausaler Zusammenhang mit der Interferontherapie wird diskutiert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Die Sarkoidose ist eine granulomatoese Gewebereaktion ungeklaerter Aetiologie . Ueber eine Induktion dieser Erkrankung als Folge einer Therapie mit Interferonen liegen bisher nur Einzelberichte vor . Wir stellen 3 Patienten vor , die unter bzw. nach einer Therapie mit Interferon-alpha eine Sarkoidose entwickelten . Ein moeglicher kausaler Zusammenhang mit der Interferontherapie wird diskutiert .

[ "Die", "Sarkoidose", "ist", "eine", "granulomatoese", "Gewebereaktion", "ungeklaerter", "Aetiologie", ".", "Ueber", "eine", "Induktion", "dieser", "Erkrankung", "als", "Folge", "einer", "Therapie", "mit", "Interferonen", "liegen", "bisher", "nur", "Einzelberichte", "vor", ".", "Wir", "stellen", "3", "Patienten", "vor", ",", "die", "unter", "bzw", ".", "nach", "einer", "Therapie", "mit", "Interferon", "-", "alpha", "eine", "Sarkoidose", "entwickelten", ".", "Ein", "moeglicher", "kausaler", "Zusammenhang", "mit", "der", "Interferontherapie", "wird", "diskutiert", "." ]

[ "umlsterm" ]

Sarkoidose is an umlsterm, Gewebereaktion is an umlsterm, Aetiologie is an umlsterm, Therapie is an umlsterm, Interferonen is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Interferon - alpha is an umlsterm, Sarkoidose is an umlsterm, Interferontherapie is an umlsterm

DerHautarzt.70480482.ger.abstr_task1

Sentence: Die Sarkoidose ist eine granulomatoese Gewebereaktion ungeklaerter Aetiologie . Ueber eine Induktion dieser Erkrankung als Folge einer Therapie mit Interferonen liegen bisher nur Einzelberichte vor . Wir stellen 3 Patienten vor , die unter bzw. nach einer Therapie mit Interferon-alpha eine Sarkoidose entwickelten . Ein moeglicher kausaler Zusammenhang mit der Interferontherapie wird diskutiert . Instructions: please typing these entity words according to sentence: Sarkoidose, Gewebereaktion, Aetiologie, Therapie, Interferonen, Patienten, Therapie, Interferon - alpha, Sarkoidose, Interferontherapie Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Die Sarkoidose ist eine granulomatoese Gewebereaktion ungeklaerter Aetiologie . Ueber eine Induktion dieser Erkrankung als Folge einer Therapie mit Interferonen liegen bisher nur Einzelberichte vor . Wir stellen 3 Patienten vor , die unter bzw. nach einer Therapie mit Interferon-alpha eine Sarkoidose entwickelten . Ein moeglicher kausaler Zusammenhang mit der Interferontherapie wird diskutiert .

[ "Die", "Sarkoidose", "ist", "eine", "granulomatoese", "Gewebereaktion", "ungeklaerter", "Aetiologie", ".", "Ueber", "eine", "Induktion", "dieser", "Erkrankung", "als", "Folge", "einer", "Therapie", "mit", "Interferonen", "liegen", "bisher", "nur", "Einzelberichte", "vor", ".", "Wir", "stellen", "3", "Patienten", "vor", ",", "die", "unter", "bzw", ".", "nach", "einer", "Therapie", "mit", "Interferon", "-", "alpha", "eine", "Sarkoidose", "entwickelten", ".", "Ein", "moeglicher", "kausaler", "Zusammenhang", "mit", "der", "Interferontherapie", "wird", "diskutiert", "." ]

[ "umlsterm" ]

Sarkoidose, Gewebereaktion, Aetiologie, Therapie, Interferonen, Patienten, Therapie, Interferon - alpha, Sarkoidose, Interferontherapie

DerHautarzt.70480482.ger.abstr_task2

Sentence: Die Sarkoidose ist eine granulomatoese Gewebereaktion ungeklaerter Aetiologie . Ueber eine Induktion dieser Erkrankung als Folge einer Therapie mit Interferonen liegen bisher nur Einzelberichte vor . Wir stellen 3 Patienten vor , die unter bzw. nach einer Therapie mit Interferon-alpha eine Sarkoidose entwickelten . Ein moeglicher kausaler Zusammenhang mit der Interferontherapie wird diskutiert . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Die Sarkoidose ist eine granulomatoese Gewebereaktion ungeklaerter Aetiologie . Ueber eine Induktion dieser Erkrankung als Folge einer Therapie mit Interferonen liegen bisher nur Einzelberichte vor . Wir stellen 3 Patienten vor , die unter bzw. nach einer Therapie mit Interferon-alpha eine Sarkoidose entwickelten . Ein moeglicher kausaler Zusammenhang mit der Interferontherapie wird diskutiert .

[ "Die", "Sarkoidose", "ist", "eine", "granulomatoese", "Gewebereaktion", "ungeklaerter", "Aetiologie", ".", "Ueber", "eine", "Induktion", "dieser", "Erkrankung", "als", "Folge", "einer", "Therapie", "mit", "Interferonen", "liegen", "bisher", "nur", "Einzelberichte", "vor", ".", "Wir", "stellen", "3", "Patienten", "vor", ",", "die", "unter", "bzw", ".", "nach", "einer", "Therapie", "mit", "Interferon", "-", "alpha", "eine", "Sarkoidose", "entwickelten", ".", "Ein", "moeglicher", "kausaler", "Zusammenhang", "mit", "der", "Interferontherapie", "wird", "diskutiert", "." ]

[ "umlsterm" ]

PRA is a Measurement, > 50 % is a Value, DSA is a Measurement, > 1500 MFI is a Value, Retransplantation is a Condition, planning to is a Mood, mycophenolate is a Drug, instead of is a Negation, everolimus is a Drug, planning for is a Mood, follow - up is a Procedure, another center is a Visit

NCT03088280_exc_task0

Sentence: PRA > 50% DSA > 1500 MFI Retransplantation Patients who are planning to receive mycophenolate instead of everolimus Patients who have planning for follow-up in another center Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Value, Visit, Procedure, Negation, Measurement, Mood, Drug

[ "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "O", "O", "O", "O", "B-Mood", "I-Mood", "O", "B-Drug", "B-Negation", "I-Negation", "B-Drug", "O", "O", "O", "O", "B-Mood", "I-Mood", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Visit", "I-Visit", "O" ]

PRA > 50% DSA > 1500 MFI Retransplantation Patients who are planning to receive mycophenolate instead of everolimus Patients who have planning for follow-up in another center

[ "PRA", ">", "50", "%", "\n", "DSA", ">", "1500", "MFI", "\n", "Retransplantation", "\n", "Patients", "who", "are", "planning", "to", "receive", "mycophenolate", "instead", "of", "everolimus", "\n", "Patients", "who", "have", "planning", "for", "follow", "-", "up", "in", "another", "center", "\n" ]

[ "Condition", "Visit", "Drug", "Mood", "Value", "Negation", "Procedure", "Measurement" ]

PRA is a Measurement, > 50 % is a Value, DSA is a Measurement, > 1500 MFI is a Value, Retransplantation is a Condition, planning to is a Mood, mycophenolate is a Drug, instead of is a Negation, everolimus is a Drug, planning for is a Mood, follow - up is a Procedure, another center is a Visit

NCT03088280_exc_task1

Sentence: PRA > 50% DSA > 1500 MFI Retransplantation Patients who are planning to receive mycophenolate instead of everolimus Patients who have planning for follow-up in another center Instructions: please typing these entity words according to sentence: PRA, > 50 %, DSA, > 1500 MFI, Retransplantation, planning to, mycophenolate, instead of, everolimus, planning for, follow - up, another center Options: Condition, Value, Visit, Procedure, Negation, Measurement, Mood, Drug

[ "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "O", "O", "O", "O", "B-Mood", "I-Mood", "O", "B-Drug", "B-Negation", "I-Negation", "B-Drug", "O", "O", "O", "O", "B-Mood", "I-Mood", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Visit", "I-Visit", "O" ]

PRA > 50% DSA > 1500 MFI Retransplantation Patients who are planning to receive mycophenolate instead of everolimus Patients who have planning for follow-up in another center

[ "PRA", ">", "50", "%", "\n", "DSA", ">", "1500", "MFI", "\n", "Retransplantation", "\n", "Patients", "who", "are", "planning", "to", "receive", "mycophenolate", "instead", "of", "everolimus", "\n", "Patients", "who", "have", "planning", "for", "follow", "-", "up", "in", "another", "center", "\n" ]

[ "Condition", "Visit", "Drug", "Mood", "Value", "Negation", "Procedure", "Measurement" ]

PRA, > 50 %, DSA, > 1500 MFI, Retransplantation, planning to, mycophenolate, instead of, everolimus, planning for, follow - up, another center

NCT03088280_exc_task2

Sentence: PRA > 50% DSA > 1500 MFI Retransplantation Patients who are planning to receive mycophenolate instead of everolimus Patients who have planning for follow-up in another center Instructions: please extract entity words from the input sentence

[ "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Condition", "O", "O", "O", "O", "B-Mood", "I-Mood", "O", "B-Drug", "B-Negation", "I-Negation", "B-Drug", "O", "O", "O", "O", "B-Mood", "I-Mood", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Visit", "I-Visit", "O" ]

PRA > 50% DSA > 1500 MFI Retransplantation Patients who are planning to receive mycophenolate instead of everolimus Patients who have planning for follow-up in another center

[ "PRA", ">", "50", "%", "\n", "DSA", ">", "1500", "MFI", "\n", "Retransplantation", "\n", "Patients", "who", "are", "planning", "to", "receive", "mycophenolate", "instead", "of", "everolimus", "\n", "Patients", "who", "have", "planning", "for", "follow", "-", "up", "in", "another", "center", "\n" ]

[ "Condition", "Visit", "Drug", "Mood", "Value", "Negation", "Procedure", "Measurement" ]

weisse is an umlsterm, Piedra is an umlsterm, Menschen is an umlsterm, Tiere is an umlsterm, Hefe is an umlsterm, Trichosporon is an umlsterm, Infektion is an umlsterm

DerHautarzt.60470638.ger.abstr_task0

Sentence: Die weisse Piedra ist eine seltene Haarerkrankung des Menschen und bestimmter Tiere durch die weitverbreitete Hefe der Gattung Trichosporon . Klinisch ist die Infektion durch weissliche , weiche und leicht abstreifbare Belaege an den Haarschaeften charakterisiert ; an umschriebenen Stellen koennen die Schaefte jedoch auch durch Invasion der Erreger zerstoert werden . Prinzipiell koennen alle Koerperhaare befallen sein ; mit 95% am weitaus haeufigsten ist jedoch die Genitalbehaarung betroffen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die weisse Piedra ist eine seltene Haarerkrankung des Menschen und bestimmter Tiere durch die weitverbreitete Hefe der Gattung Trichosporon . Klinisch ist die Infektion durch weissliche , weiche und leicht abstreifbare Belaege an den Haarschaeften charakterisiert ; an umschriebenen Stellen koennen die Schaefte jedoch auch durch Invasion der Erreger zerstoert werden . Prinzipiell koennen alle Koerperhaare befallen sein ; mit 95% am weitaus haeufigsten ist jedoch die Genitalbehaarung betroffen .

[ "Die", "weisse", "Piedra", "ist", "eine", "seltene", "Haarerkrankung", "des", "Menschen", "und", "bestimmter", "Tiere", "durch", "die", "weitverbreitete", "Hefe", "der", "Gattung", "Trichosporon", ".", "Klinisch", "ist", "die", "Infektion", "durch", "weissliche", ",", "weiche", "und", "leicht", "abstreifbare", "Belaege", "an", "den", "Haarschaeften", "charakterisiert", ";", "an", "umschriebenen", "Stellen", "koennen", "die", "Schaefte", "jedoch", "auch", "durch", "Invasion", "der", "Erreger", "zerstoert", "werden", ".", "Prinzipiell", "koennen", "alle", "Koerperhaare", "befallen", "sein", ";", "mit", "95", "%", "am", "weitaus", "haeufigsten", "ist", "jedoch", "die", "Genitalbehaarung", "betroffen", "." ]

[ "umlsterm" ]

weisse is an umlsterm, Piedra is an umlsterm, Menschen is an umlsterm, Tiere is an umlsterm, Hefe is an umlsterm, Trichosporon is an umlsterm, Infektion is an umlsterm

DerHautarzt.60470638.ger.abstr_task1

Sentence: Die weisse Piedra ist eine seltene Haarerkrankung des Menschen und bestimmter Tiere durch die weitverbreitete Hefe der Gattung Trichosporon . Klinisch ist die Infektion durch weissliche , weiche und leicht abstreifbare Belaege an den Haarschaeften charakterisiert ; an umschriebenen Stellen koennen die Schaefte jedoch auch durch Invasion der Erreger zerstoert werden . Prinzipiell koennen alle Koerperhaare befallen sein ; mit 95% am weitaus haeufigsten ist jedoch die Genitalbehaarung betroffen . Instructions: please typing these entity words according to sentence: weisse, Piedra, Menschen, Tiere, Hefe, Trichosporon, Infektion Options: umlsterm

[ "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die weisse Piedra ist eine seltene Haarerkrankung des Menschen und bestimmter Tiere durch die weitverbreitete Hefe der Gattung Trichosporon . Klinisch ist die Infektion durch weissliche , weiche und leicht abstreifbare Belaege an den Haarschaeften charakterisiert ; an umschriebenen Stellen koennen die Schaefte jedoch auch durch Invasion der Erreger zerstoert werden . Prinzipiell koennen alle Koerperhaare befallen sein ; mit 95% am weitaus haeufigsten ist jedoch die Genitalbehaarung betroffen .

[ "Die", "weisse", "Piedra", "ist", "eine", "seltene", "Haarerkrankung", "des", "Menschen", "und", "bestimmter", "Tiere", "durch", "die", "weitverbreitete", "Hefe", "der", "Gattung", "Trichosporon", ".", "Klinisch", "ist", "die", "Infektion", "durch", "weissliche", ",", "weiche", "und", "leicht", "abstreifbare", "Belaege", "an", "den", "Haarschaeften", "charakterisiert", ";", "an", "umschriebenen", "Stellen", "koennen", "die", "Schaefte", "jedoch", "auch", "durch", "Invasion", "der", "Erreger", "zerstoert", "werden", ".", "Prinzipiell", "koennen", "alle", "Koerperhaare", "befallen", "sein", ";", "mit", "95", "%", "am", "weitaus", "haeufigsten", "ist", "jedoch", "die", "Genitalbehaarung", "betroffen", "." ]

[ "umlsterm" ]

weisse, Piedra, Menschen, Tiere, Hefe, Trichosporon, Infektion

DerHautarzt.60470638.ger.abstr_task2

Sentence: Die weisse Piedra ist eine seltene Haarerkrankung des Menschen und bestimmter Tiere durch die weitverbreitete Hefe der Gattung Trichosporon . Klinisch ist die Infektion durch weissliche , weiche und leicht abstreifbare Belaege an den Haarschaeften charakterisiert ; an umschriebenen Stellen koennen die Schaefte jedoch auch durch Invasion der Erreger zerstoert werden . Prinzipiell koennen alle Koerperhaare befallen sein ; mit 95% am weitaus haeufigsten ist jedoch die Genitalbehaarung betroffen . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die weisse Piedra ist eine seltene Haarerkrankung des Menschen und bestimmter Tiere durch die weitverbreitete Hefe der Gattung Trichosporon . Klinisch ist die Infektion durch weissliche , weiche und leicht abstreifbare Belaege an den Haarschaeften charakterisiert ; an umschriebenen Stellen koennen die Schaefte jedoch auch durch Invasion der Erreger zerstoert werden . Prinzipiell koennen alle Koerperhaare befallen sein ; mit 95% am weitaus haeufigsten ist jedoch die Genitalbehaarung betroffen .

[ "Die", "weisse", "Piedra", "ist", "eine", "seltene", "Haarerkrankung", "des", "Menschen", "und", "bestimmter", "Tiere", "durch", "die", "weitverbreitete", "Hefe", "der", "Gattung", "Trichosporon", ".", "Klinisch", "ist", "die", "Infektion", "durch", "weissliche", ",", "weiche", "und", "leicht", "abstreifbare", "Belaege", "an", "den", "Haarschaeften", "charakterisiert", ";", "an", "umschriebenen", "Stellen", "koennen", "die", "Schaefte", "jedoch", "auch", "durch", "Invasion", "der", "Erreger", "zerstoert", "werden", ".", "Prinzipiell", "koennen", "alle", "Koerperhaare", "befallen", "sein", ";", "mit", "95", "%", "am", "weitaus", "haeufigsten", "ist", "jedoch", "die", "Genitalbehaarung", "betroffen", "." ]

[ "umlsterm" ]

Pathologie is an umlsterm, Eignung is an umlsterm, Diagnostik is an umlsterm, Pathologie is an umlsterm, Makuladegeneration is an umlsterm, aelteren Menschen is an umlsterm

DerOpthalmologe.90960166.ger.abstr_task0

Sentence: Hintergrund : Kleine Areale retinaler Pathologie koennen , insbesondere im Anfangsstadium , schwer zu diagnostizieren sein . Das multifokale Elektroretinogramm ( MF-ERG ) bietet seit kurzem die Moeglichkeit der topographischen retinalen Funktionspruefung . Die Eignung des MF-ERGs in der Diagnostik fokaler retinaler Pathologie soll am Beispiel der altersabhaengigen Makuladegeneration ( AMD ) geprueft werden . Die AMD , die in 75 % bilateral verlaeuft , ist die haeufigste Ursache einer Beeintraechtigung des zentralen Sehvermoegens bei aelteren Menschen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Hintergrund : Kleine Areale retinaler Pathologie koennen , insbesondere im Anfangsstadium , schwer zu diagnostizieren sein . Das multifokale Elektroretinogramm ( MF-ERG ) bietet seit kurzem die Moeglichkeit der topographischen retinalen Funktionspruefung . Die Eignung des MF-ERGs in der Diagnostik fokaler retinaler Pathologie soll am Beispiel der altersabhaengigen Makuladegeneration ( AMD ) geprueft werden . Die AMD , die in 75 % bilateral verlaeuft , ist die haeufigste Ursache einer Beeintraechtigung des zentralen Sehvermoegens bei aelteren Menschen .

[ "Hintergrund", ":", "Kleine", "Areale", "retinaler", "Pathologie", "koennen", ",", "insbesondere", "im", "Anfangsstadium", ",", "schwer", "zu", "diagnostizieren", "sein", ".", "Das", "multifokale", "Elektroretinogramm", "(", "MF", "-", "ERG", ")", "bietet", "seit", "kurzem", "die", "Moeglichkeit", "der", "topographischen", "retinalen", "Funktionspruefung", ".", "Die", "Eignung", "des", "MF", "-", "ERGs", "in", "der", "Diagnostik", "fokaler", "retinaler", "Pathologie", "soll", "am", "Beispiel", "der", "altersabhaengigen", "Makuladegeneration", "(", "AMD", ")", "geprueft", "werden", ".", "Die", "AMD", ",", "die", "in", "75", "%", "bilateral", "verlaeuft", ",", "ist", "die", "haeufigste", "Ursache", "einer", "Beeintraechtigung", "des", "zentralen", "Sehvermoegens", "bei", "aelteren", "Menschen", "." ]

[ "umlsterm" ]

Pathologie is an umlsterm, Eignung is an umlsterm, Diagnostik is an umlsterm, Pathologie is an umlsterm, Makuladegeneration is an umlsterm, aelteren Menschen is an umlsterm

DerOpthalmologe.90960166.ger.abstr_task1

Sentence: Hintergrund : Kleine Areale retinaler Pathologie koennen , insbesondere im Anfangsstadium , schwer zu diagnostizieren sein . Das multifokale Elektroretinogramm ( MF-ERG ) bietet seit kurzem die Moeglichkeit der topographischen retinalen Funktionspruefung . Die Eignung des MF-ERGs in der Diagnostik fokaler retinaler Pathologie soll am Beispiel der altersabhaengigen Makuladegeneration ( AMD ) geprueft werden . Die AMD , die in 75 % bilateral verlaeuft , ist die haeufigste Ursache einer Beeintraechtigung des zentralen Sehvermoegens bei aelteren Menschen . Instructions: please typing these entity words according to sentence: Pathologie, Eignung, Diagnostik, Pathologie, Makuladegeneration, aelteren Menschen Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Hintergrund : Kleine Areale retinaler Pathologie koennen , insbesondere im Anfangsstadium , schwer zu diagnostizieren sein . Das multifokale Elektroretinogramm ( MF-ERG ) bietet seit kurzem die Moeglichkeit der topographischen retinalen Funktionspruefung . Die Eignung des MF-ERGs in der Diagnostik fokaler retinaler Pathologie soll am Beispiel der altersabhaengigen Makuladegeneration ( AMD ) geprueft werden . Die AMD , die in 75 % bilateral verlaeuft , ist die haeufigste Ursache einer Beeintraechtigung des zentralen Sehvermoegens bei aelteren Menschen .

[ "Hintergrund", ":", "Kleine", "Areale", "retinaler", "Pathologie", "koennen", ",", "insbesondere", "im", "Anfangsstadium", ",", "schwer", "zu", "diagnostizieren", "sein", ".", "Das", "multifokale", "Elektroretinogramm", "(", "MF", "-", "ERG", ")", "bietet", "seit", "kurzem", "die", "Moeglichkeit", "der", "topographischen", "retinalen", "Funktionspruefung", ".", "Die", "Eignung", "des", "MF", "-", "ERGs", "in", "der", "Diagnostik", "fokaler", "retinaler", "Pathologie", "soll", "am", "Beispiel", "der", "altersabhaengigen", "Makuladegeneration", "(", "AMD", ")", "geprueft", "werden", ".", "Die", "AMD", ",", "die", "in", "75", "%", "bilateral", "verlaeuft", ",", "ist", "die", "haeufigste", "Ursache", "einer", "Beeintraechtigung", "des", "zentralen", "Sehvermoegens", "bei", "aelteren", "Menschen", "." ]

[ "umlsterm" ]

Pathologie, Eignung, Diagnostik, Pathologie, Makuladegeneration, aelteren Menschen

DerOpthalmologe.90960166.ger.abstr_task2

Sentence: Hintergrund : Kleine Areale retinaler Pathologie koennen , insbesondere im Anfangsstadium , schwer zu diagnostizieren sein . Das multifokale Elektroretinogramm ( MF-ERG ) bietet seit kurzem die Moeglichkeit der topographischen retinalen Funktionspruefung . Die Eignung des MF-ERGs in der Diagnostik fokaler retinaler Pathologie soll am Beispiel der altersabhaengigen Makuladegeneration ( AMD ) geprueft werden . Die AMD , die in 75 % bilateral verlaeuft , ist die haeufigste Ursache einer Beeintraechtigung des zentralen Sehvermoegens bei aelteren Menschen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Hintergrund : Kleine Areale retinaler Pathologie koennen , insbesondere im Anfangsstadium , schwer zu diagnostizieren sein . Das multifokale Elektroretinogramm ( MF-ERG ) bietet seit kurzem die Moeglichkeit der topographischen retinalen Funktionspruefung . Die Eignung des MF-ERGs in der Diagnostik fokaler retinaler Pathologie soll am Beispiel der altersabhaengigen Makuladegeneration ( AMD ) geprueft werden . Die AMD , die in 75 % bilateral verlaeuft , ist die haeufigste Ursache einer Beeintraechtigung des zentralen Sehvermoegens bei aelteren Menschen .

[ "Hintergrund", ":", "Kleine", "Areale", "retinaler", "Pathologie", "koennen", ",", "insbesondere", "im", "Anfangsstadium", ",", "schwer", "zu", "diagnostizieren", "sein", ".", "Das", "multifokale", "Elektroretinogramm", "(", "MF", "-", "ERG", ")", "bietet", "seit", "kurzem", "die", "Moeglichkeit", "der", "topographischen", "retinalen", "Funktionspruefung", ".", "Die", "Eignung", "des", "MF", "-", "ERGs", "in", "der", "Diagnostik", "fokaler", "retinaler", "Pathologie", "soll", "am", "Beispiel", "der", "altersabhaengigen", "Makuladegeneration", "(", "AMD", ")", "geprueft", "werden", ".", "Die", "AMD", ",", "die", "in", "75", "%", "bilateral", "verlaeuft", ",", "ist", "die", "haeufigste", "Ursache", "einer", "Beeintraechtigung", "des", "zentralen", "Sehvermoegens", "bei", "aelteren", "Menschen", "." ]

[ "umlsterm" ]

Aromatase is a GENE-Y, Sulfatase is a GENE-Y, 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate is a CHEMICAL, 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate is a CHEMICAL, F is a CHEMICAL, Cl is a CHEMICAL, Br is a CHEMICAL, aromatase is a GENE-Y, sulfatase is a GENE-Y, halogen is a CHEMICAL, halogen is a CHEMICAL, halogen is a CHEMICAL, methylene is a CHEMICAL, difluoromethylene is a CHEMICAL, para - cyanophenyl is a CHEMICAL, triazolyl is a CHEMICAL, imidazolyl is a CHEMICAL, imidazole is a CHEMICAL, aromatase is a GENE-Y, steroid sulfatase is a GENE-Y, phenol is a CHEMICAL, aromatase is a GENE-Y

24173_task0

Sentence: Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs). Structure-activity relationship studies were performed on these compounds, and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms, replacement of the halogen with another group, replacement of the methylene linker with a difluoromethylene linker, replacement of the para-cyanophenyl ring with other ring structures, and replacement of the triazolyl group with an imidazolyl group. The most potent in vitro DASI discovered is an imidazole derivative with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5 nM, respectively. The parent phenol of this compound inhibits aromatase with an IC50 value of 0.028 nM in the same assay. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs). Structure-activity relationship studies were performed on these compounds, and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms, replacement of the halogen with another group, replacement of the methylene linker with a difluoromethylene linker, replacement of the para-cyanophenyl ring with other ring structures, and replacement of the triazolyl group with an imidazolyl group. The most potent in vitro DASI discovered is an imidazole derivative with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5 nM, respectively. The parent phenol of this compound inhibits aromatase with an IC50 value of 0.028 nM in the same assay.

[ "Synthesis", "and", "Structure", "-", "Activity", "Relationship", "Studies", "of", "Derivatives", "of", "the", "Dual", "Aromatase", "-", "Sulfatase", "Inhibitor", "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl", "sulfamate", ".", "\n", "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl", "sulfamate", "and", "its", "ortho", "-", "halogenated", "(", "F", ",", "Cl", ",", "Br", ")", "derivatives", "are", "first", "-", "generation", "dual", "aromatase", "and", "sulfatase", "inhibitors", "(", "DASIs", ")", ".", "Structure", "-", "activity", "relationship", "studies", "were", "performed", "on", "these", "compounds", ",", "and", "various", "modifications", "were", "made", "to", "their", "structures", "involving", "relocation", "of", "the", "halogen", "atom", ",", "introduction", "of", "more", "halogen", "atoms", ",", "replacement", "of", "the", "halogen", "with", "another", "group", ",", "replacement", "of", "the", "methylene", "linker", "with", "a", "difluoromethylene", "linker", ",", "replacement", "of", "the", "para", "-", "cyanophenyl", "ring", "with", "other", "ring", "structures", ",", "and", "replacement", "of", "the", "triazolyl", "group", "with", "an", "imidazolyl", "group", ".", "The", "most", "potent", "in", " ", "vitro", "DASI", "discovered", "is", "an", "imidazole", "derivative", "with", "IC50", "values", "against", "aromatase", "and", "steroid", "sulfatase", "in", "a", "JEG-3", "cell", "preparation", "of", "0.2", "and", "2.5", " ", "nM", ",", "respectively", ".", "The", "parent", "phenol", "of", "this", "compound", "inhibits", "aromatase", "with", "an", "IC50", "value", "of", "0.028", " ", "nM", "in", "the", "same", "assay", "." ]

[ "CHEMICAL", "GENE-Y" ]

Aromatase is a GENE-Y, Sulfatase is a GENE-Y, 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate is a CHEMICAL, 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate is a CHEMICAL, F is a CHEMICAL, Cl is a CHEMICAL, Br is a CHEMICAL, aromatase is a GENE-Y, sulfatase is a GENE-Y, halogen is a CHEMICAL, halogen is a CHEMICAL, halogen is a CHEMICAL, methylene is a CHEMICAL, difluoromethylene is a CHEMICAL, para - cyanophenyl is a CHEMICAL, triazolyl is a CHEMICAL, imidazolyl is a CHEMICAL, imidazole is a CHEMICAL, aromatase is a GENE-Y, steroid sulfatase is a GENE-Y, phenol is a CHEMICAL, aromatase is a GENE-Y

24173_task1

Sentence: Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs). Structure-activity relationship studies were performed on these compounds, and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms, replacement of the halogen with another group, replacement of the methylene linker with a difluoromethylene linker, replacement of the para-cyanophenyl ring with other ring structures, and replacement of the triazolyl group with an imidazolyl group. The most potent in vitro DASI discovered is an imidazole derivative with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5 nM, respectively. The parent phenol of this compound inhibits aromatase with an IC50 value of 0.028 nM in the same assay. Instructions: please typing these entity words according to sentence: Aromatase, Sulfatase, 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate, 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate, F, Cl, Br, aromatase, sulfatase, halogen, halogen, halogen, methylene, difluoromethylene, para - cyanophenyl, triazolyl, imidazolyl, imidazole, aromatase, steroid sulfatase, phenol, aromatase Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs). Structure-activity relationship studies were performed on these compounds, and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms, replacement of the halogen with another group, replacement of the methylene linker with a difluoromethylene linker, replacement of the para-cyanophenyl ring with other ring structures, and replacement of the triazolyl group with an imidazolyl group. The most potent in vitro DASI discovered is an imidazole derivative with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5 nM, respectively. The parent phenol of this compound inhibits aromatase with an IC50 value of 0.028 nM in the same assay.

[ "Synthesis", "and", "Structure", "-", "Activity", "Relationship", "Studies", "of", "Derivatives", "of", "the", "Dual", "Aromatase", "-", "Sulfatase", "Inhibitor", "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl", "sulfamate", ".", "\n", "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl", "sulfamate", "and", "its", "ortho", "-", "halogenated", "(", "F", ",", "Cl", ",", "Br", ")", "derivatives", "are", "first", "-", "generation", "dual", "aromatase", "and", "sulfatase", "inhibitors", "(", "DASIs", ")", ".", "Structure", "-", "activity", "relationship", "studies", "were", "performed", "on", "these", "compounds", ",", "and", "various", "modifications", "were", "made", "to", "their", "structures", "involving", "relocation", "of", "the", "halogen", "atom", ",", "introduction", "of", "more", "halogen", "atoms", ",", "replacement", "of", "the", "halogen", "with", "another", "group", ",", "replacement", "of", "the", "methylene", "linker", "with", "a", "difluoromethylene", "linker", ",", "replacement", "of", "the", "para", "-", "cyanophenyl", "ring", "with", "other", "ring", "structures", ",", "and", "replacement", "of", "the", "triazolyl", "group", "with", "an", "imidazolyl", "group", ".", "The", "most", "potent", "in", " ", "vitro", "DASI", "discovered", "is", "an", "imidazole", "derivative", "with", "IC50", "values", "against", "aromatase", "and", "steroid", "sulfatase", "in", "a", "JEG-3", "cell", "preparation", "of", "0.2", "and", "2.5", " ", "nM", ",", "respectively", ".", "The", "parent", "phenol", "of", "this", "compound", "inhibits", "aromatase", "with", "an", "IC50", "value", "of", "0.028", " ", "nM", "in", "the", "same", "assay", "." ]

[ "CHEMICAL", "GENE-Y" ]

Aromatase, Sulfatase, 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate, 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate, F, Cl, Br, aromatase, sulfatase, halogen, halogen, halogen, methylene, difluoromethylene, para - cyanophenyl, triazolyl, imidazolyl, imidazole, aromatase, steroid sulfatase, phenol, aromatase

24173_task2

Sentence: Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs). Structure-activity relationship studies were performed on these compounds, and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms, replacement of the halogen with another group, replacement of the methylene linker with a difluoromethylene linker, replacement of the para-cyanophenyl ring with other ring structures, and replacement of the triazolyl group with an imidazolyl group. The most potent in vitro DASI discovered is an imidazole derivative with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5 nM, respectively. The parent phenol of this compound inhibits aromatase with an IC50 value of 0.028 nM in the same assay. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs). Structure-activity relationship studies were performed on these compounds, and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms, replacement of the halogen with another group, replacement of the methylene linker with a difluoromethylene linker, replacement of the para-cyanophenyl ring with other ring structures, and replacement of the triazolyl group with an imidazolyl group. The most potent in vitro DASI discovered is an imidazole derivative with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5 nM, respectively. The parent phenol of this compound inhibits aromatase with an IC50 value of 0.028 nM in the same assay.

[ "Synthesis", "and", "Structure", "-", "Activity", "Relationship", "Studies", "of", "Derivatives", "of", "the", "Dual", "Aromatase", "-", "Sulfatase", "Inhibitor", "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl", "sulfamate", ".", "\n", "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl", "sulfamate", "and", "its", "ortho", "-", "halogenated", "(", "F", ",", "Cl", ",", "Br", ")", "derivatives", "are", "first", "-", "generation", "dual", "aromatase", "and", "sulfatase", "inhibitors", "(", "DASIs", ")", ".", "Structure", "-", "activity", "relationship", "studies", "were", "performed", "on", "these", "compounds", ",", "and", "various", "modifications", "were", "made", "to", "their", "structures", "involving", "relocation", "of", "the", "halogen", "atom", ",", "introduction", "of", "more", "halogen", "atoms", ",", "replacement", "of", "the", "halogen", "with", "another", "group", ",", "replacement", "of", "the", "methylene", "linker", "with", "a", "difluoromethylene", "linker", ",", "replacement", "of", "the", "para", "-", "cyanophenyl", "ring", "with", "other", "ring", "structures", ",", "and", "replacement", "of", "the", "triazolyl", "group", "with", "an", "imidazolyl", "group", ".", "The", "most", "potent", "in", " ", "vitro", "DASI", "discovered", "is", "an", "imidazole", "derivative", "with", "IC50", "values", "against", "aromatase", "and", "steroid", "sulfatase", "in", "a", "JEG-3", "cell", "preparation", "of", "0.2", "and", "2.5", " ", "nM", ",", "respectively", ".", "The", "parent", "phenol", "of", "this", "compound", "inhibits", "aromatase", "with", "an", "IC50", "value", "of", "0.028", " ", "nM", "in", "the", "same", "assay", "." ]

[ "CHEMICAL", "GENE-Y" ]

TACR1 is a gene

47_task0

Sentence: Fine mapping of the 2p11 dyslexia locus and exclusion of TACR1 as a candidate gene. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: gene

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "O", "O", "O", "O", "O" ]

Fine mapping of the 2p11 dyslexia locus and exclusion of TACR1 as a candidate gene.

[ "Fine", "mapping", "of", "the", "2p11", "dyslexia", "locus", "and", "exclusion", "of", " ", "TACR1", " ", "as", "a", "candidate", "gene", "." ]

[ "variant", "gene" ]

TACR1 is a gene

47_task1

Sentence: Fine mapping of the 2p11 dyslexia locus and exclusion of TACR1 as a candidate gene. Instructions: please typing these entity words according to sentence: TACR1 Options: gene

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "O", "O", "O", "O", "O" ]

Fine mapping of the 2p11 dyslexia locus and exclusion of TACR1 as a candidate gene.

[ "Fine", "mapping", "of", "the", "2p11", "dyslexia", "locus", "and", "exclusion", "of", " ", "TACR1", " ", "as", "a", "candidate", "gene", "." ]

[ "variant", "gene" ]